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Abstract 
 
 
Encephalitis caused by the alphaherpes viruses HSV 1, HSV 2 and VZV can be 
devastating and rapid, accurate diagnosis is required. Whilst existing molecular techniques 
are invaluable in diagnosing acute disease, detection of antibody is needed to confirm 
infection and to make a diagnosis after the acute stage or during post-infectious 
encephalitis.  Current immunoassays are limited by the volume of sample required. The 
aim of this project was to develop a rapid, accurate, low sample volume assay to improve 
diagnosis using Luminex technology. 
 
The immunodominant proteins of HSV and VZV, glycoprotein D (gD) and glycoprotein E 
(gE), were expressed in insect cells using a baculovirus expression vector. Expressed 
proteins were purified, characterised and used to develop in-house enzyme-linked 
immunosorbent assays (ELISA) to detect HSV and VZV type-specific antibodies. The 
performance of each newly developed in-house ELISA was compared with commercial 
ELISA assays using well characterised serum panels. An excellent correlation between the 
in-house ELISAs and the commercial ELISA assays (100% for HSV gD and 99% for VZV 
gE) was observed. To differentiate between HSV-1 and HSV-2 a new commercial ELISA 
assay (Omega) utilising a branched chain peptide (peptide 55 which provides immune 
selection of HSV-2 specific antibody) was evaluated against two commercially available 
HSV-2 ELISA assays. The Omega assay showed an overall agreement of 97.6% with 
Western blot and other ELISA assays.   
 
The two expressed proteins, together with peptide 55, were used to develop a triplex 
fluorescent microbead immunoassay for the simultaneous detection and quantitation of 
anti-viral antibody in human sera. Initially a monoplex assay for each analyte was 
developed and optimised individually and then the three assays were mixed together in a 
triplex assay. Results for HSV-1 gD and VZV gE obtained from the triplex assay showed a 
100% agreement with HSV-1 and VZV in-house ELISA results. In the case of peptide 55, 
the triplex assay results showed better sensitivity than the Omega ELISA assay with an 
overall agreement with Western blot and other assays of 98.4%. In addition, in order to 
facilitate the diagnosis of alphaherpesviruses CNS infections the triplex assay was joined 
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together with a biplex fluorescent microbead immunoassay designed for detecting and 
measuring human IgG and albumin in CSF and serum samples. The sensitivity and 
reproducibility of the resultant five-analyte multiplex immunoassay and the previous 
triplex assays were compared and found to have equivalent sensitivity and specificity. The 
sensitivity and minimal sample requirements of the new assay suggests that it will be a 
powerful tool for the diagnosis and study of both acute and post-infectious viral 
encephalitis. 
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1. The Human Central Nervous System 
 
1.1 Central Nervous System Infection  
 
Infection of the CNS can be caused by any of four main pathogen groups: bacterial, viral, 
fungal and protozoal (Stone and Hawkins 2007; Granerod et al., 2010). Bacterial infections 
can produce pyogenic infections (e.g., meningitis; brain abscess; subdural and epidural 
abscesses), or be caused by Mycobacterium tuberculosis, Treponema pallidum, or M. 
Leprae (Whitley and Gnann, 2002). Fungal infections may cause meningitis or 
meningoencephalitis, brain abscess, or spinal epidural infection. Protozoal infections 
include toxoplasmosis, malaria and amoebic infection. Viral infections may cause 
meningitis, encephalitis, myelitis, acquired immune deficiency syndrome (AIDS), and 
post-infectious syndromes (Solomon et al., 2007). Experimental studies have improved the 
understanding of how viruses enter the host, invade host defence mechanisms and infect 
the CNS. Viruses have developed many mechanisms for invading the nervous system and 
can enter the CNS through two distinct routes: neuronal or haematogenous. 
 
 
1.2 Encephalitis  
Encephalitis is a particularly life threatening inflammation of the brain parenchyma which 
occurs with various clinical presentations (Stone and Hawkins 2007; Solomon et al., 
2007). From an epidemiological and pathophysiological perspective, encephalitis is 
distinct from meningitis, although on clinical evaluation, both often co-exist with signs and 
symptoms of meningeal inflammation, such as photophobia, headache or a stiff neck. 
Encephalitis may be due to an acute infection; a post-infectious immune-mediated process; 
or a paraneoplastic syndrome. In addition there are a number of non-infectious causes 
including autoimmune diseases and cardiovascular conditions, which can cause illnesses 
indistinguishable from infectious encephalitis (De Marcaida and Reik., 1999; Reznicek et 
al., 2010a). 
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1.2.1 Viral Encephalitis 
 
Encephalitis is an uncommon manifestation of human viral infection; it may develop 
during or after infection with any of more than 100 different viruses, producing infection 
which varies in epidemiology, modes of transmission and clinical features (Debiasi and 
Tyler 2004; Philip 2009; Reznicek et al., 2010a). The disease can be either classified either 
according to the causative agent or the clinical presentation. Based on the clinical features 
encephalitis can be divided into three distinctive categories: acute viral encephalitis, 
postinfectious encephalomyelitis and chronic encephalitis (Domingues 2009).  
 
 
1.2.2 Clinical Classification of Encephalitis  
 
1.2.2.1 Acute Viral Encephalitis 
 
Acute encephalitis is a severe neurological syndrome usually associated with significant 
morbidity and mortality. There are two form of acute encephalitis: epidemic (affecting a 
significant number of people in a community examples being encephalitis caused by 
arboviruses and enteroviruses) or sporadic (affecting non-related individuals) such as 
encephalitis caused by herpes simplex type 1 (HSV-1). 
 
 
1.2.2.1.1 Epidemic Acute Viral Encephalitis  
Arboviruses are common causes of epidemic encephalitis. The term arbovirus refers to 
Arthropod-borne viruses that include viruses passed to humans by members of the phylum 
Arthropoda (which includes insects and spiders). The major causes of arbovirus 
encephalitis include the members of the viral families Togaviridae (such as Eastern equine 
encephalitis, Western equine encephalitis, and Venezuelan equine encephalitis), 
Flaviviridae (St.Louis encephalitis, Japanese encephalitis, Tick-borne encephalitis, Murray 
Valley encephalitis, Russian spring-summer encephalitis, and Powassan), and 
Bunyaviridae (California encephalitis) (Reznicek et al., 2010b). The most common times 
of year for these illnesses are summer and autumn when mosquitoes and ticks are most 
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prevalent. Damp environments favour large populations of mosquitoes thus increasing the 
risk of arbovirus infections. 
 
1.2.2.1.2 Sporadic Acute Viral Encephalitis 
 
Herpes simplex type 1 (HSV-1) is one of the most important causes of sporadic fatal 
encephalitis, with a 95% mortality rate if not treated, and significant morbidity in survivors 
such that only about 2.5% of those affected regain complete normal function (Tyler, 2004; 
Wilhelimina et al., 2006 ; Reznicek et al., 2010a). Herpes simplex type 1 is responsible for 
90-95% of cases while herpes simplex type 2 (HSV-2) contributes the remaining 5-10% of 
herpes simplex encephalitis (HSE) cases (Stone and Hawkins 2007). The incidence of HSE 
is estimated to be approximately 1 in 250,000 to 1 in 500,000 individuals per year 
(Whitley, 2006). The classical clinical presentation of HSE is of subacute progression of 
fever, hemicranial or generalized headache, behavioural abnormalities, focal seizure 
activity and focal neurological deficits, most often dysphasia or hemiparesis. Clinical 
recognition and laboratory investigation can aid early specific antiviral therapy which can 
significantly reduce the morbidity and mortality of cases.    
 
 
1.2.2.2 Sub-Acute Viral Encephalitis  
Post or para-infectious encephalitis appears to be an acute autoimmune monophasic 
disorder of the CNS triggered by either vaccination or a variety of common viral infections 
such as the childhood exanthems measles or varicella. Symptoms usually begin five to 10 
days after the onset of the disease. The most common subtype is acute disseminated 
encephalomyelitis (ADEM) characterised neuropathologically by perivenular inflammation 
and demyelination and typically seen in children and adolescents (Reznicek et al., 2010a). 
It is very difficult to distinguish ADEM from encephalitis clinically, however it can be 
distinguished pathologically from acute encephalitis. Infection with measles virus can lead 
to subacute sclerosing panencephalitis (SSPE). This develops some years after infection 
with the virus (range from 2 to 12 or more years). It may be related to virus reactivation 
within infected neuronal cells and the subsequent immune response to the infection. It is 
characterised by intractable seizures and progressive neurologic deterioration.  
Postinfectious encephalomyelitis is a disease of white matter, while acute viral encephalitis 
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is predominantly a disease of grey matter, although white matter may also be infected; 
especially basal ganglia, thalami and in some cases brainstem (Heininger and Seward 
2006).  
 
 
1.2.2.3 Chronic Viral Encephalitis   
 
Chronic encephalitis is a rare progressive neurological disorder. Paraneoplastic limbic 
encephalitis is an example of a chronic autoimmune condition that produces depression, 
memory loss, remote malignancy and seizures. While symptoms progress with time, the 
diagnosis is usually based on finding of a malignancy (lung cancer) in 80% of cases (Stone 
and Hawkins 2007). In immunosuppressed patients (HIV, organ transplantation, severe 
combined immunodeficiency (SCID), hyperimmunoglobulinemia M, Multiple Sclerosis 
(MS) and Crohn’s) reactivation of human polyomavirus JC enhance viral replication 
resulting in cytolytic destruction of oligodendroglia, leading to a clinical manifestation 
known as Progressive Multifocal Leukoencephalopathy (PML) (Khalili and White 2006; 
Maginnis and Atwood 2009). In such case the disease is characterised by multiple foci of 
demyelination of cerebral white matter. Symptoms include ataxia, hemiplegia, paralysis, 
vision loss and speech impairment. Diagnosis of PML is based on viral DNA detection in 
CSF and/or detecting white matter lesions by magnetic resolution imaging (MRI) 
(Maginnis and Atwood 2009).       
 
 
1.3 Herpes Viruses    
 
As mentioned above a number of different viruses can cause encephalitis, however the 
Herpesviridae family contains the most important causes of viral encephalitis. Herpes 
simplex encephalitis (HSE) and acute disseminated encephalomyelitis (ADEM) are the 
most important neurological disorders caused by herpes simplex (HSV) and varicella 
zoster viruses (VZV) respectively. These viruses are closely related, however they can 
cause different forms of encephalitis, this project therefore focuses on these viruses and 
their neurological complications.   
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1.3.1 Introduction and History 
 
The name herpes comes from the ancient Greek ' ρπης' meaning to creep or crawl, and 
refers to the spreading nature of the infectious lesions typically caused by this virus. A 
medical historian (Celsus) was the first to describe an actual herpetic lesion: he stated that 
they were initially rounded but with time became diffused "as a serpent" to form a belt 
(Roizman et al., 2007). The association between continuous eruptions and fever was first 
noted by the Roman scholar Herodotus; he noted a relationship between lip vesicles, mouth 
ulcers and fever, and defined the above association as “herpes febrilis”. This was later 
elaborated on by Galen who found that HSV recurrences developed at the same original 
anatomical site. From these early descriptions and up until the 17th Century, the term 
herpes was used to describe many skin lesions. In the 18th Century smallpox and varicella 
were distinguished as two individual diseases by Heberden (1767), and in 1892 it was 
suggested that varicella and herpes zoster had an infectious aetiology and were closely 
related (Cohen et al., 2007b).  In 1893 Vidal recognized the route of transmission of HSV 
from one individual to another and by the 19th Century the vesicular nature of lesions 
associated with herpetic infections was well recognised (Roizman et al., 2007). As the 20th 
century progressed and electron microscopy become available, Almeida et al. (1962) 
demonstrated that the virions found in varicella and herpes zoster vesicle fluid were 
identical.  In 1984, Straus et al. compared VZV DNA from an immunocompromised 
patient with varicella to DNA taken from the same patient during a later episode of herpes 
zoster, using restriction endonucleases, and showed that herpes zoster resulted from 
reactivation of the varicella virus (Straus et al., 1984). 
By the beginning of the 20th Century the infectious nature of HSV was unequivocally 
recognised by Lowenstein (Roizaman et al., 2007). He inoculated a rabbit cornea with 
fluids obtained from lesions of HSV keratitis and from vesicles of HSV labialis. He found 
that by using these fluids he was able to produce lesions similar in nature to those found in 
the human. Furthermore, vesicle fluid from patients with herpes zoster failed to produce 
similar lesions in the rabbit eye model.  Advances in viral culture allowed the virus to be 
propagated in a variety of laboratory animals, and led to the understanding that HSV could 
infect not only the eye, but other sites in the human body such as the skin and the CNS 
(Whitley and Roiza man, 2001). In the 1930s, Andrews and Carmichael detected 
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neutralizing antibody to HSV in serum of patients suffering from herpetic lesions 
(Roizman et al., 2007). They noted that some of these patients later developed fresh labial 
lesions; however these lesions were typically less severe than the earlier ones. It was 
believed that HSV could apparently occur in the presence of existing humoral immunity 
resulting in the recognition of an important biologic property of HSV: the ability to 
establish a latent infection and subsequently reactivate from latent infection. In 1968 
antigenic and biologic differences between HSV types were demonstrated by Nahmias and 
Dowdle who detected the antigenic differences between herpes simplex type 1 (HSV-1) 
and herpes simplex type 2 (HSV-2) (Nahmias and Dowdle 1968). In addition they also 
established the principle that HSV-1 is more frequently associated with non-genital 
infection, "above the belt", whilst HSV-2 is predominantly responsible for genital infection 
“below the belt".  
  
 
1.3.2 Classification 
 
The International Committee for the Taxonomy of Viruses (ICTV)  classifies members of 
the family Herpesviridae in the recently established order Herpesvirales, and into three 
subfamilies Alphaherpesvirinae (α), Betaherpesvirinae (β), and Gammaherpesvirinae (γ), 
mainly on the basis of their biologic and molecular properties (Davison et al., 2009). 
Members of each of the subfamilies are further classified into different genera on the basis 
of their genome organisation and deoxyribonucleic acid (DNA) sequence homology. To 
date, over 100 different herpes viruses have been recognised infecting a diverse range of 
both warm and cold-blooded species, however, only eight are known to infect humans 
(Table 1.1). Of these eight, 3 are members of the alpha herpesviruses (HSV-1, HSV-2 and 
VZV) and have a relatively broad host range, a short replication cycle (18-24 hours) which 
is cytolytic, producing a cytopathic effect (CPE) in cell cultures characterised by 
eosinophilic intranuclear inclusion bodies and multinucleated giant cells with subsequent 
cell death. The alphaherpes viruses establish latent infections primarily in sensory neurons. 
In contrast, the beta herpesviruses cytomegalovirus (CMV) and human herpes virus types 6 
and 7 (HHV-6 and HHV-7) have a longer reproductive cycle with restricted host range.  
Infected cells typically become enlarged and latency is maintained within lymphocytes and 
cells of the reticulo-endothelial system, kidney, secretory glands and other tissues. The 
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gamma herpesviruses; Epstein-Barr virus (EBV) and human herpes virus type 8 (HHV-8) 
also have a restricted host range (T or B lymphocytes) and latency is most commonly 
established in lymphoid tissue (Roizman et al., 2007).     
 
 
 
Table 1.1 The Classification of Human Herpesviruses 
 
Virus Abbreviation Genus Designation 
G + C 
content (mol 
%) 
Genome (bp) 
Herpes simplex 
virus type 1 HSV-1 α 1 
Human 
herpesvirus 1 67 152,261 
Herpes simplex 
virus type 2 HSV-2 α 1 
Human 
herpesvirus 2 69 154,746 
Varicella- zoster 
virus VZV α 2 
Human 
herpesvirus 3 46 124,884 
Epstein–Barr 
virus EBV γ 1 
Human 
herpesvirus 4 60 171,823 
Human 
cytomegalovirus HCMV β 1 
Human 
herpesvirus 5 57 230,283 
Human 
herpesvirus 6 HHV-6 β 2 
Human 
herpesvirus 6 43 
159,321 
161,573 
162,114 
Human 
herpesvirus 7 HHV-7 β 2 
Human 
herpesvirus 7 40 
144,861 
153,080 
Kaposi’s 
sarcoma-
associated 
herpesvirus 
(KSHV) 
HHV-8 γ 2 Human herpesvirus 8 54 ~140,500 
 
Adapted from Davison and Clements 2005. 
 
 
1.3.3 Viral Structure  
 
1.3.3.1 Herpesvirion 
 
The herpesvirus virion has characteristic architecture, and is composed of four distinct 
structural elements; a core containing a linear double-stranded DNA, an icosadeltahedral 
capsid surrounding the core, an amorphous asymmetric material surrounding the capsid 
called the tegument and an outer lipid bilayer envelope with viral glycoprotein spikes on 
its surface (Figure 1.1). Herpesviruses are relatively large in size, ranging from 120-
300nm, due to the varying thickness of the tegument, and contain more than 30 distinct 
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proteins designated as virion polypeptides (VP). These proteins include 8 capsid 
constituents, at least 20 tegument components and more than 11 proteins; mostly 
glycosylated, in the envelope (Roizman et al., 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Schematic representation of herpesvirus structure (Adapted from Novak and 
Peng 2005) 
 
 
 
1.3.3.2 Envelope  
 
The sensitivity of virions to lipid solvent and detergents indicates that the envelope of the 
herpesviruses contains lipids, presumably derived from patches of altered cellular 
membranes (Spear and Roizman 1972; Roizman et al., 2007). Electron microscopic 
analysis of virus particles has shown that the envelope has the typical trilaminar 
appearance of the host cell membrane, and it appears that herpesvirus acquires its envelope 
lipids from its host nuclear membrane, modified by the insertion of virus glycoprotein 
spikes (Cleator and Klapper 1995). Transmission electron microscopy (TEM) and 
monoclonal antibody studies, particularly immuno-gold labelling techniques, have been 
used to shows that herpesviruses have numerous protrusions of glycoprotein spikes, each 
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constructed from only one type of virus glycoprotein (Stannard et al., 1987). In a recent 
detailed study by Grunewald et al., 2003 using Electron cryomicroscopy (Cryo-EM), the 
number of spikes in the envelope of HSV-1 was shown to range from 595 to 758 with a 
mean of 659 per virion, with the average centre–to-centre spacing between 9-13 nm; 
however the glycoproteins were not evenly dispersed on the surface and some regions of 
the envelope were quite sparsely populated. The same study found that the length of spikes 
ranged from 10 to 25 nm, they were around 4 nm wide, and most were terminated in a 
globule approximately 6 nm across.  
 
 
1.3.3.2.1 Glycoproteins  
 
The envelope of herpes viruses encodes several types of glycoproteins and the glycoprotein 
composition of the spikes varies between species. Some are unique to a particular 
subfamily or virus; whilst others are conserved throughout the herpes virus family 
suggesting that these glycoproteins play an essential role in the infection cycle (Shin et al., 
2003).  HSV and VZV contain more than 30 distinct proteins; of these 11 (HSV) and 7 
(VZV) glycosylated glycoproteins are found on the virion envelope and are also exposed 
on the surface of the infected cells. These glycoproteins are first synthesised as non-
glycosylated nascent polypeptides and during transit through the Golgi apparatus undergo 
extensive post-translational modification. After trimming of some mannose residues and 
addition of high mannose oligosaccharides in the Golgi apparatus they form complex type 
oligosaccharides. Finally the processed, mature glycoproteins will be inserted in the 
nuclear or cellular membranes. The functions of these glycoproteins have been shown to 
include virus attachment, penetration, envelopment, egress and membrane fusion. They 
also act as major antigenic determinants for the cellular and humoral immune responses of 
the host (Avitabile et al., 1994; Roizman et al., 2007). 
 
 
1.3.3.2.2 HSV Glycoproteins 
 
The envelope of HSV contains 11 glycoproteins designated  as; (glycoprotein B (gB), 
glycoprotein C (gC), glycoprotein D (gD), glycoprotein E (gE), glycoprotein G (gG), 
glycoprotein H (gH), glycoprotein I (gI), glycoprotein K (gK), glycoprotein L (gL).  
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1.3.3.2.2.1 Glycoprotein B (gB) 
 
The gene encoding glycoprotein B is found within the unique sequences of the long 
component of UL27, it is known as VP7, and consists of a 904 amino acids (aa) sequence, 
with an molecular weight of 110 kd. Glycoprotein B is an essential protein containing two 
or three transmembrane segments, and is required for viral entry, cell-cell fusion and viral 
growth in cell culture (Roizman et al., 2007). Glycoprotein B is conserved in all the human 
herpesviruses, and it is an important target for both humoral and cell-mediated immune 
responses (Manservigi el al. 1990). Studies have shown that mutant viruses containing a 
temperature sensitive (ts) mutation in the gB gene fail to synthesise mature gB and cannot 
produce infectious virions at non-permissive temperatures (Little et al 1981). Ali and 
Forghani (1990) studied the immune response to gB and found that nearly all human sera 
reacted with gB meaning that HSV infection in humans induces gB-reactive antibodies that 
are directed against the total molecule. Animal studies by Ghiasi et al., (1994) found also 
that mice inoculated with recombinant gB expressed in a baculovirus system were 
protected from lethal challenge with HSV-1. 
 
 
1.3.3.2.2.2 Glycoprotein C (gC) 
 
The gene encoding glycoprotein C is found within the unique sequences of the long 
component UL44, it is known as VP7.5, and consists of 511aa sequences. This 
glycoprotein is a non-essential protein and is heavily N- and O-glycosylated (Roizman et 
al., 2007). It plays a role in the interaction with complement component C3b to stop 
complement activation, and has also been reported to play a role in the adsorption of the 
virus to the cell surface by binding to either glycosaminoglycans of the heparan sulphate or 
chondroitin sulphate (Lubinski et al., 1999; Roizman et al., 2007).  Experimental studies 
found that gC is non essential because viruses with mutations in this gene can grow 
normally in tissue culture. In vitro experiments using monoclonal antibodies raised against 
gC show that it can neutralise HSV-1 and protect animals against lethal HSV-1 challenge 
(Balachandran et al., 1982). Animal studies also showed that antibodies raised in mice 
vaccinated with a recombinant gC are protective against lethal challenge with HSV-1 
(Ghiasi et al., 1992).  
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1.3.3.2.2.3 Glycoprotein D (gD) 
 
The gene encoding glycoprotein D is found within the unique sequences of the short 
component US6, it is known as VP17/18 and consists of a 394 aa residue. This 
glycoprotein is the strongest inducer of neutralizing antibodies. gD is essential for 
infectivity and for penetration of the virus into the cell. Glycoprotein D interacts with 
different cellular receptors such as HveA, nectin 1, and a modified heparan sulphate 
(Ankel et al 1998; Roizman et al., 2007). Glycoprotein D in HSV-1 and HSV-2 is 
essentially identical making it a type common antigen for herpes simplex viruses. 
Serological studies have shown gD is an important target for both humoral and cell-
mediated immune responses to HSV infection, and antibody against gD appears earlier 
than those directed against other glycoproteins (Ikoma et al., 2002). Ankel et al., 1998 also 
found that in insect cells (Sf9) expressing individual HSV-1 glycoproteins (gB, gC, gD, 
gE, gG) on their surface, gD was the most potent IFN-α inducer in the viral envelope. 
Furthermore, animal studies showed that mice vaccinated with recombinant gD were 
protected against lethal challenge, and that gD induced some killer cell activity (Ghiasi et 
al., 1999). 
 
 
1.3.3.2.2.4 Glycoprotein e (gE) and Glycoprotein I (gI) 
 
The genes encoding glycoprotein E and Glycoprotein I are found within the unique 
sequences of the short component of the herpesvirus genome. The protein encoded by US8 
and US7 are of 550 and 390 aa sequences respectively. Glycoprotein E and gI form a 
heterodimer and can bind to the Fc portion of immunoglobulin (Bell et al., 1990). This 
binding may help HSV-1 to escape from immune cytolysis by blocking or altering the 
function of Fc. Animals studies have shown that mice vaccinated with recombinant gE 
produce low levels of complement-dependent neutralizing antibody. However Ghiasi et al., 
(1992) showed that mice vaccinated with gE developed a delayed type hypersensitivity 
response to HSV-1 and that mice systemically vaccinated with gE were protected from 
lethal intraperitoneal and lethal ocular HSV-1 challenge.  
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1.3.3.2.2.5 Glycoprotein G (gG) 
 
The gene encoding glycoprotein G is found within the unique sequences of the short 
component US4, gG consists of a 238 aa residue in HSV-1, and 699 aa in HSV-2 (Ashley 
et al., 1999). gG-1 and gG-2 have similar sequences at their amino terminal, especially a 
segment of 153 amino acids on their carboxyl termini. However, the N-terminal part of the 
cell-associated gG-2 is unique for HSV-2. Therefore, it was suggested as a prototype 
antigen for detection of type-specific antibodies against HSV-2 (Ashley et al., 1998). 
Sequencing studies have determined the size of gG in HSV-1 as being approximately 25 
kd, and during infection the polypeptide is partially glycosylated to give an apparent 
molecular weight of 60 kd, whereas for HSV-2 the fully glycosylated form appears to be 
92kd (Parkes et al., 1991). This glycoprotein has been widely used in serological assays as 
a type-specific antigen for serological studies in individuals infected with HSV-1 and/or 
HSV-2 (Ashley et al., 1998). 
 
 
1.3.3.2.2.6 Glycoprotein H (gH) and Glycoprotein L (gL) 
 
The genes encoding glycoprotein H and glycoprotein L are found within the unique 
sequences of the long component UL22 and UL1 of the herpes simplex virus genome. The 
proteins are 535 aa and 224 aa respectively. Both glycoproteins are conserved in all human 
herpesviruses: gH is an essential protein and it seems to play a role in infectivity of the 
virus and cell to cell fusion (Roizman et al., 2007). Studies have shown that viruses which 
lack gH can egress from the cell but are not infectious. Antibody to gH can neutralize virus 
infection and prevent cell-cell spread (Gompels and Minson 1989; Blacklaws et al., 1990). 
On the other hand, inoculation of experimental animals with recombinant gH does not 
protect against subsequent viral infection (Gompels et al., 1991). Out of the 11 
glycoproteins in the HSV-1 envelope, gH and gL alone are present as a hetero-dimer in the 
viral envelope and plasma membranes of the infected cells. The complex has an essential 
function in viral fusion and in the cell-to-cell spread of virions (Forrester et al., 1992). The 
formation of a hetero-dimer is essential for correct folding and processing of gH. 
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1.3.3.2.2.7 Glycoprotein K (gK) and Glycoprotein M (gM) 
 
The genes encoding glycoprotein K and glycoprotein M are found within the unique 
sequences of the long component UL53 and UL10. Glycoprotein K and glycoprotein M 
consist of 338 and 473aa sequences respectively. Sequence studies suggested that 
glycoprotein K contains three or four transmembrane segments and is not an essential 
protein but is required to prevent an infected cell fusing with adjacent cells (Avitabile et 
al., 2003). In contrast gM contains six to eight transmembrane segments, and whilst it is 
not a protein essential for the replication of virus in cell culture it is required for efficient 
capsid envelopment and exocytosis.  
 
 
 
1.3.3.2.2.8 Glycoprotein J (gJ) 
 
Glycoprotein J gene is found within the unique sequences of the short component US5, and 
consists of 92 aa protein.  Glycoprotein J is a minor non essential glycoprotein and is 
reported to block apoptosis during infection of cells with gD (Zhou et al., 2000).  
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Table 1.2 Characteristics of Individual HSV Glycoproteins 
 
 
Antigen Gene Encoding 
Molecular 
Weight   Function 
Required 
for 
Infectivity 
Glycoprotein 
B UL 27 110 Kd 
Required for viral entry, cell 
fusion, and  needed for  viral 
growth in cell culture  
Essential 
Glycoprotein 
C UL 44 130 Kd 
Binds to the C3b component of 
complement, may play a role in 
blocking host response to 
infection. If  deleted it appears to 
enhance viral pathogenicity 
Non essential 
Glycoprotein 
D US 6 60 Kd 
Related to viral infectivity 
The most potent inducer of 
neutralizing antibodies 
Essential 
Glycoprotein 
E US 8 80 Kd 
Forms complex with gI binds to 
the Fc portion of IgG thus it  may 
help virus infected cells to escape 
from immune cytolysis  
Non essential 
Glycoprotein 
G US 4 
HSV-1 25 Kd 
HSV-2 60 Kd 
Antigen specific to herpes simplex 
virus type eg. HSV-1 gG-1, HSV-
2 – gG-2. 
Non essential 
Glycoprotein I US 7 70 Kd Thought to be involved with gE at the Fc receptor  Non essential 
Glycoprotein 
H UL 22 110 Kd 
Forms a complex with gL, 
required for transport of both 
proteins to plasma membrane, 
attachment, penetration, egress     
envelopment, membrane fusion 
and cell-to-cell spread. 
Essential 
Glycoprotein 
L UL 1  
Forms a complex with gH (see 
above) required for entry 
mediated by gH and fusion.  
Essential 
Glycoprotein J US 5  Minor glycoprotein reported to block apoptosis. Non essential 
Glycoprotein 
K UL 53 40 Kd 
Required for efficient viral 
exocytosis; contains syn-locus but 
not found in plasma membrane.  
Non essential 
Glycoprotein 
M UL 10 53 to 63 Kd 
Myristoylated protein; required 
for efficient capsid envelopment 
and exocytosis. 
Non essential 
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1.3.3.2.3 VZV Glycoproteins 
 
As for HSV, the VZV genome encodes 7 glycoproteins termed as gB, gC, gE, gH, gI, gL 
and gK.  
 
1.3.3.2.3.1 Glycoprotein B (gB) 
 
Glycoprotein B is the second most abundant glycoprotein in the VZV envelope; it is 
encoded by a unique sequence of the short component ORF 31. VZV gB shares 49% 
amino acid similarity with HSV-1 gB (Cohen et al., 2007). Therefore, antibodies (either 
polyclonal or monoclonal) to HSV-1 gB can detect both HSV-1 and VZV gB. Because of 
its homology with HSV-1, gB is suggested to be important for VZV entry into the host 
cell.  gB appears in infected cells as two polypeptides bound by disulfide residues. Under 
non-reducing conditions gB appears to have a molecular weight of a 140 Kd. In contrast, 
under reducing conditions it resolves as two proteins with a molecular weight of 60 and 70 
Kd. Two tyrosine-based motifs can be found in its cytoplasmic domain these are needed 
for endocytosis in the Golgi network.  It also contains N and O-linked sugars and is 
sialylated, sulphated and palmitylated (Cohen et al., 2007).      
 
 
1.3.3.2.3.2 Glycoprotein C (gC) 
 
As for VZV gB, VZV gC has 34% homology with HSV-1 gC, and is encoded by the 
unique sequences of the short component ORF 14. Due to its similarity with HSV-1 gC it 
is believed that gC has a role in virus entry. Glycoprotein C contains N-linked sugars, and 
because there are several strains of VZV, gC can range in size from 80 to 170 kd (Cohen et 
al., 2007). Due to this variation the amount of gC found on the surface of the infected cells 
varies depending on the virus strain. gC is nonessential for viral growth in cell culture, 
because mutant strains lacking gC can replicate efficiently in cell culture. However animal 
studies show that gC deficient strain cannot replicate in foetal human skin implanted in 
Severe Combined Immunodeficiency Disease (SCID) mice (Moffat et al., 1998).  
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1.3.3.2.3.3 Glycoprotein E (gE) 
 
Glycoprotein E is a typical type I transmembrane glycoprotein and it is known as the most 
abundant VZV glycoprotein found on the surface of infected cells, with an apparent 
molecular weight of 85 to 100 kd (Grose 1990; Cohen et al., 2007). The gene encoding gE 
is found within the unique sequences of the short component ORF68. Several studies have 
showed that gE has an essential role in VZV infectivity, is required for virus replication, 
syncytium formation, and is an integral part of VZV fusion machinery (Mo et al., 2002; 
Cole et al., 2003; Berarducci et al., 2006). Glycoprotein E is highly modified by N-linked 
and O-linked glycosylation, sialylation and sulphation. Antibodies to VZV gE can 
neutralize virus infectivity. During viral infection, gE forms a protein complex with gI (Mo 
et al., 2002). Studies have shown that on the surface of infected cells the gE-gI complex 
can function as a virus-encoded Fc receptor for nonimmune IgG (Litwin et al., 1992).  
 
 
1.3.3.2.3.4 Glycoprotein I (gI) 
 
The gene encoding glycoprotein I is found within the unique sequences of the short 
component ORF67. Glycoprotein I is translated as a 58 to 62 kd, protein, contains N- and 
O-linked sugars and is part of the heterodimeric gE-gI Fc receptor (Roizman et al., 2007). 
Glycoprotein I is not essential for virus replication in human cultured cells. However it is 
required for replication in Vero cells, human skin and T-cell xenografts in SCID mice. It is 
required for normal maturation of gE and suitable distribution of gE on the cell surface. 
The gE and gI complex can be found in virus-infected cultures and in vesicular lesions in 
patients suffering from varicella and zoster. Both gE and gI undergo endocytosis from the 
cell membrane however the gE-gI complex undergoes endocytosis more efficiently than 
either protein alone (Olson and Grose 1998). 
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1.3.3.2.3.5 Glycoprotein H (gH) 
 
Glycoprotein H is a product of the unique sequences of the short component ORF68. It 
appears as a 118 kd protein and contains N-linked but not O-linked sugars (Roizman et al., 
2007). gH is highly conserved among herpes viruses and is known to be  the third most 
abundant glycoprotein among VZV glycoproteins. It requires gL to be processed in the 
Golgi network in order to be transported to the cell surface (Maresova et al., 2000). It 
contains a tyrosine-based motif (YNKI) within the short cytoplasmic tail that mediates 
clathrin-dependent endocytosis in the infected cells (Cohen et al., 2007). This results in 
reduced cell surface expression and decreased cell-to-cell fusion. Monoclonal antibody 
studies found that gH plays a role in virus entry, cell-to-cell spread and egress of the virus 
from infected cells (Rodriquez et al., 1993).  
 
 
1.3.3.2.3.6 Glycoprotein L (gL) 
 
The gene encoding glycoprotein L is found within the unique sequences of the long 
component ORF60. gL appears as a 20 kd and is thought to contain N-linked sugars. It 
forms a complex with gH. In contrast with gH, gL does not require gH for maturation, 
therefore it is fully processed in the Golgi network in the absence of gH (Cohen et al., 
2007). Glycoprotein L accumulates in the cytoplasm but not on the surface of the 
transfected cells when it is expressed alone or with gH (Duus and Grose, 1996). Expression 
of both gL and gH together leads to syncytia formation, which does not happen if each 
protein is expressed alone.   
 
 
1.3.3.2.3.7 Glycoprotein K (gK) 
 
The gene encoding glycoprotein K is found within the unique sequences of the short 
component ORF5. Glycoprotein K appears as a 40 kd protein glycosylated with N-linked 
sugars and appear to be required for viral replication (Mo et al., 1999). In wild type VZV 
virus, overexpression of gK leads to inhibition of syncytia formation.   
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Table 1.3 Characteristics of Individual VZV Glycoproteins 
 
Antigen Gene Encoding 
Molecular 
Weight   Function 
Required 
for 
Infectivity 
Glycoprotein 
B ORF 31 140 Kd 
The second most abundant 
glycoprotein, required for 
virus entry   
Essential 
Glycoprotein 
C ORF14 80-170 Kd 
virus entry Non 
essential 
Glycoprotein 
E ORF 68 85-100 Kd 
The most abundant VZV 
glycoprotein, it is required 
for virus infectivity, 
replication and syncytium 
formation. 
Essential 
Glycoprotein 
H ORF 37 110 Kd 
The third most abundant 
glycoprotein, required for 
virus entry, cell-to-cell 
spread and egress. 
Essential 
Glycoprotein I ORF 67 58-62 Kd Required for normal maturation of gE 
Non 
essential 
Glycoprotein 
L ORF 60 20 Kd 
Require for gH maturation Essential 
Glycoprotein 
K ORF  5 40 Kd 
Required for viral 
replication 
Non 
essential 
 
 
 
1.3.3.3 Tegument 
 
The tegument is the electron dense material located between the capsid and the envelope; 
it occupies about two-thirds of the volume enclosed within the virion membrane. It lacks 
distinctive features when viewed in thin section, however it appears to be fibrous on 
negative staining (Roizman et al., 2007). The thickness of the tegument is variable 
depending on the location of the virion within the infected cell. Thus, viral particles found 
within the cytoplasmic vacuoles seem to have thicker tegument than those found within 
the perinuclear space. However it appears that the virus, rather than the infected cell, 
controls this variation (Roizman et al., 2007). The tegument serves as a delivery 
compartment for proteins that are needed early in infection. In HSV it contains at least 20 
viral proteins, the function of only some of which are known e.g. VP16 virion 
transactivator protein, virion host shut-off (VHS) protein, VP 1-2 (may be responsible for 
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releasing DNA at the nuclear pore during viral entry), VP22 (confers the ability of spread 
from cell to cell) (Vittone et al., 2005; Roizman et al., 2007). 
  
 
1.3.3.4 Capsid  
 
All members of the Herpesviridae family have an icosahedral capsid, and 
alphaherpesviruses have a diameter ranging from 125 to 130 nm and are composed of 162 
capsomers. Cryo-EM Studies found that the outer shell of the capsid is composed of five 
proteins, VP5 (149 kd), VP26 (12kd), VP23 (34 kd), VP19C (50kd) and UL6. The VP5 
protein is the major capsid protein and forms the structural subunits of the capsomers 
(Roizman et al., 2007). For herpes simplex viruses Cryo-EM studies found that the HSV 
capsid is composed of an outer and intermediate layer arranged in a T= 16 symmetry and 
T= 4 lattice respectively. The symmetric unit consists of 1 penton subunit, 15 hexon 
subunits and 51/3 triplexes. 
 
 
1.3.3.5 Genome   
 
The genomes of herpesviruses are single linear double stranded DNA genomes (ranging 
from 124-230 kb in length) which encodes at least 70 to 74 genes respectively (Kemble et 
al., 2000; Zerboni et al., 2005; Cohen et al., 2007).  There are two covalently linked 
components, designated as long (L) and short (S) sequences. Each component consists of 
unique sequences bracketed by inverted repeats (Sheldrick and Berthelot, 1975; 
Wadsworth et al., 1975). The genome organisation is similar among all herpesviruses, 
however the genome sequence varies in the specific proteins that are encoded and the 
percentage of G+C; HSV-1 has 67%, HSV-2 69% and VZV 46% (Roizman and Whitley 
1993). In general the sequence arrangement of herpesviruses DNA is characterised by the 
presence of a reiterated terminal sequence of greater than 100 base pairs in length. Based 
on the format of this sequence the herpesviruses were placed into six groups from A to F; 
HSV-1 and HSV-2 are in group E whilst VZV is in group D (Pellett and Roizman 2007).       
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1.3.3.6 Replication  
 
The replication of herpesviruses is initiated by the interaction between viral glycoproteins 
and cell surface receptors. Replication of Herpesviridae has been most intensively studied 
with HSV-1, however it is basically the same for all herpesviruses. Entry of HSV into cells 
depends upon interaction of gB, gC, gD and gH/gL glycoproteins with multiple cellular 
receptors, resulting in fusion of the envelope with the cell membrane. It has been reported 
that initial attachment of HSV with host cell is mediated by association with gC and/or gB, 
by binding to glycosaminoglycans (GAG) of heparan sulphate. While this interaction 
significantly enhances the efficiency of HSV infection it is not essential, at least not for the 
infection of tissue culture, since gC¯mutant virus can grow normally (Herold et al., 1991; 
Spear 2004). Glycoprotein D together with other glycoproteins (gB, gH and gL) enables 
the fusion of the envelope with the plasma membrane (Bender et al., 2005). Upon 
attachment, the HSV envelope fuses with the plasma membrane and the nucleocapsid and 
the tegument proteins are released into the cytoplasm.  
 
Entry of the nucleocapsid and the tegument protein into the cytoplasm results in absolute 
cessation of cellular metabolism and division. Most of the tegument proteins contribute to 
the early shut-off of cell function, however two of these are particularly important; α-trans-
induction factor (α-TIF) and virion host shut-off protein (VHS) (Roizman, 2007). The α-
TIF acts to initiate viral DNA transcription, whilst VHS destabilises and degrades host cell 
mRNA and subsequently causes early shut-off of cellular metabolism and protein 
synthesis. Soon after the VHS destabilises and degrades viral immediate-early (α-), early 
beta (β-) and late gamma (γ-) mRNA, leading to the sequential regulation of viral gene 
expression. The nucleocapsid is transported to the nuclear pores, the capsid starts to 
degrade, and the viral DNA is released into the host nucleus, where it is immediately 
circularised (Whitley et al., 1998). In order to start transcription the circularised viral DNA 
binds to a cellular protein known as OCT-1 via a cis-acting site. α-TIF binds a cellular 
factor C1 and this in turn binds to the OCT-1-DNA complex which acts in trans to induce 
transcription of the α or early, gene products. Initially six α-proteins are synthesised; five 
are regulatory proteins whereas the sixth hinders the presentation of antigenic peptides on 
the infected cell surface. These proteins regulate viral genes and their expression is 
essential for the expression of early β and late γ genes. After production of alpha proteins, 
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mRNA encoding beta gene products appear 5-7 hours post-infection. The early β gene 
products are composed of several enzymes and DNA-binding proteins involved in DNA 
replication and nucleic acid metabolism (e.g. ribonucleotide reductase, thymidine kinase, 
thymidylate synthase, alkaline DNase, DNA polymerase, helicase).  
 
Viral DNA is replicated by a rolling circle mechanism yielding head-to-tail concatemers. 
During virion assembly these concatemers are cleaved into monomers. The production of β 
proteins induces transcription of γ genes and the resulting late γ mRNA is translated into γ 
or structural proteins involved in the assembly of the progeny virion. After synthesis of 
capsid proteins, capsid assembly occurs in the cell nucleus in several stages. Viral DNA is 
cleaved and packaged into nucleocapsids and then associates with patches of nuclear 
membrane which have been modified by insertion of viral glycoproteins, on the inside of 
which tegument proteins have aggregated. Mature nucleocapsids bud through the nuclear 
membrane and acquire envelope and tegument. The enveloped virion is then processed by 
transit through the Golgi, de-enveloped and then re-enveloped in the transGolgi network. 
Finally, the re-enveloped virions are transported in vesicles to the plasma membrane where 
they are released into the extracellular space (Roizman 2007). The entire replication cycle 
takes about 18 to 24 hours and the process leads to cytolysis. 
 
 
1.3.3.7 Latency 
 
Most humans become infected with one or more of the herpesviruses during childhood, 
and after clearance of acute infection, herpesviruses enter a dormant state known as 
latency. Each virus has developed a different mechanism by which it can remain latent 
within the infected cell, thus evading host cell immune defences. Herpes simplex types 1 
and 2 and VZV establish latency in the dorsal root ganglia. HSV Infection starts by 
intimate contact with an individual who is shedding the virus. Virus enters the host via a 
mucosal surface (oral or genital) or breaks within the skin. Following entry, the virus 
replicates in the epithelial cells and establishes a productive infection that spreads to the 
surrounding tissue, leading to the virus entering the nerve endings. It then travels to the 
nuclei of sensory ganglia by retrograde movement where it establishes latency (Figure 1.2).  
During latency, virus replication occurs only in a minute number of sensory neurons with 
the virus remaining in an episomal form. Reactivation of the virus occurs in some of the 
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infected neurons due to a number of stimuli such as stress, fever, exposure to ultraviolet 
light and immunosuppression (Roizman et al., 2007).  
 
Viral gene expression is essential for reactivation; during latency productive viral genes are 
transcriptionally inactive, the cytopathic effects of productive infection are therefore absent 
and only the latency associated transcripts (LAT) are expressed (Kang et al., 2003). Once 
reactivation occurs, the virus travels back along the nerve (antegrade transport) to the nerve 
endings, at the initial site of infection, and infects the mucosal surface and the surrounding 
tissue. Reactivation, when it occurs, can be asymptomatic in some patients, whereas in 
others the characteristic blisters of HSV infection can be seen. By contrast VZV latency is 
less well characterised: following primary infection (chickenpox), virus becomes latent in 
sensory nerve ganglia, the virus may then reach the ganglia either through haematogenous 
spread or by centripetal neural transport.  Unlike HSV, VZV has a unique mode of latency 
where it has been demonstrated within the ganglia in both neural and non-neural cells, and 
multiple genes are transcribed during latency. Furthermore, reactivation of VZV leads to 
zoster (shingles) where the herpetic lesions are limited to the path of the infected nerve.         
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 The mechanism by which HSV infects epidermal tissue innervated by sensory 
neurons. Productive infection follows infection of the peripheral tissue, however entry of 
the virus into neurons leads to latent infection in a significant proportion of individuals. 
Taken from http://darwin.bio.uci.edu/~faculty/wagner/hsv7f.html (Accessed 16/7/2010). 
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1.3.4 Herpesvirus Infection 
 
HSV has been associated with infection of oral mucous membranes (gingivostomatitis, 
herpes labialis, and pharyngitis), genital membranes (genital herpes), neonatal and 
congenital infection, eczema herpeticum (in patients with underlying atopic dermatitis, 
Darier’s disease or Sezary syndrome), visceral HSV infection (in immunocompromised 
hosts), encephalitis, myelitis, meningitis, and ocular complications (Remeijer et al., 2004; 
Whitley 2004; Kimberlin 2005; Kimberlin and Whitley 2005). VZV has been associated 
with a number of clinical manifestations ranging from a mild illness such as chickenpox to 
potentially significant complications such as those involving the central nervous system 
(Koskiniemi et al., 2002; Frenos et al., 2007). 
 
 
1.3.4.1 HSV Infection 
 
1.3.4.1.1 Epidemiology 
 
Herpes simplex viruses are found throughout the world, and have been reported in 
developed and developing countries. Humans are the only reservoir, and no seasonal or 
gender variation has been observed. Both viruses are capable of causing a variety of 
clinical illnesses range from mild illness to sporadic, severe and life-threatening illness in 
all age groups. Transmission usually occurs from infected people, who excrete the virus 
symptomatically or asymptomatically, to a susceptible person during close personal 
contact. The mode of transmission differs between the viral types, and whilst different 
parts of the body are usually affected, there is considerable overlap between the 
epidemiology and clinical manifestations of the two viruses (Roizman et al., 2007). 
Infection with HSV-1 is usually acquired during early childhood and adolescence. It is 
estimated that 90% of the population become HSV-1 seropositive by the fourth decade of 
their lives (Smith and Robinson 2002; Weiss, 2004; Roizman et al., 2007). The 
transmission route of HSV-1 in younger age groups (< 5 years) appears to be from their 
mothers through kissing, whereas in older age (>15 years) the main route is from their 
infected partners. The prevalence of HSV-1 infection correlates with age, socioeconomic 
statues, race and geographical location (Nahmias et al., 1990; Rosenthal et al., 1997; 
Whitley et al., 1998). In less developed countries, approximately 33% of children (< 5 
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years) have serological evidence of HSV-1 infection, and this goes up to 70-80% by early 
adolescence (Whitley and Roizman 2001). In comparison, in the middle and upper classes 
of more developed countries, individuals become infected later; seroconversion appears in 
only about 20% of children by the age of 5 years, rising to 40-60% by the age of 24-40 
years (Whitley and Roizman 2001). In the United States, race affects acquisition of HSV-1 
the National Health and Nutritional Examination (NHANES) survey showed that more 
than 35% of African-American children and 18% of white children are HSV seropositive 
by age 5 (Roizman et al., 2007).  
 
The prevalence of HSV-1 between countries varies. In the UK, Vyse et al., (2000) found 
that the prevalence of HSV-1 antibodies in cohorts born in 1986-1987 increased from 34% 
to 41% compared to those born 1994-1995. In other countries such as Brazil, Estonia, 
India, Morocco and Sri Lanka, the prevalence of HSV-1 was found to vary by geographical 
site ranging from 78.5%-93.6% in adult males, to 75.5%-97.8% in adult females. In 
addition, in a recent study of the prevalence of HSV-1 and HSV-2 in European countries, 
Bulgaria and Czech Republic had the highest rate for HSV-1 83.9% and 80.6% 
respectively, whereas the lowest was found to be in Finland 52.4% (Pebody et al., 2004). 
Although various studies reported that HSV-1 seroprevalence increases significantly with 
age, in both sexes, in all countries, it is suggested that due to the improvement in 
socioeconomic status the epidemiology of HSV-1 has changed (Cowan et al., 2003). 
Nahmias et al (1990) reported that the prevalence of HSV-1 antibodies in Iceland has 
decreased from 80% to 74% between 1979 and 1985. More recently, in the UK, the 
prevalence of HSV-1 antibodies increased from 34% in those born in 1986-1987 to 41% in 
those born 1994-1995. Above the age of 15 years, the prevalence continued to increase 
(Vyse et al., 2000). In addition, the prevalence of HSV-1 antibodies in 10-14 years olds 
declined from 34% in 1986-1987 to 24% in 1994-1995 (Vyse et al., 2000). In the UK, 
during the early 1990s, 44% of blood donors and 59.5% of STD clinic attendees were 
HSV-1 seropositive (Cowan et al., 1996). In a large recent study by Pebody et al (2004), it 
was found that the median age of HSV-1 acquisition between European countries varied, 
ranging from 5-9 years in Bulgaria and Czech Republic in contrast to > 25 years in 
Finland, Netherlands and England and Wales.  
 
Historically HSV-2 is associated with genital infection, however recent studies have 
reported an increased number of genital and neonatal cases caused by HSV-1 (Looker and 
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Garnett 2005; Xu et al., 2006). In a study by Xu et al., (2006) to assess secular trends of 
HSV-1 and HSV-2 in the USA population using the 1988-1994 and 1999-2004 National 
Health and Nutritional Examination (NHANES) data, an increasing number of genital 
herpes cases caused by HSV-1 (1.8%) was found in the 1999-2004 data, in comparison 
with the 1988-1994 data (0.4%). Despite recent declines in HSV-1 genital infection, HSV-
2 was responsible for most genital lesions worldwide. A number of risk factors influence 
the acquisition of HSV-2 genital infection such as age, sex, tobacco use, education level, 
socioeconomic status, recreational drug use and number of lifetime sexual partners (Wald 
2004; Beydoun et al., 2010). Pebody et al., (2004), found that HSV-2 was widely 
distributed in the general population (>12 years) of European countries.  The prevalence of 
HSV-2 was found to be higher in women than men and it was higher in Bulgaria (23.9%) 
in comparison with 4.2%, 13.9%, 13.4%, 8.8% and 6% in England and Wales, Germany, 
Finland, Belgium and Netherlands respectively (Pebody et al., 2004). In USA the 
seroprevalence of HSV-2 was found to be 21.9% in age groups 12 years and older and it is 
higher in women (25.6%) than men (17.8%), especially among blacks (45.9%) rather than 
whites (Malkin 2004). In addition it is estimated that 30% to 65% of pregnant women in 
the USA are suffering from genital herpes (Corey et al., 2009).   
 
 
1.3.4.1.2 Pathogenesis 
 
Infection with HSV begins when the virus comes into contact with mucosal epithelium or 
damaged cutaneous epithelium and invades cells. HSV infection can occur at a variety of 
sites, however it is most commonly found in oropharyngeal and genital mucosa (Miller and 
Dummer, 2007). The first time an individual become infected with HSV of either type this 
infection is called a primary infection. Such primary infection occurs in a completely non-
immune person. However if an individual already exposed to HSV-1 becomes infected 
with HSV-2, or vice versa, then the infection is described as an initial infection. Following 
virus replication at the initial site of infection the virus is retrogradally transported via 
neurons to dorsal ganglia where it become latent. Since oral and genital infections are by 
far the most common sites of infection, the trigeminal (HSV-1) and sacral (HSV-2) ganglia 
are the usual sites of latent infection. Subsequently reactivation of the latent virus will lead 
to another round of infection and this is called recurrent infection (Roizman et al., 2007). It 
is also possible for an individual to be re-infected with his own strain of virus but at 
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another site, which is described as an endogenous re-infection, or if it is a different strain 
as an exogenous re-infection. Primary or recurrent HSV infection will lead to cellular death 
due to the cytolytic activity of viral replication and as a result of the inflammatory 
response. During HSV infection the immune system will eliminate viral replication by both 
specific and non-specific host defence mechanisms.  Non-specific responses are usually 
related to the production of α- and β interferons, leading to the stimulation of macrophages 
and natural killer cells (NK), followed by cytotoxic T lymphocyte response (Avgil and 
Ornoy 2006). Later in the course of infection the CD8+ T lymphocyte will be present and 2 
to 6 weeks later neutralising and antibody-dependent cytotoxic T-cells will be present, and 
will persist for life. However it does not prevent infection with HSV during a recurrent or 
re-infection stage. This explains why neonatal infection cannot be entirely avoided in the 
presence of maternal transplacental antibodies (Dwyer and Cunningham 1993).   
 
 
1.3.4.1.3 Clinical Manifestations 
 
1.3.4.1.3.1 Oropharyngeal Infection 
 
Primary oral infection with HSV-1 occurs early in life and can be asymptomatic, or present 
with a number of symptoms such as fever, sore throat, oedema, anorexia and malaise. 
Classically it presents as multiple painful sores on the tongue, nose, lips and on the skin 
around the mouth. Symptomatic infection in younger age groups can be painful the child 
usually feels sick and has a fever, headache and the intraoral lesions and associated 
swelling makes eating and drinking liquids extremely difficult (Roizman et al., 2007). 
Therefore, children may require hospitalisation for dehydration. In younger adults infection 
is usually associated with pharyngitis and mononucleosis like syndrome (Annunziato and 
Gershon 1996). The duration of the incubation period ranges from 2 to 12 days whilst the 
duration of the illness may take 2 to 3 weeks. During that time virus can be isolated from 
the mouth and saliva of asymptomatic children for as long as 23 days with an average of 7 
to 10 days (Amir et al., 1997). Recurrent infection with HSV-1 appears as a cluster of 
vesicles (3-5), which are milder, localized and/or as recurrent keratoconjunctivitis, and 
cause illness that is often of shorter duration than primary or initial infection. Recurrence 
may occur in the absence of any clinical symptoms (Collier et al., 2000). Recurrence is 
usually triggered by a variety of stimuli, including sunlight, physical trauma, stress, 
respiratory infections and hormonal changes, however it is not known whether these 
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stimuli act by a common pathway. Recurrent infection starts with pain, burning, tingling 
and itching at the site of the primary infection and/or in adjacent areas, due to either 
centrifugal spread via peripheral nerves or contiguous spread to new epithelial cells 
(Steiner 1996). This is followed by the appearance of blisters or vesicles approximately 
24h later at the mucocutaneous junction of the lip or inside the mouth. However, it can also 
be found in other sites innervated by the affected neurone such as the chin and inside the 
nose (Figure 1.3). Vesicles usually crust over within 72 h, although complete healing takes 
from 8 to 10 days. During this time the virus is shed from the vesicles and the amount of 
shedding decreases as the lesion crusts over (Liljeqvist et al., 2009). The frequency of 
recurrence varies between different individuals, however it may occur from 1 to 6 times 
per year and 5% to 10% of affected people will have more frequent recurrences (Miller et 
al., 2004).  
 
 
 
 
 
 
 
 
 
 
Figure 1.3 shows a characteristic appearance of a cold sore on the mucocutaneous junction 
of the upper lip in combination with considerable tissue oedema (arrows) and vesicle 
formation (A). In the other picture (B), a cold sore involving the mucocutaneous junction 
of the nostrils appears in its later stage where the ulcerated areas (arrows) have crusted 
over. Taken from http://www.healthcliniconline.co.uk/genitalherpesinfo.htm. (Accessed in 
16/7/2010). 
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1.3.4.1.3.2 Genital Infection 
 
Genital herpes is one of the most common sexually transmitted diseases (STDs). 
Historically, HSV-2 has been associated with genital infection, however recent reports 
suggest that a considerable and increasing number of genital isolates are of HSV-1, 
especially in developed countries (Lafferty et al., 2000; Scoular et al., 2002; Anzivino et 
al., 2009). Primary infection with HSV-2 may be asymptomatic or sub-clinical, however 
primary infection is usually more severe than recurrent infection (Whitley et al., 1998). 
Infection starts with the appearance of small raised macules and papules in the infected 
area, and then develops into diverse vesicles and papules that progress later to develop 
ulcers. Symptoms usually last for approximately 3 weeks and differ between the sexes; in 
females there is the appearance of painful lesions located in the vulva and cervix, 10-15% 
of patients may suffer from urinary retention syndrome, and up to 25% will develop 
aseptic meningitis, whereas in males lesions occur on the glans penis or penile shaft, 
however other parts of the body such as buttocks, thighs and perineum may also be 
affected (Roizman et al., 2007). In severe primary infection sacral radiculomyelitis can 
occur leading to urinary retention and meningoencephalitis (Roizman et al., 2007). The 
clinical course of primary genital herpes infections among patients with HSV-1 and HSV-2 
are similar, however there are differences in the epidemiology and natural history of the 
disease caused by the two viral subtypes (Kinghorn, 1994). Primary genital HSV-1 
infection is less likely than HSV-2 infection to result in recurrent disease (Benedetti et al., 
1994; Engelberg et al., 2003). Genital HSV-1 infections are also characterised by lower 
levels of asymptomatic shedding, lower transmission frequency to new partner, longer 
intervals between recurrence and lower clinical recurrence rates (Mindel et al., 1986; 
Ghani et al., 1996). Infection with HSV-1 in childhood may protect adults from most 
genital HSV-1 infections. The clinical course of HSV recurrent genital infection is usually 
mild with a duration from 7 to 10 days: in females it causes minor vulvar irritation, whilst 
in males it is characterised by the appearance of a limited number of vesicles (3-5) on the 
penis shaft (Roizman et al., 2007). However, although recurrent infection is mild it is 
problematic as it can occur as a frequent event. 
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1.3.4.1.3.3 Dermal Infection  
 
Skin infection with HSV can occur at any part of the body especially if there is disruption 
of the skin integrity. Such infections include herpes gladiatorium, herpetic whitlow, and 
eczema herpeticum. The latter is the most common skin infection in patients suffering from 
skin disorders such as atopic dermatitis. The most frequently affected part of the body is 
the head and neck (Wollenberg et al., 2003). Patients with eczema herpeticum present with 
dome shaped vesicles along with fever, malaise and lymphadenopathy. The herpetic 
lesions can be either localised like those of VZV with a dermatomal distribution or 
disseminated like those in Kaposi's varicella-like eruption (Roizman et al., 2007).  Herpes 
gladiatorium is a type of HSV infection mainly found in wrestlers, judo players or other 
athletes who are in very close skin contact with each other. Transmission occurs through 
abraded skin, and the most infected area is the upper parts of the body such as head, neck 
and face (Larkin 2004).  
 
Herpetic whitlow is a painful infection of the digits recognised since 1909 and caused by 
either HSV-1 or HSV-2.  It is mostly seen among health care professionals especially 
doctors and dentists who are accidently inoculated from an infected patient or 
contaminated instrument (Walker 2004; Bowling et al., 2005; Wu and Schwartz  2007). In 
such cases infected doctors or dentists who do not use medical gloves can cause HSV oral 
infection in their patients: it is therefore an occupational hazard among doctors and dentists 
(Cleator and Klapper, 1995). Gill et al., (1988) estimated the incidence of herpetic whitlow 
among health care professionals to be 2.4 cases per 100000 individuals per year. However 
this figure was decreased dramatically after implementation of universal precautions (Wu 
and Schwartz  2007). A similar infection can also be found in children who suck their 
thumbs. Walker et al., (1990) reported that 80% of children with digital HSV-1 infection 
had oral infection.  
 
 
1.3.4.1.3.4 Ophthalmic Infection  
 
HSV infection of the eye is less common than oral and genital infection, although it 
remains a predominant cause of unilateral infectious corneal blindness worldwide 
(Liesegang 2001). HSV-1 and HSV-2 can both cause ocular disease but HSV-1 is 
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responsible for more than 95% of herpes ocular infections especially beyond the newborn 
age. However recent studies have reported that HSV-2 ocular infection may be increasing 
(Pepose et al., 2006). Ocular infection can occur as result of primary infection or as 
endogenous re-infection caused by auto-inoculation from either primary or recurrent 
infection sites (Roizman et al., 2007). Recurrent ocular infection by HSV can cause several 
ocular pathologies such as blepharitis, conjunctivitis, epithelial keratitis and stromal 
keratitis. In neonates the most common manifestations of ocular infection are conjunctivitis 
and keratitis, however other infections such as neonatal herpes, fatal meningoencephalitis 
or disseminated disease (immunocompromised patient) have been reported (Leflore et al., 
2000; Whitley and Roizman 2001; Klemann 2003).   
 
 
1.3.4.1.3.5 Neonatal Infection  
 
Neonatal herpes is a devastating consequence of vertical transmission of HSV to neonates 
(Brady and Bernstein 2004). Infection occurs as a result of primary or recurrent genital 
infection with either HSV-1 or HSV-2, although the incidence of infection by each type 
varies with geographical region (Gaytant et al., 2002). Neonatal infection can occur 
transplacentally or during birth when the baby is exposed to maternal lesions or secretions 
during vaginal birth. Prenatally infection is thought to be responsible for 75 – 80% of cases 
(Brady and Bernstein 2004; Roizman et al., 2007). In contrast 10% of neonatal infection 
occurs after birth, through contact with an infected medical staff or family member who is 
shedding HSV-1 (Kimberlin 2005; Roizman et al., 2007). The clinical presentation of 
neonatal herpes is variable, but it is usually symptomatic and whilst the initial signs and 
symptoms are often nonspecific, it may be fatal. In such cases mortality and morbidity 
rates are high even with therapy (Rudnick et al., 2002). Based on the clinical presentation, 
neonatal herpes is divided into three categories: disseminated disease with visceral organ 
involvement, CNS disease and infection limited to skin, eyes and mucosa (SEM). SEM and 
CNS associated infection comprise about 45% and 30% respectively of most cases (Parker 
and Montrowl 2004; Corey and Wald 2009).  
 
In CNS infection, morbidity varies depending on the HSV subtype; neonates with CNS 
HSV-2 infection have higher morbidity rates than those infected with HSV-1. Even after 
treatment with Aciclovir, 50% of neonates will have developed moderate to severe 
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neurological abnormalities by one year of age (Corey and Wald 2009). Morbidity plus 
mortality rates with disseminated infection are higher than CNS infection, even with 
Aciclovir treatment the mortality rate is up to 30% (Kimberlin et al., 2001). Transmissions 
of HSV from mother to baby are affected by a number of factors including type of 
maternal infection (primary, recurrent), maternal antibody levels and type of delivery 
(vaginal or caesarean). Mothers suffering from primary HSV genital lesion near or at the 
time of delivery are at greater risk of transmitting HSV to their babies than those having 
recurrent infection, due to either the low level or the absence of protective maternal 
antibodies during delivery. The infant infection rates where the mother has a primary 
infection range from 30% to 50%, in comparison to less than 2% in those with recurrent 
infection. It is therefore recommended for pregnant women with acute genital herpes, near 
or at the time of the delivery, to have a Caesarean rather than vaginal delivery. 
Furthermore it is believed that infant infection rates are reduced in recurrent infection 
when the genital lesions are absent, due to the presence of protective, maternal 
transplacental antibodies. The incidence of neonatal herpes infection is estimated to be 1 in 
1,700 to 1 in 8,200 in USA, whereas it is 1.65 in 100,000 per annum in UK (Kimberlin and 
Whitley 2005; Corey and Wald 2009). 
 
 
1.3.4.1.3.6 Neurological Complications 
 
Various neurological complications have been associated with primary or recurrent HSV 
infection. These complications include meningitis, Bell’s palsy, myelitis, Alzheimer’s 
disease, intractable focal epilepsy, multiple sclerosis myelitis, radiculitis and encephalitis 
(Craig et al., 1973; Gantz et al., 1999; Furuta et al., 1998; Steiner et al., 2001; Mori et al., 
2004). Of these, encephalitis is the most serious and is usually caused by HSV-1. It is 
believed to be the most commonly diagnosed sporadic fatal encephalitis in developed and 
developing countries. A number of factors influence the incidence of HSV neurological 
infections including age and host immune status, however, generally such infection leads 
to significant morbidity and mortality even after treatment.  Meningitis can be caused by 
HSV and it is seen most commonly in patients suffering from primary genital infection, 
with a percentage incidence ranging from 30% in women to 13% in men (Philip, 2009). 
However it is an unusual manifestation during recurrent infection, as the patient should 
have presenting protective antibody (of either type). In addition as the prevalence of oral 
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HSV-1 in developed countries turns out to be decreasing in younger age groups, the 
incidence of meningitis is increasing (Philip  2009).  
 
1.3.4.1.3.7 Herpes Simplex Encephalitis (HSE) 
 
1.3.4.1.3.7.1 Pathogenesis 
 
Epidemiological studies show that 90% of the population have antibodies to HSV-1 by 
their 4th decade of life, and recurrent infection (usually cold sores) occurs in 38% of 
individuals. This indicates that HSV-1 is present in the population through recurrent 
infection (Roizman et al., 2007). Primary infections occur when the virus comes in contact 
with mucosal surfaces. Following binding of viral glycoproteins to cellular receptors, 
initial viral replication occurs at the site of infection. The virus is transported via neurons 
to the dorsal root ganglia (HSV-1) or sacral dorsal ganglia (HSV-2) where latency is 
established. Whether HSE is cause by primary infection or viral reactivation or both is 
uncertain, and the exact mechanism by which HSV enters the brain and causes disease is 
still undetermined. However several studies have suggested that the virus can reach the 
brain during (1) primary infection of the CNS; (2) viral reactivation in the trigeminal 
ganglion with subsequent virus spread via the trigeminal nerve to the temporal lobes; (3) 
in-situ reactivation of latent virus from CNS tissue (Steiner et al., 2007; Solomon et al., 
2007). There has also been suggestion that the virus can enter the brain via the olfactory 
route (Mori et al., 2004). This is supported by the observation of HSV virus particles in the 
olfactory tract of patients suffering from HSE. Animal studies showed that when the 
olfactory tract was infected with the virus, the virus was able to reach to the CNS (Steiner 
et al., 2007).  
  
A number of studies have set out to determine whether HSE is caused by primary infection 
or reactivation. Using restriction endonuclease typing methods on HSV isolates from HSE 
patients, it was found that in one-third of HSE cases the virus apparently enters the CNS 
via primary infection, whereas in two-thirds of cases the infection results from viral 
reactivation (Whitley and Gnann, 2002). Whatever the cause of infection whether primary 
or reactivated, infection is usually subacute with a  progressively deteriorating course with 
commonly recognised symptoms such as high fever, severe headache, nausea, personality 
changes, motor seizures and dysphasia. Raschilas et al., (2002) reported that the most 
common feature in 85 out of 93 HSE patents was disorientation (76%), speech 
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disturbances (59%) and behavioural changes (41%). Furthermore, seizures were noted in 
one third of the patients.  
 
1.3.4.1.3.7.2 Epidemiology 
 
As stated previously HSV-1 is principally associated with oral mucocutaneous lesions and 
HSV-2 with genital lesion. Similarly, HSV-1 is most commonly associated with HSE 
beyond the neonatal period, whereas HSV-2 is associated with neonatal meningitis and 
encephalitis. Over 90% of HSE cases in adults and children is caused by HSV-1, whereas 
the remaining cases (10%) are due to HSV-2 (Mori et al., 2004; Whitley, 2006; Granerod 
and Crowcroft 2007). In a population-based study in the UK, Davison et al., (2003), 
analysed hospital admissions reports for all adults and children less than 17 years of age 
from 1/4/1989 to 31/3/1998 using the World Health Organisation International 
Classification of Disease (ICD) codes, and found that 6414 of adults and children were 
hospitalised with a diagnosis of viral encephalitis. Out of these cases, 2574 were 
specifically diagnosed, 52% of cases had HSV infection. A similar result was found in 
USA, Khetsuriani et al., (2002) reported that HSV was found to be the causative agent of 
74% of all hospitalised viral encephalitis cases. Moreover in multicenter study by Lee et 
al., (2003) in Taiwan to determine the causative agent in patients suffering from acute 
encephalitis using PCR, the most frequently identified virus was found to be  HSV (52%), 
followed by VZV (18.6%). Furthermore in a study by Glaser et al., (2003) HSV-1 was also 
found to be the most frequently identified viral agent in the first 2.5 years of the California 
Encephalitis Project, followed by enterovirus and VZV virus.  
 
The incidence of acute encephalitis varies between different countries. In the UK Davison 
et al., (2003) estimated an annual rate of 1.5/100,000 in the general population and 
2.8/100,000 in children, with the highest incidence in infants under the age of one 
(8.7/100000). In the USA the incidence was found to be between 1 in 250,000 to 1 in 
500,000 individuals per year (Whitley 2006). One-third of cases are less than 20 years of 
age and on-half older than 50 years (Whitley & Gnann 2002). Rantalaiho et al., (2001) also 
studied the incidence of acute encephalitis in Finland and found that 3231 cases were 
reported during the years 1967 to 1991, with an average incidence of 1.4/100000 
adults/year, and the percentage of cases increased from 36% during 1967-1971 to 59% 
during 1987-1991. In the study, HSV was identified most often (16%), followed by VZV 
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(5%), although the leading cause of encephalitis in patients aged 65 years or older was 
VZV. Moreover, in a study using PCR to detect various viruses in the CSF of over 3000 
patients with encephalitis, VZV was the most frequently detected virus found in 29 % of 
patients this was followed by HSV (11%) (Koskiniemi  2001).  
 
 
 
1.3.4.2 VZV Infection 
 
1.3.4.2.1 Epidemiology 
 
Varicella–zoster virus has a worldwide geographic distribution and is the casual agent of 
two distinct viral syndromes; in unvaccinated populations, primary VZV infection presents 
as varicella (chickenpox), a contagious disease that occurs usually in early childhood, and 
can cause epidemics in non-vaccinated children or young adults in temperate and tropical 
climates (Katz et al., 2004; Liesegang 2008). Reactivation of the virus leads to another 
form of infection known as zoster (shingles) which occurs mainly in older adults. VZV is 
transmitted from an infected person to a susceptible person via inhalation of aerosol 
droplets from the infected person. Such transmission has been reported in susceptible 
family members, military institutions, hospitals and day care centres (Kelly et al., 1991; 
Sawyer et al., 1994; Wharton 1996; Liesegang 2008; Weaver 2009). The peak age for 
infection varies between 1-4 and 5-9 years in different countries.  Climate, and social 
factors can affect the acquisition of varicella; in most temperate climates the incidence of 
acquisition is more than 90% before adolescence, whereas in tropical climates the disease 
is acquired later in life and children are less susceptible than adults, due to the reduction of 
VZV transmission (Koskiniemi et al., 1997; Mandal et al., 1998; Lolekha et al., 2001). 
The seroepidemiology of varicella has changed dramatically since the introduction of 
vaccination, however in the UK where there is no routine population-wide vaccination 
schedule, 80% of the population has been infected by the age of 10 years. In a study by 
Brisson (2003), it was reported that average incidence rates of varicella and zoster between 
1991 and 2000 were 1.921 and 3.73 per 100,000 populations respectively with an 
equivalent hospitalisation rates. In other European countries, a larger study by Nardone et 
al., (2007) to determine the sero-epidemiology of VZV within 11 countries in the 
European region reported that 50% of children in all 11 countries become seropositive by 
the age of 5, whereas it is 86.0% to 97% in children older than 5 years of age and this 
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increases to 90% in adolescents. In the Netherlands, the seropositivity increases sharply 
with age, from 18.4% in younger age groups (0-1 years) to 48.9%, 59.0%, 75.7% and 
93.0% for 2, 3, 4 and 5 year olds respectively, reaching a rate that varies between 97.5% 
and 100% for older age groups (de Melker et al., 2006). In contrast, in the USA where the 
vaccine was introduced in 1995 the incidence has diminished and the average rate of 
mortality from varicella infection has reduced from 0.37 to less than 0.15 per 1 million of 
population (Nguyen et al., 2005; Liesegang 2008).  
 
A number of factors influence the reactivation of latent VZV including age, sex, ethnicity, 
genetic susceptibility, exogenous boosting of immunity from varicella contacts, underlying 
cell-mediated immune disorders, mechanical trauma, psychological stress, and 
immunotoxin exposure (Thomas and Hall 2004). Age plays an important role in the 
incidence and severity of herpes zoster (HZ); in those older than 60 years, 20 to 30% will 
develop HZ at some stage of their lives and this increases to 50% in those aged 85 years or 
more with an approximately 1% chance of more than one attack of zoster (Cooper 1987; 
Chapman et al., 2003; Oxman et al., 2005; Weaver 2009). In addition to age, the immune 
status also plays an important role in development of HZ, 15% of bone marrow transplant 
patients experience herpes zoster after transplantation. In addition the incidence in HIV 
patients is estimated to be 15 to 25 times higher than it is in the general population 
(Buchbinder et al., 1992).    
 
 
1.3.4.2.2 Pathogenesis 
 
Primary infection with VZV occurs as results of direct contact with vesicular fluid or 
through inhalation of respiratory droplets from an infected person. After adhering to the 
mucosal surface the virus may replicate in the epidermal cells or may also replicate in the 
reticulo-endothelial organs such as liver and spleen where it infects T cells. Although the 
exact mechanism is still unknown, animal experiments suggest that soon after entering the 
circulation, the virus is transported to skin by infected T cells (Arvin 2000; Cohen et al., 
2007). The process of spread to the skin is countered by a pronounced innate immune 
response mediated by epidermal cells. The process of spread form the initial site of 
infection takes 10 to 21 days, and is followed by the appearance of skin lesions throughout 
the body (Amlie-Lefond and Jubelt 2009). During this time viraemia continues as a result 
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of T cell trafficking along infected skin and visceral tissues and may continue even after 
the appearance of lesions. It is believed that infected T cells play an important role in 
primary infection, particularly tonsillar T cells that express skin homing markers (Cohen et 
al., 2007b). After primary infection, the virus becomes latent at the sensory ganglia and 
thoracic ganglia. Later in life and influenced by various factors may reactivate, and infect 
the skin in the dermatome innervated by the nerve, causing the manifestation known as 
shingles. In addition, in some cases reactivation may again lead to generalised infection 
especially in immunocompromised patients, resulting in granulomatous arteritis (Amlie-
Lefond and Jubelt 2009). In such cases there may be a number of complications including 
stroke, myelitis, meningitis and encephalitis. These complications may occur without the 
appearance of skin lesions.        
 
 
1.3.4.2.3 Clinical Manifestations  
   
1.3.4.2.3.1 Varicella (chickenpox)  
  
Varicella or chicken pox is the outcome of VZV primary infection. It generally develops in 
healthy children within 15 days (range 8-21 days) after exposure to the virus and is 
characterised by fever, headache; malaise or pharyngitis, followed by the development of 
generalised vesicular rash within the first 48 hours (Thomas and Liesegang 2008). Lesions 
are usually pruritic and appear as successive crops of vesicles within a 3 to 4 day period, 
usually appearing first on the face and scalp and then spreading to the trunk and later to the 
extremities (Figure 1.4). Lesions may also be found in the mucous membranes of the 
oropharynx and conjunctivae. New lesion formation continues for 3 to 6 days reaching a 
total number ranging from 10 to 2000, however in most children the number of lesions is 
less than 300 (Cohen et al., 2007). After the onset of the first cutaneous lesions, fever, 
irritability, listlessness and anorexia are prominent for 24 to 72 hours. Lesions are formed 
from clear fluid-filled vesicle surrounded by an irregular erythematous margin and become 
turbid and start to crust within 24 to 48 hours after their appearance. The course of 
varicella is usually self limited in immunocompetent individuals, however in some cases it 
may lead to several complications including secondary bacterial infection, CNS 
involvement, and pneumonia. In very rare cases complications may lead to death (Steiner 
et al., 2007; Rack et al., 2009). The most frequent bacterial complication is with group A 
β- haemolytic streptococci such as 2Staphylococcus aureus and Streptococcus pyogenes. 
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These organisms can cause secondary bacterial skin infection, cellulitis, bacterial 
lymphadenitis or subcutaneous abscesses (Cohen et al., 2007).  
 
Varicella pneumonia is often transient, but interstitial pneumonitis with severe hypoxemia 
that progresses rapidly to cause respiratory failure may occur in severe cases. During 
pregnancy, primary varicella places the foetus at risk from two routes: infection in utero 
and neonatal infection. Congenital varicella syndrome may occur in 0.4-2% of children 
born to mothers with primary varicella zoster infection during the first 20 weeks of 
gestation. This results in disabling abnormalities, including large area of scarring on the 
skin, hypoplastic limbs, chorioretinitis, cataracts and brain abnormalities (Harger et al., 
2002; Thomas and Liesegang 2008).Varicella hepatitis may occur and may be associated 
with severe vomiting. Aspirin is contraindicated in children with varicella because it 
predisposes to liver damage (Reyes syndrome).  Varicella infection is more severe in 
immunocompromised hosts including those with malignancy, HIV infection, or 
undergoing immunosuppressive therapy or solid organ transplantation. In these patients 
with varicella infection, skin lesions will continue to appear for several weeks, vesicles 
will become large and hemorrhagic, pneumonia will develop and the patient will suffer 
from disseminated intravascular coagulation (Feldman et al., 1975). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Vesicles of chickenpox appear on the face, trunk and the extremities. Taken 
from http://howtodealwithstuff.com/how-to-deal-with-chicken-pox/  (accessed on 
17/7/2010). 
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1.3.4.2.3.2 Zoster (shingles) 
 
Herpes zoster is the other form of clinical manifestation caused by VZV and occurs usually 
when the virus reactivates from the sensory nerve ganglia resulting in a unilateral vesicular 
rash adjacent to sensory dermatomes. The zoster rash is characterised by clusters of 
vesicular lesions on an erythematous base, founded on the skin along the path of the 
infected nerve or nerves (Cohen et al., 2007).  Individual lesions start to appear at one site 
or different sites along the affected dermatome, and are initially similar to those of the 
varicella rash. Later, as the disease progresses, the lesions become large and fluid-filled 
and may involve the entire dermatome. The appearance of new lesions lasts for 3 to 7 days 
they then crust and heal within about 14 days in most cases, although healing may be 
extended to 4 to 6 weeks in some cases. The disease is usually associated with a number of 
symptoms including a prodrome fever, malaise, headache and pain in the dermatome. In 
addition the patient may suffer from prolonged disorders such as anorexia, mood changes, 
post herpetic neuralgia (PHN), insomnia and severe depression (Thomas and Liesegang 
2008). The intractable pain associated with the latter is believed to be the leading cause of 
suicide in the elderly.   
 
 
1.3.4.2.3.3 Neurological Complications 
 
Several recent reports confirm the association of VZV infection with a number of 
neurological complications. These complications can be divided into three categories, 
those associated with primary infection, those associated with recurrent infection and those 
that result from administration of varicella vaccine (Levin et al., 2008; Persson et al., 2009; 
Chouliaras et al., 2010). In primary infection, the most common complications associated 
with the CNS are cerebellar ataxia, meningitis, Reye’s syndrome, Guillain–Barré 
syndrome, and encephalitis (Liptai et al., 2009). Acute cerebellar ataxia develops a week to 
3 weeks following the appearance of the rash in children below 15 years of age and 
presents as gait ataxia, tremor, vomiting and headache. The exact mechanism by which the 
disease occurs is still unknown, and it has never been reported in association with zoster 
(Steiner et al., 2007). Guillain–Barré syndrome (GBS), a rare complication accounts for 
about 7% of all primary infection complications, and it has also been associated with 
zoster. There are no characteristic differences between these complications and similar 
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ones caused by other infections. As GBS can occur as a result of primary or reactivated 
infection by several viruses, the exact incidence due to VZV is unknown (Steiner et al., 
2007).  
 
Reye's syndrome is a non-inflammatory encephalopathy reported to occur in children aged 
5 to 14 years (Gilden 2004)). The disease is characterised by intractable vomiting, lethargy, 
and coma and in some cases leads to permanent neurological deficit or death.  Acute 
encephalitis is a rare disorder of varicella infection, however it is a serious complication 
with mortality rates reaching approximately 10% and it occurs most often in children aged 
5 to 14 years (Fairley and Miller 1996). Other neurological disorders such as transient 
focal deficits, aseptic meningitis, transverse myelitis and hemiplegia have been reported 
only infrequently. Reactivation of the virus from ganglia may lead to other neurological 
complications. The most usual and serious complication of zoster is post herpetic neuralgia 
(PHN). The disease is characterised by hypersensitivity of the skin to touch or temperature 
changes persisting for several months or years (Whitley et al., 1998). Pain is a feature of 
disease, however in some patients, a severe debilitating and chronic pain after the 
clearance of the lesion can be seen (Whitley et al., 1998). Age is the most important 
predictor of PHN, in patients who develop zoster after age 60, the risk for PHN is as high 
as 45% (Klinschmidt-DeMasters and Gilden, 2001). In immunocompromised patients 
zoster develops after radiation therapy; bone marrow transplantation; or in association with 
lymphoma, leukaemia, cancer, AIDS, or even prolonged steroid use. In addition, in these 
patients VZV is considerably more likely to disseminate after zoster to multiple cutaneous 
sites and internal organs and to spread to the CNS. The other cause of VZV neurological 
complication is related to VZV vaccination: although introduction of VZV vaccine reduces 
the fatal complications, hospital admissions, and socioeconomic consequences of the 
disease, a number of adverse events have been reported, and it is estimated these occur in 
52.7 per 100,000 doses, of which 2.6 per 100,000 are serious (Chaves et al., 2008). Acute 
disseminated encephalomyelitis (ADEM) is an uncommon disorder of the central nervous 
system that occurs after viral illness or vaccination. ADEM resulting from VZV 
vaccination is estimated to occur in 1 in every 1000 cases of ADEM (Idrissova et al., 
2003). Symptoms usually occur after days (2 to 30 days) of neurological illness and are 
characterised by an acute onset of focal neurological signs and encephalopathy (Sonneville 
et al., 2009). Symptoms include; neck stiffness, seizures and fever, and although the latter 
is not a constant feature, it is present in 75% of severe cases (Sonneville et al., 2009).  
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1.4 Diagnosis of Encephalitis  
 
The diagnosis of primary or recurrent HSV and VZV infection with neurological 
involvement depends mainly on laboratory investigation (Linde et al. 1997). These 
laboratory investigations include detecting the viral antigens or nucleic acids in the brain, 
cerebrospinal fluid examination (CSF), imaging studies and/or the demonstration of the 
intrathecal production of specific antibodies. Because of the high morbidity and mortality 
of the disease, an accurate diagnosis is important particularly for HSV and VZV 
encephalitis since several effective antiviral drugs are widely available for their treatment 
(Najioullah et al. 2000).  
 
 
 
1.4.1 Clinical Evaluation 
 
Clinical evaluation of a patient with encephalitis is usually not diagnostic, because a 
number of infective agents and non-infective causes must be considered (Sauerbrei and 
Wutzler 2002; Kennedy 2004). However, knowing the full history of vaccination, viral 
disease and observation of skin or mucous membrane lesions present, tonsil hypertrophy, 
lymphadenopathy, splenic enlargement etc, will help to narrow the list of causes and may 
give clues to the presence of particular viral infections, leading to determine the best 
diagnostic test to be used (Reznicek et al., 2010a). Evidence of a systematic infection such 
as gastrointestinal, upper respiratory and pulmonary diseases also limits the spectrum of 
any viral agent. However, in some cases evidence of infection may not help. For example 
in HSE patients, it has been noted that when signs and symptoms of patients with biopsy-
proven HSE were compared with those who did not have HSV CNS infection, no 
distinguishing clinical characteristic was found (Whitley and Gnann 2002). In addition, in 
several cases of VZV infection of the CNS, no classical skin manifestations were reported 
(Koskiniemi et al., 2002).  
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1.4.2 Brain Biopsy 
 
Since the early 1990s, the gold standard diagnostic test for HSE encephalitis by direct 
detection of the virus in the brain was brain biopsy (Debiasi et al. 2002). Whilst this is an 
invasive technique, it provides a definitive diagnosis of HSE but it is now only applied in 
very rare cases. Through a burr-hole craniotomy or trephine flap surgery a brain biopsy is 
performed by taking a wedge or needle aspirate of brain tissue. The tissue sample is then 
examined using immunofluorescence or immunocytochemistry staining techniques or is 
viewed under an electron microscope. Even with enhanced neuroimaging techniques this 
procedure carries its own morbidity and mortality through surgical complications, and at 
the same time it suffers from the disadvantage that as the sample is very small, not all parts 
of the brain can be sampled (Granerod et al., 2010). Nowadays, with the advent of 
molecular diagnostic methods the need for brain biopsy has been reduced and it is only 
used when a specific diagnosis cannot be established by another procedure or when the 
information obtained from brain biopsy is considered of sufficient value to justify the risks 
of the surgery undertaken (Kennedy and Chaudhuri 2002). 
  
 
1.4.3 Neurodiagnostic Test  
 
Many neurodiagnostic tests including computed tomographic (CT) scan, 
electroencephalogram (EEG), and magnetic resonance imaging (MRI) scan can be used to 
identify abnormalities that are indicative of HSV or VZV encephalitis. The sensitivity of 
EEG in such cases is about 84%, whereas the specifity is only 32 %, (Whitley and 
Kimberlin 2005; Whitley 2006). Studies have reported a lateralised EEG abnormality in a 
significant percentage of cases that are not proven to be caused by HSV (Booss and Esiri 
2003). CT scans can suggests a diagnosis of HSE, however they are not sensitive in the 
early stage of the illness and only show abnormality in 30% of patients suffering from 
ADEM (Whitley 2006; Sonneville et al., 2009). Approximately 40% of patients with HSV 
encephalitis have normal CT scans. In contrast MRI is a more sensitive diagnostic tool 
than EEG and CT and it allows the revelation of damage to the blood-brain barrier, 
together with oedema and necrosis in the temporal lobe (Tyler 2004). MRI can be used for 
diagnosis of early stages of HSE infection, however in approximately 10% of HSE cases 
MRI scans appear normal (Sener 2002; Whitley et al., 2004). In general although 
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neurodiagnostic methods can yield diagnostic information, the do not replace CSF 
examination and should only be employed as a supportive method in diagnosis of HSE or 
ADEM.      
 
 
 
1.4.4 Cerebrospinal Fluid Examination 
 
Cerebrospinal fluid (CSF) examination can be helpful in diagnosis and can help to exclude 
bacterial cases. However, its collection is contraindicated in the presence of high 
intracranial pressure, severe cerebral oedema, and in those with brain shift. In more than 
90% of viral infections of the CNS the CSF cell count is abnormal (Debiasi and Tyler 
2004). It should be noted however that in 5% to 10% of paediatric HSE cases CSF findings 
are not diagnostic because similar results are found in confirmed cases and in those with 
diseases that mimic HSE (Whitley 2006). Moreover, in 19 to 33% of ADEM patients CSF 
findings can be normal (Lin et al., 2007). White blood cell count and protein in CSF will 
become elevated as the disease progresses. Increases in protein level are due to the 
production of local immunoglobulin, and to the effect of cerebral vascular permeability as 
a result of inflammation. Glucose concentration in viral infection is normal, but on rare 
occasions, the CSF glucose will be reduced in the presence of viral meningoencephalitis. 
As for neurodiagnostic methods, CSF examination alone is not sufficient for a definitive 
diagnosis of HSE and ADEM. 
 
1.4.5 Polymerase Chain Reaction Assay (PCR) 
 
 PCR is a powerful tool; it can be used in diagnosis of many diseases where nucleic acid 
(DNA or RNA) can be detected (DeBiasi et al., 2002). Since the last decade, the advent of 
PCR techniques has improved the diagnosis of central nervous system infections especially 
those caused by viruses (Fredrick and Relman 1999). PCR on CSF was first used in the 
early ‘90s to diagnose HSE and enteroviral meningitis; lumbar puncture for collection of 
CSF is substantially less invasive than brain biopsy, and it has now replaced this as the 
gold standard for the diagnosis of HSE (Puchhammer-Stockl et al., 1990; Debiasi et al., 
2002). The success of PCR in neurovirological diagnosis is due to the sensitivity and 
rapidity of the procedure. Therefore it has been applied in many studies to investigate 
encephalitis caused by HSV-1 and VZV and other viruses associated with neurological 
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disease (Klapper et al., 1990; Cassinotti et al., 1996; Casas et al., 1997). Although 
sensitivity and specificity of PCR in the diagnosis of neurological disease, particularly in 
the case of HSE, was found to be 98% and 94% respectively in comparison to brain biopsy 
(Kennedy and Chaudhuri 2002). However PCR results are most likely to be positive during 
acute infection, when the amount of replicating virus is maximal, and virus often 
disappears within 7 to 14 days of Aciclovir treatment (Klapper and Cleator 1998; Sauerbrei 
et al., 2000; Tyler 2004). In a study to diagnose different causes of neurological infectious 
by Sindic et al., (2003), it was reported that HSV DNA was detectable during the first 2 to 
12 days of onset of neurological illness, but the CSF became negative by the late phase of 
the disease. PCR is a sensitive and specific test for detecting HSV DNA in CSF, however it 
is less helpful in detecting VZV DNA in CSF samples (Nau et al., 1998; Gilden et al., 
2002; Nagel and Gilden 2007). VZV infection can involve different parts of the central and 
peripheral nervous system and, unlike HSV, which follows an acute course it can be 
subacute or chronic. Gilden et al., (1998) studied four patients with subacute to chronic 
VZV infection of the CNS; he found that PCR was positive only when frank neurologic 
deficit and multiple lesions on MRI scanning were evident. The study concluded that PCR 
could not always provide such exquisite sensitivity for the diagnosis of VZV-mediated 
neurological disease. A similar result was found by Nagel et al., (2007), who reported that 
VZV DNA was only detected in 4 (28%) out of 14 samples of patients proven to have 
VZV vasculopathy based on clinical and laboratory investigation (imaging, angiographic 
and CSF abnormalities). This demonstrated that using PCR exclusively for diagnosis of 
VZV vasculopathy resulted in misdiagnosis of 10 (70%) samples. Thus, a positive PCR for 
VZV DNA in CSF is helpful, but a negative PCR does not exclude the diagnosis. 
In general it is important that a PCR result is interpreted cautiously and is considered in 
relation to the clinical presentation and the duration of antiviral therapy.  False-negative 
test results have also been reported due to limited virus replication and to the presence of 
PCR inhibitors in CSF (Puchhammer-Stöckl et al. 1990; Tyler 2004). On the other hand, 
the likelihood of finding a positive PCR result is reduced following a few days of acyclovir 
treatment and in untreated patients from whom CSF samples are obtained late after the 
onset of neurological symptoms (Lakeman and Whitley 1995; Chataway et al., 2004). 
Finally, because PCR is so sensitive, any contamination of the sample either from the 
environment or during sample handling will affect the result and may give a false positive 
result. Thus, whilst PCR can be a highly sensitive and specific technique, it does have 
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limitation, particularly in viral neurological applications. For this reason an ideal 
diagnostic route would include serological methods for detection of intrathecal antibody, 
interpreted in relation to clinical and imaging information.      
 
1.4.6 Serological Tests 
 
Serologic methods have been used to provide indirect evidence of CNS viral infection by 
detection of IgM or IgG in serum and CSF samples. In HSV primary infection antibody is 
produced 4-10 days after the initial infection and more than 90% of the population 
becomes seropositive by their 4th decade of life. Because HSE occurs as a consequence of 
primary, reinfection, or reactivated latent infection, interpretation of serum antibody alone 
in the diagnosis of HSE must be exercised with caution. Capillary circulation within the 
CNS has unusually non-leaky vessel walls with tight endothelial intercellular junctions 
forming the so-called blood brain barrier (BBB). The BBB is a specific system of capillary 
endothelial cells that protect the brain from harmful substances in the blood stream, while 
supplying the brain with the required nutrients for proper function. The peripheral 
capillaries allow relatively free exchange of substances across and between cells. However 
the BBB strictly limits transport into the brain through both physical and metabolic 
barriers. The BBB blocks all molecules except those that cross cell membranes by means 
of lipid solubility (such as oxygen, carbon dioxide, ethanol, and steroid hormones) and 
those that are allowed in by specific transport systems (such as sugars and some amino 
acids). The structure of the blood brain barrier is illustrated in Figure 1.5. 
 
The BBB acts to prevent the free passage of antibody present in peripheral blood from the 
brain. In normal circumstances only about 1/500th of the concentration of antibody found 
in peripheral blood will traverse the BBB and be found in CSF. When a CNS infection 
occurs, the amount of antibody found in the CSF will increase as a result of localized, 
intra-brain, synthesis of antibody to the invading pathogen. To demonstrate this intrathecal 
production of antibody, investigation of the CSF to detect specific oligoclonal IgG bands in 
CSF can be performed or a decrease in the ratio of antibody in CSF compared to blood can 
be determined. The presence of intrathecal antibody synthesis provides evidence of recent 
neurologic infection (Linde et al., 1997). The IgG index is the ratio of IgG to albumin in 
the CSF and serum (Cinque and Linde 2003(B)), and the albumin CSF: serum quotient 
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(Qalb) is an indicator of blood-CSF barrier function. Albumin (produced by the liver) is a 
natural marker for BBB function, and is neither synthesised nor metabolised intrathecally; 
therefore its presence in CSF provides an indicator of BBB function. IgG can be produced 
intrathecally by perivascular infiltrates of B lymphocytes residing in the CNS but can also 
appear as a result of transfer from peripheral blood through the BBB as a result of 
inflammation or trauma to the BBB. Thus increasing levels of IgG found within the CNS, 
can be explained either by increasing production of IgG as a result of infection or as a 
result of BBB dysfunction. In such cases comparing Qalb to QIgG will help in discrimination 
between the two cases. Several indices have been devised including Delpech and 
Lichtblau’s IgG index, Tourtellottes IgG index and Reiber hyperbolic discrimination 
function (Delpech and Lichtblau 1972(b); Tibbling et al., 1977; Link and Tibbling 
1977(b); Reiber and Peter 2001).  
Klapper et al., (1981) proposed a modification of the formula to calculate an antibody 
specific index (IA) to relate the serum:CSF HSV antibody ratio with the serum:CSF 
albumin ratio. In the study antibody to HSV was measured by radioimmunoassay. The 
study showed a raise in antibody index (AI) in 24 (92.31%) out of 26 patients with proven 
herpes encephalitis. Moreover, a raised AI was observed by the 3rd day of two cases with 
neurological disease, however most of the patients, had had the disease for at least 10 days 
before HSV specific antibody could be detected. Thus while the technique was useful for 
the diagnosis of infection in those presenting in the later stages of infection it was not 
useful for the diagnosis of acute infection. As for HSE, serological methods have an 
important role in the diagnosis of VZV CNS infections (Nagel et al., 2007; Nigel et al., 
2008; Amlie-Lefond and Jubelt 2009). In a study by Nagel et al., (2007) to evaluate the 
detection of VZV IgG in comparison to detection of VZV DNA in CSF for the diagnosis of 
VZV vasculopathy; it was reported that anti-VZV IgG was detected in 14 (100%) patients 
with vasculopathy and in a later study in 28 (93%) of 30 patients with VZV vasculopathy 
compared with only 9 who had VZV DNA in the CSF (Nagel et al., 2008).  
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Figure 1.5 The structure of the Blood-Brain Barrier. Taken from 
www.stanford.edu/.../mechanism%20of%20action.htm (acceded on 16/7/ 2010) 
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1.4.7 The need for a Simple and Sensitive Assay for Diagnosis of Encephalitis 
 
It is important to differentiate between viral encephalitis and post-infectious 
encephalomyelitis, since the management and prognosis are often quite different. As stated 
earlier, the diagnosis of acute HSV and VZV infections of the CNS is usually based upon 
the detection of viral DNA in CSF. Patients presenting late in infection or in convalescence 
post-treatment can be shown to have specific intrathecal IgG production within the CSF. In 
contrast in post-infectious encephalitis viral DNA has rarely if ever been demonstrated 
within the CSF of patients with this form of encephalitis. Detection of specific intrathecal 
IgG synthesis in post-infectious encephalitis can provide the aetiology of the infection.  
 
 
Two methods are currently used for the measurement of antigen specific IgG in CSF: 
calculation of specific-antibody indexes and antigen-specific immunoblotting of 
oligoclonal IgG (Linde et al. 1997). Both methods involve comparing viral specific 
antibodies in CSF and serum samples taken on the same day and they have similar 
sensitivity and specifity for the diagnosis of HSV and VZV encephalitis (Monteyne et al., 
1997; Chataway et al., 2004). Whilst these assays are useful in confirming antigen-specific 
antibody, within CSF they are labour intensive, require replication with multiple antigens, 
are time consuming and may require relatively large sample volumes for the test. Since 
encephalitis is a serious disease with a high morbidity and mortality rate, a simple and 
sensitive assay with a rapid turnaround time would be helpful to screen for the presence of 
multiple antigen-specific antibodies within the CSF. In recent years, it has been of 
increasing interest to find an assay for simultaneous measurement of many proteins within 
the same sample. The recent advent of particle-based flow cytometric assays such as the 
Luminex-Based technology (Figures 1.6 and 1.7) has increased hopes that many of these 
limitations can be overcome. Such assay techniques allow the detection of multiple 
analytes within the sample with high sensitivity using very low sample volumes. 
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Figure 1.6 Luminex technology, colour coding of microspheres allows discrimination of 
different sets of beads taken from http://www.panomics.com/product/96/ (accessed 
29/4/2010). 
 
 
 
 
 
 
 
 
 
Figure 1.7 Luminex technology, immunoassays are performed (one target per bead set) and 
the reaction read in a flow through cell (analogous to a flow cytometer) using 2 excitation 
lasers. One laser identifies the bead set (thereby identifying the immunoassay analyte) and 
the second laser is used to excite the fluorescently labelled reporter molecule present in the 
immunoassay. Taken from http://www.panomics.com/product/96/  (accessed 29/4/2010). 
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1.5 Study Aim 
 
The aim of this study is to investigate the feasibility of using Luminex-based technology to 
improve the diagnosis of CNS infections especially those caused by HSV and VZV. A 
microsphere-based multiplexed serological array will be developed to allow the 
simultaneous detection and measurement of the total IgG specific IgG to HSV-1, HSV-2 
and VZV and serum albumin within the same sample (CSF and serum). To allow 
maximum sensitivity of detection and ensure specificity in detection of viral-specific IgG 
in CSF highly purified antigens of HSV and VZV are needed. This will be achieved by 
expression of highly immunogenic viral glycoproteins. As discussed above HSV and VZV 
express several antigenically distinct glycoproteins on their envelope. Many of these 
glycoproteins are specific to genera or subfamilies. For example, three of the HSV 
glycoproteins (gD, gG, gJ) lack counterparts in VZV, and only gB, gH, gL and gM are 
found in all the α-, β- and γ- herpesviruses. In HSV several immunological studies have 
found that the major structural glycoproteins are gB, gC and gD. These glycoproteins are 
inducers of cellular and humoral immune responses within the infected host. Of these gD 
an HSV type common antigen (found in HSV-1 and HSV-2) is the most potent inducer and 
antibodies to gD appear early in the course of infection.  The most abundant glycoproteins 
within the VZV envelope are gE, gB and gH respectively. However, many immunological 
studies have reported that gE is the most abundant glycoprotein within the infected host.  
 
In order to provide suitable antigens to be used in the assay HSV gD and VZV gE will be 
expressed in insect cells using a baculovirus expression system. Expressed proteins will be 
then purified and characterised. The proteins will be evaluated in standard ELISA 
procedures using well characterised serum panels. For differentiation between HSV-1 and 
HSV-2 antibodies a novel immunodominant epitope of glycoprotein G2 presented in a 
branched chain format (peptide 55) will be utilised. The peptide together with the 
recombinant proteins will be used to develop a triplex Luminex immunoassay. Finally 
another multiplex assay will be developed, in this assay a modified assay for the detection 
and measurement of human IgG and albumin in CSF and serum developed in this 
department by Al-Jinden (2009) will be included with the triplex assay. Once the multiplex 
assay has been established, the assay will be applied to samples from patients with proven 
herpes encephalitides caused by HSV-1, HSV-2 and VZV. In addition to improving 
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diagnosis, development of such an assay promises to lead to an improvement in the 
understanding of the pathogenesis of these infections and thereby contribute to the design 
of new treatment strategies.   
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Chapter 2 
Materials and Methods 
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2. Materials and Methods 
 
2.1  Materials 
 
2.1.1  Chemicals and Reagents 
 
Guanidine thiocyanate (GuSCN), Tri-sodium citrate di-hydrate, Sodium dodecyl sulphate 
(SDS), N-lauroyl-sarcosine (sodium salt), ethylenediaminetetraacetic acid (EDTA), Trizma 
base, Ethidium bromide solution, Dithiothreitol (DTT), Carbenicillin, Dimethyl sulfoxide 
(DMSO), Potassium Chloride (KCl), Potassium Phosphate, Sodium Phosphate 
(Na2HPO4.7H2O, dibasic, heptahydrate), Sodium Chloride (NaCl), sodium hydroxide 
(NaOH), Glycerol, Tween 20 (polyoxyethylenesorbitan-monolaurate), Bicinchoninic acid 
(BCA) protein assay, sucrose, Trypan blue, FASTTM BCIP/NBT Tablet (4-Chloro-2-
methylbenzenediazonium/3-Hydroxy-2-naphthoic acid 2,4-dimethylanilide phosphate),  
Anti-Human IgG peroxidase (γ-chain) specific conjugate, Anti-mouse IgG (whole 
molecule-peroxidase antibody), Mouse monoclonal anti-polyhistidine-peroxidase antibody 
and Kanamycin (50mg/ml) were purchased from Sigma  Aldrich Ltd., Poole, UK. 
 
Laboratory disinfectants TriGene, was purchased from Scientific Laboratory Supplies Ltd., 
(SLS), Nottingham UK. 
 
Propanol-2-ol (Isopropanol), Ethanol, Hydrochloric acid and Acetone were purchased from 
BDH Chemicals Ltd., Poole, UK. 
 
Deoxynucleoside  triphosphates (dNTPs) , HyperLadder™ I  and  HyperLadder™ II were 
purchased from Bioline Ltd., London, UK. 
 
AmpliTaq Gold™ DNA polymerase (5U/µL), GeneAmp 10X PCR Buffer (contains 15 
mM MgCl2), were purchased from Applied Biosystems, Warrington, UK. 
 
E-Gel® Low Range Quantitative DNA Ladder, E-Gel 2% Agarose, TlowE buffer (10 mM 
Tris HCl, 0.1 mM EDTA, pH 8.0), NuPAGE® Novex 4-12% Bis-Tris Gels 1.0 mm,  
Novex® Sharp Pre-Stained Protein Standard, Invitrolon™ PVDF Filter Paper Sandwich 
(0.45μm), NuPAGE LDS Sample buffer (4x), NuPAGE® MES SDS Running Buffer 
(20x), NuPAGE® Transfer Buffer (20x), NuPAGE® sample reducing agent (10x), 
NuPAGE® Antioxidant, SimplyBlue™ SafeStain, T10X Blue Juice™ gel loading buffer, 
and 10X TBE buffer, Ultra pure water (UPW), XCELL SureLock™ Mini-Cell 
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electrophoresis running devise, XCELL II™ blotting module, filter papers and blotting 
pads were purchased from Invitrogen Life Technologies, Paisley, UK.  
 
T4 DNA Polymerase (LIC-qualified), 10X T4 DNA Polymerase Buffer, 100 mM DTT, 25 
mM dATP, 25 mM EDTA, Nuclease-free  sterile distilled water, SOC Medium, Mobius 
200 Columns, Mobius 200 Filters, Mobius Buffer Kit, RNase A Solution, Bacterial 
Resuspension Buffer, Bacterial Lysis Buffer, Mobius Neutralization Buffer, Detox Agent, 
Mobius Equilibration Buffer, Mobius Wash Buffer, Mobius Elution Buffer,  BacVector®  
insect cell medium, Insect CytoBuster Reagent, His-Binding Purification Kit, and  N-a-
Tosyl-L-Lysine Chloromethyl Ketone Hydrochloride (TLCK) , were purchased from 
Merck,  Novagen, Nottingham, UK. 
 
Magnesium chloride, Glycogen, Agarose, bovine serum albumin (BSA), ABTS (2,2’-
Azinobis [3-ethylbenzthiazoline-6-sulfonic acid]-diammonium salt) tablets and  substrate 
buffer (Sodium perborate, citric acid and disodium hydrogen phosphate) were purchased 
from Roche diagnostics Gmbh, Mannheim, Germany. 
 
Mouse monoclonal antibody to human IgG heavy Chain (Cat: 05-4500), was purchased 
from Zymed laboratory, South San Francisco, California, USA. 
 
PhycoLink Streptavidin R-Phycoerythrin (Cat: PZPJ31S), was purchased from Europa 
Bioproducts Ltd., Cambridge UK. 
 
R-phycoerythrin-conjugated goat anti-human IgG (FC(Y) chain specific) (Cat:109-116-
098), was purchased from Stratech Scientific Newmarket, Suffolk, UK. 
 
Mouse anti-human albumin (Cat: RDI-TRK4T24-15C7), was purchased from Fitzgerald 
Industries International, Inc., Concord, USA. 
 
Biotin conjugated with goat (Fab-segment) anti-human albumin (Cat: BI-3825) was 
purchased from Cambridge Biosciences Ltd., Cambridge, UK. 
 
SeroMAP Carboxylated microspheres regions 10, 15, 20, 25, and 30 were purchased from 
Luminex Corporation, Austin, Texas, USA. 
 
N-Hydroxy-sulphosuccinimide (Sulpho-NHS), (Cat: 24510) and 1-ethly-3-(3-
dimethylaminopropyl)-carbidiimide hydrochloride (EDC), (Cat: 22980) were purchased 
from Perbio, North Nelson Industrial Estate Cramlington, Northumberland, UK. 
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Newborn bovine serum (NBBS) was purchased from MP Biomedicals, Ohayo, UAS. 
 
Pyrogen free water, injectable water, was purchased from Phoenix Pharmaceuticals Ltd, 
Gloucester, UK. 
 
Absolute ethanol, methanol, propanol were purchased from Fisher Scientific, 
Leicestershire, UK. 
 
Rabbit polyclonal anti-human IgG-H&L covalently liked to Horseradish peroxidase 
(ab6759), Rabbit anti-mouse IgG-H&L–F2 fragment and anti-human IgG-H&L covalently 
liked to alkaline phosphatase, mouse monoclonal to HSV-1 and HSV-2 gD clone (2C10)) 
and VZV gE clone (9C9), Rabbit polyclonal anti-mouse IgG-H&L F (ab) 2 fragment 
(ab5763)  and Rabbit polyclonal anti-human IgG-H&L covalently liked to Alkaline 
Phosphatase (ab6760) were purchased from Abcam, Cambridge, UK. 
 
Fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse polyclonal antibodies was 
purchased from DAKO, Glostrup, Denmark. 
 
Bactotryptone was purchased from DIFCO laboratories, Detroit, USA. 
 
Bacto-yeast extract was purchased from Beta Lab., Surrey, UK. 
 
LB agar was purchased from Oxoid, Hampshire, UK. 
 
Micron YM-100 Centrifugal F Micron YM-100 Kit, was purchased from Millipore 
Corporation Bedford, USA. 
 
Potassium Chloride (200mM) was purchased from Clear Diagnostic, LLC., Alamed, USA. 
 
 
2.1.2  Equipment and Instruments: 
 
Omnifuge 2.0 centrfuge, Megafuge 1.0 centrifuge, 27 0C and 37 0C incubator from 
Heraeus equipment Ltd., Essex, UK. 
 
Shaker incubator model G25, New Brunswick Scientific Co. Inc., New Jersey USA. 
 
Laminar flow cabinet from Envair Ltd., Lancashire, UK. 
 
Ultraviolet illumination Herolab E.A.S. UV-T-28 MP system, from Anachem Ltd., Luton, 
UK). 
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Ultraviolet absorbance spectrophotometry (GeneQuant II) from Pharmacia Biotech, UK). 
 
BIOMAT class II microbiological safety cabinet from Medical Air Technology Ltd., 
Manchester, UK. 
 
Weighing balances (Sartorius type 1518 MP) from Data Weighing systems, Chicago, USA.  
 
Water bath (Grant instruments Ltd., Cambridge, UK). 
 
Sharp microwave from Sharp Electronics, LTD, UK.  
 
Labpette Discovery pipette {AK-00134 (range from 5 µl–10 µl), AK-11879 (range from 
50 µl – 200 µl), and AK-32058 (range from 200 µl-1000 µl)} from Accutek Laboratories, 
San Diego, USA.  
 
Beckman ultracentrifuge and centrifugation tubes were purchased from Beckman, 
California, USA. 
 
BioPlex 100 workstation from Bio-Rad, USA. 
 
pH meter PHM 92 from Lab Radiometer, Copenhagen, Denmark. 
 
Immunofluorescent microscope type BH2 RFCA from Optivision Ltd., Olympus, Japan. 
 
Vacuum filtration manifold from Millipore Corporation, Bedford Massachusetts, MA, 
USA. 
 
Dot Blot manifold I from Schleicher&Schuell, Germany. 
 
Tissue culture plate and flasks, 15ml and 50ml plastic tubes, sterile screw capped 
cryovials, Scotlab cryofreezing container were purchased from Greiner bio-one (Cellstar), 
Gloucestershire, UK. 
 
Glass culture bottles 50ml, 250ml 500ml and 1 L from Schott Duran, Germany. 
 
ELISA plates Nunc “high binding” (Life Technologies Ltd, Paisley, UK), Costar “medium 
binding” (Corning, Costar Incorporated, USA), Falcon (Becton Dickinson Lab ware, 
California, USA).  
 
96-well filter bottom microtitre plate was purchased from Fisher Scientific, Loughborough, 
UK. 
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Automated ELISA plate washer (ELx 50) and Reader (ELx808) from Biotek Northstar 
Scientific Ltd., Biotek instruments, USA. 
 
Glass bottles automated washing machine LANCE 910 from Lancer UK Ltd., Cambridge, 
UK. 
 
Agarose gel carrier (gel electrophoresis apparatus GNA-100), Hoefer SE 250 Mighty small 
II apparatus, Power supply ESP 500/400, ultra-violet spectrophotometer  from Pharmacia 
Biotec, Amersham, UK. 
 
Thermocycler machine (GeneAmp®PCR System 9700) from applied Biosystems, 
Warrington, UK. 
 
Nikon digital camera coolpix 995 type, Japan. 
 
 
2.1.3  DNA Controls and Plasmids 
 
Varicella Zoster virus DNA (1 X 104 DNA copies/µl), was purchased from Autogen 
Bioclear, Ltd., Wiltshire, UK. Herpes simplex virus type 1 DNA, was provided by the 
Department of Virology, University of Manchester. The DNA was extracted from HSV-1 
Macintyre strain (VR3) grown in Vero cell containing 104 TCID50/ml. Bacterial  Plasmids 
(pIEx/Bac-3 3C/LIC), 3C/LIC β-gal Control Insert and test plasmid (ampicillin resistant) 
was purchased from Merck,  Novagen, Nottingham, UK. 
 
2.1.4  Oligonucleotides 
 
1. HSV-1 gD and VZV gE primers were purchased from Invitrogen, Life Technologies, 
UK. 
 
Virus Primers Sequence Length 
Sense 5’-CAGGGACCCGGTATGGGGGGGGCT-3’ 24 bp 
HSV-1 
Anti-sense 5’GGCACCAGAGCGTTCTAGTAAAACAAGGGCTGG-3’ 33 bp 
Sense 5’-CAGGGACCCGGTATGGGGACAGTTAATAAA-3’ 30 bp 
VZV gE  
Anti-sense 5’-GGCACCAGAGCGTTTCACCGGGTCTTATCTAT-3’ 32 bp 
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2. Vector Upstream and Downstream primers were purchased from Merck, Novagen, 
Nottingham, UK. 
 
Genes Primers Sequence 
IE1 Promoter  Sense 5′- TGGATATTGTTTCAGTTGCAAG -3′ 
IE1Terminator Anti-sense 5′- CAACAACGGCCCCTCGATA -3′ 
 
 
 
2.1.5  Insect and Competent Cells 
 
1. NovaBlue GigaSingles™ Competent Cells and Sf9 insect cells were purchased from 
Merck, Novagen, Nottingham, UK. 
 
Strain Genotype 
Sf9 Insect cells 
Sf9 cell line was derived from pupal 
ovarian tissue of the Fall army worm 
Spodoptera frugiperda. 
NovaBlue GigaSingles™ Competent 
Cells 
 
 
 
2.1.6  Enzyme-linked Immunosorbent assay (ELISA)  
 
 BioKit Bioelisa HSV-2 IgG was purchased from Biokit, Barcelona, Spain. Focus 
HerpeSelect HSV-2 IgG was purchased from Focus Diagnostic, Cypress, California, USA. 
PATHOZYME™ Viro HSV-2 ELISA IgG was purchased from Omega Diagnostics Ltd., 
Scotland, UK.Virotech HSV-1 IgG ELISA kit was purchased from Genzyme Virotech 
GmbH, Germany. 
 
ELISA Coating buffer  
1- 1x Phosphate buffered saline (PBS) pH 7.3. 
2- 0.1 Carbonate/bicarbonate buffer pH 9.6. 
 
Wash buffer: 1x PBS, 0.05 % v/v Teen 20. 
Blocking buffer:  2% w/v skimmed milk in 50ml 1x PBS pH 7.3,  0.1% v/v Tween 20. 
Sample diluent buffer:  1x PBS pH 7.30, 0.1% v/v Tween 20.  
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2.1.7  Protein Expression Systems  
 
InsectDirect™ System and BacMagic™ Transfection kits were purchased from Merck, 
Novagen, Nottingham, UK. 
 
 
 
2.1.8  Software and Databases 
 
1- BioMath-Tm Calculation for Oligos (http://www.promega.com/biomath/calc11.htm). 
2.The National Center for Biotechnology Information (GenBank) 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=Nucleotide&itool=toolbar). 
3.Basic Local Alignment Search Tool (BLAST) databases ( 
http://www.ncbi.nlm.nih.gov/BLAST/). 
5. BioEdit Biological Sequence Alignment Editor (Version 7.0.5.3), a free programme 
(http://www.mbio.ncsu.edu/BioEdit/bioedit.html) Copyright 1997-2005 by Tom Hall.  
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2.2  Methods 
 
2.2.1  Clinical Specimens 
 
2.2.1.1  Control Serum Samples  
 
1-     A clinical standard positive serum (highly positive for HSV-1, HSV-2 and VZV) and 
8 known negative samples (negative for HSV-1, HSV-2 and VZV) were provided by 
Clinical Virology, Manchester Medical Microbiology Partnership, Manchester Royal 
Infirmary. 
 
2- IgG deficient serum (Cat no: S5143) and normal human standard serum (Cat no: 
H4522) was purchased from Sigma-Aldrich , Dorset, UK. 
 
 
2.2.1.2  HSV and VZV Serum Samples 
 
A total of 6 panels of serum were used during this project, all specimens were re-used for 
this study in accordance with current Royal College of Pathologists Guideline (Guidance 
on the use of clinical samples retained in the pathology laboratory, 2007 
http://www.rcpath.org/resources/pdf/G035GuidanceUseofClinicalSamplesSept07.pdf). 
Specimens and associated clinical data were collected; the specimens were anonymised by 
renumbering and removal of all patient identifiers from the data before use in this study. 
Serum panels are as follows:  
 
 
1- Panel 1: consisted of 254 human sera, samples were collected from the serum bank of 
Clinical Virology Manchester Royal Infirmary between January 2006 and June 2007 
and stored in 100 µl aliquots at -700C. All samples had been routinely tested for the 
presence of HSV IgG antibody using a HSV type common and type specific assays. 
Out of the 254 samples 90 samples were previously tested for the presence of VZV IgG 
antibody using Human VZV IgG assay.  
 
2- Panel 2: consisted of 93 human sera from 57 patients with proven HSV infection. 
Samples were collected from the serum bank of Clinical Virology Manchester Royal 
Infirmary between January 1994 and April 1998 and stored in 100 µl aliquots at -700C. 
All samples had been tested for the presence of HSV antibody using indirect 
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immunofluorescence test. Samples were also tested and subtyped for HSV-1 and HSV-
2 IgG antibody using a number of type specific assays. 
 
3- Panel 3: consisted of 400 human sera from female commercial sex workers in Dacca, 
Bangladesh. Samples were collected from collected from female prostitutes in 
Bangladesh and stored in 100 µl aliquots at -70 0C. All samples had been tested and 
subtype for the presence of HSV-1 and HSV-2 IgG antibody using a number of type 
specific assays. 
 
4- Panel 4: consisted of 200 human sera selected from among 8,000 samples taken from 
pregnant woman attending Antenatal Clinic at Manchester Royal Infirmary for 
serological screening for antibodies to rubella, syphilis and other sexually transmitted 
diseases (STDs). Samples were collected between January 1994 and April 1998 and 
stored in 100 µl aliquots at -700C. All samples had been tested and subtyped for the 
presence of HSV-1 and HSV-2 IgG antibody using Bioelisa HSV-1 and HSV-2 IgG 
type specific assays. 
 
5- Panel 5: consisted of 60 human sera originally obtained from patients with proven HSV 
infection, attending the Genito-Urinary Medicine Clinic (GUM) at Manchester Royal 
Infirmary. Samples were collected between January 1994 and April 1998 and stored in 
100 µl aliquots at -700C. All samples had been tested and subtype for the presence of 
HSV-1 and HSV-2 IgG antibody using Bioelisa HSV-1 and HSV-2 IgG type specific 
assays. Patient age ranged from 13 to 67 years and the group comprised of 28 males 
and 32 females.  
 
6- Panel 6: consisted of 100 human sera, samples were collected from the serum bank of 
Clinical Virology Manchester Royal Infirmary between January and June 2008 and 
stored in 100 µl aliquots at -700C. All samples had been tested for the presence of VZV 
IgG antibody using the Liaison VZV IgG assay, and 37 samples out of 100 samples 
were tested by the AtheNA Multi-Lyte® MMRV IgG Plus assay for the detection of 
Measles, Mumps, Rubella and Varicella antibody. 
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2.2.2  DNA Extraction using Guanidinium Thiocyanate (GUSCN) 
 
VZV DNA was extracted from clinical samples using the GuSCN method as described by 
Casas et al. (1995). Briefly,  a volume of 200 µL freshly prepared lysis buffer (4M 
GuSCN, 0.5% N-lauroyl sarcosine, 1mM dithiothreitol, 25mM sodium citrate and 20µg/ml 
glycogen) was placed into a sterile 1.5 ml Eppendorf tube then mixed with 50 µL of 
specimen (or sterile distilled water for extraction negative control) and incubated at room 
temperature for 10 minutes. To precipitate the DNA 25µL of 3M sodium acetate was 
added to each tube followed by 275 µL of ice-cold isopropanol. Tubes were incubated at 
room temperature for 5 minutes. DNA pellets were then collected by centrifugation for 10 
minutes at 12000 g. The supernatant was discarded and the DNA pellet was washed with 
500 µL of 70% ice-cold ethanol followed by centrifugation as above, to collect the DNA. 
The supernatant was then gently removed and the pellet left to air dry at room temperature 
for 10 min before being re-suspended in 50 µL sterile deionised water. The samples were 
stored at -200C in single-usage aliquots (10 µL). 
 
 
2.2.3  Construction of Recombinant Plasmid Containing the Full open Reading 
Frame of HSV-1 gD and VZV gE genes.  
  
2.2.4.1  Determining the Sequence of HSV-1 gD and VZV gE genes 
 
The sequence of HSV-1 gD and VZV gE were obtained by examining all published 
genome sequences in Genbank, 10 VZV and 8 HSV sequences were taken and compared 
by analysing all sequences from the 5’ to 3’ ends using BioEdit Sequence Alignment 
Editor Programme.  
 
 
2.2.3.2  Primer Design and Preparation 
 
The published HSV-1 genome sequence  (accession NC-001806) and VZV gE 
genome sequence (accession  NC-001348) found in Genbank were used to design 
primers for amplification the entire open reading frame containing gD, from 
138419bp to 139419bp and gE, from 115808 to 117679. To generate a specific vector-
compatible overhang, primers incorporated a tail at the 5'-end. The G + C content and 
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melting temperature were calculated using BioMath Oligo calculator. Blast alignment of 
the primers was also performed. All primers were diluted in Tris acetate buffer (10mM 
Tris and 1mM EDTA) to give a primer stock concentration of 100µM and then divided 
into 100µl aliquots and kept at -200C.  The 100µl stock aliquot was further diluted in 400µl 
ultra pure water to give a working concentration of 20µM of each primer. The working 
stock was aliquoted into 100 µl volumes and further aliquoted into 10 µl volumes and 
stored at -200C for later use.  
 
 
2.2.3.3  Polymerase Chain Reaction (PCR) 
 
2.2.3.3.1  Contamination Control 
 
PCR assay contamination was prevented by carrying out standard precautions as described 
by Kwok and Higuchi (1989). Briefly all pre and post PCR reagents and specimens were 
stored in separate areas. Separate sets of supplies (pipettes, racks, test tubes, lab coats, 
gloves and plugged tips) were used for setting up PCR mixtures and for sample 
preparation. PCR were carried out using three different rooms. PCR master mix and all 
reagents were contained within the first room ("DNA free" room) which was controlled 
strictly so that no contaminating DNA source was brought in to this room. DNA extraction 
and addition of the DNA samples to the master mix was performed in a separate "DNA 
preparation" room. The DNA amplification took place in a third room “PCR product 
detection”. Nothing was transferred from the DNA preparation room to the DNA free 
room, and both rooms were periodically subjected to ultra-violet (UV) irradiation to 
destroy any extraneous DNA before and after every operation. In addition, work surfaces 
were cleansed with 1N HCL, negative controls consisting of ultra pure water were included 
for each DNA extraction and PCR run. Moreover, all reagents that were need for 
preparation of the PCR master mix were kept in the DNA free room and aliquoted into 
single-usage volumes for storage. 
 
 
2.2.3.3.2  PCR Amplification of HSV-1 gD and VZV gE 
 
For amplification of HSV-1 gD a 45 µl master mix reaction containing 5 µl of 10×buffer 
(50mM KCl, 1.5mM MgCl2 and10mM Tris-HCl; pH 8.3), 1 µl (10mM) of  dNTPs, 1 µl of 
each oligonucleotide primer, 36.5 µl SDW and 0.5 U of AmpliTaq Gold polymerase were 
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prepared in the DNA free room. In the DNA preparation room a 5 µl volume of each 
sample, including a negative control, was added (in a final volume of 50 µl). The cycling 
comprised a single initial denaturation at 940C for 6 min followed by 40 cycles of 
denaturation at 940C for 1 min, annealing at 580C for 1 min, extension at 72 0C for 1 min 
using the PCR thermocycler.  Amplification of VZV gE was carried out using the same 
master mix reaction volumes and cycling conditions except that the extension time was 
extended to 1 min 30 second rather than 1 min at 72 oC. 
 
 
2.2.3.3.3  Detection of PCR Products by E-Gel Electrophoresis  
 For detection of the PCR product a volume of 9µl PCR product  was mixed with 1 µl of 
10x loading buffer (65% (w/v) sucrose, 10 mM Tris-HCl (pH 7.5), 10 mM EDTA, and 
0.3% (w/v) bromophenol blue), plus 10 µl of deionised water. Thereafter 20µl of each 
sample was analysed using 2% w/v Agarose E-Gel electrophoresis at 12 volts for 15 min. 
Ten microliters of ladder (Hyper Ladder™ II) was added to 10 µl of deionised water and 
loaded into the first well. This ladder contains 15 regularly spaced bands ranging from 
50bp – 2000bp.  Any empty wells were loaded with 20 µl of deionised distilled water. 
 
 
2.2.3.3.4  Purification of PCR Product 
 
For purification of PCR products a modified Microcon centrifuge method (YM-100 
Centrifugal F Micron YM-100 Kit) was used. Briefly: a microconcentrator was assembled 
(1.5 ml collection tube and spin column), 300 µl of KCL (200 mM) was then added, and a 
50μl PCR product was added to the spin column. The microconcentrator was centrifuged at 
500 x g for 15 minutes, and then 300 µl of sterile deionised water was added to the 
reservoir of the microconcentrator. After another round of centrifugation for 15 minutes, 
35 µl of TlowE Buffer (10 mM Tris HCL, 0.1mM EDTA, pH 8.0) was added. The 
microconcentrator was removed and inverted into a new 1.5 ml tube, and centrifuged at 
500 x g for 5 minutes. The microconcentrator was then discarded and 10 µl of the purified 
product was analysed using a 2% E gel electrophoresed at 12 volts for 15 minutes. The 
remainder of the purified product was stored at -200C for the next stage.  
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2.2.3.4  Preparation of the 3C/LIC insert for HSV-1 gD and VZV gE 
 
The 3C/LIC insert for each PCR product of each virus was prepared as follows: 10 µl of 
each purified PCR product was mixed with 2 µl 10X T4 DNA polymerase buffer, 2 µl 25 
mM dATP, 1 µl 100 mM DTT, 5.6 µl Nuclease-free water, and 0.4 µl 2.5 U/µl T4 DNA 
Polymerase (final volume 20 µl) in a sterile 1.5 ml tube kept on ice. Four microliters of the 
3C/LIC ß-gal control insert (3081bp with a concentration of 2µg/pmol) and negative 
control (4µl of deionised water) was added.  The reaction was started by adding the T4 
DNA Polymerase enzyme. The mixture was incubated in a water bath at 220C for 30 
minutes. The enzyme was then inactivated by re-incubating the tubes in a water bath at 
750C for 20 minutes. The treated PCR product was then stored at -200C.  
 
 
2.2.3.5  Annealing the Vector and 3C/LIC Insert 
 
Annealing of the 3C/LIC Insert for each virus into the pIEx/Bac-3 3C/LIC plasmid vector 
was formed by assembling an annealing reaction in a sterile 1.5 ml tube, containing 1 µl of 
3C/LIC vector, 2 µl T4 DNA polymerase treated 3C/LIC insert  (0.02 pmol). The 
annealing reaction was started by adding 1 µl of (25mM) EDTA with stirring by a pipette 
tip; the tubes were then incubated in a water bath at 220C for 5 min.  
 
 
2.2.3.6  Transformation 
 
2.2.3.6.1  Preparation of Luria-Bertani (LB) Broth Medium 
 
Luria Bertani (LB) medium was prepared by dissolving 5g Bactotryptone, 2.5g yeast 
extract and 5g NaCl in 450ml distilled water, the volume was then made up to 500ml  and 
pH was adjusted to 7.5 with sodium hydroxide. The solution was then autoclaved for 15 
minutes at 1200C, and after autoclaving the LB media was allowed to cool to room 
temperature. Five hundred microliters Carbenicillin was then added (to reach a final 
concentration of 50µg/ml). The media was then stored in the cold room (40C).  
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2.2.3.6.2  Preparation of 1.5% w/v LB Agar Media  
 
LB agar media was prepared by adding 6 grams of LB agar to 500 ml of LB broth medium 
in a 1L bottle and mixed well. The mixture was autoclaved for 15 minutes at 1200C. After 
autoclaving the LB agar was left to cool to approximately 400C and then 500 µl of 
Carbenicillin was added (to reach a final concentration of 50µg/ml). The media was then 
poured into plates (approximately 25ml/plate) and left at room temperature for 15 minutes 
before storage at 40C.  
 
 
2.2.3.6.3  Transformation of Competent Cells 
  
Two ampoules containing 0.2ml of competent cells (NovaBlue GigaSinglesTM were taken 
from the freezer (-700C) and placed on ice and left to thaw for 5 min. The tubes were then 
flicked gently 4 times to mix the contents and aliquoted into 20µl in labelled 1.5 ml  tubes 
and left on ice. To each tube 1 µl of the annealing reaction (samples, negative and positive 
control) was added. To determine the transformation efficiency 1 µl (0.2 ng) of test 
plasmid was added to a separate tube, and incubated for 5 min on ice. The tubes were then 
heated in a 420C water bath for 30 seconds and then placed on ice for 2 minutes. Two 
hundred and fifty microliters of SOC medium (at room temperature) was then added to 
each tube on ice. Tubes were then incubated on an orbital shaker at 370C with shaking at 
250 rpm for 60 minutes. After incubation 25 µl, 50 µl, and 70 µl from each tube was plated 
on LB agar medium (50µg/ml Carbenicillin). The plates were left on the bench for 10 
minutes to allow excess liquid to be absorbed and then inverted and incubated overnight at 
370C.   
 
 
2.2.3.6.4  Colony Screening for Recombinant Plasmid 
 
 
After overnight incubation at 370C 5 colonies (approximately 1mm in diameter) from each 
plate were taken with a sterile 200 µl pipette tip (a copy of each colony was touched in 
another plate) in a sterile 0.5 ml tube containing 50 µl sterile water. The tube was then 
vortexed to disperse the cells, and placed in a heating block at 990C for 5 minutes to lyse 
the cells. The tubes then centrifuged at 12,000 g for 1 minute to remove the cell debris. Ten 
µl of the supernatant was then transferred into another sterile tube placed on ice. For each 
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reaction 10 µl of each sample was added to 40 µl master mix reaction containing 5 µl of 
10×buffer (50mM KCl, 1.5mM MgCl2 and10mM Tris-HCl; pH 8.3), 1 µl (10mM) of each 
dNTP, 1 µM of each oligonucleotide primer (5 pmol/ µl), 31.5 µl SDW and 0.25 µl  of 
AmpliTaq Gold polymerase (1.25 U). The cycling parameters for 35 identical cycles of; a 
denaturation step at 940C for 1 minute, annealing step at 550C for 1 minute and extension 
step at 72 oC for 2 minutes and the last step was extended for 5 minutes. PCR was 
performed using vector-specific primer alone, or in combination with HSV-1 gD or VZV 
gE gene specific primers. The PCR product was then analysed using 2% w/v Agarose E-
Gel.  
 
 
 
2.2.3.6.5  Preparation of Plasmid DNA 
 
A single pure bacterial colony from a freshly streaked plate containing either HSV-1 gD or 
VZV gE recombinant plasmid was inoculated into 5 ml LB  broth containing Carbenicillin 
(50µg/ml) and incubated at 370C with vigorous shaking (300 rpm) for 8 h. A few drops of 
the broth culture was then transferred into a further bottle containing 35 ml LB broth 
(50µg/ml Carbenicillin) and incubated at 370C with vigorous shaking (300 rpm) for 18 h. 
Cells were harvested at 5000x g for 10 min and supernatant was discarded, tubes were 
inverted for several seconds to drain any remaining medium.   
 
 
2.2.3.6.6  Purification of Plasmid DNA 
 
Extraction of the recombinant plasmid was performed using the Ultra Mobius 200 Plasmid 
Purification kit. Briefly: the bacterial pellet was resuspended in 2.1 ml of bacterial 
resuspension buffer, and gently vortexed for 1 minute. A 2.1 ml volume of bacterial lysis 
buffer was then added to the mixture and tubes were incubated at room temperature for 5 
minutes, then   2.1 ml of MobiusTM neutralizing buffer was added. The tube was mixed 
gently and incubated for a further 5 minutes. After incubation the tube was centrifuged at 
10,000 X g for 2 minutes to remove the bulk of insoluble materials. During centrifugation 5 
ml of Mobius equilibration buffer was added to the Mobius 200 column reservoir. The 
column was then placed into a 15 ml conical tube and the entire clarified lysate was added 
to the column reservoir. Five ml of washing buffer was added and the entire volume was 
left to flow through column by gravity. The column was placed in a new 15 ml conical 
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tube and 2 ml of Mobius elution buffer was added. The eluted plasmid DNA was then 
collected and concentrated and desalted by adding 1.4 ml of isopropanol and centrifuged at 
15000 x g for 20 minutes.  The pellet was then washed by adding 2 ml of 70 % ethanol 
(room temperature) and centrifuged at 15000 x g for 10 minutes. Finally the supernatant 
was discarded and the pellet was resuspended in 150µl nuclease-free water.  
 
 
2.2.3.6.7  Determining the purity and concentration of the plasmid DNA 
 
The concentration and purity of the plasmid DNA was measured using ultraviolet 
absorbance spectrophotometry at a wavelength of 260nm. Quantitation of the DNA 
samples was estimated from the equivalence between an OD260 reading of 1.0 and a 
concentration of double-stranded DNA of 50 µg/ml. In addition, the purity of the DNA 
preparation was evaluated from the ratio of the OD260 and OD280 reading with an 
OD260/OD280 ratio of 1.8 being characteristic of protein-free DNA. The DNA was then 
stored in single aliquots (20µl) at -20 0C.  
 
  
2.2.4  Insect Cell Culture 
 
2.2.4.1  Recovery of Frozen cells 
 
A frozen vial (5x106 cells/ml) of Spodoptera frugiperda 9 (Sf9) insect cells was retrieved 
from liquid nitrogen storage and immediately immersed in a 280C water bath until cells 
were fully thawed (approximately 2-3 min). Under a laminar flow hood cleaned with 70% 
ethanol, the outside of the vial was sterilised with 70% ethanol and cells were transferred 
to a sterile 50ml polypropylene centrifuge tube. A 10ml amount of pre-warmed (280C) 
media (BacVector® Insect Cell Medium) was added drop wise to the cells. The cells 
suspension was gently pipetted (3-5 times) and the entire contents were then transferred to 
a 75cm2   cell culture flask. The flask was gently rocked by hand to evenly disperse the cells 
and placed in a humidified incubator at 280C for 30-60 min. Cells were then examined 
under an inverted microscope to verify attachment to the bottom of the flask, the medium 
(containing residual DMSO from frozen cells) was then removed and replaced with a 20ml 
fresh pre-warmed media containing 5% (v/v) foetal calf serum, the flask was then 
incubated at 280C. Cells were examined daily until the monolayer become 85-95% 
confluent (3-4 days).  
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2.2.4.2  Insect Cells Count 
 
Cells were counted using the trypan blue exclusion method. Briefly: a 100 µl volume of 
Sf9 cells was added to 100 µl of trypan blue solution (0.4% Trypan blue in 0.85% saline) 
and was pipetted 3-5 times. Twenty microliters of the mixture was immediately added to 
the haemocytometer (Fast Read Cell counter 102, ISL Paignton, Devon, UK). Live cells 
(unstained by trypan blue) were counted in 4 large squares. The total number of cells/ml 
was calculated as follows:  
 
Number of cells in squares counted/ Number of squares counted x (104 x dilution factor).  
Cells viability was determined as follows:  
Total live cells counted / total cell count (live cells + dead cells). 
 
 
2.2.4.3  Monolayer Sf9 Culture 
 
The media from a confluent monolayer in a 75-cm2 flask (85-95%) was removed and 
replaced by 5ml fresh pre-warmed media. Flasks were then tapped by hand (approximately 
3-5 times) to dislodge cells, the suspension was transferred to a sterile 50 ml tube. Cells 
were examined, counted (as previously described) and seeded in new 75-cm2 flasks 
containing 15 ml of antibiotic free BacVector® Insect Cell Medium at a density of 2-5 x105 
viable cells/ml. Flasks were then incubated at 280C and examined on a daily basis under an 
inverted microscope and sub-cultured when it formed an 85-95% confluent monolayer (3-4 
days).  
 
 
2.2.4.4  Suspension Sf9 Culture 
 
Sf9 cells for suspension culture were prepared as described above, except that cells were 
seeded in a 250 ml culture bottles containing pre-warmed BacVector® Insect Cell Medium 
at 5-6 x105 viable cells/ml, in 20 or 30 ml culture volumes. The cultures were incubated at 
150rpm on orbital shakers at 280C. The caps contained a 0.2 µm filter (Sarstedt, 
Aktiengesellschaft & Co, Germany), and no antibiotics were used. For larger experiments, 
500 ml or 1000 ml culture bottles, with up to 100 ml or 300 ml respectively volumes were 
used. Cells were examined daily and counted every 48 hours as previously described using 
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the trypan blue method and were subcultured when the cells density reached 4-5 x106 
viable cells/ml.  Culture bottles were routinely washed before and after any experiment 
using an automated glass bottle washing machine and then autoclaved for 40 min at 1210C.  
 
 
2.2.4.5  Cells Storage 
 
A suspension culture of Sf9 cells with a density of 4-5 x106 cells/ml and more than 90% 
viability was transferred to a 50 ml tube, cells were harvested by centrifugation at 1500g 
for 10 min. Cell were then re-suspended in freezing media containing an equal volume of 
BacVector® Insect Cell Medium containing 20% (v/v) DMSO and 5%(v/v) fetal calf 
serum. Cells were gently pipetted 2-3 times to ensure complete mixing, and an aliquot of 1 
ml of cells suspension was transferred to a sterile cryogenic vial. Vials were then placed in 
Scotlab polystyrene box (freezing box) containing isopropanol and stored at -200C for 2h, 
then transferred to - 700C for 12-18 h, and finally placed in a liquid nitrogen tank for 
longer storage.         
 
 
 
2.2.5  Protein Expression   
 
2.2.5.1  Insect Direct Expression System  
 
2.2.5.1.1  Monolayer Culture (6-Well Plate) 
 
Protein expression for each virus was carried out using a 6-well culture plate. Briefly: 12 
ml freshly diluted of Sf9 cells (5 x105 viable cells/ml) was prepared from an exponentially 
growing shaker culture. Two ml of diluted cell suspension was added to each well. The 
plate was gently rocked by hand to evenly disperse the cells and incubated at 280C for 60 
min. For each well (except the negative control well) 2 µl of plasmid DNA was mixed with 
100 µl of antibiotic free BacVector® Insect Cell Medium in 0.5 ml tube, 10 µl of Insect 
GeneJuice Transfection reagent was then mixed with 100 µl in a 0.5 ml tube. Diluted 
plasmid DNA was then added dropwise to the diluted GeneJuice Transfection reagent and 
mixed gently to avoid precipitation, and incubated at room temperature for 15 min. Media 
in each well was then aspirated, and an 800 µl volume of media was mixed with each tube 
and the entire volume added to each well, plates were incubated for 48 to 72 h at 280C.    
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2.2.5.1.2  Suspension Culture  
 
For protein expression 10 ml of suspension culture was used. Eight ml of a fresh dilution 
of Sf9 cells (1 x107 viable cells/ml) was prepared from an exponentially growing shaker 
culture. In a 1.5 ml tube, 20 µl of plasmid DNA was diluted in 1 ml of BacVector® Insect 
Cell Medium, at the same time 100 µl of GeneJuice Transfection reagent was diluted in 
1ml of the same media in a 1.5 ml tube. The diluted plasmid DNA was then added 
dropwise to the diluted GeneJuice Transfection reagent and was mixed gently to avoid 
precipitation, and left at room temperature for 15 min. Finally the entire volume was added 
to the cells and incubated for 48 hours at 150rpm on orbital shakers at 280C with caps 
containing a 0.2 µm filter. 
 
 
2.2.5.2  BacMagic Expression System 
 
2.2.5.2.1  Construction of Recombinant Baculovirus   
 
2.2.5.2.1.1  Preparation of Cell Culture for Transfection 
 
Cell culture for transfection was prepared using a 25-cm2 flask. Briefly: 1 h before starting, 
three 25-cm2 flasks (sample, positive and negative control) were seeded with a 2 ml 
dilution of Sf9 cells (1 x106 viable cells/ml) from an exponentially growing shaker culture. 
Flasks were then gently rocked to evenly disperse the cells and incubated at 280C for 30 
min to allow the cells to attach to the bottom of the flask. 
 
 
2.2.5.2.1.2  Preparation of Transfection Mixture 
 
The transfection mixture was prepared using a sterile 1.5 ml tube, briefly a 1.5 ml tube 
containing 1ml BacVector® Insect Cell Medium, 5 µl Insect GeneJuice, 5 µl BacMagic 
DNA (100 ng total), and 5µl recombinant plasmid were prepared for each transfection. For 
the negative control 5 µl of the same media was added instead of the recombinant transfer 
plasmid and for the positive control a transfection control plasmid was used (500 ng). 
Tubes were then mixed with gentle agitation and incubated at room temperature for 30 
min. 
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2.2.5.2.1.3  Co-Transfection     
 
Co-transfection was carried out by removing the culture media from each flask using a 
sterile pipette, 1 ml of the transfection mixture was added dropwise to the centre of the 
flask. Flasks were incubated overnight at 280C and 1 ml of BacVector® Insect Cell 
Medium was added to each flask after the initial incubation period was finished. Flasks 
were re-incubated for 5 days; and examined daily under the inverted microscope for signs 
of infection.  When cells demonstrated late signs of infection, cells were harvested by low 
speed centrifugation 1500 x g for 10 min. The supernatant (containing the recombinant 
virus) was transferred to a new sterile tube and stored at 40C for the next stage.  
 
 
 
2.2.5.2.1.4  Recombinant Virus Amplification 
  
 
Virus amplification was carried out using a 50 ml suspension culture. A 50 ml dilution of 
Sf9 cells (1 x106 viable cells/ml) from an exponentially growing shaker culture was 
transfected at low multiplicity of infection (MOI) of < 1 pfu/cell. The MOI was calculated 
based on the expected virus titer (1 x107 pfu/ml) using the following formula: required 
inoculum (ml) = multiplicity of infection (pfu/cell) x total number of cells / titre of viral 
stock (pfu/ml). The required volume of recombinant virus was added to the bottle and 
incubated at 150rpm on an orbital shaker at 28°C with caps containing a 0.2 µm filter for 
4-5 days. Cells were then harvested by low speed centrifugation at 1000 x g for 10 min, 
and the supernatant was transferred to another sterile bottle containing 5% (v/v) foetal calf 
serum and stored in the dark at 40C.  
 
 
2.2.5.2.1.5  Recombinant Virus Titration (TCID50) 
 
Recombinant virus titration was carried out using the tissue culture infectious dose 50% 
(TCID50) method. Briefly, a 96 well plate was seeded with Sf9 cells (2 x106 viable 
cells/ml) from an exponentially growing shaker culture. One hundred µl added to each well 
(2 x104 viable cells/100µl) and the plate was incubated for 2h at 280C to allow the cells to 
attach to the bottom of the plate. During that time a 10 fold serial dilution (10-1 - 10-10) of 
the virus was prepared in 1.5 ml tubes using BacVector® Insect Cell Medium. After 
incubation the media was removed and 100 µl of the diluted virus was added (8 duplicates 
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for each dilution), the last column was left as a negative control (containing 100 µl of non 
infected cells). Plates were then incubated for 1 h at 280C to allow the virus to be adsorbed, 
later the medium was removed and replaced by 200 µl of fresh media and the plate was 
incubated at 280C in a humidified incubator for 4-5 days. Wells containing signs of 
infection were counted and the virus titration end-point was calculated using the 
Spearman-Karber formula. An example of the calculation is shown below in Table 2.1.  
 
According to the Spearman-Karber formula: 
Log10 Median Dose = X0 – (d/2) = d (∑ri/ni) 
Where  :  
X0 = log10 of the reciprocal of the highest dilution at which all test inocula are positive. 
D =   log10 of the dilution factor (the difference between the log dilution intervals). 
ni = number of test inocula used at each individual dilution. 
ri = number of positive test inocula (out of ni). 
∑(ri/ni) = ∑ (P) = sum of the proportion of positive tests beginning at the highest dilution 
showing 100% positive results (this summation starting at dilution X0).  
 
Table 2.1 Example Results Obtained Using 8 Wells per Dilution and 0.1 cm3 
Inoculum 
 
 Virus Dilution Ni ri 
Proportion Positive 
(P) 1-P 
10-1 8 8 1 0.00 
10-2 8 8 1 0.00 
10-3 8 8 1 0.00 
10-4 8 8 1 0.00 
10-5 8 8 1 0.00 
10-6 8 8 1 0.00 
10-7 8 5 0.625 0.375 
10-8 8 2 0.250 0.750 
10-9 8 1 0.125 0.875 
10-10 8 0 0.000 0.1 
  
X0 6.0; d = 1.0 
Log 10 50% end-point dilution = (6-0.5) + (1x (8/8 + 5/8 + 2/8 +1/8))   
                  = (6-0.5) + 1 x (1+ 0.625 + 0.25 + 0.125)  
                                                   = 5.5 + 2  
                                                    = 7.5 
  
99 
 
 
Infection dose = Log10 TCDI50 inoculated (0.1cm3) = 7.5 = 107.5 TCID50 
Titre = TCID50/unit volume, usually 1cm3.  
Therefore the titre = 108.5 TCID50/cm3    
 
 
2.2.6  Protein Expression  
 
2.2.6.1  Protein Expression Optimisation 
  
Protein expression optimisation was carried out using different multiplicities of infection 
(MOI) and time duration in small scale protein expression experiments. Glass culture 
bottles (9x50ml) were seeded with 10 ml dilutions of Sf9 cells (2x106 viable cells/ml) from 
an exponentially growing shaker culture. Bottles were divided into three groups (3bottles 
for each group), each was inoculated with different MOI (5, 7, 10) and incubated at 280C. 
A bottle from each group was harvested either at 48, 72 or 96 h post-infection (POI) and 
analysed for protein expression. The optimum MOI and time of harvest was used for large 
scale protein expression. 
  
 
2.2.6.2  Large Scale Protein Expression  
 
Large scale protein expression was carried out using 100–300 ml volumes of suspension 
culture. Based on the protein optimisation results 500 or 1000 ml culture bottles were 
seeded with 100 or 300 ml of Sf9 cells (2x106 viable cells/ml) from an exponentially 
growing shaker culture. Each bottle was transfected at an MOI of 10 and incubated on an 
orbital shaker at 280C with caps containing a 0.2 µm filter for 72 h. Transfected cells were 
examined before harvesting for the appearance of late signs of infection using an inverted 
microscope. The cell pellet were either used immediately for protein purification or stored 
at -200C after performing 3 washes with ice-cold PBS (pH 7.3).   
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2.2.6.3  Protein Purification 
 
2.2.6.3.1  Protein Solubilisation 
 
Protein solubilisation was carried out using a suspension culture; Sf9 cells (2.5x108) were 
transfected at a MOI of 10 and then incubated for 3 days on an orbital shaker at 28°C. 
After late signs of infection were observed, cells were harvested by low speed 
centrifugation (2000g x 10 min), and washed 3 times with ice-cold PBS (pH 7.3). Cell 
pellets (5x107/ml) were then resuspended in ice-cold solubilising buffer (20mM Tris-HC., 
pH 7.8, 2 mM Phenylmethylsulfonyl fluoride (PMSF), 1 mM Tosyl-Lys-
chloromethylketone (TLCK)) and  then  the same volume of  buffer containing 2% (v/v) of 
Pentaethyleneglycolmonodecylether (C10E5) was added (final detergent concentration 1%). 
Cell suspensions were then incubated on ice for 2 h. After incubation cell debris was 
removed by low speed centrifugation (2000g x 10 min) and the supernatant was 
ultracentrifuged (70000g x 1h, 40C). Fifty µl of the final supernatant (containing 
solubilised protein) was stored at +40C for protein analysis and the remainder was used in 
the purification step.  
 
 
2.2.6.3.2  Protein Purification 
 
The purification was carried out using the his-bind purification kit. Briefly: in a 20 ml tube 
500 µl of Ni-NTA his-binding resin was mixed with the remainder of the solubilised 
protein (~ 10 ml). The tube was then placed on an orbital shaker (150 rpm) at room 
temperature for 2h. The purification column was assembled (chromatography column + 15 
ml collecting tube), and then the entire volume was added into the reservoir of the column. 
The column was left to flow by gravity (~ 5-10 min) at room temperature and then 
transferred to a new collecting tube and 4 ml of washing buffer was added to the column 
and left to flow through. The washing step was repeated once and the column was 
transferred to a new collecting tube and 1 ml of 1x elution buffer (4 M imidazole, 2 M 
NaCl, 80 mM Tris-HCl, pH 7.9) was added. The elution step was repeated using 500 µl in 
a new collecting tube to ensure no protein was left over in the column. All tubes were 
stored at +40C and 15 µl from each tube was used for protein analysis. 
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2.2.6.3.3  Protein Quantification  
 
The purified recombinant protein concentrations were determined using Bicinchoninic acid 
(BCA) protein assay. The assay was carried out according to the manufacturer’s 
instructions, briefly; serial dilutions of bovine serum albumin (BSA) ranging from 0 to 
100µg/ml were prepared in sterile water from a 1 mg/ml stock. Twenty five µl of each 
sample (BSA standards and protein samples) were added in triplicate into the 96-well 
assay plate, followed by the addition of 200 µl of working solution. The plate was 
incubated at 370C for 30 min and was then cooled to room temperature. The concentrations 
of BSA standard and purified proteins were then determined by measuring absorbance at 
562 nm using an ELx808 Universal Microplate Reader.  Using Microsoft Windows Excel 
2003, BSA standards results were used to create a standard curve which was used to 
determine the concentration of each purified protein in each sample.  
 
 
2.2.7  Protein Characterisation  
 
2.2.7.1  Indirect Immunofluorescence (IF) Assay  
 
Indirect immunofluorescence (IF) analysis was performed using fluorescein-conjugated 
rabbit anti mouse IgG (cell surface, cytoplasmic). Briefly, Sf9 cells were infected with 
recombinant baculoviruses expressing either HSV-1 gD or VZV gE at an MOI of 10 and 
incubated at 280C for 72 h. To examine cell surface immunofluorescence, 100 µl of cells 
were incubated with 100 µl of 1/100 dilution of either mouse anti gD or gE monoclonal 
antibody for 1 h at 370C with gentle agitation. Cells were then washed with PBS and a 20 
µl of cells were applied to the appropriate spot of the Lab-Tek chamber slides and placed 
on heating block to dry at 400C for 15 min. Slides were then fixed with 99% v/v acetone 
for 10 min at room temperature,  washed 2 times for 5 min on an orbital shaker with sterile 
distilled water, washed again and incubated with fluorescein-conjugated rabbit anti-mouse 
IgG antibody for 1 h at 370C. After incubation slides were washed again and left to air dry 
at room temperature for 10 min. To examine intracellular (total cell) immunofluorescence, 
cells were washed with PBS, and 20 µl of cells were applied to the appropriate spot on the 
slide and placed on a heating block to dry at 400C for 15 min. Slides were fixed with 99% 
v/v acetone for 20 min, washed and dried as above and incubated with 1/200 dilution of 
either mouse anti gD or gE monoclonal antibody for 1 h at 370C. Cells were then washed 
  
102 
 
and dried and incubated with fluorescein-conjugated rabbit anti-mouse IgG antibody for 1 
hr at 370C. Slides were washed again and left to air dry for 10 min at room temperature. 
Finally slides were mounted with 50 µl volume of mounting medium (glycerine buffer, 
PBS, pH 7.3) examined with an incident light fluorescence microscope. A negative control 
(non infected cells) was included in each slide for comparison. 
 
2.2.7.2  Sodium Dodecyl Sulphate Polyacrylamide gel Electrophoresis (SDS-PAGE) 
 
To determine the size of the expressed proteins, proteins were separated by sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) under denaturing and 
reducing conditions. Fourteen µl of sample (transfected cells (5x103/ml), solubilised 
protein, purification flow, first wash, second wash, first elute and second elute) were mixed 
with sample loading buffer (4µl of NuPAGE LDS sample buffer, 6µl deionised water and 
1µl reducing agent). Samples were heated at 700C for 10 min and 16µl of each sample was 
analysed using NuPAGE 4–12% Bis-Tris gel for 45 min at 200V with running buffer 
(50ml running buffer, 950ml deionised water). A Novex® Sharp Pre-Stained Protein 
Standard containing 12 pre-stained protein bands in the range of 3.5 - 260 kDa was 
electrophoresed in parallel with the test samples. The gel was removed from the tank and 
placed in a plastic container, rinsed three times for 5 minutes with 100 ml deionised water 
to remove SDS and buffer salts. Excess water was drained and 20ml of Coomassie Blue 
stain was added and kept on a shaker for 1 h at room temperature. For maximum staining 
sensitivity 20 ml of 20% NaCL was added to the same water and left on the shaker for 
another 2 h.  
 
 
2.2.7.3  Immunoblot 
 
2.2.7.3.1  Western Blot 
 
Western blot analyses were carried out under denaturing reducing conditions. After 
electrophoresis, proteins were transferred to a polyvinylidene difluoride (PVDF) 
membrane, and further developed by immunoblotting with the appropriate antibody and 
the antigen/antibody complex visualised with alkaline phosphatase- labelled antibody. In 
brief, a piece of PVDF membrane was soaked in transblotting buffer (50ml transfer buffer, 
200 ml Methanol, 750ml deionised water) for 20 min. A sandwich was made as in Figure 
  
103 
 
2.1, with a rolling motion to avoid trapping air bubbles. The sandwich cassette was 
lowered into the tank with the membrane towards the anode (+) electrode. The 
electrophoretic transblot was performed at 100 V for 50 minutes. The transblotted PVDF 
membrane was then left in blocking buffer (2.5 mg skimmed milk, 50ml PBS pH 7.3, 0.1% 
Tween 20) overnight at 40C. The PVDF membrane was incubated with gentle agitation 
either anti-HSV gD or anti-VZV gE monoclonal antibody IgG (1:2000), diluted in 
blocking buffer for 1 h at 370C. The   membrane was then washed 3 times with washing 
buffer (15ml PBS, 0.05% Tween 20) at room temperature for 5 min and incubated with 
anti mouse IgG alkaline phosphatase conjugate (1:2000) for 1h at 370C. Both primary and 
secondary antibodies were prepared in diluent buffer (10mM PBS, 0.1% Tween 20). After 
washing the membrane was incubated with one tablet of FASTTM BCIP/NBT dissolved in 
10 ml of deionised water on a rotor at room temperature until the bands appeared (10-15 
min). The membrane was rinsed with distilled water and left to dry on filter paper. 
 
 
 
 
                
Figure 2.1 Figure shows the different layers of the sandwich assembly of the western 
blotting apparatus. It consisted of 3 layers of filter paper, NuPAGE 4–12% Bis-Tris gel, 
PVDF membrane and another 3 layers of filter paper. 
  
3 Layers of Filter Paper  
NuPAGE 4–12% Bis-Tris gel
PVDF Membrane 
3 Layers of Filter Paper  
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2.2.7.3.2  Dot Blot  
 
All samples i.e. transfected cells (5x103/ml), solubilised protein, purification flow, first 
wash, second wash and eluted protein were used in dot blot analysis. Samples (35µl) were 
transferred to dot blot manifold and vacuum-absorbed onto a 0.45µ nitrocellulose 
membrane. Each sample was washed three times with 100 µl of washing buffer  (10mM 
PBS, 0.05% Tween 20) air-dried and then blocked in blocking buffer (2.5 mg skimmed 
milk, 50ml PBS pH 7.3, 0.1% Tween 20) overnight at 4°C. The membrane was then 
incubated with anti-HSV gD or anti-VZV gE monoclonal antibody IgG (1:2000), diluted in 
blocking buffer for 1 h at 370C with gentle agitation. Membranes were then washed 3 times 
with washing buffer (15ml PBS, 0.05% Tween 20) at room temperature for 5 min and 
incubated with anti mouse IgG alkaline phosphatase conjugate (1:2000), diluted in diluent 
buffer (10mM PBS + 0.1% Tween) for 1 h at 370C. After further washing at room 
temperature, membrane was immersed in a solution of one tablet of SIGMA FASTTM 
dissolved in 10 ml of deionised water on a rotor at room temperature until the bands 
appeared (10-15 min). The membrane was rinsed with distilled water and left to dry on 
filter paper. 
 
 
2.2.7.4  Enzyme-linked Immunosorbent Assay (ELISA) 
 
All samples i.e. transfected cells (5x103/ml), purification flow, first wash, second wash and 
1 and 2 eluted protein for each virus was used in ELISA analysis. A two-fold dilution of 
each sample from 1:100 to 1:800 of HSV-1 gD and VZV gE was prepared in coating 
buffer (PBS pH 7.3), and 100 µl of each diluted protein was added to selected wells and 
incubated overnight at 40C. The plate was then washed 5 times with washing buffer 
(10mM PBS pH 7.3, 0.05% Tween 20) using an automated universal microplate washer. 
one hundred µl of diluted (1/2000) mouse monoclonal antibody against HSV gD or VZV 
gE in diluent buffer (10mM PBS pH 7.3, 0.1% Tween 20) was added to the appropriate 
well and incubated at 370C for 1 h in humid box. The plate was washed and dried, and 100 
µl of anti-mouse IgG horseradish peroxidase (HRP) conjugate (1:2000) was added to all 
wells and incubated for 30 min at 370C. Plates were then washed again and colour reaction 
was developed by adding 100 µl of ABTS substrate to each well. After incubation at room 
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temperature for 10 to 15 min, absorbances were read at 405 nm using an ELx808 Universal 
microplate reader.  
 
 
 
2.2.8  Evaluation of the Performance of Peptide 55 Assay for Detecting HSV-2 IgG 
Antibody in Human Serum 
 
To evaluate the performance of the PATHOZYME™ VIRO HSV-2 ELISA IgG assay 
based on peptide 55 for the detection of HSV-2 IgG antibodies, the assay was compared 
with 2 other commercially available ELISA kits; HerpeSelect HSV-2 (Focus Diagnostics, 
Cypress, CA, USA), based on purified recombinant type-specific gG-2 antigen and 
Bioelisa HSV-2 IgG type specific assay (Biokit, S.A, Barcelona-Spain) based on purified 
gG2 protein. The three assays are referred to in this study as the HerpeSelect, Bioelisa, and 
Omega assays, respectively. A well characterised serum panel consisting of 254 serum 
samples were used for the evaluation of the Omega assay (Panel 1) 
 
 
 
2.2.8.1  Omega Assay 
 
According to the manufacturer’s instructions, kit components and test serum were brought 
to room temperature (200C to 250C) before starting the assay. Coated plates were soaked 
with 300 µl of diluted washing buffer and incubated for 5 min at room temperature. The 
buffer was removed by striking the wells (upside down) against absorbent paper. A 50 µl 
volume of assay controls (ready-to-use high-positive, low-positive and negative) or diluted 
test sera (1:10 in serum diluent reagent) were added to the appropriate well in the plate. 
Assay controls were tested in duplicate and 1 well was left empty to serve as a substrate 
“blank”. The plate was covered with a lid and incubated for 1 h at 370C and then washed 3 
times with an automated ELISA plate washer. Fifty microliters of anti-human IgG HRP 
conjugate was added to each well and covered with a lid and incubated for 30 min at 370C. 
The plate was washed as above and a 100 µl of substrate was added per well including the 
blank well. After 15 min incubation at room temperature, the enzymatic reaction was 
stopped by addition of 100 µl of stop solution. Absorbances were read on an automated 
ELx808 Universal Microplate Reader at 450 nm immediately after stopping the reaction.         
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2.2.8.2  HerpeSelect Assay  
 
Assay components were brought to room temperature prior to starting the assay and the 
coated plate was soaked with 300 µl of diluted washing buffer which was  incubated for 5 
min at room temperature and buffer removed by striking the wells against absorbent paper. 
A 100 µl volume of the sample diluent for the “blank” well and 100 µl of each 
specimen; assay control (negative and positive) calibrators were tested in duplicate and test 
sera (diluted 1:101 in serum diluent reagent) added to the appropriate wells in the plate. 
The plate was covered with a lid and incubated for 1 h at room temperature (200C to 
250C), before being washed 3 times with washing buffer. One hundred microliters of anti-
human IgG HRP conjugate was added to each well, the plate was covered with a lid and 
incubated for 30 min at room temperature. The plate was washed as above and a 100 µl 
of substrate was added per well including the blank well. After 10 min incubation at room 
temperature, the enzymatic reaction was stopped by addition of 100 µl of stop solution and 
absorbances were read at 450 nm within 1 hour of stopping the assay.  
 
 
 
2.2.8.3  Bioelisa Assay 
 
Assay components were brought to room temperature and gently mixed prior to use, then 
100 µl of each diluted specimen (1/100); test sera or controls were added to the 
corresponding wells, the blank well left empty.  The plate was covered with lid, incubated 
for 1 h at 370C, washed 3 times with washing buffer and then left on absorbent tissue to 
remove any excess liquid from the wells. One hundred microliters of anti-human IgG HRP 
conjugate was added to each well except the blank. The plate was covered with a lid and 
incubated for 30 min at 370C. The plate was then washed as above and a 100 µl of 
substrate-TMB solution was added to each well including the blank. After 30 min 
incubation at room temperature, the enzymatic reaction was stopped by addition of 100 µl 
of stop solution and absorbances were read at 450 nm. 
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2.2.8.4  Virotech HSV-1 Assay 
 
All samples (254) were retested using Virotech HSV-1 type specific gG-1 IgG assay 
according to the manufacturer’s instructions. Assay components were first brought to room 
temperature and gently mixed prior to use, 100 µl of the ready to use sample diluent for 
the “blank” well and 100 µl of the assay negative control and cut-off control were tested 
in duplicate.  Test sera (diluted 1:100 in serum diluent reagent) were added to the 
appropriate well in the plate. The plate was covered with a lid, incubated for 30 min at 
370C, washed 4 times with washing buffer and then left on absorbent tissue to remove any 
excess liquid from the wells. One hundred microliters of anti-human IgG HRP conjugate 
was added to each well which was covered with a lid and incubated for 30 min at 370C. 
The plate was washed as above and 100 µl of substrate solution was added to each well. 
After 30 min incubation at 370C, the enzymatic reaction was stopped by addition of 50 µl 
of stop solution and absorbances were read at 450/650 nm. 
 
 
2.2.8.5  Western blot Assay  
 
All samples that gave discordant results with the three assays where sent to Alva 
Diagnostics Laboratories (Omega, Scotland, UK) for Western blot analysis. Briefly; assay 
was performed using a Mini-Protean 3 Electrophoresis Cell (Bio-Rad Laboratories, Hemel 
Hempstead, UK) according to the manufacturers instructions. HSV antigens were prepared 
from baby hamster kidney cells infected with either HSV-1 strain 17 syn
+ 
(Brown et al., 
1973) or HSV-2 strain HG52 (Timbury, 1971). Proteins were separated by SDS 
polyacrylamide gel electrophoresis using concentrations of acrylamide in the stacking and 
resolving gels of 5% and 7% respectively. Gels were made with acrylamide cross linked 
with bis-acrylamide (19 to 1). After transfer of the proteins to a nitrocellulose membrane, 
the membrane was blocked with blocking buffer (4% newborn calf serum and 3% bovine 
serum albumin in Tris-buffered saline) then the membrane was cut into strips. The strips 
were incubated overnight in blocking buffer with either human serum diluted 100-fold, or 
gG1 or gG2-specific monoclonal antibodies diluted 10,000-fold (East Coast Bio Inc., 
Miami, USA, cat. no. H1A020 and H2A023 respectively). Strips were washed and bound 
human antibodies were detected with peroxidise-conjugated goat anti-human antibodies 
while bound gG1- and gG2-specific mouse monoclonal antibodies were detected with 
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peroxidise-conjugated goat anti-mouse antibodies. Following visualisation of bands with a 
fluorometric substrate the sera were scored as positive or negative for HSV-2 antibodies 
according to whether a typical gG2 band appeared. 
 
 
2.2.8.6  Index Value Calculation 
 
The Index Value of each assay was calculated according to the manufacturer’s instructions. 
Briefly:  In HerpeSelect an index values was obtained for each sample run, based on the 
absorbance of the patient sample divided by the mean absorbance of the cut-off calibrator; 
an index value of <0.9 and > 1.1 were defined as negative and positive respectively and  a 
value of  ≥ 0.9  but ≤ 1.1 was considered equivocal. In the Omega  and Bioelisa ELISA kits 
index values were obtained for each sample run, based on the absorbance of the patient 
sample divided by the mean absorbance of the cut-off  (low-positive control). A ratio of 
<0.9 and > 1.1 was considered negative and positive respectively and a ratio of ≥ 0.9 but ≤ 
1.1 was considered equivocal. In the Virotech assay results were expressed as Virotech 
units, where < 9.0 was considered negative and from ≥ 9.0 but ≤11.0 was considered 
equivocal and > 11.0 was considered positive.  
 
 
 
2.2.8.7  Statistical analysis 
 
The correlation (r) between Omega assay and other ELISA assays was calculated in 
Microsoft® Excel 2007 using the Pearson’s product-moment coefficient function. The 
probability (P) of observing each r value (if the null hypothesis that there is no relation 
between the two measurements was true) was calculated using correlation P calculator in 
Microsoft® Excel 2007. Assay sensitivity, specificity, positive and negative productive 
value was calculated using the Focus assay as a reference test according to the following 
method: 
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Test Results (ELISA Assay) 
 
 Positive Negative 
Positive d c Reference Test 
Negative b a 
 
Where: d: True Positive c: False Negative 
  b: False Positive a: True Negative 
 
Therefore:  
 
Sensitivity = d / (c+d) x 100 
Specificity = a / (a+b) x 100 
Positive productive value = d / (b+d) x 100 
Negative productive value = a / (a+c) x 100 
 
 
2.2.9  Development of an In-house ELISA Using HSV-1 gD and VZV gE 
 
The HSV-1 gD and VZV gE recombinant proteins were used to develop an in-house 
ELISA to detect IgG antibody against each virus in human sera. Optimisation of the in-
house ELISA assay was carried out by checkerboard titration using different ELISA plate 
and coating buffers. 
 
 
2.2.9.1  Determining the Optimal Dilution of Antigen and Human Serum 
 
A two-fold dilution series from 1:25 to 1:3200 of HSV-1 gD and VZV gE was prepared in 
coating buffer (PBS pH 7.3). A 100 µl volume of each diluted antigen was added to all 
wells in each column on the 96 microtitre plate from column 1-11 and incubated overnight 
at 40C. Plates were then washed 5 times with washing buffer (10mM PBS pH 7.3, 0.05% 
Tween 20) using an automated universal microplate washer. For determining the optimal 
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dilution of human serum a two-fold dilution of a clinical standard reference serum (high 
positive for HSV-1 and HSV-2) starting from 1:25 to 1:3200 was prepared in serum diluent 
buffer (10mM PBS pH 7.3, 0.1% Tween 20) and was added to all rows from A1-A10. 
Column 11 was used as a serum control (no human serum was added) and column 12 was 
used as blank. The plates were then incubated at 37°C for 1 h in a humid box before 
washing as above. A 100 µl volume of anti-human IgG HRP conjugate (1:2000) was added 
to all wells and plates were incubated for 30 min at 370C and then washed as above. Later 
plates were washed again and colour reaction was developed by adding 100 µl of substrate 
ABTS to each well and incubating at room temperature for 10 to 15 min. Absorbances 
were read at 405 nm using an ELx808 Universal microplate reader. Based on the 
optimisation results, human sera from each individual panel were tested using the standard 
ELISA method.                          
  
 
2.2.9.2  ELISA Standard Method   
  
Costar microtitre ELISA ”medium binding” plates were coated with 100μl of recombinant 
HSV gD or VZV gE protein  diluted to a final optimized concentration of 0.50µg/ml in 
coating buffer (PBS, pH 7.3), and incubated overnight at 40C. The plates were washed 5 
times with washing buffer (PBS, 0.05% Tween 20, pH 7.3) and tapped dry on paper towels 
then blocked with blocking buffer (2% BSA in wash buffer) for 1h at 370C, and then 
washed and dried.  A standard curve was generated by making two-fold dilutions (1/10 to 
1/10240) using a clinical standard reference serum (strongly positive for HSV-1, HSV-2 
and VZV antibody) tested in duplicate, other samples, patient serum, and  controls  were 
diluted 1:100 in sample diluent buffer (PBS, 0.1% Tween 20, pH 7.3). One hundred 
microliters of each diluted sample, standard, controls (positive and negative sample) and 
patient serum were added to the coated plates and incubated at 37 0C for 1h, then washed 5 
times with wash buffer. After washing 100 µl of diluted mouse anti-human IgG (1/2000) 
conjugated with horseradish peroxidase in sample diluent buffer was added to the plates 
and incubated for 30 min at 370C. The plate was washed again and colour reaction was 
developed by adding a 100 µl of substrate ABTS to each well and incubating at room 
temperature for 10 to 15 min. Absorbances were read at 405 nm using an ELx808 
Universal Microplate Reader. A diagram of the ELISA experiment procedure is shown in 
Figure 2.2.  
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Figure 2.2  ELISA plate was coated with the recombinant protein overnight at 40C, 
washed and then incubated at 370C with the 100 µl of selected sample. Plates were washed 
again and re-incubated with antibody conjugated to horseradish peroxidase. Finally 100 µl 
of anti-human IgG conjugated with substrate was added and left until the colour developed 
at room temperature and the absorbance was read at 405nm. 
 
 
 
 
2.2.9.3  Statistical Analysis of ELISA Results 
 
The cut-off point of each assay was determined by calculating the mean absorbance of 8 
negative control samples plus 3 standard deviations. Intraplate, interplate, and day-to-day 
variation of the ELISA was evaluated by repeated analysis of 10 serum samples (negative 
and positive). Sensitivity, specificity, positive and negative predictive values were 
determined as described above (section 2.2.11.5) using Western blot and Liaison assays as 
a reference test  for HSV-1 gD and VZV gE respectively. 
                                   Step 1:                                   Step 2:                                         Step 3:                                        Step 4: 
                                                       
                        Coat plate with            Human or Mouse-anti-HSV-1 gD      Goat-anti-Human or Mouse        Substrate ABTS      
                     HSV-1gD or VZV gE              or VZV gE antibody                             IgG-Peroxidase    
          
   
 
                           Proteins ® Conc. 
M
easure color
     
change           
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2.2.10  Development of a Fluorescence Microbead Immunoassay (FMIA) for the 
Detection of IgG Antibody to HSV-1, HSV-2 and VZV in Human Sera 
 
2.2.10.1  Acceptance Criteria for HSV-1 gD, Peptide 55 and VZV gE Microbead 
Immunoassay 
 
To ensure accurate measurement and maximum reproducibility of the assay the acceptable 
criteria for evaluation of assay results were defined as follows:-  
 
1- Fluorescence analysis data for each well should be obtained from 100 
beads/region/well.  
2- Beads aggregation percentage for each replicate well should be ≤ 50%. 
3- Background readings for each antigen (Blank well) should be ≤ 100 mean 
fluorescence intensity (MFI). 
4- The standard deviation between each duplicate reading should be ≤ 30% between 
all standard replicates.  
5- When the plate met the acceptance criteria, each antigen was assessed individually.  
 
 
2.2.10.2  Standard Curve Generation  
 
To generate a standard curve for each analyte the same clinical standard positive serum 
sample used in the ELISA assay was included in each plate. In order to quantitate the 
concentration of any analyte, the response that was produced by the tested sample was 
compared with the standard curve. The unknown sample concentration was determined by 
interpolation from the standard curve. Since the amounts of the antibody for each virus in 
the clinical positive standard serum were unknown the standard was defined to contain an 
arbitrary number of units of specific antibodies AB units (ABU), the standard serum 
contained 3200 ABU for VZV and 4800 ABU for HSV-1 and 4800 ABU for HSV-2. 
Results for each tested sample were reported as ABU/mL of specific antibody. 
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2.2.10.3  Microsphere Coupling Method 
 
The purified recombinant proteins HSV-1 gD, VZV gE and peptide 55 were coupled to 
different SeroMAP carboxylated microspheres, using a standard modified two step 
carbidiimide reaction (Staros et al., 1986). The coupling procedure was carried out using 
6.25x 106 (500 µl) of the original microspheres (region 10, 15, or 20). Beads were 
collected by vacuum filtration and washed twice with freshly prepared PBS (0.14M 
sodium chloride, 0.021M potassium phosphate, 0.013M sodium phosphate, and 0.0021M 
potassium chloride pH 7.3) by centrifugation at 13,000g for 2 min, aspiration of the 
supernatant, addition of 200 µl of PBS, sonification for 30 seconds, and resuspension of 
the pellet in 500 µl of PBS. Five hundred µl of freshly prepared activation buffer (PBS, 5 
mg/ml of EDC, 5mg/ml Sulpho-NHS, pH 7.3) was added to each set of beads, the 
suspension was then incubated for 30 min at room temperature on an orbital shaker in the 
dark. The activated beads were washed twice as described above and resuspended in 100 μl 
of gD (50µg/ml), gE (50µg/ml) and peptide 55 (25µg/ml) diluted in pyrogen free water and 
incubated for 1.5 h at room temperature on an orbital shaker in the dark. Microspheres 
were then pelleted by centrifugation, washed again, and resuspended in 1 ml of PBS and 
stored at 40C in the dark until use.  
 
 
2.2.10.4  Beads Calculation 
 
Bead suspensions were counted by adding  9 µl of bead suspension to a fast read counting 
chamber under a light microscope, the number of beads in the large squares were counted 
(contains 16 small squares). The total number of beads in each 1 ml was calculated as 
follows: 
 
Number of beads in 1 ml (n) = (Total number of beads ÷ no of grids counted) 106   
15000 / region/ 25 µl to be added  
Bead dilution = (beads count / 40) ÷ 15000 
Total PBS volume required = ((no of wells x 2) + 2) 25 
Beads volume required = total volume required ÷ beads dilution   
PBS volume required = total volume required – bead volume 
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Example  
If the total beads count was = 5.5 x 106 
Beads dilution = (5.5 x 106 ÷ 40)/ 15000 = 9.17 
Total volume required = (96 wells x2) +2) 25 = 4850 µl  
Beads volume required = 4850 ÷ 9.17 = 525.9 µl  
PBS volume required = 4850 – 525.9 = 4324.1 µl 
 
 
2.2.10.5  Triplex Microbead Immune Assay for the Quantitation of HSV-1, HSV-2 
and VZV IgG in Human Sera   
 
A standard curve was generated by making two-fold dilutions (1/10 to 1/10240) using the 
standard clinical serum sample tested in duplicate. Other patient serum and controls 
(known positive and negative samples) were diluted 1:100 (2 µl sample + 198 µl of serum 
diluent) in sample diluent buffer (1% NBBS, PBS pH 7.3, 0.05% Tween 20). Twenty five 
µl of each sample (diluted standard, assay controls, patient sera) was added in duplicate to 
each well of a 96-well filter bottom microtitre plate. In each plate 25 µl of sample diluent 
was added to the first 2 wells of the plate as a blank. Then 25 µl of premixed coupled 
microsphere bead (5000/region/well) was added to each well and the plate was protected 
from exposure to light and incubated at room temperature on an orbital shaker for 30 min. 
Plates were then washed 3 times with 100 µl of wash buffer (PBS, 0.05 % Teen 20) using a 
vacuum filtration manifold, 100 µl per well of 2.5 µg/ml of R-Phycoerythrin-conjugated 
goat anti-human IgG was added. Following 30 min incubation at room temperature and 
washing, the microspheres were resuspended in 125 µl of washing buffer and read using a 
BioPlex 200 workstation. Sample data were produced from a 5-parameter logistic curve 
(5PL). 
 
 
2.2.10.6  Beads Interference Testing   
 
The interference between all bead sets were carried out by comparing the results of the 
standard curves obtained from each assay for each single analyte and the triplex analyte 
assays. 
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2.2.10.7  Statistical Analysis  
 
The cut-off point of each assay was determined by calculating the mean MFI of 10 
negative samples plus 3 standard deviations and the minimal levels of detection were 
determined for each assay. Assay reproducibility was determined by measuring intra and 
inter assay variation, for intra-assay variation the mean percentage coefficient of variation 
(CV) of 10 samples tested in duplicate within the same plate were calculated. Inter-assay 
variation was determined by testing 10 serum samples in duplicate on two different days, 
and the CV was calculated. Sensitivity and specificity were determined for all assays by 
comparing the results from each assay with its related ELISA assay.  
 
 
 
2.2.11  Development of Bi-plex Assay for the Quantitation of Albumin and IgG in 
Human Serum and CSF samples 
 
2.11.1  Microsphere Coupling Method  
 
The development of the bio-plex assay for the quantitation of albumin and IgG was 
modified from the method described by Al Jindan (2009). Briefly, five hundred µl (6.25x 
106) of SeroMAP carboxylated microspheres beads (region 25 and 30), were washed and 
activated as described before (section 2.10.5). Activated beads were then resuspended in 
100 µl of monoclonal anti-human IgG, or monoclonal anti-human albumin diluted in 
pyrogen free water to a final optimised concentration of 2.5 μg/ml. Beads were then 
incubated for 1.5 h at room temperature on an orbital shaker in the dark, pelleted by 
centrifugation, resuspended in 125 µl of washing buffer and read using a BioPlex 200 
workstation. The standard carve was a 5-parameter logistic curve (5PL). 
 
 
2.2.11.2  Biplex Assay for the Quantitation of Albumin and IgG in Human Serum and 
CSF samples 
 
A standard curve was generated by making 10 two-fold dilutions (1/10 to 1/10240) of the 
human serum standard tested in duplicate starting from (3.9µg/dl for IgG and 5µg/dl for 
albumin), other samples and controls were diluted 1/10000. Beads were then collected by 
vacuum filtration and washed twice with freshly prepared PBS, and a 25 µl of premixed 
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coupled microspheres for both anti-human IgG and anti-human albumin (5000/regen/well) 
was added to each well of the 96-well filter bottom microtitre plate. One hundred µl per 
well 2.5 μg/ml of R-Phycoerythrin-conjugated goat anti-human IgG and 100 µl of 2.0 
μg/ml of biotin conjugated with goat anti-human albumin was added to each well. 
Following 30 min incubation at room temperature and 2 washing steps, 100 µl of 
streptavidin R-Phycoerythrin was added to each well. After another 30 min incubation and 
washing, the microspheres were resuspended in 125 µl of washing buffer and read using a 
BioPlex 200 workstation. The standard curve was a 5-parameter logistic curve (5PL). 
 
 
2.11.3  Statistical Analysis  
 
The cut-off point of the assay was determined by calculating the mean MFI of 10 blank 
samples plus 3 standard deviations and the minimal levels of detection were determined for 
each assay. Assay reproducibility was determined by measuring intra and inter assay 
variation, for intra-assay variation the mean percentage coefficient of variation (CV) of 10 
samples tested in duplicate within the same plate were calculated. Inter-assay variation was 
determined by testing 10 serum samples in duplicate on two different days, and the 
percentage CV was calculated.  
 
 
2.2.12 Development of Multiplex Microbead Immunoassay for Detection and 
Quantitation of IgG Antibody Response to HSV-1, HSV-2, VZV, Albumin and IgG in 
Human Serum and CSF 
 
A standard curve was generated by making 12, 4-fold dilutions (1/10 to 1/10485760), of 
the clinical standard serum sample (starting from 0.3g/l for albumin and 0.05g/l for IgG) 
tested in duplicate, other samples and controls were diluted to 1/500 and 1/5000 for serum 
and CSF respectively. Beads were then collected by vacuum filtration and washed twice 
with freshly prepared PBS, and 25 µl of premixed coupled microspheres (25000/well) was 
added to each well of the 96-well filter bottom microtitre plate. One hundred µl per well of 
diluted R-Phycoerythrin-conjugated goat anti-human IgG (1/200) and 100 µl of diluted 
biotin conjugated with goat anti-human albumin (1/999) was added to each well. 
Following 30 min incubation at room temperature and 2 washing steps, 100 µl of 
streptavidin R-Phycoerythrin (1/400) was added to each well. After 30 min incubation and 
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a second washing step the microspheres were resuspended in 125 µl of washing buffer and 
read using a BioPlex 200 workstation. The standard carve was a 5-parameter logistic curve 
(5PL). 
 
 
2.2.12.1  Beads Interference and Statistical Analysis 
 
Bead interference was tested as described before, the results obtained from the standard 
curves of each assay for each single analyte were compared with its relevant curve in the 
multiplex assays. The cut-off point of the assay was determined by calculating the mean 
MFI of 10 blank samples for human IgG and albumin and 10 negative samples for HSV-1, 
HSV-2 and VZV plus 3 standard deviations.  The high and minimal levels of detection 
were also determined. Assay reproducibility was determined by measuring intra and inter 
assay variation. 
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3. Results   
 
3.1 Determining the Sequence of gD of HSV-1 and VSV gE 
 
 
 
Nine complete sequences for the full HSV-1 gD gene and 12 sequences for the VZV gE 
gene obtained from Gene Bank were analyzed and compared with each other. Alignment 
analyses used the BioEdit Sequence Alignment Editor Programme. Both HSV-1 gD and 
VZV gE sequences were found to be identical for all isolates. The full length of HSV-1 
was 1185 bp spanning the region 138419 to 139603bp of HSV-1 genome, and the full 
length of VZV gE was 1872bp spanning the region 115808 to 117679 of the VZV genome. 
The sequence of HSV-1 gD (accession NC001348) and VZV gE (accession NC001348) 
gene was selected for this study. Both selected sequences are shown in Tables 3.1 and 3.2.  
 
 
 
Table 3.1 The Full Open Reading Frame Sequence of HSV-1 gD (Accession 
NC001348) 
 
 Sequence 
      1 
    61 
  121 
  181 
  241 
  301 
  361 
  421 
  481 
  541 
  481 
  541 
  601 
  661 
  841 
  901 
  961 
1021 
1081 
1141 
atgggggggg ctgccgccag gttgggggcc gtgattttgt ttgtcgtcat agtgggcctc 
catggggtcc gcggcaaata tgccttggcg gatgcctctc tcaagatggc cgaccccaat 
cgctttcgcg gcaaagacct tccggtcctg gaccagctga ccgaccctcc gggggtccgg 
cgcgtgtacc acatccaggc gggcctaccg gacccgttcc agccccccag cctcccgatc 
acggtttact acgccgtgtt ggagcgcgcc tgccgcagcg tgctcctaaa cgcaccgtcg 
gaggcccccc agattgtccg cggggcctcc gaagacgtcc ggaaacaacc ctacaacctg 
accatcgctt ggtttcggat gggaggcaac tgtgctatcc ccatcacggt catggagtac 
accgaatgct cctacaacaa gtctctgggg gcctgtccca tccgaacgca gccccgctgg 
aactactatg acagcttcag cgccgtcagc gaggataacc tggggttcct gatgcacgcc 
cccgcgtttg agaccgccgg cacgtacctg cggctcgtga agataaacga ctggacggag 
attacacagt ttatcctgga gcaccgagcc aagggctcct gtaagtacgc cctcccgctg 
cgcatccccc cgtcagcctg cctctccccc caggcctacc agcagggggt gacggtggac 
agcatcggga tgctgccccg cttcatcccc gagaaccagc gcaccgtcgc cgtatacagc 
ttgaagatcg ccgggtggca cgggcccaag gccccataca cgagcaccct gctgcccccg 
gagctgtccg agacccccaa cgccacgcag ccagaactcg ccccggaaga ccccgaggat 
tcggccctct tggaggaccc cgtggggacg gtggcgctgc aaatcccacc aaactggcac 
atcccgtcga tccaggacgc cgcgacgcct taccatcccc cggccacccc gaacaacatg 
ggcctgatcg ccggcgcggt gggcggcagt ctcctggcag ccctggtcat ttgcggaatt 
gtgtactgga tgcaccgccg cactcggaaa gccccaaagc gcatacgcct cccccacatc 
 cgggaagacg accagccgtc ctcgcaccag cccttgtttt actag
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Table 3.2 The Full Open Reading Frame Sequence of VZV gE (accession NC001348) 
 
No Sequence 
      1 
    61 
  121 
  181 
  241 
  301 
  361 
  421 
  481 
  541 
  481 
  541 
  601 
  661 
  841 
  901 
  961 
1021 
1081 
1141 
1201 
1261 
1321 
1381 
1441 
1501 
1561 
1621 
1681 
1741 
1801 
1861 
atggggacag ttaataaacc tgtggtgggg gtattgatgg ggttcggaat tatcacggga 
acgttgcgta taacgaatcc ggtcagagca tccgtcttgc gatacgatga ttttcacatc 
gatgaagaca aactggatac aaactccgta tatgagcctt actaccattc agatcatgcg 
gagtcttcat gggtaaatcg gggagagtct tcgcgaaaag cgtacgatca taactcacct 
tatatatggc cacgtaatga ttatgatgga tttttagaga acgcacacga acaccatggg 
gtgtataatc agggccgtgg tatcgatagc ggggaacggt taatgcaacc cacacaaatg 
tctgcacagg aggatcttgg ggacgatacg ggcatccacg ttatccctac gttaaacggc 
gatgacagac ataaaattgt aaatgtggac caacgtcaat acggtgacgt gtttaaagga 
gatcttaatc caaaacccca aggccaaaga ctcattgagg tgtcagtgga agaaaatcac 
ccgtttactt tacgcgcacc gattcagcgg atttatggag tccggtacac cgagacttgg 
agctttttgc cgtcattaac ctgtacggga gacgcagcgc ccgccatcca gcatatatgc 
ttaaaacata caacatgctt tcaagacgtg gtggtggatg tggattgcgc ggaaaatact 
aaagaggatc agttggccga aatcagttac cgttttcaag gtaagaagga agcggaccaa 
ccgtggattg ttgtaaacac gagcacactg tttgatgaac tcgaattaga cccccccgag 
attgaaccgg gtgtcttgaa agtacttcgg acagaaaaac aatacttggg tgtgtacatt 
tggaacatgc gcggctccga tggtacgtct acctacgcca cgtttttggt cacctggaaa 
ggggatgaaa aaacaagaaa ccctacgccc gcagtaactc ctcaaccaag aggggctgag 
tttcatatgt ggaattacca ctcgcatgta ttttcagttg gtgatacgtt tagcttggca 
atgcatcttc agtataagat acatgaagcg ccatttgatt tgctgttaga gtggttgtat 
gtccccatcg atcctacatg tcaaccaatg cggttatatt ctacgtgttt gtatcatccc 
aacgcacccc aatgcctctc tcatatgaat tccggttgta catttacctc gccacattta 
gcccagcgtg ttgcaagcac agtgtatcaa aattgtgaac atgcagataa ctacaccgca 
tattgtctgg gaatatctca tatggagcct agctttggtc taatcttaca cgacgggggc 
accacgttaa agtttgtaga tacacccgag agtttgtcgg gattatacgt ttttgtggtg 
tattttaacg ggcatgttga agccgtagca tacactgttg tatccacagt agatcatttt 
gtaaacgcaa ttgaagagcg tggatttccg ccaacggccg gtcagccacc ggcgactact 
aaacccaagg aaattacccc cgtaaacccc ggaacgtcac cacttatacg atatgccgca 
tggaccggag ggcttgcagc agtagtactt ttatgtctcg taatattttt aatctgtacg 
gctaaacgaa tgagggttaa agcctatagg gtagacaagt ccccgtataa ccaaagcatg 
tattacgctg gccttccagt ggacgatttc gaggactcgg aatctacgga tacggaagaa 
gagtttggta acgcgattgg agggagtcac gggggttcga gttacacggt gtatatagat 
 aagacccggt ga 
 
 
 
3.2 Primer Design  
 
 
 
 
Since there was no variation between the sequences obtained from Genbank for HSV-1 
and VZV, the full published genome sequence for both viruses was used to design primers 
for amplification. The forward and reverse primers for each virus were designed by adding 
an extra sequence from the 5’ end (underlined) to develop an overhang for the directional 
cloning target of the PCR product in the 3C/LIC vector. There were no virus encoding 
sequences present after the termination codon (TAG) at the 3' end. Blast alignment results 
showed 100% homology with all published isolates for both viruses, primers were then 
synthesised commercially (Invitrogen). Primers used for amplification of each gene are 
detailed in Table 3.3 and 3.4. 
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Table 3.3 Primers Used for Amplification of the Full Length of HSV-1 gD  
 
Primer 
name (gene) 
 
Primer sequence 
 
Length 
Product 
size 
(bp) 
HSVgDF 5’-CAGGGACCCGGTATGGGGGGGGCT-3’ 24 bases 
HSVgDR 5’GGCACCAGAGCGTTCTAGTAAAACAAGGGCTGG3’ 33 bases 
1211 bp 
 
 
Table 3.4 Primers Used for Amplification of the Full Length of VZV-1 gE  
 
Primer 
name (gene) 
 
Primer sequence 
 
Length 
Product 
size 
(bp) 
VZVgEF 5’-CAGGGACCCGGTATGGGGACAGTTAATAAA-3’ 30 bases 
VZVgER 5’-GGCACCAGAGCGTTTCACCGGGTCTTATCTAT-3’ 32 bases 
1898 bp 
 
 
 
3.3 Amplification and Thermo-cycling Profile  
 
3.3.1 Amplification of HSV-1 gD 
 
 
 
 
Amplification of HSV-1 gD was carried out using the GeneAmpR PCR system 9700 
thermal cycler. The first attempt was carried out using 5 µl of the positive controls added 
to a 45 µl master mix reaction (in a final volume of 50 µl), containing 5 µl of 10×buffer 
(50mM KCl, 1.5mM MgCl2 and10mM Tris-HCl; pH 8.3), 1 µl (10mM) of dNTP, 0.5 
(50mM) of MgCl2, 0.25 µM of each oligonucleotide primer, 38 µl SDW and 0.25 U of 
AmpliTaq DNA polymerase. The cycling program used included a single initial 
denaturation at 94 oC for 12 min followed by 40 cycles of denaturation at 94 oC for 30 
seconds, annealing at 500C for 30 seconds and extension at 72 0C for 30 seconds. Results 
showed inadequate amplification was observed when using AmpliTaq DNA polymerase 
(Figure 3.1). AmpliTaq Gold was therefore used together with some modification in 
cycling parameters and reagent concentration.  The reaction mixture comprised: 5 µl of 
10×buffer (50mM KCl, 1.5mM MgCl2 and10mM Tris-HCl; pH 8.3), 1µl (10mM) of each 
dNTP, 1µM of each oligonucleotide primer, 36.5 µl SDW and 0.5 U of AmpliTaq gold 
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DNA polymerase. The cycling program used included a single initial denaturation at 940C 
for 6 min followed by 40 cycles of denaturation at 940C for 1 minute, annealing at 580C for 
1 min and extension at 720C for 1 min. Results showed a clear band with the expected size 
(1210 bp). The PCR product was then purified using a modified Microcon centrifuge 
method and stored at -200C (Figure 3.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 2% E-Gel® agarose gel electrophoresis illustrating the first attempts at 
amplifying HSV-1 gD. Lane 1 contains E-Gel® Low Range Quantitative DNA Ladder. 
Lane 2, 3 and 4 PCR products. Negative controls Lane 5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
1211 bp 
1 2 3 4 5
2000 bp 
  800 bp 
400 bp 
  200 bp 
100 bp 
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Figure 3.2 2% E-Gel® agarose gel electrophoresis shows a clear HSV-1 gD PCR product 
with the expected size (1210pb) in lane 2 and 3. Negative controls lane 4. 
 
 
 
 
3.3.2 Amplification of VZV gE 
 
 
 
Difficulty was encountered in amplifying the full open reading frame containing VZV gE. 
In initial experiments 5 µl of the positive control was added to 45 µl of master mix reaction 
(giving a final volume of 50 µl), containing 5 µl of 10×buffer (50mM KCl, 1.5mM MgCl2 
and10mM Tris-HCl; pH 8.3), 1 µl (10mM) of dNTP’s, 1.5 µl (50mM) of MgCl2, 0.75 µM 
of each oligonucleotide primer, 36.5 µl SDW and 0.25 U of AmpliTaq Gold DNA 
polymerase. The cycling program used included a single initial denaturation at 940C for 6 
min followed by 40 cycles of denaturation at 940C for 1 min, annealing at 580C for 1 min 
and extension at 720C for 1 min. However, no product was detected. Modification of 
MgCl2 2.25 (50mM), concentration and cycling parameters was then attempted. The 
cycling parameters included, a single initial denaturation at 940C for 6 min followed by 40 
cycles of denaturation at 940C for 1 min, annealing at 550C for 1.30 min and extension at 
720C for 1 min. However still, no band could be detected.  To confirm that the starting 
1210 bp 
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400 bp 
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100 bp 
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material (positive control) used was not the problem, another PCR was performed using 
primers amplify a 275 bp target in the thymidine kinase gene of VZV (Table 3.5). The 
amplification conditions were as follows: 5 µl of 10×buffer (50mM KCl, 1.5mM MgCl2 
and10mM Tris-HCl; pH 8.3), 1 µl (10mM) of each dNTP, 1.5 (50mM) of MgCl2, 0.75 µM 
of each oligonucleotides primer, 35.8 µl SDW and 0.2 U of AmpliTaq Gold DNA 
polymerase. The cycling program used included a single initial denaturation at 940C for 7 
min followed by 45 cycles of 940C for 1 min, 720C for 1 min. The PCR product was then 
analyzed on 2% E-Gel. Results showed that a PCR product with the expected size was 
detected (Figure 3.3). 
 
At this stage the experiment was repeated using the same reagent concentrations and 
cycling parameters used for amplifying HSV-1 gD with the slight modification that the 
annealing step was extended for 1.30 min rather than 1 min at 580C. Results showed that a 
PCR product with the expected size was detected (Figure 3.4). The PCR product was then 
purified using a modified Microcon centrifuge method and stored at -200C (Figure 3.5). 
     
 
 
 
 
3.5 Primers Used to Amplify the 275 bp Target in the Thymidine Kinase gene of VZV 
gene. 
 
Primer 
name (gene) 
 
Primer sequence 
 
Length 
Product 
size 
(bp) 
VZV 1 5’-AGTACCTGGGATTGAAGACACGTTATTCG-3’ 29 
bases 
VZV 2 5’-AAGTGTTGTCCTGAACGGCATTAACAAGC-3’ 29 
bases 
275bp 
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Figure 3.3 2% E-Gel® agarose gel electrophoresis illustrating the result of amplification of 
the 275bp product of the thymidine kinase gene of VZV. Lane 1 contains E-Gel® Low 
Range Quantitative DNA Ladder, Lanes 2, 3, 4, 5 and 6 show a PCR product with the 
expected size. Negative control lane 7.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 2% E-Gel® agarose gel electrophoresis illustrating the result of amplification of 
VZV gE using the same reagent concentrations as for HSV-1 gD amplification with slight 
modification of the annealing step. Lane 1 contains E-Gel® Low Range Quantitative DNA 
Ladder, Lane 2, 3 and 4 shows a PCR product with the expected size (1898bp). Negative 
control lane 5.  
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Figure 3.5 2% E-Gel® agarose gel electrophoresis illustrating the result of purification of 
VZV gE PCR product. Lane 1 contains E-Gel® Low Range Quantitative DNA Ladder, 
Lanes 2 and 3 show the PCR product after purification.  
 
 
 
 
3.4 Gene Cloning  
 
3.4.1 Cloning Strategy   
 
 
 
 
The cloning procedure for HSV-1 gD and VZV gE was based on ligation-independent 
cloning (LIC); this include the preparation of the 3C/LIC insert and insertion of this into 
the pIEx/Bac-3 3C/LIC plasmid vector. Finally, recombinant plasmids were then 
transformed into competent cells (InsectDirect system) or used to generate the recombinant 
baculovirus (BacMagic system). The plasmid pIEx/Bac-3 3C/LIC full circular map is 
shown in Figure 3.6. 
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3.4.2 Construction of the Recombinant Plasmids 
 
 
 
 
The strategy for the construction of the recombinant plasmids containing the complete 
open reading frame of HSV-1 gD or VZV gE is shown in Figure 3.7. The 3C/LIC insert of 
each gene was created by treating the PCR product with T4 DNA polymerase in the 
presence of dATB to generate vector compatible overhangs. The 3C/LIC inserts were 
annealed into the pIEx/Bac-3 3C/LIC and the resultant plasmids was transformed into 
NovaBlue GigaSingle competent cells. The annealing and the efficiency of transformation 
were tested by including a test plasmid as a positive control.  LB agar medium was used 
for plating of competent cells and colonies were observed after overnight incubation. 
Colonies containing the recombinant plasmids was detected by PCR using vector specific 
primers (Table 3.6) and a combination of vector sense primer with antisense primer of each 
virus gene to confirm that each colony contained the correct insert and reading frame. PCR 
screening results using vector specific or the combination primer showed that a plasmid 
containing HSV-1 gD or VZV gE with the right size was generated (Figure 3.8 and 3.9 a 
and b).  
 
 
 
 
 
Table 3.6 Vector Specific Primers Used for Screening of Recombinant Colonies 
 
Primer 
name (gene) 
 
Primer sequence 
 
Length 
Product 
size 
(bp) 
IE1 
Promoter 
Primer 
5′- TGGATATTGTTTCAGTTGCAAG-3′ 22 
bases 
IE1 
Terminator 
Primer 
5′- CAACAACGGCCCCTCGATA -3′ 19 
bases 
435 bp 
+ 
Interest 
gene 
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Figure 3.6 Vector pIE/Bac-3 3C/LIC circular map (6802bp) containing the baculovirus hr5 
enhancer, IE1 immediate early promoter to drive transcription in the transient transfection 
mode and the p10 promoters to allow protein expression in the early and late stage of 
baculovirus infection. Taken from: http:// 
www.emdbiosciences.com/html/NVG/pIExBacTable.html (accessed26 July2010). 
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Figure 3.7 Details of the 3C/LIC cloning strategy, PCR product containing the 3LIC 
extension was treated with LIC-qualified T4 DNA polymerase in the presence of dATB, 
and then annealed to the pIEx/Bac-3 3C/LIC plasmid vector. Taken from: http:/ / 
www.emdbiosciences.com/html/NVG/pIExBacTable.html (accessed 26 July 2010) 
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Figure 3.8 PCR colony screening results of the recombinant plasmids containing the full 
open reading frame of HSV-1 gD or VZV gE using vector specific primers. Lane 1 DNA 
marker (Hyper Ladder II), Lanes 2-5: HSV-1gD colony screening result (5 colonies), Lane 
7 negative control, Lanes 8-12: VZV gE colony screening result (5 colonies). 
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Figure 3.9 Screening of the recombinant plasmid containing the full open reading frame of 
HSV-1 gD (A) and VZV gE (B) using sense primer of vector and antisense primer of each 
virus gene. 
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3.4.3 Plasmid DNA Purity and Concentration  
 
 
 
Plasmid concentration was determined using UV spectrophotometry. The plasmid DNA 
yield with A260/A280 absorbance > 1.7 was found to be 25µg/ml and 30µg/ml for HSV-1 
gD and VZV gE respectively. The plasmid copy number for each virus insert was 
calculated using the formula:  
 
Plasmid molecular weight = Number of base pairs x molecular mass of deoxynucleoside 
base pair  
 
 
For HSV-1 gD plasmid the molecular weight of the pIEx/Bac-3 3C/LIC (6763bp) plus 
HSV-1 gD (1242) = (6.763+1.242) x 103 x 660 = 5.28 x 106 Dalton  
Each 1 Mole of plasmid contains 5.28 x 106 g and with Avogadro’s number = 6.023 x 1023 
then each plasmid contains 6.023 x 1023  molecules 
Using the UV spectrophotometer the concentration of HSV-1 gD plasmid was found to be 
25µg/ml, therefore:  
25µg of recombinant plasmid contains:  6.023 x 1023 x 20 / 5.28 x 106 x 106  
= 22.81 x 1011 copy/ml (11.4 x 109 copy/5µL). 
 
For VZV gE plasmid the molecular weight the pIEx/Bac-3 3C/LIC (6763bp) plus VZV gE 
(1934) = (6.763+1.934) x 103 x 660 = 5.74 x 106 Dalton 
30 µg of recombinant plasmid contains:  6.023 x 1023 x 20 / 5.74 x 106 x 106  
= 20.99 x 1011 copy/ml (10.5 x 109 copy/5µL). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
133 
 
 
 
3.5 Insect Cell Culture 
 
 
 
Insect cells (Sf9) were grown in BacVector® Insect Cell medium (serum free) either as a 
monolayer or suspension culture with variable densities. Cells were used for transfection 
with recombinant plasmid or baculovirus, virus amplification and for protein expression. 
Stock cells (for long term storage) were prepared first from an original vial of Sf9 cells by 
preparing an exponentially growing suspension culture supplemented with 5% v/v foetal 
calf serum. Cell viability was determined by examining and counting cells at intervals 
using a Trypan blue exclusion method. Healthy cells were not stained with Trypan blue 
and appeared rounded with distinct cell boundaries when compared to unhealthy stained 
granular cells (Figure 3.10). Cells at low passage number were adjusted to cell density of 
4-5x106 cells/ml and frozen and stored in liquid nitrogen as described before (section 
2.2.6.5). A number of experiments were carried out to optimize cell growth conditions and 
protein expression. The cell doubling time was found to be 72 h and 24 h for monolayer 
and suspension cultures respectively.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 A 100 µl suspension of Sf9 cells was mixed with 100 µl of trypan blue 
solution, 20 µl of the mixture was immediately added to the haemocytometer chamber, the 
figure shows the appearance of live cells and some dead cells which appeared blue under 
the inverted microscope.  
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3.6 Protein Expression 
 
3.6.1 InsectDirectTM System 
 
 
 
In the InsectDirectTM expression system HSV-1 gD and VZV gE were expressed using 6 
well plates and 10 ml suspension cultures. Cells were examined daily (24, 48 and 72 h p.i) 
no clear signs of infection were observed in comparison with uninfected cells. Transfected 
cells continued to grow normally and beyond confluency, as they were not subjected to 
contact inhibition. However after 72 h p.i signs resembling those of an unhealthy culture, 
such as floating cells, appearance of granules and cells lysis were observed in both 
transfected and non transfected cells. Protein expression was observed by 48 h (50-65% of 
cells) and maximum protein expression was found at 72 h p.i (95% of cells) as assessed by 
immunofluorescence assay.  
 
 
 
3.6.2 BacMagic Expression System 
 
 
 
Recombinant baculovirus for both genes of interest was prepared using a 25-cm2 flask 
seeded with a 2 ml dilution of Sf9. A mixture of Insect GeneJuice, BacMagic DNA and 
recombinant plasmid was prepared and incubated at room temperature for 30 min and then 
added dropwise to the centre of the flask. The transfected cells were then incubated at 280C 
and examined on a daily basis for the appearances of signs of infection. After incubation 
(3-5 days), signs of infection were observed and classified as early, late and very late based 
on the time of appearance. Early signs of infection were observed after 48 h p.i, cells 
increased in diameter (30-50%) and nuclei in some cells appeared to fill the whole of the 
cell (Figure 3.11b). Late signs of infection appeared between 48 and 72 h p.i, cells stopped 
growing, and showed granular and vesicular appearance when compared to the uninfected 
cells (Figure 3.11c). Finally the very late signs appear after 72 h p.i when cells started to 
detach from the plate and the remaining attached cells started to lyse and show signs of 
clearing (Figure 3.11d).  
 
Infected cells medium was then collected by low speed centrifugation and subjected to 
DNA purification. PCR analysis of the recombinant baculovirus using vector specific 
primer or combination primer confirmed the presence of each insert. Recombinant 
baculovirus was then amplified from the first virus stock (expected virus titre 1 x107 
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pfu/ml) using 50 ml suspension and the tissue culture infectious dose 50% (TCID50) was 
calculated for each virus stock. Results showed that the 50% (TCID50) was 109 TCID50/ml 
for HSV-1 gD and 1010 TDCI50/ml for VZV gE. Optimisation was then carried out using 
10 ml of suspension culture, in which different MOI and harvesting times were 
investigated. Based on the IF test result an MOI of 10 and harvesting time of 72-96 h were 
found to be the optimum conditions for protein expression, therefore these condition were 
used in the large scale expression using a 100ml suspension culture.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 Appearance of the non-infected sf9 cells grown in 75-cm2 flask at a density of 
2-3x106 cells/ml in serum free medium (A) and viral infected cells with recombinant 
baculovirus at multiplicity of infection of 10. Transfected Sf9 cells with recombinant 
baculovirus began to stop dividing and showed increasing cell diameter 48 h p.i (B). At 72 
h p.i cells started to vesiculate and showed a granular appearance (C), and nuclear 
enlargement (C), with cell lysis at 96 h p.i (D).  
 
 
 
A B
C D 
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3.7 Protein Purification and Quantification  
 
 
 
Since the large amount of the fully glycosylated form of HSV-1 gD and VZV gE was 
found to be integrated into the outer membrane of Sf9 cells, extraction of the proteins from 
the cell membrane was considered an essential step in protein purification. A number of 
methods were evaluated such as disruption of cell membrane with glass beads or 
solubilising membrane protein with detergents. Use of a non-ionic detergent (C10E5) was 
found to be the most suitable method. Protein quantification results using the BCA assay 
showed that yields of purified protein from the small scale suspension cultures of the 
InsectDirectTM expression system ranged from 25 to 60µg/10ml, whereas 130 to 210 
µg/10ml was obtained with the BacMagic expression system. For large scale protein 
expression; the purified protein yield of the BacMagic expression system ranged from 0.5 
to 1.5 mg /100 ml. An example of the protein quantification method and the mechanism of 
action of detergent on integral and peripheral membrane protein are illustrated in Figure 
3.12-14.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 Absorbance of each well of the standard and 3 samples (triplicate) were read 
at 562 nm using a microtitre plate reader. BSA standards were used to create a standard 
curve using Microsoft Windows Excel (2003), which was then used to determine the 
unknown protein concentration in each sample.  
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Figure 3.13 Purified proteins of HSV-1 gD and VZV gE concentrations were measured 
using BSA protein assay, with BSA as a standard. A standard curve was used to determine 
each protein concentration in each sample. 
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Figure 3.14 Solubilisation of membrane proteins. Cell membranes are bilayers of lipid 
molecules, detergents will insert into the bilayer (A and B) and at high concentrations will 
form mixed micelles with lipids and membrane proteins, rendering the proteins soluble 
(C). Taken from www.currentprotocols.com/protocol/ps0408 (accessed 22/6/2010). 
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3.8  Protein Characterisation 
 
Protein characterisation is an important step in protein expression as it allows 
determination of the size, purity and immune reactivity of the expressed protein.  A 
number of methods were employed including Indirect Immunofluorescence (IF) assay, 
Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE), Immunoblot 
(Western blot and dot blot) and Enzyme-Linked Immunosorbent Assay (ELISA).  
 
 
 
 
3.8.1 Indirect Immunofluorescence (IF) assay 
 
 
 
To determine the efficiency of protein expression and the localisation of the expressed 
proteins, indirect immunofluorescence staining was carried out using anti HSV gD and 
VZV gE monoclonal antibodies. Both expressed glycoproteins were detected in the 
cytoplasm of acetone-fixed transfected cells (Figure 3.15 A and C) and at the cell 
membrane of the unfixed cells (Figures 3.15 B and D). To determine the specificity of the 
staining in the assay, transfected cells with recombinant plasmid containing HSV gD were 
reacted with VZV gE monoclonal antibody and vice versa. No staining was observed 
(Figure 3.15 E) in comparison with the negative control (Figure 3.15 F). Expressed 
proteins were observed at 48h p.i in both the InsectDirect and BacMagic expression 
systems. The percentage of positive cells ranged from 50% to 75%. Optimum expression 
of the protein was observed at 72h (95%).  
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Figure 3.15 Expression of HSV-1 gD and VZV gE in insect cells. Cells were infected with 
recombinant plasmid or baculovirus. At 72h p.i., transfected cells were analysed for 
synthesis and localisation of the viral glycoproteins within the cell and at the cell surface. 
Expressed glycoproteins gD and gE were detected in the cytoplasm of the acetone-fixed 
transfected cells (A and C) and on cell membranes of the unfixed cells (B and D). Neither 
antibody reacted with the negative control (E).       
 
 
 
3.8.2 SDS-PAGE and Immunoblot Analysis 
 
 
 
The effects of various MOI and expression times of infected cells on the production of 
recombinant proteins were examined by SDS-PAGE analysis. In the InsectDirect 
expression system Sf9 cells were transfected with each recombinant plasmid and the 
synthesis of each protein was analysed using SDS-PAGE at different harvesting time 
points (48, 72 and 96h). Recombinant proteins were first solubilised using a 1% non-ionic 
detergent (C10E5), purified and then subjected to 4-12 % SDS-PAGE under denaturing 
B 
E F 
A 
C D 
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reducing conditions. Results showed that both recombinant proteins were expressed in Sf9 
cells at 48h; however the peak of expression was obtained after 72 h p.i (Figure 3.16). 
Coomassie blue-stained SDS–PAGE showed that recombinant HSV-1gD and VZV gE 
appeared as single bands with a molecular weight of 64 kda and 98 kda respectively 
(Figure 3.17). Similar results were obtained using the BacMagic expression system, Sf9 
cells were transfected with each recombinant baculovirus with different MOI (5, 7, and 10) 
and harvested at different time points (48, 72  and 96h) and then subjected to 4-12 % SDS-
PAGE under denaturing reducing condition. Results showed that maximal protein 
expression levels were obtained at 72h p.i with an MOI of 10 (Figure 3.18). Western blot 
and dot blot analysis of the expressed proteins using monoclonal anti HSV-1 gD and VZV 
gE also showed that each protein was expressed in Sf9 cells (Figure 3.19 and 3.20). In 
comparison with the molecular weight markers, the full glycosylated form of HSV-1gD 
and VZV gE appeared as 64 kd and 98 kd proteins respectively. SDS-PAGE and immune 
blot analysis of recombinant infected cell medium did not detect any of the expressed 
proteins.  
 
 
 
 
 
 
 
Figure 3.16 HSV-1 gD time course Coomassie blue staining of recombinant plasmid 
infected Sf9 cell extract following SDS-PAGE. Sf9 cells were infected with the HSV-1 gD 
recombinant plasmid and at 72 h p.i cells were harvested and the expressed proteins were 
solubilised, purified and then lysed directly in sample loading buffer. Gels were then run 
on 4-12 % SDS-PAGE under denaturing reducing conditions. Lane 1 molecular weight 
marker; Lane 2 transfected cells; Lane 3 solubilised protein; Lane 4 purification flow; Lane 
5 first wash;   Lane 6: 48 h eluted protein; Lane 7: 72 h eluted protein.  
1 2 3 4 5 6 7
64 kd 
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Figure 3.17 Coomassie blue staining of recombinant proteins following SDS-PAGE under 
denaturing reducing conditions. HSV-1gD (A) and VZV gE (B) recombinant proteins 
appeared as single bands with a molecular weight 64 kda and 98 kda respectively. Lane 1 
molecular weight marker; Lane 2 transfected cells; Lane 3 solubilised protein; Lane 4 
purification flow; Lane 5 first wash;  Lane 6: 48 h eluted protein; Lane 7: 72 h eluted 
protein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18 Coomassie blue staining of infected Sf9 cells transfected with HSV-1 gD 
recombinant baculovirus at an MOI of 10 and harvested after 72 h p.i. Lane 1 molecular weight 
marker; Lane 2 transfected cells; Lane 3 solubilised protein; Lane 4 purification flow ; Lane 5 first 
wash;  Lane 6: 48 h eluted protein; Lane 7: 72 h eluted protein. 
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Figure 3.19 Western blot analyses of the expressed proteins using monoclonal anti HSV gD (A) 
and monoclonal anti VZV gE (B). Sf9 cells were transfected with the selected recombinant 
baculovirus and cells extract were subjected to 4-12% SDS-PAGE under denaturing reducing 
conditions. Proteins were then transferred to PVDF membrane and incubated with the selected 
antibody, washed, then incubated with peroxidase-labelled antibody. The membrane was then 
incubated with fast red substrate until the bands appeared. Lane 1 molecular weight marker; lane 2 
second  eluted recombinant protein; lane 3 first eluted recombinant protein; lane 4 purification 
wash; lane 5 purification flow; lane 6 solubilised protein; lane 7 transfected cells; Lane 8 
transfected cell media. 
 
 
 
 
 
 
Figure 3.20 Dot blot analyses of HSV-1 gD (A) and VZV gE (B) recombinant protein. Samples 
were transferred to dot blot manifold and vacuum-absorbed onto a 0.45 µm nitrocellulose 
membrane, incubated with the selected antibody and washed, then incubated with peroxidase-
labelled antibody. The membrane was then incubated with fast red substrate until the bands 
appeared. Lane 1 transfected cells; lane 2 solubilised protein; lane 3 purification flow; lane 4 first 
wash; lane 5 second wash; lane 6 negative control (non infected cells were subjected to the same 
purification process); lane 7 infected cell media; lane 8 eluted recombinant protein.   
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3.8.3 Enzyme-Linked Immunosorbent Assay (ELISA)  
 
 
 
The immune reactivity of each expressed protein was evaluated using an ELISA assay with 
mouse monoclonal antibody against each protein. The ELISA plate was coated either with 
cells transfected with the recombinant baculovirus or diluted purified proteins (Figure 
3.21).   
 
 
 
 
 
 
 
 
           
 
 
 
 
 
 
 
Figure 3.21 ELISA analyses of HSV-1 gD and VZV gE recombinant proteins. ELISA 
plate were coated with each sample dilution, incubated overnight at 40C, washed and 
incubated with the selected monoclonal antibody, washed again and then incubated with 
HRP antibody. Colour reaction was developed by ABTS substrate.  
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3.9 Evaluation of the Performance of Truncated Peptide  (Peptide 55) for Detecting 
HSV-2 IgG Antibody in Human Serum 
 
The performance of the Omega assay to detect and serologically differentiate HSV-2 
antibody was evaluated using 254 serum samples (Panel 1). Samples had been tested by 
the clinical laboratory (Clinical Virology Manchester Royal Infirmary) using an HSV type 
common IgG assay DIAMEDIX Herpes 1+2 IgG (IVAX Diagnostics, Inc., Miami, USA). 
HSV positive samples were further tested by Biokit HSV-2 type specific gG-2 IgG (Biokit, 
S.A, Barcelona-Spain), and Virotech HSV-1 type specific gG-1 assay (Appendix 1 Table 
1). Based on these assays results sera were grouped into one of four groups: group 1 sera 
were HSV-1 positive and HSV-2 negative (n= 143), group 2 sera were HSV-1 negative 
and HSV-2 positive (n= 39), group 3 were HSV-1 and HSV-2 positive (n= 37), and group 
4 were negative for both HSV-1 and HSV-2 (n= 35). 
 
All samples were tested with each of the three HSV-2 type specific assays (Omega, 
HerpeSelect and Bioelisa) according to the manufacturer’s instructions. Absorbances were 
read at 450 nm for all assays. The details of these assays were as follows: HerpeSelect and 
Bioelisa required a 1:101 dilution of serum; high-positive, low-positive, and negative 
controls. Omega assay required a 1:10 dilution of serum HerpeSelect required a 1 h serum 
incubation, a 30 min conjugated incubation and a 10 min substrate incubation at room 
temperature (20 to 250C), whereas Omega and Bioelisa ELISA kits required a 1 h serum 
incubation, a 30-min conjugate incubation and  15 and 30 minutes respectively for 
substrate incubation at 370C. Samples with discordant results were retested in duplicate 
using the three ELISA assays and further tested using Western blot as a gold standard 
assay. Analysis of the results obtained from all 3 ELISA assays showed that 55 (22.65%) 
samples were positive for HSV-2 antibody and 176 (69.29%) samples were negative in all 
three assays (Appendix 1 Table 2). The remaining 23 (9.1%) samples that gave discordant 
results between the three kits were retested by western blot assay. Western blot analysis 
showed that 21 samples were positive for HSV-2 and only one sample was negative for HSV-
2; the remaining sample showed only a very faint band typical of an HSV infection but it was 
not possible to detect a band corresponding to either gG1 or gG2, therefore this sample was 
classified as Western blot equivocal. Of the 21 positive results, 3 (14.3%) were detected using 
Bioelisa, 14 (66.7%) were detected using HerpeSelect and 16 (76.2%) were detected using 
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Omega. Western blot results showed that of the 22 discordant samples, 17 (77.3%) were in 
agreement with Omega, 15 (68%) were in agreement with HerpeSelect and 3 (13.6%) were in 
agreement with Bioelisa (Table 3.7). The concordance between the tests was: Omega / 
HerpeSelect 94.9%, Omega / Bioelisa 89.8% and HerpeSelect / Bioelisa 89.8%. Sensitivity, 
specificity, positive predictive value and the negative predictive value was calculated for each 
kit (as described in section 2.2.11.7) using the HerpeSelect assay as a reference standard (Table 
3.8). The correlation (r) between the Omega assay and HerpeSelect and Bioelisa was 0.96 and 
0.86 respectively. Assay results were also plotted to generate a scattergram and a regression 
line of the results obtained with 95% confidence intervals. Regression analysis (r2) results are 
shown in Figures 3.22-24.   
 
Table. 3.7 Discordant Test Results Obtained by the Three ELISA Tests Retested by 
Western Blot 
 
Omega Assay  HerpeSelect Assay Bioelisa Assay Western 
Blot 
Positive Equivocal Negative Positive Equivocal Negative Positive Equivocal Negative 
Positive 16 0 4 14 2 5 3 0 18 
Equivocal 1 0 0 0 0 0 0 0 0 
Negative 0 0 1 0 0 1 0 1 0 
Total 22 22 22 
  
 
Table 3.8 Omega and Bioelisa Assay Results in Comparison to HerpeSelect Assay 
 
Omega Assay Bioelisa Assay HerpeSelect 
Assay Positive Negative Equivocal Positive Negative Equivocal 
Positive 73 5 0 58 23 0 
Negative 8 167 1 3 170 0 
Equivocal 0 0 0 0 0 0 
Total 254 254 
 
Sensitivity: 93.6 % and 71.6 % respectively, for Omega and Bioelisa. 
Specificity: 96.6 % and 98.3 % respectively, for Omega and Bioelisa. 
Positive Predictive Value: 90.1% and 95.1 % respectively, for Omega and Bioelisa. 
Negative Predictive Value: 97.1% and 88.1 % respectively, for Omega and Bioelisa. 
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Figure 3.22 Regression analysis on 254 sera where HSV-2 antibody concentration was 
determined by the Omega assay (X axis) and the HerpeSelect assay (у axis).  
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Figure 3.23 Regression analysis on 254 sera where HSV-2 antibody concentration was 
determined by the Omega assay (X axis) and the Bioelisa assay (у axis).  
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Figure 3.24 Regression analysis on 254 sera where HSV-2 antibody concentration was 
determined by the HerpeSelect assay (X axis) and the Bioelisa assay (у axis).  
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3.10 Development of the In-house ELISA Assay 
 
 
 
To develop an in-house ELISA for detecting antibody to HSV and VZV using the 
expressed proteins, the optimal working dilutions of each antigen, antibody conjugate, and 
serum dilution were determined by checkerboard titration using different ELISA plates, 
coating buffers and blocking buffers. 
 
 
3.10.1 Optimal Dilution of Antigen and Human Serum 
 
 
 
To determine the optimal dilution of antigen that gave the highest OD reading a two-fold 
dilution of each protein was titrated against different dilutions of the clinical standard 
reference serum. A positive control serum with a dilution of 1/100 was tested with each 
protein dilution in each plate. Based on the results a sample dilution of 1/100 with a protein 
concentration of 50µg/ml, appeared to be the optimum working dilution for both HSV-1 
gD and VZV gE. Therefore this sample dilution and protein concentration was selected for 
the standard assay (Table 3.9 and 3.10). 
 
 
Table 3.9 Titration of HSV-1 gD Recombinant Protein Against the Reference Clinical 
Standard Serum  
 
 
OD Reading at 405nm  
 
HSV-1 gD Protein Dilution  
Standard 
Serum 
Dilution 
1/25 1/50 1/100 1/200 1/400 1/1600 1/3200 
1/25 4* 4* 3.125 1.812 0.821 0.575 0.328 
1/50 4* 4* 2.225 1.328 0.668 0.497 0.194 
1/100 4* 3.951 1.594 0.985 0.539 0.454 0.110 
1/200 2.281 2.109 0.817 0.682 0.413 0.334 0.082 
1/400 1.554 1.218 0.628 0.426 0.297 0.233 0.080 
1/800 0.895 0.692 0.351 0.298 0.231 0.176 0.083 
1/1600 0.487 0.386 0.243 0.179 0.120 0.098 0.080 
1/3200 0.231 0.165 0.176 0.120 0.079 0.080 0.080 
Neg Serum 
Control 1/100 0.121 0.121 0.115 0.112 0.101 0.095 0.099 
Blank 0.065 0.065 0.057 0.055 0.058 0.052 0.051 
 
* Represents the maximum OD reading of the plate reader     
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Table 3.10 Titration of VZV gE Recombinant Protein Against the Reference Clinical 
Standard Serum  
 
 
OD Reading at 405nm  
 
VZV gE Protein Dilution 
Standard 
Serum 
Dilution 
1/25 1/50 1/100 1/200 1/400 1/1600 1/3200 
1/25 4* 4* 3.325 1.913 0.923 0.675 0.328 
1/50 4* 4* 2.289 1.298 0.696 0.456 0.214 
1/100 4* 3.921 1.574 0.955 0.598 0.398 0.150 
1/200 2.186 2.199 0.837 0.674 0.448 0.311 0.082 
1/400 1.754 1.278 0.528 0.399 0.259 0.258 0.083 
1/800 0.899 0.599 0.381 0.220 0.199 0.196 0.079 
1/1600 0.521 0.352 0.211 0.169 0.137 0.088 0.072 
1/3200 0.301 0.265 0.155 0.110 0.089 0.080 0.070 
Neg Serum 
Control 1/100 0.129 0.125 0.123 0.119 0.117 0.111 0.099 
Blank 0.066 0.062 0.064 0.055 0.054 0.062 0.051 
 
* Represents the maximum OD reading of the plate reader     
 
 
 
 
 
 
3.10.2 Optimal Dilution of the Anti-Human Conjugate (HRP) 
 
 
 
To determine the optimal dilution of the anti-human conjugate a serial dilution of the 
conjugate were titrated against a 1/100 dilution of the reference serum. A negative control 
serum was included in each plate. Results showed that whenever the conjugate 
concentration was increased an increase in OD was observed. Since there was a little 
difference between the OD values at 1/1500 and 1/2000 dilution the 1/2000 dilution was 
selected for the standard assay in order to minimise reagent use (Table 3.11 and 3.12). 
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Table 3.11 Optimisation of the Anti-Human Conjugate with HSV-1 gD 
 
 
HSV-1 gD Protein OD Reading at 405nm using PBS as a coating buffer 
 
Conjugate Dilution 
Conjugate 
Dilution 
1/500 1/1000 1/1500 1/2000 1/2500 1/3000 1/3500 
Reference 
Serum 1/100 4* 4* 3.902 3.550 3.612 3.385 2.985 
Neg Serum 
Control 1/100 0.124 0.119 0.120 0.122 0.119 0.085 0.075 
Blank 0.059 0.073 0.058 0.067 0.060 0.065 0.068 
 
* Represents the maximum OD reading of the plate reader     
 
 
 
Table 3.12 Optimisation of Anti-Human Conjugate with VZV gE 
 
 
VZV gE Protein OD Reading at 405nm using PBS as a coating buffer 
 
Conjugate Dilution 
Sample  
1/500 1/1000 1/1500 1/2000 1/2500 1/3000 1/3500 
Reference 
Serum 1/100 4* 4* 3.815 3.621 3.426 3.112 2.832 
Neg Serum 
Control 1/100 0.115 0.101 0.099 0.087 0.089 0.092 0.085 
Blank 0.069 0.063 0.075 0.075 0.067 0.071 0.059 
 
* Represents the maximum OD reading of the plate reader     
 
 
 
 
3.10.3 Effect of Coating Buffer type on the In-House ELISA 
 
To determine the optimum coating buffer to be used for the assay, 2 coating buffers were 
evaluated; 0.1 M carbonate/bicarbonate (pH 9.6) and PBS (pH 7.3). Recombinant proteins 
were diluted in each coating buffer and then the standard ELISA method was carried out. 
Results showed a slight reduction in the OD reading when the carbonate buffer was used in 
comparison to the PBS (Table 3.13 and 3.14). Therefore the PBS was selected as a coating 
buffer for the standard assay. 
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Table 3.13 HSV-1 gD OD Reading Using Carbonate as a Coating Buffer  
 
 
HSV-1 gD  Protein OD Reading at 405nm  
 
Conjugate Dilution Sample  
1/50
0 1/1000 1/1500 1/2000 1/2500 1/3000 1/3500 
Reference 
Serum 1/100 4* 4* 3.615 3.210 3.126 2.912 2.512 
Neg Serum 
Control 1/100 0.110 0.111 0.089 0.077 0.081 0.112 0.111 
Blank 0.057 0.063 0.065 0.052 0.061 0.062 0.055 
 
* Represents the maximum OD reading of the plate reader     
 
 
 
 
 
Table 3.14 VZV gE OD Reading Using Carbonate as a Coating Buffer  
 
 
VZV gE Protein OD Reading at 405nm  
 
Conjugate Dilution 
Sample  
1/500 1/1000 1/1500 1/2000 1/2500 1/3000 1/3500 
Reference 
Serum 1/100 4* 4* 3.621 3.210 3.022 2.989 2.732 
Neg Serum 
Control 1/100 0.115 0.111 0.081 0.083 0.082 0.113 0.101 
Blank 0.065 0.053 0.065 0.072 0.075 0.066 0.098 
 
* Represents the maximum OD reading of the plate reader   
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3.10.4 Effect of Microtitre Plate type on the In-House ELISA 
 
 
 
The type of ELISA plate is an important factor in developing an in-house ELISA.  
Different types of ELISA plate are found commercially, each made from different 
materials. Three ELISA plates were tested to determine which one could be used in the 
standard ELISA. Recombinant proteins were diluted in PBS (50µg/l) and each plate was 
coated overnight at 4ºC, and then tested with the standard method. Results showed that 
different OD readings were obtained from each plate. Although the Nunc plate “high 
binding” give a better OD reading with the positive control, a high OD reading was 
observed in the serum control well (no antigen added). The Costar “medium binding” plate 
was therefore selected for use as it gave a good signal to noise ratio to serum control well 
(Table 3.15 and 3.16).  
 
 
Table 3.15 OD reading of HSV-1 gD from Different ELISA Plates 
 
 
HSV-1 gD  Protein OD Reading at 405nm  
 
Conjugate Dilution 
Sample  
1/500 1/1000 1/1500 1/2000 1/2500 1/3000 1/3500 
 Costar “medium binding” Polystyrene   
Reference 
Serum 1/100 4* 4* 4* 3.950 3.612 3.285 2.985 
Neg Serum 
Control 1/100 0.111 0.119 0.110 0.109 0.102 0.085 0.075 
Blank 0.059 0.073 0.058 0.067 0.060 0.065 0.068 
OD Ratio 40.54 37.82 38.01 38.1 35.41 39.82 39.8 
 Nunc “high binding” Polystyrene  
Reference 
Serum 1/100 4* 4* 4* 4* 3.812 3.585 2.995 
Neg Serum 
Control 
1/100 
0.254 0.210 0.190 0.151 0.129 0.119 0.109 
Blank 0.089 0.083 0.078 0.077 0.069 0.065 0.068 
OD Ratio 17.72 21.43 23.68 29.47 29.55 30.12 27.48 
 Falcon ( Nylon)  
Reference 
Serum 1/100 3.924 3.752 3.210 2.814 2.542 2.210 1.985 
Neg Serum 
Control 
1/100 
0.105 0.119 0.115 0.110 0.105 0.093 0.076 
Blank 0.045 0.049 0.050 0.043 0.048 0.042 0.040 
OD Ratio 37.37 31.53 27.9 28.42 24.21 23.76 26.12 
* Represents the maximum OD reading of the plate reader     
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Table 3.16 OD Reading of VZV gE from Different ELISA Plates 
 
 
VZV gE Protein OD Reading at 405nm  
 
Conjugate Dilution 
Sample  
1/500 1/1000 1/1500 1/2000 1/2500 1/3000 1/3500 
 Costar “medium binding” Polystyrene   
Reference 
Serum 1/100 4* 4* 4* 3.810 3.626 3.212 2.832 
Neg Serum 
Control  1/100 0.115 0.101 0.099 0.087 0.089 0.092 0.085 
Blank 0.069 0.063 0.075 0.075 0.067 0.071 0.059 
OD Ratio 39.13 44.55 56.2 47.24 38.5 33.83 33.32 
 Nunc “high binding” Polystyrene  
Reference 
Serum 1/100 4* 4* 4* 4* 3.902 3.611 2.864 
Neg Serum 
Control  1/100 0.194 0.198 0.201 0.182 0.152 0.135 0.118 
Blank 0.059 0.073 0.058 0.067 0.060 0.065 0.068 
OD Ratio 23.21 22.73 24.29 23.13 25.67 26.75 24.27 
 Falcon ( Nylon)  
Reference 
Serum 1/100 3.851 3.721 3.125 3.091 2.984 2.612 2.210 
Neg Serum 
Control  1/100 0.102 0.089 0.091 0.079 0.068 0.077 0.067 
Blank 0.056 0.051 0.059 0.048 0.052 0.049 0.057 
OD Ratio 37.75 40.89 39.56 39.13 43.88 33.92 32.99 
* Represents the maximum OD reading of the plate reader     
 
 
 
 
 
 
3.10.5 ELISA Assay Reproducibility 
 
 
 
Assay reproducibility was determined by measuring the intra and inter assay variation of 
the mean percentage of coefficient of variation (CV %) for 10 samples tested in duplicate 
using the same plate on the same day or on two different days. Results showed that assays 
reproducibility (intraplate and interplate) CVs was found to vary by less than 10% (Table 
3.17). 
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Table 3.17 ELISA Intra and Inter Assay Reproducibility Results 
 
  
Assays Reproducibility 
 
 
 
Intra assay variation 
 
 
Inter assay variation 
 
 
 
 
Sample 
Number* 
HSV-1 gD ELISA 
% CV 
VZV gE ELISA 
% CV 
HSV-1 gD ELISA 
% CV 
VZV gE ELISA 
% CV 
1 3.21 5.23 3.32 5.14 
2 1.23 2.63 1.79 3.23 
3 3.12 2.11 2.15 3.26 
4 2.63 6.81 3.81 5.28 
5 1.98 2.25 2.23 3.45 
6 2.91 6.82 3.91 3.11 
7 5.21 6.29 3.58 5.12 
8 1.21 6.11 7.21 6.21 
9 3.51 2.81 5.25 4.01 
10 6.28 4.56 2.87 6.02 
*Samples were selected from serum panel 1 
 
 
 
 
3.11 Evaluation of In-house ELISAs for the Determination of Serological Status of 
HSV and VZV in Human Sera 
 
All serum panels (section 2.2.1.2) were tested using the developed in-house ELISA assay 
with the standard method. The cut-off point for each assay was calculated using 8 negative 
sera as described before (section 2.2.10.2.5). An optical density (O.D) value of less than 
0.177 for HSV-1 gD or 0.215 for VZV gE was considered negative, a sample with an O.D 
equal to or greater than 0.177 for HSV-1 gD and 0.215 for VZV gE was considered 
positive. Samples were tested at a dilution of 1/100 and any samples with an OD value 
equal to the cut-off point values were re-tested in duplicate. Assay controls (positive and 
negative sample) and a blank well were included in each assay run.  The highest and 
lowest assay detection levels were calculated based on the checkerboard titration result. 
The highest levels of detection were found to be 4800 ABU and 3200 ABU for HSV-1 gD 
and VZV gE respectively, the lowest level was 4.8 ABU and 3.2 ABU respectively.  
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3.11.1 HSV Serum Panels 
 
3.11.1.1 Panel 1 Sera 
 
The HSV-1 gD in-house ELISA was used to test serum panel 1, these samples were 
previously tested to determine the serological status of HSV using an HSV type common 
and a type specific assay, based on these assay results they were grouped into four groups 
(section 3.10). Additionally this panel was further used to evaluate the Omega HSV-2 
assay. The discordant samples between all ELISA kits were retested by Western blot assay 
as the gold standard assay (section 3.10). Samples were tested by the in-house ELISA and 
results showed that 86.22% (219/254) of samples were positive for gD and 13.78% 
(35/254) were negative for gD (Appendix 1 Table 3). On the basis of these results and the 
previous results obtained from different ELISAs the in-house was found to have good 
correlation with the other assays (Table 3.18 and 3.19).  Assay sensitivity, specificity, 
negative predictive value and positive predictive value were calculated using Western blot 
as a reference test. Results showed that the in-house ELISA has a 100% agreement with 
the Western blot results.     
 
Table 3.18 Comparison of Panel 1 Test Results with HSV-1 gD In-House ELISA 
Results 
 
DIAMEDIX 
Herpes 1+2 IgG Assay 
Biokit HSV-2  IgG Assay Biokit HSV-1  IgG Assay Virotech HSV-1 IgG 
Assay 
HSV-1 
gD 
ELISA Positive Negative Equivocal Positive Negative Equivocal Positive Negative Equivocal Positive Negative Equivocal 
Positive 103 15 0 60 47 0 122 21 0 110 3 0 
Negative 0 32 0 1 0 0 0 29 0 3 31 0 
Equivocal 0 0 0 0 0 0 0 0 0 0 0 0 
Total 150 108 172 147 
 
Table 3.19 Comparison of Panel 1 Test Results for the Omega Assay Evaluation and 
the HSV-1 gD In-House ELISA 
 
Omega HSV-2 Assay Biokit HSV-2  IgG Assay Focus HSV-2 IgG Assay  
 
Western Blot Assay  
 
HSV-1 
gD 
ELISA 
Positive Negative Equivocal Positive Negative Equivocal Positive Negative Equivocal Positive Negative Equivocal 
Positive 79 140 0 61 158 0 81 138 0 23 0 0 
Negative 0 35 0 0 35 0 0 35 0 0 0 0 
Equivocal 0 0 0 0 0 0 0 0 0 0 0 0 
Total 254 254 254 23 
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3.11.1.2 Panel 2 Sera  
 
Samples were previously tested to determine the sub-type of HSV using complement 
fixation test (CFT), Immunofluorescence assay (IF), an in-house ELISA, Bioelisa HSV-1 
and HSV-2 IgG ELISA (BioKit S.,A., Barcelona. Spain), Gull HSV Type 1 and Type 2 
Specific IgG (Gull Laboratories, Salt Lake City, Utah, USA),  CAPTIA Select HSV2-G 
test (Centocor, Malvern, USA), Biotest Herpes Simplex 1 and 2  IgG, Biotest Herpes 
Simplex IgG Index (Biotest Srl, Trezzano sul Naviglio, Italy), Clark HSV-1 and HSV-2 
assays (Clark Laboratories, Jamestown. USA) and Chiron Riba HSV Type 1 and 2 Strip 
Immunoblot Assay (Chiron, Cergny Pontoise, France). Tests results are detailed in 
Appendix 2 Table 1. Serum samples were tested randomly by the in-house ELISA and they 
were all found to be positive for HSV-1 gD antibody. Comparison of panel 2 in-house 
ELISA results with the results obtained from the Chiron assay (gold standard assay) 
showed that test results agreed in 95.7% (89/93) samples. The remaining 4 sample were 
positive by the in-house ELISA and negative by the Chiron assay and other ELISA assays 
(Table 3.20). 
 
 
 
Table 3.20 Comparison of Panel 2 Test Results with HSV-1 gD In-House ELISA 
Results 
 
Sample 
No CFT FAT 
HSV 
In-
house 
ELISA 
HSV 
Immunoblot 
assay 
HSV type 
by 
Bioelisa 
test 
HSV 
type 
by Gull 
test 
HSV type 
by 
CAPTIA 
Select 
HSV-2 
HSV-1 
In-house 
gD 
ELISA 
*Anticipated 
9 <1:10 1 - - - - - Positive Primary HSV-1 
39 <1:10 - - - - - - Positive Primary HSV-1 
82 <1:10 1 - - - - - Positive Primary HSV-2 
92 1:10 1&2 - - - - - Positive Primary HSV-2 
 
* Anticipated results based on available laboratory and clinical information provided 
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3.11.1.3   Panel 3 Sera  
 
Samples were previously tested to determine the serological status of HSV using Chiron 
RIBA HSV Type 1 and 2 Strip Immunoblot Assay (Chiron, Cergny Pontoise, France). A 
selection of 90 samples from this panel was retested with Bioelisa, Gull, CAPTIA Select 
HSV-2-G, Biotest and Clark assays. Tests results are detailed in Appendix 2, Table 2. 
Samples of this panel were tested randomly by the in-house ELISA and results showed that 
all tested sera were positive for HSV-1gD antibody. Comparing panel 3 in-house ELISA 
results with the results obtained from the Chiron assay revealed 100% agreement.   
 
 
3.11.1.4   Panel 4 Sera  
 
Panel 4 consisted of 200 human sera from among 8,000 samples from pregnant woman 
attending an Antenatal Clinic. Samples were previously tested to determine the serological 
status to rubella, syphilis and other sexually transmitted diseases (STDs). To determine the 
serological status of HSV, samples had been tested using Bioelisa HSV-1 and HSV-2 type 
specific assay. Samples were tested randomly by the in-house ELISA and results showed 
that all samples were positive for HSV-1 gD antibody. Comparing panel 4 in-house ELISA 
results with the results obtained from the Bioelisa showed 100% agreement. The remaining 
53 samples were positive by the in-house ELISA and negative by the HSV-1 and HSV-2 
Bioelisa (Appendix 2, Table 3).  
 
 
3.11.1.5   Panel 5 Sera 
 
Panel 5 consisted of 60 human sera originally obtained from patients with proven HSV 
infection, attending the Genito-Urinary Medicine Clinic (GUM). Samples were previously 
tested to determine the serological status of HSV using Bioelisa HSV-1 and HSV-2 type 
specific assay (Appendix 2 Table 4). For 45 out of 60 samples data on virus isolation and 
subtype by PCR was available. Samples were tested randomly by the in-house ELISA and 
results showed that all samples were positive for HSV-1 gD antibody. Comparing panel 5 
in-house ELISA results with the results obtained from the Bioelisa showed that test results 
agreed in 66.67% (40/60) and the remaining 20 samples were positive by the in-house 
ELISA and negative by the HSV-1 and HSV-2 Bioelisa.  
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3.11.2 VZV Serum Panels  
 
To evaluate the VZV gE in-house ELISA assay, two serum panels were used. Panel 1 
comprised; 90 samples out of the 254 originally selected for the evaluation of the Omega 
assay. These were tested for the presence of VZV IgG using Human VZV IgG assay 
(HUMAN Diagnostics, Germany), and the Liaison VZV IgG assay (Appendix1, Table 3). 
The other panel was used panel 6 (100 samples) these were also tested for the presence of 
VZV IgG antibody using the Liaison VZV IgG assay. Thirty seven samples out of the 100 
sample were also tested for presence of VZV IgG with the AtheNA Multi-Lyte® MMRV 
IgG Plus assay (Zeus Scientific, Inc., New Jersey, USA). The two serum panels were 
tested in the in-house ELISA, panel 1 results showed that 92.9% (236/254) of samples 
were positive and 5.91% (15/254) were negative for VZV gE, whereas panel 6 showed that 
93% (93/100) of samples were positive and 7% (7/100) were negative for VZV gE 
(Appendix 2 Table 1).  
 
 
Comparing panel 1 in-house ELISA results with the results obtained from the Liaison VZV 
and Human VZV IgG assay revealed that the test results agreed in 98.8% of samples 
(251/254) for the Liaison and 100% (100/100) of Human test (Table 3.21). Three samples 
were positive by the in-house ELISA and equivocal by the Liaison assay (even after 
retesting the sample in duplicate) were positive by the Humane assay. Comparing panel 6 
in-house ELISA assay results with the results obtained from the Liaison VZV IgG assay 
and AtheNA Multi-Lyte® MMRV IgG Plus assay revealed that test results agreed in 99% 
(99/100) for the Liaison and 100% (37/37) for the AtheNA Multi-Lyte® MMRV IgG Plus 
assays (Table 3.22). The equivocal sample with the Liaison assay was positive by the 
AtheNA Multi-Lyte® MMRV IgG Plus assay. Using the Liaison VZV IgG as a reference 
test the sensitivity, specificity, positive and negative predictive values for the in-house 
ELISA in each  panel were 98.75%, 100%, 100%, 100% for panel 1 and 98.93 %, 100%, 
100% and 100% respectively for panel 6 (Table 3.25). Assay results were also plotted to 
generate a scattergram and a regression line of the results obtained with 95% confidence 
intervals. Regression analysis (r2) results are shown in Figure 3.25.  
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Table 3.21 Comparison between VZV gE In-House ELISA and LIAISON VZV IgG 
and HUMAN VZV IgG Assay for their Ability to Detect VZV Antibody in Panel 1 
Sera.  
 
 
LIAISON VZV IgG Assay 
 
 
HUMAN  VZV IgG Assay 
 
VZV gE 
In-House 
ELISA Positive Negative Equivocal Positive Negative Equivocal 
Positive 236 0 3 81 0 0 
Negative 0 15 0 0 9 0 
Equivocal 0 0 0 0 0 0 
Total 254 90 
 
 
 
 
 
Table 3.22 Comparison between VZV gE In-House ELISA and LIAISON VZV IgG 
and AtheNA Multi-Lyte® MMRV IgG Plus Assay for Their Ability to Detect VZV 
Antibody in Panel 6 Sera. 
 
 
LIAISON VZV IgG Assay 
(100) Samples 
 
 
AtheNA Multi-Lyte Assay 
(37) Samples 
 
VZV gE 
In-House 
ELISA Positive Negative Equivocal Positive Negative Equivocal 
Positive 92 0 1 30 0 0 
Negative 0 7 0 0 7 0 
Equivocal 0 0 0 0 0 0 
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Figure 3.25 Regression analysis on 254 sera with VZV antibody concentration determined 
by VZV gE In-house ELISA assay (X axis) and the Liaison VZV IgG assay (у axis).  
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3.12 Development of a Triplex Fluorescence Microbead Immunoassay (FMIA) for 
the Detection of IgG Antibody to HSV-1, HSV-2 and VZV in Human Sera 
 
A fluorescence microbead immunoassay to detect and measure HSV-1, HSV-2 and VZV 
antibody levels in human serum was developed. Using a standard modified two step 
carbidiimide reaction (Figure 3.26); each antigen (HSV-1 gD, VZV gE and peptide 55) 
was coupled directly to the different SeroMAP carboxylated microspheres. A monoplex 
assay for each antigen was developed individually and then the three assays were mixed in 
a triplex assay for simultaneous detection of these viruses. A standard curve was then 
generated using the same clinical standard serum sample used to develop the in-house 
ELISA for HSV-1 gD and VZV gE.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.26 The figure shows the two step carbidiimide reactions EDC and Sulpho-NHS 
for conversion of the carboxyl groups on the microsphere surface into stable amine 
reaction groups. 
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3.12.1 Assays Optimisation 
 
To determine the optimal assay condition for each antigen to be used a number of factors 
were investigated such as serum dilution, bead and antigen concentration, conjugate 
dilution and sample diluent buffers. Each assay was tested individually using three 
different diluted antigen (100µl/ml, 50µl/ml and 25µl/ml), sample dilution (1/50, 1/100 and 
1/500) prepared in different sample diluent buffer (PBS+0.05% Tween, PBS + 0.05% 
Tween +1% NBBS and PBS + 0.05% Tween +2% NBBS ), anti-human phycoerythrin-
streptavidin conjugate (1/100, 1/200, 1/300) and bead concentration (2500, 5000). Beads 
were coupled as described in section 2.2.10.3 and then the standard curve for each antigen 
was generated using a two fold dilution of the standard clinical reference serum starting 
from 3200 ABU/mL for VZV and 4800 ABU/mL for HSV (1/10 to 1/10240). Results 
obtained from each assay showed that the optimal standard curve with maximum 
Fluorescent intensity were obtained from beads (5000/well) conjugated with 50µl/ml, 
50µl/ml and 25µl/ml of HSV-1 gD, VZV gE and peptide 55 prepared in 1% NBBS, PBS 
pH 7.3, 0.05% Tween 20 of sample diluent buffer respectively, tested with 1/100 dilution 
of human serum dilution and detected with 1/200 dilution of conjugate (Tables 3.23-25 and 
Figures 3.27-29). Other serum and conjugate dilutions, antigens and bead concentrations 
failed to generate a good working standard curve as the observed concentration of some of 
the standards were not detected or below the expected concentration in some assays or the 
florescence intensity obtained was very low in others (examples are shown in Figures 3.30-
32). Based on these results a bead concentration of (5000/well) with a 1/100 serum dilution 
and detected with a 1/200 dilution of conjugate, were selected for use in further assays. 
Using the optimal standard curve for each assay, the bead sets were mixed together in a 
single assay. Conjugated beads (5000/region/well) were used to generate a standard curve 
using a two fold dilution of the standard serum as mentioned above and the assay was 
performed as described in section 2.13.6.  
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Table 3.23 Standard Curve Values for Peptide 55 Monoplex assay using 
Microspheres (5000/well) Conjugated with 25µg/mL of the Peptide  
 
Sample Fluorescent Intensity  
Fluorescent  
Background 
Standard 
Deviation 
CV 
 %  
Observed  
Concentration 
Expected 
Concentration 
Recovery Rate  
% 
B 27 27 2.12 7.86    
S1 6919 6892 121 1.75 4676.63 4800 97 
S2 5624 5597 469 8.38 2507.55 2400 104 
S3 3587 3560 67 1.88 1155.64 1200 96 
S4 2192 2165 39 1.78 616.37 600 103 
S5 1137 1110 39 3.47 293.21 300 98 
S6 637 610 13 2.09 156.15 150 104 
S7 316 289 18 6.24 72.67 75 97 
S8 177 150 6 3.78 37.81 37.5 101 
S9 99 71 5 6.45 18.77 18.75 100 
 
B: blank  S: standard,  
Florescence intensity: the median fluorescence intensity of the selected analyte  
CV %: Percentage coefficient of variation  
Recovery rate (Observed concentration /Expected concentration) x 100%  
 
 
Table 3.24 Standard Curve Values for HSV-1 gD Monoplex Assay Using 
Microspheres (5000/well) Conjugated with 50µg/mL of Recombinant Protein 
 
Sample Fluorescence Intensity 
Fluorescence  
Background 
Standard 
Deviation % CV 
Observed 
Concentration 
Expected 
Concentration 
Recovery Rate 
% 
B 26.3 26 1.06 4.04    
S1 17372 17346 335.88 1.94 4741.98 4800 99 
S2 14466 14440 39.24 0.27 2424.5 2400 101 
S3 10495 10466 399.87 3.82 1214.45 1200 101 
S4 6459 6432 301.93 4.69 576.24 600 96 
S5 4081 4055 102.18 2.52 316.89 300 105 
S6 2179 2153 54.09 2.51 147.37 150 98 
S7 1210 1184 64.7 5.46 73.11 75 98 
S8 682 656 51.97 7.93 37.72 37 100 
S9 376 349 0.35 0.1 18.52 18.5 101 
S10 213 186 38.18 2.5 9.31 9.75 104 
S11 110 84 1.06 1.26 4.48 4.88 97 
 
B: blank  S: standard 
Fluorescence intensity: the median fluorescence intensity of the selected analyte  
CV %: Percentage coefficient of variation  
Recovery rate (Observed concentration /Expected concentration) x 100%  
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Table 3.25 The Standard Curve Values for VZV gE Monoplex Assay Using 
Microspheres (5000/well) Conjugated with 50µg/mL of Recombinant Protein 
 
Sample Fluorescence Intensity  
Fluorescence  
Background 
Standard 
Deviation %CV 
Observed  
Concentration 
Expected 
Concentration 
Recovery Rate 
%  
B 34 33.5 2.19 6.54    
S1 24528 24495 73.54 0.3 432.96 3200 14 
S2 24570 24537 9.19 0.04 470.88 1600 30 
S3 24671 24637 176.78 0.72 755.14 800 95 
S4 24574 24540 116.32 0.47 421.31 400 108 
S5 23686 23652 259.15 1.1 215.45 200 107 
S6 17761 17727 79.9 0.45 94.05 100 94 
S7 11684 11650 109.25 0.94 53.99 50 108 
S8 5197 5163 14.14 0.27 23.11 25 92 
S9 3113 3078 221.68 7.2 13.45 12.5 108 
S10 1605 1571 123.39 7.85 6.11 6.25 98 
 
B: blank  S: standard 
Fluorescence intensity: the median fluorescence intensity of the selected analyte  
CV %: Percentage coefficient of variation  
Recovery rate (Observed concentration /Expected concentration) x 100%.  
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Figure 3.27 The standard curve generated from Peptide 55 monoplex assay using 
microsphere beads (5000/well) conjugated with 25µg/mL of the peptide  
prepared in (PBS + 0.05% Tween +1% NBBS) of serum diluent buffer and detected with 
1/200 of the conjugate.  
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Figure 3.28 The standard curve generated from HSV-1 gD monoplex assay using 
microsphere beads (5000/well) conjugated with 50µg/mL of the gD antigen prepared in 
(PBS + 0.05% Tween +1% NBBS) of serum diluent buffer and detected with 1/200 of the 
conjugate.  
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Figure 3.29 The standard curve generated from VZV gE monoplex assay using a 
microsphere beads (5000/well) conjugated with 50µg/mL of the gE antigen prepared in 
(PBS + 0.05% Tween +1% NBBS) serum diluent buffer and detected with 1/200 of the 
conjugate.  
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Figure 3.30 Standard curve generated from HSV-1 gD monoplex assay using microsphere 
beads (5000/well) conjugated with 100µg/mL of the recombinant  protein prepared in 
(PBS + 0.05% Tween + 2% NBBS)  serum diluent buffer and detected with 1/100 dilution 
of the conjugate.  
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Figure 3.31 Standard curve generated from Peptide 55 monoplex assay using microsphere 
beads (5000/well) conjugated with 100µg/mL of the peptide prepared in (PBS + 0.05% 
Tween +2% NBBS) serum diluent buffer and detected with 1/200 dilution of the conjugate. 
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Figure 3.32 Standard curve generated from VZV gE monoplex assay using a microsphere 
beads (5000/well) conjugated with 100µg/mL of the recombinant  protein prepared in 
(PBS + 0.05% Tween +2% NBBS) serum diluent buffer and detected with 1/100 dilution 
of the conjugate.  
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3.8.2 Triplex Assay Validation 
 
3.8.2.1  Bead Interference 
 
Bead interference was tested by comparing the results obtained from the standard curve 
generated from each antigen as a monoplex assay with the standard curve results generated 
as a triplex assay. A similar result was obtained from assays for each antigen with slight 
reduction in the fluorescence intensities between HSV-1 gD assay as a monoplex and 
triplex (Figures 3.33-35). There was no difference in the median fluorescence intensity 
(MFI) of the blank well in each assay (Tables 3.26-28).    
 
 
3.8.2.2  Assay Sensitivity 
 
Assay sensitivity was determined by calculating the mean values of MFIs generated from 
10 blank wells plus 3 standard deviations the assay detection limit was determined in 
ABU/mL by interpolation from the standard curve.  Based on the results the highest 
detection level was 3200 ABU/mL and 4800ABU/mL for VZV and HSV antibody 
respectively, and lowest assay detected levels were found to be 1.2 ABU/mL and 
1.5ABU/mL for VZV and HSV respectively.   
 
 
 
3.8.2.3  Assay Reproducibility 
 
Assay reproducibility was determined by measuring intra and inter assay variation, the 
mean percentage of coefficient of variation (CV %) of 10 samples tested in duplicate 
within the same plate on the same day or on two different days was calculated. Assay 
reproducibility (intra and inter assay) was found to be less than 10% (Table 3.29 and 3.30). 
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Figure 3.33 Standard curve generated from HSV-1 gD triplex assay using microsphere 
beads (5000/well) conjugated with 50µg/mL of the recombinant  protein prepared in (PBS 
+ 0.05% Tween +1% NBBS)  serum diluent buffer and detected with 1/200 dilution of the 
conjugate.  
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Figure 3.34 Standard curve generated from peptide 55 triplex assay using  microsphere 
beads (5000/well) conjugated with 25µg/mL of the peptide prepared in (PBS + 0.05% 
Tween +1% NBBS) serum diluent buffer and detected with 1/200 dilution of the conjugate.  
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Figure 3.35 Standard curve generated from VZV gE triplex assay using microsphere beads 
(5000/well) conjugated with 50µg/mL of the peptide prepared in (PBS + 0.05% Tween 
+1% NBBS) serum diluent buffer and detected with 1/200 dilution of the conjugate.  
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Table 3.26 Standard Curve Values Obtained from the VZV gE Triplex Assay  
 
Sample Fluorescence Intensity  
Fluorescence  
Background 
Standard 
Deviation %CV 
Observed  
Concentration 
Expected 
Concentration 
Recovery Rate 
%  
B 15 15 39.95 9.76    
S1 27424 27359 687.66 2.51 1632 3200 51 
S2 27591 27526 82.38 0.3 832 1600 52 
S3 26778 26712 16.26 0.06 720 800 90 
S4 25225 25159 43.13 0.17 412 400 103 
S5 20306 20240 96.87 0.48 200 200 100 
S6 13662 13596 14.5 0.11 100 100 100 
S7 8316 8251 330.57 4.01 50.5 50 101 
S8 4480 4414 936.92 8.22 22.75 25 91 
S9 3435 3369 585.84 6.39 12.75 12.5 102 
S10 1500 1435 42.07 2.93 5.69 6.25 91 
 
B: blank  S: tandard,  
Fluorescence intensity: the median fluorescence intensity of the selected analyte  
CV %: Coefficient of variation (Standard Deviation / Fluorescent Background) x 100% 
Recovery Rate: (Observed concentration /Expected concentration) x 100%  
 
 
Table 3.27 Standard Curve Values from the HSV-1 gD Triplex Assay 
 
Sample Fluorescence Intensity  
Fluorescence  
Background 
Standard 
Deviation %CV 
Observed  
Concentration 
Expected 
Concentration 
Recovery Rate 
%  
B 18 18 0.71 3.93 0 0 0 
S1 14780 14762 82.38 0.56 4741.98 4800 99 
S2 11401 11383 42.43 0.37 2423.5 2400 101 
S3 7891 7873 53.74 0.68 1215.45 1200 101 
S4 5478 5460 224.15 4.1 578.24 600 96 
S5 3335 3317 70.36 2.12 317.89 300 105 
S6 1867 1849 52.33 2.83 145.37 150 98 
S7 1023 1005 10.96 1.09 73.51 75 98 
S8 565 547 25.1 4.58 36.92 37 100 
S9 293 275 5.66 2.06 18.22 18.5 101 
S10     9.51 9.75 104 
 
B: blank  S: standard,  
Fluorescence intensity: the median fluorescence intensity of the selected analyte  
CV %: Coefficient of variation (Standard Deviation / Fluorescent Background) x 100% 
Recovery Rate: (Observed concentration /Expected concentration) x 100%  
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Table 3.28 Standard Curve Values from Peptide 55 Triplex Assay 
 
Sample Fluorescence Intensity  
Fluorescence  
Background 
Standard 
Deviation %CV 
Observed  
Concentration 
Expected 
Concentration 
Recovery Rate 
%  
B 17 17 1.47 8.62 0 0  
S1 7350 7332 107.13 1.46 4741.87 4800 99 
S2 4480 4463 155.21 3.48 2413.49 2400 101 
S3 2515 2497 108.19 4.33 1214.25 1200 101 
S4 1381 1364 79.55 5.83 588.24 600 98 
S5 784 766 38.18 4.98 314.09 300 105 
S6 426 408 5.66 1.38 147.37 150 98 
S7 235 217 13.44 6.17 74.51 75 99 
S8 125 107 7.78 7.25 36.98 37 100 
S9     18.32 18.5 99 
S10     9.51 9.75 104 
 
B: blank  S: standard,  
Fluorescence intensity: the median fluorescence intensity of the selected analyte  
CV %: Coefficient of variation (Standard Deviation / Fluorescent Background) x 100% 
Recovery Rate: (Observed concentration /Expected concentration) x 100%  
 
 
Table 3.29 Triplex Intra Assay Reproducibility Results 
 
 
Intra assay variation 
 
HSV-1 gD  VZV gE  Peptide 55 
Sample 
Number
Fluorescence 
MFI  
Standard 
Deviation  CV % 
Fluorescence 
 MFI 
Standard 
Deviation  CV % 
Fluorescence 
 MFI 
Standard 
Deviation  CV % 
1 205 8.49 4.14 510 21.92 4.3 228 19.04 8.32 
2 7700 56.21 0.73 176 2.12 1.21 4267 10.25 0.24 
3 5515 62.23 1.13 2188 32.53 1.49 647 16.26 2.51 
4 5641 34.29 0.61 302 4.95 1.64 1240 47.73 3.85 
5 3105 159.81 5.15 202 5.66 2.8 299 12.73 4.26 
6 245 2.47 1.01 143 3.54 2.46 496 4.24 0.86 
7 153 7.07 4.62 503 9.9 1.97 312 4.98 1.68 
8 8566 457.14 5.34 239 16.97 7.08 42 0.71 1.68 
9 1962 21.92 1.12 80 3.54 4.42 206 9.55 4.63 
10 8927 331.63 3.71 256 1.06 0.41 100 3.18 3.16 
 
CV %: Percentage coefficient of variation recovery rate (Observed concentration 
/Expected concentration) x 100%  
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Table 3.30 Triplex Assay Inter Assay Reproducibility Results 
 
 
Inter assay variation 
 
HSV-1 gD  VZV gE  Peptide 55 
Sample 
Number
Fluorescence 
 MFI 
Standard 
Deviation  CV % 
Fluorescence 
 MFI 
Standard 
Deviation  CV % 
Fluorescence 
MFI 
Standard 
Deviation  CV % 
1 215 8.65 4.21 509 21.82 4.2 208 20.24 9.69 
2 7720 55.21 0.71 169 2.02 1.11 4297 10.55 0.22 
3 5495 61.23 1.10 2190 32.63 1.39 647 16.26 2.51 
4 5641 34.29 0.61 302 4.95 1.64 1239 47.63 3.82 
5 3105 159.81 5.15 202 5.66 2.8 299 12.73 4.26 
6 255.3 2.37 1.11 149 3.54 2.35 489 4.14 0.84 
7 149 7.17 4.60 513 9.5 1.95 322 4.88 1.59 
8 8576 457.84 5.21 229 16.87 7.10 41 0.71 1.66 
9 1966 21.98 1.15 85 3.59 4.45 216 9.85 4.42 
10 8917 335.23 3.61 259 1.02 0.42 110 3.28 3.19 
 
CV %: Percentage coefficient of variation recovery rate (Observed concentration 
/Expected concentration) x 100%  
 
 
3.8.3 Evaluation of the Triplex Fluorescence Microbead Immunoassay for the 
Determination of Serological Status of HSV and VZV in Human Sera 
 
 
The triplex assay was evaluated by testing panel 1 sera. The serological status of HSV-1, 
HSV-2 and VZV in this panel had been previously determined using the developed in-
house ELISAs and other HSV specific assays (Omega, Focus, Biokit and Virotech). 
Samples were tested as described in section 2.13.6, each assay was first evaluated based on 
the acceptance criteria (section 2.13.2), and then the results from each individual assay 
were compared with the relevant ELISA assay. Results showed a 100% agreement 
between both the In-house ELISA and the fluorescence microbead assay for HSV-1 gD 
and VZV gE (Tables 3.31 and 3.32). For Peptide 55 the two assays agreed in 99.2 % 
(252/254). The remaining two samples were positive by the fluorescence microbead assay 
and negative by the Omega assay (Table 3.33). The correlation (r) between each ELISA 
assay with its fluorescence microbead assay was 0.988, 0.956 and 0.968 for peptide 55, 
HSV-1 gD and VZV gE respectively. Furthermore, in comparison to Liaison VZV IgG 
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Assay, the VZV fluorescence microbead assay gave similar results to VZV gE in-house 
ELISA assay and HUMAN VZV IgG Assay (Table 3.23). Assay results were plotted to 
generate a scattergram and regression analysis (r2) results are shown in Figures 3.36-39.   
 
 
Table 3.31 Comparison of Results Obtained from HSV-1 gD In-House ELISA and gD 
Fluorescence Microbead Immunoassays  
 
 
VZV gE  Fluorescence Microbead Immunoassay 
 
VZV gE 
In-House ELISA Positive Negative Equivocal 
Positive 239 0 0 
Negative 0 15 0 
Equivocal 0 0 0 
Total  254 
 
 
 
Table 3.32 Comparison of Results Obtained from VZV gE In-House ELISA and gE 
Fluorescence Microbead Immunoassays  
 
 
HSV-1 gD Fluorescence Microbead Immunoassay 
 
HSV-1 gD 
In-House ELISA Positive Negative Equivocal 
Positive 219 0 0 
Negative 0 35 0 
Equivocal 0 0 0 
Total  254 
 
 
 
Table 3.33 Comparison of Results Obtained from Peptide 55 ELISA and 
Fluorescence Microbead Immunoassays  
 
 
Peptide 55 Fluorescence Microbead Immunoassay 
 Omega Assay 
Positive Negative Equivocal 
Positive 77 0 0 
Negative 2 175 0 
Equivocal 0 0 0 
Total  254 
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Figure 3.36 Regression analysis on measured serum HSV-2 antibody concentration 
comparing Omega ELISA (χ axis) and the Peptide 55 fluorescence microbead 
immunoassay (у axis). The measurements were performed on 254 sera; regression was 
98.8 % (R2 regression coefficient).    
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Figure 3.37 Regression analysis on measured serum HSV antibody concentration 
comparing HSV-1 gD in-house ELISA (X axis) and the HSV-1 gD fluorescence microbead 
immunoassay (у axis). The measurements were performed on 254 sera; regression was 
95.6 % (R2 regression coefficient).    
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Figure 3.38 The figure shows the results of regression analysis on measured serum 
comparing VZV antibody concentration between VZV gE in-house ELISA (X axis) and 
the VZV gE fluorescence microbead immunoassay (у axis). The measurements were 
performed on 254 sera; regression was 96.79 % (R2 regression coefficient).    
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Figure 3.39 Regression analysis on measured serum VZV antibody concentration 
comparing Liaison VZV IgG Assay (X axis) and the VZV gE fluorescence microbead 
immunoassay (у axis). The measurements were performed on 254 sera; regression was 
91.09 % (R2 regression coefficient).    
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3.9 Development of a Biplex Assay for the Quantitation of Albumin and IgG in 
Human Serum and CSF samples 
 
In order to generate a suitable standard curve that could be used to detect and quantitate 
both human IgG and albumin in serum and CSF samples a series of 8 two fold dilution of 
the human standard serum starting from 3.9µg/dl for IgG and 0.5µg/dl for albumin were 
used. the assay was evaluated based on the acceptance criteria (section 2.13.2). Results 
showed that the assay was able to detect both analytes in the same sample (Figures 3.40-
41). In addition using the triplex condition (bead type, serum diluent, washing buffer and 
incubation times) the median Fluorescent intensity (MFI) of the blank well in each assay 
was less than 350 (Tables 3.34-35). Assay reproducibility was also determined by 
measuring intra and inter assay variation of 10 samples tested in duplicate. Assay 
reproducibility was found to be less than 10% (Table 3.36 and 3.37). the limit of the 
detection of the assay was found to be 0.03 µg/dl and 0.3 µg/dl for IgG and Albumin. 
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Figure 3.40 Standard curve generated from Albumin biplex assay using microsphere beads 
(5000/well) conjugated with 100µg/mL of the anti-human albumin prepared in (PBS + 
0.05% Tween +1% NBBS)  serum diluent buffer.  
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Figure 3.41 Standard curve generated from IgG biplex assay using microsphere beads 
(5000/well) conjugated with 100µg/mL of the anti-human albumin prepared in (PBS + 
0.05% Tween +1% NBBS)  serum diluent buffer . 
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Table 3.34 Standard Curve Values Obtained from the Albumin Biplex Assay  
 
Sample Fluorescence Intensity  
Fluorescence  
Background 
Standard 
Deviation %CV 
Observed  
Concentration 
Expected 
Concentration 
Recovery Rate 
%  
B 246 249 25 9.65    
S1 22590 21578 551.65 2.56 35942.58 39000 92% 
S2 21016 20005 946.46 4.73 20265.63 19500 104% 
S3 9984 9795 324.5 3.31 9580 9750 102% 
S4 9671 8659 791.25 9.14 4781.61 4875 98 
S5 5526 4514 408.43 9.05 2507.79 2437.5 103 
S6 2921 2310 180.48 4.1 1209.5 1218.75 99 
S7 1667 655 15.91 2.43 601.11 609.38 99 
S8 1056 944 33.23 3.52 307.63 304.69 101 
 
B: blank  S: standard,  
Fluorescence intensity: the median fluorescence intensity of the selected analyte  
CV %: Coefficient of variation (Standard Deviation / Fluorescent Background) x 100% 
Recovery Rate: (Observed concentration /Expected concentration) x 100%  
 
 
 
Table 3.35 Standard Curve Values Obtained from the IgG Biplex Assay  
 
Sample Fluorescence Intensity  
Fluorescence 
Background 
Standard 
Deviation %CV 
Observed  
Concentration 
Expected 
Concentration 
Recovery Rate 
%  
B 310 315      
S1 16964 16419 904.5 5.51 5142.81 5000 103 
S2 9564 9390 209 2.13 2470 2500 102% 
S3 5282 4937 455.94 9.23 1158.48 1250 93 
S4 3301 2756 62.58 2.27 621.11 625 99 
S5 2248 1703 39.24 2.3 360.55 312.5 115 
S6 1317 772 50.56 6.54 149.35 156.25 96 
S7 962 867 84.15 9.7 75.25 78.13 96 
S8 781 656 63.99 5.64 39.38 39.06 101 
 
B: blank  S: standard,  
Fluorescence intensity: the median fluorescence intensity of the selected analyte  
CV %: Coefficient of variation (Standard Deviation / Fluorescent Background) x 100% 
Recovery Rate: (Observed concentration /Expected concentration) x 100%  
 
  
189 
 
 
 
 
 
 
Table 3.36 Bioplex Intra Assay Reproducibility Results 
 
 
Intra assay variation 
 
IgG Albumin 
Sample 
Number 
Fluorescence 
Intensity 
Standard 
Deviation CV % 
Fluorescence 
Intensity 
Standard 
Deviation CV % 
1 4027 48.79 1.21 20101 202.37 1.01 
2 10390 253.85 2.44 22301 2.47 0.11 
3 8641 1025.3 11.87 15173 1794.64 11.83 
4 9754 374.06 3.83 4060 83.09 2.05 
5 11364 21.92 0.19 6517 136.47 2.09 
6 5508 51.62 0.94 18384 552.25 3 
7 1711 41.01 2.4 21089 117.73 0.56 
8 11214 863.73 7.7 16977 724.08 4.27 
9 6278 184.91 2.95 1628 152.74 9.38 
10 3176 124.8 3.93 12110 158.75 1.31 
 
 
 
 
Table 3.37 Biplex Inter Assay Reproducibility Results 
 
 
 
Inter assay variation 
 
 
IgG Albumin 
Sample 
Number 
Fluorescence 
Intensity 
Standard 
Deviation CV % 
Fluorescence 
Intensity 
Standard 
Deviation CV % 
1 3988 38.12 0.96 20290 101.5 0.5 
2 10119 190.92 1.89 21931 28.21 0.13 
3 9012 860.9 9.55 16011 1661.53 11.83 
4 9233 360.1 3.90 4120 73.11 1.77 
5 11174 31.82 0.28 6822 141.27 2.07 
6 5913 61.34 1.04 19324 572.55 2.96 
7 1689 39.1 2.31 22014 217.03 0.99 
8 10909 790.23 7.24 16169 741.28 4.58 
9 6199 154.72 2.5 1920 139.94 7.29 
10 3250 128.9 3.97 13090 176.55 1.35 
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3.10 Development of a Multiplex Microbeads Immunoassay for Detection and 
Quantitation of IgG Antibody Response to HSV-1, HSV-2, VZV, Albumin and 
IgG in Human Serum and CSF 
 
In order to generate a suitable standard curve for the multiplex assay and due to the 
difficulty of obtaining a commercial standard serum for the 5 analytes, the previous 
standard serum was used. The concentration of IgG and albumin in the clinical standard 
serum was determined by testing serial dilution of the clinical standard using the biplex 
assay. Based on the biplex assay results the IgG and albumin concentration was found to 
be 3g/l and 0.5g/l respectively. A standard curve for the 5 analytes was then generated by 
12 4-fold dilution of the clinical standard serum. Results have showed that the generated 
curves were suitable for determining the concentration of each analyte in the same sample 
(Figures 3.42-46). MFI background of the multiplex assay was generally found to be les 
than 350 MFI. Assay sensitivity and reproducibility was tested and the CVs values for each 
analyte were found to be les than 10% (Tables 38-39).          
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Figure 3.42 Standard curve generated from albumin multiplex assay using microsphere 
beads (5000/well) conjugated with 100µg/mL of the anti-human albumin prepared in (PBS 
+ 0.05% Tween +1% NBBS) serum diluent buffer.  
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Figure 3.43 Standard curve generated from IgG multiplex assay using microsphere beads 
(5000/well) conjugated with 100µg/mL of the anti-human albumin prepared in (PBS + 
0.05% Tween +1% NBBS) serum diluent buffer. 
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Figure 3.44 Standard curve generated from HSV-1 gD multiplex assay using microsphere 
beads (5000/well) conjugated with 100µg/mL of the anti-human albumin prepared in (PBS 
+ 0.05% Tween +1% NBBS)  serum diluent buffer. 
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Figure 3.45 figure shows the standard curve generated from peptide 55 multiplex assay 
using microsphere beads (5000/well) conjugated with 100µg/mL of the anti-human 
albumin prepared in (PBS + 0.05% Tween +1% NBBS) of serum diluent buffer. 
 
 
 
 
 
Figure 3.45 Standard curve generated from peptide 55 multiplex assay using microsphere 
beads (5000/well) conjugated with 100µg/mL of the anti-human albumin prepared in (PBS 
+ 0.05% Tween +1% NBBS)  serum diluent buffer. 
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Figure 3.46 Standard curve generated from peptide VZV gE multiplex assay using 
microsphere beads (5000/well) conjugated with 100µg/mL of the anti-human albumin 
prepared in (PBS + 0.05% Tween +1% NBBS) serum diluent buffer. 
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Table 3.38 Multiplex Intra Assay Reproducibility Results 
 
 
 
Intra assay variation 
 
Albumin IgG HSV-1 gD Peptide 55 VZV gE 
Sample 
Number
Fluorescence 
MFI 
Standard 
Deviation CV % 
Fluorescence 
MFI 
Standard 
Deviation CV % 
Fluorescence 
 MFI 
Standard 
Deviation CV % 
Fluorescence 
 MFI 
Standard 
Deviation CV % 
Fluorescence 
MFI 
Standard 
Deviation CV % 
1 19367 852.77 4.4 11085 305.82 2.76 3860 267.29 6.92 1009 69.3 6.86 15769 1092.83 6.93 
2 14016 111.02 0.79 6869 189.5 2.76 2907 139.3 4.79 8934 795.5 8.9 19783 43.84 0.22 
3 7706 492.15 6.39 2460 24.75 1.01 1144 63.29 5.53 5973 211.07 3.53 15454 208.95 1.35 
4 3822 250.32 6.55 1254 108.19 8.62 363 12.02 3.31 2334 170.41 7.3 7906 85.21 1.08 
5 528 7.42 1.4 16366 602.81 3.28 6701 540.94 8.07 521 43.84 8.41 2149 31.82 1.48 
6 11640 818.48 7.03 11364 938.33 8.26 3589 93.69 2.61 243 12.37 5.09 2149 31.82 1.48 
7 8568 356.03 4.16 15395 985.71 5.36 923 56.21 6.09 1552 21.92 1.41 1493 19.8 1.33 
8 11327 756.6 6.68 10687 388.2 3.63 21087 419.21 2 1465 28.64 1.95 763 57.63 7.55 
9 8697 672.1 7.73 17154 1653.92 9.64 10953 56.57 0.52 4340 255.97 5.9 20086 387.49 1.93 
10 5396 358.5 6.64 16570 560.74 3.38 4499 130.11 2.89 12084 422.85 3.5 6701 540.94 8.07 
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Table 3.39 Multiplex Inter Assay Reproducibility Results 
 
 
Inter assay variation 
 
Albumin IgG HSV-1 gD Peptide 55 VZV gE 
Sample 
Number
Fluorescence 
MFI 
Standard 
Deviation CV % 
Fluorescence 
MFI 
Standard 
Deviation CV % 
Fluorescence 
 MFI 
Standard 
Deviation CV % 
Fluorescence 
 MFI 
Standard 
Deviation CV % 
Fluorescence 
 MFI 
Standard 
Deviation CV % 
1 18537 711 3.84 10095 335.5 3.3 4160 292.9 7.04 1108 85.01 7.67 16319 995.53 6.1 
2 13516 211.82 1.67 6266 212.5 3.4 3401 199.8 5.87 9135 775.52 8.45 18353 63.8 0.35 
3 6909 442.66 6.41 2950 54.15 1.84 2114 73.39 3.47 5853 221.33 3.78 16424 198.94 1.21 
4 4212 320.11 7.6 1198 112.15 9.35 459. 11.82 2.57 3139 140.5 4.48 8497 92.31 1.09 
5 628 40.56 6.5 15396 592.41 3.84 6199 590.84 9.5 629 53.85 8.55 1978 49.12 2.48 
6 12820 718.40 0.06 13129 831.13 6.33 4099 103.5 2.52 360 18.09 5.02 2620 41.5 1.58 
7 7967 276.8 3.5 16325 991.21 6.07 1013 85.8 8.5 2259 29.08 1.29 1877 23.5 1.25 
8 12129 696.5 5.74 11686 710.2 6.01 22004 329.5 1.5 1962 30.55 1.56 813.5 67.11 8.25 
9 6999 492.6 7.04 16112 1463.12 9.08 11551 86.47 0.75 5310 512.87 9.66 19855 415.49 2.09 
10 6281 395.5 6.3 15980 492.34 3.08 4097 130.11 3.18 11055 352.85 3.19 6090 520.5 8.55 
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4. Discussion  
 
 
Conventional methods for detecting CNS infection with alphaherpesviruses (HSV-1, HSV-
2, VZV) and determining intrathecal IgG antibody production are time and sample 
consuming. They can exhaust up to 1 ml of sample and the assays may take more than 24 h 
to produce results. A more rapid assay requiring minimal sample volume and time to 
produce results would therefore be an important diagnostic tool for use in patients with 
CNS infection. The overarching aim of the present study was to improve the diagnosis of 
viral CNS infections. In the present study an immunoassay capable of detecting HSV-1, 
HSV-2 and VZV IgG and human IgG antibody and albumin within serum and CSF 
samples was developed. A number of factors were taken into consideration in the 
development of such an assay including assay sensitivity, specificity, simplicity, 
reproducibility, reliability, multiplicity, cost per test and time to result. The developed 
assay requires approximately 2.5 hours for full analysis of results and uses as little as 2 µl 
of sample. 
 
In recent years the need for high-throughput screening and rapid progress in serological 
assays has stimulated the development of a number of new serological array methods such 
as the Luminex test (Hsu et al., 2009). The Luminex technology was developed based on 
an earlier technology used for the enumeration and characterisation of suspensions of 
mammalian cells called flow-cytometry. The assay uses up to 100 different microsphere 
sets dyed by internal red and infrared fluorochromes with different intensities (Figure 1.6). 
Each microsphere set can be coupled individually with a different analyte (antigen, 
peptide, antibody) through a simple chemical conjugation. The captured analyte can then 
be revealed through the attachment of a second ligand labelled with a fluorophore 
(phycoerythrin). The conjugated microspheres are then lined up in a single file to enter the 
detection chamber, where two lasers are used for detection. A red laser (635nm) is used to 
excite the internal red and infrared dyes of the microsphere which allows the classification 
of each microsphere (by determination of the region number), and a green laser (532nm) 
detects the second labelled antibody associated with the binding of the analyte (Figure 1.7). 
Data gathered from the detection chamber can then be analysed via software that controls 
the instrument and results are displayed as a histogram and bead map which is 
continuously updated during the reading process (Giavedoni 2005).  
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The Luminex system was first used by Lisi et al., (1982) to develop an assay for detecting 
soluble antigens (IgG), and since that time a number of assays have been established to 
detect and quantify antibodies against several targets (Mc Hugh et al., 1986; Mc Hugh et 
al., 1989; Scillian et al., 1989; Syrjala et al., 1991; Best et al., 1992; Stewart et al., 1993; 
Laakel et al., 1996; Drouvalakis et al., 1999). Results of these studies have proven the 
speed, efficiency and utility of the Luminex technology for simultaneous, rapid, sensitive 
and specific antibody detection. It has been suggested that it could be an alternative 
method to ELISA, since it reduces labour, sample volume, and reagent costs, as well as 
assay time. Nowadays, with the advances in instrumentation, software, microsphere 
technology and assay reagents, Luminex based assays have been widely used to detect and 
quantify antibodies against several types of viruses (Dias et al., 2005; Waterboer et al., 
2005; Johnson et al., 2005; Lukacs et al., 2005; Dias et al., 2005; Martins et al., 2008; 
Binnicker et al., 2008; Watson et al., 2009; Martins et al., 2009a; Xia et al., 2010).  
 
Although the Luminex technology seemed to be a promising approach in this project for 
the diagnosis of herpes infections, a major challenge in developing such an assay was 
obtaining high quality, fully functional proteins for each virus that displayed 
conformation-dependent epitopes capable of detecting type specific/common antibody in 
serum and CSF samples. As stated earlier, herpesvirus glycoproteins are highly 
immunogenic. Among these glycoproteins HSV gD and VZV gE are the most abundant of 
the glycoproteins found on the virion surface and they elicit both humoral and cell 
mediated immunity. A number of prokaryotic and eukaryotic expression systems have 
been used for in vitro production of HSV gD and VZV gE including bacteria (Watson et 
al., 1982), yeast (Valenzuela et al., 1983; Stanberry et al., 1987; Van Kooij et al., 2002), 
Vaccinia (Paoletti et al., 1984), mammalian cells (Stanberry et al., 1988; Haumont et al., 
1996) and baculovirus (Krishna et al., 1989; Ghiasi et al., 1991;Landolfi et al., 1993; Sisk 
et al., 1994; Kimura et al., 1997; Ikoma et al., 2002).  Although E.coli and yeast 
expression systems have been used for the last 20 years as an invaluable resource for 
production of large quantities of proteins, proteins expressed by these systems lack many 
of the post translational modifications associated with proteins produced by eukaryotic 
cells (glycosylation and cleavage). Other systems are also limited in terms of safety and 
the quantity of recombinant protein produced. However, baculovirus expression systems 
have been found to be the most useful system to produce fully functional glycosylated  
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glycoproteins similar to their authentic counterparts from mammalian cells (Fotouhi et al., 
2008). 
 
Several important features that make baculovirus a successful expression vector include; 
(1) its large genome (134 kb) which contains a number of non essential genes that can be 
replaced by an exogenous gene; (2) many of these genes, particularly the very late ones, 
are under the control of a powerful promoter (polyhedron and P10) that allow abundant 
expression of the recombinant gene (Ooi et al., 1989). Finally baculoviruses are safer 
expression systems as compared to other mammalian viruses due to their limited insect 
host range. The baculovirus expression system is based on the introduction of a foreign 
gene into a non-essential region of the viral genome via homologous recombination with a 
transfer vector containing the cloned gene. The production of foreign protein is then 
achieved by infection of insect cell cultures with the resultant recombinant virus. The 
system was first used to express HSV-1 gD by Krishna et al., (1989), aiming to study the 
antigenic regions within HSV-1 gD that are recognised by the immune system. In the 
study, recombinant baculovirus was generated using HSV-1 strain SC16 DNA as template 
to clone the full ORF of gD gene. SF21 cells were transfected with the recombinant virus, 
and the expressed gD was purified and characterised using SDS-PAGE and 
immunoblotting. The study showed that HSV-1 gD was expressed in insect cells, and 
appeared as 48kd, however it was slightly smaller than virion HSV-1 gD made in baby 
hamster kidney (58kd). The study found that antibody taken from mice infected with HSV-
1 reacted with both proteins. Immunisation of mice with an extract of the expressed gD 
induced a high titre of complement and independent neutralising antibody (Krishna et al., 
1989). In a further study to investigate the possibility of using baculovirus to express a 
large quantity of HSV-1 gD, Ghiasi et al., (1991), constructed a recombinant baculovirus 
containing the full-length of HSV-1 gD using HSV-1 strain KOS as the template. In the 
study, SF9 cells were transfected and the recombinant protein was purified using 
immunoaffinity selection. Characterisation of the recombinant protein was carried out 
using SDS, immunofluorescence, western blot and ELISA. The study showed that 
recombinant protein was expressed, transported to the membrane of Sf9 cells and reacted 
with gD specific antibody. Although the expressed protein was slightly bigger than that 
reported previously (52kd), it still appeared to be slightly smaller than HSV-1 gD made in 
Vero cells.  Landofi et al., (1993) also expressed the full-length of HSV-2 gD, aiming to 
study the viability of using gD2 as a vaccine subunit. In the study, recombinant 
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baculovirus was generated using HSV-2 strain 12 DNA as the template to clone the full-
length gD gene. Sf9 cells were transfected and the recombinant protein was solubilised 
using CHAPS detergent and purified. Characterisation of the recombinant protein was 
carried out using SDS denaturation, Western blot and ELISA. The study showed that 
HSV-2 gD was expressed in insect cells and appeared as 57.5kd. In addition the expressed 
protein reacted with the gD specific monoclonal and polyclonal antibody. Serum obtained 
from mice immunised with the recombinant gD2 reacted with both native gD1 and gD2 
proteins. Similar results were also obtained by Fotouhi et al., (2008), when expressing gD2 
in Sf9 cells. Recombinant baculovirus containing the full-length HSV-1 gD was used to 
transfect Sf9 cells and the expressed protein was characterised using SDS, Western blot 
and ELISA. Western blot results showed two bands with approximately molecular weights 
of 41-43 kd and 52-55 kd. The latter corresponding to the glycosylated form of gD2, in 
addition, immunisation of guinea pigs with the recombinant protein elicited humoral 
responses. Other truncated soluble forms of HSV-1 gD have also been expressed in 
baculovirus for various reasons. Sisk et al., (1994) expressed two forms of gD, a truncated 
form gD-1(306t) that has three signals for addition of N-Linked oligosaccharides (N-CHO) 
and a full-length gD (QAA) that contain 3 mutations to eliminate the addition of N-CHO. 
Both proteins were expressed in insect cells, however the latter was retained in the cell, 
rather than being transported to the cell membrane.  The other protein was secreted in the 
media. Western blot analysis showed that both proteins reacted with specific monoclonal 
antibody. Protein yield obtained from each form was different, in the case of the gD (306t) 
the protein yield was 20mg/l whereas it was 1 -5 mg/l from the gD (QAA).   
 
In the case of VZV, Wu et al., (1997), expressed the full-length and truncated forms of 
VZV gE (the amino-terminal (N) region and the carboxy-terminal (C) region), aiming to 
determine the neutralising epitopes found within gE using  a library of monoclonal 
antibodies (MAbs). Three recombinant baculoviruses were generated using VZV Boston 
strain as a template to clone the different forms of gE. Sf9 cells were transfected with the 
recombinant viruses, and the expressed gD was characterised using SDS-PAGE, 
immunofluorescence and Western blot. The study showed that all forms of gE were 
expressed 72 h p.i in insect cells and, based on the immunofluorescence results, the 
localisation of the expressed protein was found inside the cell and in the cell membrane. In 
addition Western blot results showed that all MAbs reacted strongly with 4 protein bands 
with the apparent molecular weight ranging between 70 to 98kd which resembles the full-
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length glycosylated form of gE. Furthermore, dot blot analysis of the cell media also 
reacted with the antibodies, indicating that another soluble form of gE was secreted into 
the media. This soluble form resembled the N region of the gE since it did not contain a 
TMR core and was therefore secreted in the cell media. The study concluded that VZV gE 
contains 3 distinct antigenic domains which reacted with all the MAbs.  
 
Although the baculovirus system has been widely used for the production and study of 
structural and non-structural proteins of a number of viruses including, human 
polyomavirus, poliovirus, influenza virus, human papillomavirus and herpesvirus (Possee, 
1986; Neufeld et al., 1991; Ghiasi et al. 1991b; Sisk et al., 1993; Landolfi et al., 1993; 
Ghiasi et al., 1994; Kimura et al., 1997; Kimura et al., 1998; Ikoma et al., 2002;) 
traditional baculovirus expression methods have several disadvantages in terms of low 
frequency of recombination, protein production and the requirement for several rounds of 
plaque purification (Fotouhi et al., 2008).  Nowadays, most of these problems have been 
overcome by improved cloning methods, transfer vector generation, recombinant virus 
isolation, cell culture technology and simplification of recombinant protein purification.  
 
In order to determine a suitable strategy for protein expression and purification using 
baculovirus, a number of commercially available expression systems (Bac-N-Blue, Bac-to-
Bac, BaculoDirect (Invitrogen), InsectDirect system, BacMagic system, BacVector system 
(Merck Bio Sciences)), and purification methods (Immunoaffinity chromatography and 
His-Tag purification strategy using NI-NTA resin) were critically evaluated. Based on the 
evaluation results two systems were found to be suitable to be used in the present study, 
the InsectDirect and BacMagic expression systems. These systems employ a combination 
of expression vector, high efficiency transfection reagent, lysis reagents and Ni- NTA His-
Bind Resin for affinity purification of his-tag fusion proteins (Loomis et al., 2005). 
Selection of these systems was based on a number of factors including; (1) simplicity and 
efficiency of vector plasmid construction; (2) no requirement for restriction enzyme 
digestion; (3) plaque assay purification was not required; (4) plasmid vectors contained a 
10 his-tag on the N-terminal to simplify purification of the expressed proteins; (5) both 
systems could use the same plasmid construct and cell type. To date, this is the first time 
that these systems have been used for expressing HSV and VZV glycoproteins.  
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The InsectDirect System is a plasmid-based expression system that enables rapid small-
scale expression in insect cells. It can be scaled up to isolate milligram quantities of target 
protein without the need to generate a recombinant baculovirus. However, as expression of 
the target protein in large-scale was required the BacMagic expression system was also 
selected. The BacMagic system is an improved baculovirus expression system that consists 
of an Autographa californica nuclear polyhedrosis virus (AcNPV) genome that lacks a 
1629 bp region of the ORF of the polyhedron (polh) coding region. This deletion in the 
polh coding region was replaced by bacterial artificial chromosome (BAC). During 
reconstruction of the recombinant virus in insect cells, only homologous recombination 
within the cells can restore the function of the viral ORF 1629 and replace the BAC 
sequence in the BacMagic DNA with a promoter and the target coding sequence. This 
unique combination has two important features:- it prevents non-recombinant baculovirus 
from replicating in insect cells, and it allows the viral DNA to be propagated as circular 
DNA in bacterial cells (competent cells). Because only recombinant baculovirus can 
replicate in insect cells, a plaque assay step is not required. In traditional baculovirus 
expression systems plaque assay is required in order to isolate and purify the recombinant 
virus and this process may take from 7 to 14 days.     
 
 
In order to get the full benefit of these two expression systems, the pIEx/Bac-3 3C/LIC 
plasmid vector was chosen. This vector is a dual-purpose vector that offers unique 
flexibility for cloning and expression of proteins in insect cells. It can be used directly for 
transfection of insect cells to produce the recombinant protein or as a donor plasmid that 
can be used to generate a recombinant baculovirus in the BacMagic system. The pIEx/Bac-
3 3C/LIC plasmid vector has a unique 3C/LIC site which is designed for directional 
cloning of the gene of interest efficiently and without the need for restriction enzyme 
digestion (Loomis et al., 2005). Moreover, it contains the baculovirus enhancer/immediate 
early promoter combination (hr5/ie1) for plasmid-mediated expression and early 
baculovirus expression (see Figure 3.9 for plasmid circular map). Furthermore it contains 
the baculovirus p10 very late promoter for robust baculovirus-mediated expression. This 
vector also encodes a 10 his-tag sequence at the N-terminal to simplify purification of 
expressed protein.  
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In order to clone HSV-1 gD and VZV gE genes into the LIC site of the plasmid vector the 
appropriate gene sequences that are capable of producing fully functional gD and gE 
proteins in insect cells had to be identified. Identification of the sequences was carried out 
by comparing several published sequences for each virus obtained from GenBank. 
Alignment results of these sequences revealed that both genes are highly conserved among 
HSV and VZV isolates and no variation was observed. Therefore, a single sequence for 
each virus was selected to design a primer that amplifies the full ORF of each gene. 
Primers were designed manually using the selected sequences. The primers start with 
sequences at the 5’-ends to create a specific vector-compatible overhang, followed by the 
first ATG in the coding region sequence. A stop codon (TAG) was also included at the 3’ 
ends and no HSV or VZV noncoding sequences were present after the stop codon. Blast 
alignment of both primers sequence showed homology of approximately 100%. 
 
For amplifying HSV-1 gD a number of cycling parameters and conditions were evaluated. 
Since the final aim of the amplification was to produce product of the correct size rather 
than to develop a sensitive PCR assay for diagnostic purposes, the sensitivity of the PCR 
was not tested. Initial experiments using routine cycling parameters and conditions 
routinely used in the department for HSV-1 amplification were used. However this 
approach produced a poor yield of product, inadequate for the purposes required. 
Therefore, these parameters were optimised by alteration of magnesium chloride (MgCl2) 
concentration, increase of the annealing temperature to 58°C and extension of each step in 
the cycling by 30 seconds. These optimising conditions significantly improved the 
amplification of HSV-1 gD and PCR results showed an adequate yield of PCR product of 
the correct size.  
 
A similar difficulty was encountered in amplification of VZV gE, cycling parameters, and 
conditions were adapted from an existing PCR used in the department, however in this 
instance no PCR product was detected at all. Alteration of magnesium chloride 
concentration and cycling parameters did not improve the PCR results. At first it was 
suspected that the starting material (VZV DNA) used as a template was not viable. 
Therefore a PCR using a different primer that amplifies a 275pb product in the thymidine 
kinase gene of VZV DNA was used. Results showed a distinct band with the expected size. 
This suggested that the starting material was viable and the PCR protocol needed to be 
further optimised. Therefore a further round of optimisation step was carried out, and the 
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best results were obtained when the annealing step was increased from 1 min to 1.5 min at 
58 ºC and a PCR product with the correct size was produced.  
  
The cloning procedure for HSV-1 gD and VZV gE was carried out as described by the 
manufacturer. PCR products for each virus were purified to remove any remaining primers, 
dNTPs, or short PCR products and the concentration of the purified PCR product was 
calculated by comparing the appearance of the PCR product band on 2% E gel with a low 
range quantitative ladder. Ten µl of the PCR product was estimated to contain 
approximately 0.2 pmol of DNA. As mentionend previously the pIEx/Bac-3 3C/LIC 
plasmid vector contains the LIC site, this method takes advantage of the 3´ → 5´ 
exonuclease activity of T4 DNA Polymerase to create very specific 11 or 12 base single-
stranded overhangs in the presence of dATP. Therefore, the PCR product was treated first 
with LIC-qualified T4 DNA Polymerase to generate the specific vector-compatible 
overhangs. Constructed plasmid containing either gD or gE and the necessary expression 
cassettes was generated efficiently using a ligation-independent cloning strategy. Results 
were confirmed by PCR using vector specific primers in one experiment, and a 
combination of vector specific sense primer with HSV-1 gD or VZV gE antisense primers 
in another (Figure 3.11 and 3.12). Such results suggest that both genes have been 
efficiently cloned in the right orientation within the LIC site of the plasmid and 
downstream of the P10 promoter. Additionally, it demonstrates the simplicity of generation 
of the pIEx/Bac-3 3C/LIC plasmid vector and efficiency of the cloning strategy. 
Recombinant plasmid was scaled up and purified using the UltraMobius plasmid kit, which 
provides a low endotoxin transfection-quality plasmid for transfection of insect cells. At 
this stage the recombinant plasmid required for the InsectDirect expression system 
(plasmid based expression system) and for generating recombinant baculovirus was ready 
to use. In order to construct the recombinant baculovirus containing either HSV gD or 
VZV gE the desired plasmid was mixed with BacMagic DNA in the presence of Sf9 cells. 
Generation of recombinant baculovirus was confirmed by the appearance of signs of 
infection in Sf9 cells and by PCR results obtained from amplification of the target gene 
and the surrounding sequences. Recombinant baculoviruses were then amplified and virus 
titer was determined (109 to 1010 TCID50/ml). 
 
For protein expression, several types of insect cells have been used previously including 
Sf9, Sf21 and High Five cell lines. These cells are suitable for InsectDirect and baculovirus 
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systems and can produce a fully functional protein similar to the native form. Although 
High Five cells allow better protein secretion and post-translational processing of 
recombinant proteins, compared to Sf9 and Sf21, they are difficult to grow and maintain in 
routine lab work. Therefore Sf9 and Sf21 are used for protein expression more frequently. 
Sf21 cells are somewhat more disparate in size and form producing rather more irregular 
monolayers and plaques than Sf9 cells. Therefore Sf9 was selected for protein expression 
in this study. Protein expression was first carried out using the InsectDirect system on a 
small scale using 6 well plates and then scaled up to 10ml suspension culture. In order to 
transfect Sf9 cells with the recombinant plasmid an Insect GeneJuice Transfection Reagent 
(Merck property) was used. This Reagent is a liposome-based transfection reagent 
designed for transfection of insect cells (Loomis et al., 2005). During protein expression 
using this system no signs of infection were observed in the transfected cells even 96 h 
postinfection. Cells continued to grow normally until they started to detach from the plate 
and the remaining cells, attached to the plate, started to lyse. This observation was in 
accordance with previous reports, confirming that recombinant plasmids use endogenous 
insect cell transcriptional machinery for production of the recombinant protein (Loomis et 
al., 2005). The traditional cytopathic effect caused by baculovirus infection during protein 
expression is absent in this system. In this case protein expression can only be monitored 
by obtaining samples of transfected cells every day for SDS and IF analysis. In the 
BacMagic system optimisation of protein expression was carried out using 25 cm2 flasks, 
this was then scaled up to 10ml and 300 ml of suspension culture. To determine the 
optimal expression conditions the effects of different MOI and harvesting times, were 
investigated. As for the InsectDirect system, samples from each step were analysed using 
SDS and IF.  
 
Production of each protein in insect cells was confirmed and monitored using IF and SDS. 
Immunofluorescence is an important method that can provide valuable information on the 
production and localisation of the expressed proteins. Acetone fixed and unfixed 
transfected Sf9 cells with recombinant plasmid or baculovirus reacted with the appropriate 
monoclonal antibody. In addition there was no cross reactivity between each protein when 
it was treated with the opposite monoclonal antibody. Such results indicate that 
recombinant proteins were expressed in both systems and each expressed protein contained 
the epitopes that were recognised by the monoclonal antibody. The IF results also show the 
localisation of the expressed protein. In acetone-fixed cells the expressed protein was 
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found to be localised within the cytoplasm and the nucleus of the infected cells. However, 
in unfixed cells, the expressed protein was found in the cell membrane. These localisation 
results are in accordance with previous studies and confirm that recombinant proteins were 
synthesised and, because they have membrane anchored sequences, they were correctly 
transported to the cell membrane resembling the formation of glycoproteins (as when HSV 
or VZV infects cells)  (Ghiasi et al., 1991; Wu et al., 1997; Olson et al., 1997). Moreover 
SDS and IF results showed that HSV-1 gD and VZV gE were expressed 48 h post infection 
in both systems. However the highest level (95% by IF) of expression of protein was 
observed between 72h to 96h post infection. In addition the peak time for protein 
expression in the BacMagic system was obtained at an MOI of 10 combined with a 
harvesting time between 72 to 96 h post infection. During optimisation of protein 
expression of the BacMagic system it was noticed that harvesting the cells after 96h did 
not increase the production of the protein. This suggests that a shut down in cell protein 
production occurred during baculovirus protein expression (O’Reilly et al., 1992). Thus, an 
MOI of 10 with cell harvesting time between 72 to 96 h were considered to be the optimal 
conditions for production of both proteins in the BacMagic system and these were used in 
large scale protein expression.  
 
Immunoreactivity of the recombinant proteins was also studied by Immunoblot (western 
blot and dot blot) using monoclonal antibody targeted against each protein. In immunoblot, 
samples (cell lysate, solubilised protein, purification flow and wash, transfection media and 
negative control (solubilised protein from uninfected cells) were analysed using the 
appropriate monoclonal antibody. Results showed that cell lysate, solubilised proteins and 
purified proteins samples reacted with the monoclonal antibody, whereas the negative 
control as well as the media of the transfected cells did not. This confirmed that both 
proteins were expressed and either retained in the cell or cell membrane and not secreted 
into the medium. Such results are in accordance with previous studies (Ghiasi et al., 1991; 
Wu et al., 1997; Fotouhi et al., 2008). SDS and western blot results showed that gD and gE 
were expressed and present as proteins of relative molecular weight of 64 kd and 98kd 
respectively. In the case of HSV-1 gD the observed size (64kd) was larger than any 
previously reported recombinant protein expressed in insect cells using other baculovirus 
expression systems (Krishna et al., 1989; Ghiasi et al., 1991; Fotouhi et al., 2008). Such 
results suggest that in this project the baculovirus expressed gD underwent more extensive 
post-translation addition of carbohydrate than other reported proteins using this system. In 
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the case of VZV gE the observed size (98 kd) was similar to that reported by Wu and 
Forghani (1997) and bigger than that reported by Olson et al., (1997). In both studies VZV 
gE was expressed using traditional baculovirus systems under the control of the 
polyhedron promoter. The results obtained from SDS, immunoblot and IF assays 
confirmed that these recombinant proteins were antigenically and functionally similar to 
their authentic counterparts, therefore production and purification of these proteins was 
carried out.       
 
As stated previously, one of the unique features of using this expression system is the 
simplicity of purification of the recombinant protein. The plasmid contains a 10 
polyhistidine tag sequence upstream of the cloning site (3C/LIC). In this case the fused 
protein will be expressed with an N-terminal his-tag, which can be used later to purify the 
expressed protein using the nickel-nitrilotriacetic acid (Ni-NTA) system. In addition, 
expression of the target protein immediately downstream of the HRV 3C protease cleavage 
site helps the removal of the encoded fused sequences after purification of the recombinant 
protein if it is needed. Other purification methods have been also reported in similar 
experiments such as immunoaffinity chromatography, immunoselection using magnetic 
beads, high-performance liquid chromatography (HPIEC) and gel filtration (Ghiasi et al., 
1991a; Sisk et al., 1994; Damhof et al., 1994; Welling-Wester et al., 1998). However, the 
Ni-NTA method has proven to be a powerful tool for purification of a number of his-tag 
recombinant proteins (Westar et al., 2001; Dobrovetsky et al., 2007). The Ni-NAT is an 
immobilised metal affinity chromatography (IMAC), which works on the interaction 
between the Ni2+ ions immobilised on the NTA matrix and specific amino acid chains like 
histidine. Peptides that contain the polyhistidine tag can be retained by IMAC and eluted 
using imidazole or by altering of the pH concentration. Based on the immunofluorescence 
results, the localisation of the recombinant protein was found within the cell and cell 
membrane. Proteins found within the cell resemble the non or partially glycosylated form, 
whereas the full glycosylated form is found on the surface of the infected cells. The latter 
proteins are similar to those found on the native virus and contain all epitopes that are 
recognised by human antibody. Therefore the next focus of the work was to purify these 
proteins.  
 
Purification of integral membrane proteins is always challenging since the aim is to isolate 
these proteins in their native form in a highly purified state. In general integral membrane 
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proteins consist of two parts; a hydrophilic part exposed to the outer environment and a 
hydrophobic part bound to the hydrocarbon chains of the lipids in the cell membrane. 
Thus, in order to isolate these proteins the cell wall of the transfected cells must be 
disrupted first. For disruption of cell walls several methods are used; mechanical (glass 
beads, sonication, high-pressure homogenizer) and non mechanical (enzymatic methods). 
However, based on critical review of previous studies similar to this work we decided to 
use detergents for isolation of these proteins (Landolfi et al., 1993; Damhof et al., 1994; 
Welling-Wester et al., 1998). Solubilising proteins using detergent is based on mimicking 
the lipid bilayer found in the insect cell wall. Detergents contain a polar group at one end 
and a long hydrophobic carbon chain on the other. During the solubilising process the 
polar group of the detergent binds with water molecules via hydrogen bounds, while the 
hydrocarbon chains aggregate via hydrophobic interaction. This aggregation process leads 
to the formation of micelles. In such cases membrane proteins can incorporate these 
micelles via hydrophobic interaction. The hydrophobic part of the protein will be 
surrounded by several layers of detergent molecules and the hydrophilic part will be 
exposed to the aqueous medium. The resulting protein-detergent complex allows such 
proteins to stay in solution.  
 
Several types of detergents are available for solubilising membrane proteins and selecting 
the most suitable detergent is important since some proteins are susceptible to denaturation 
during isolation. Previous studies have used different types of detergents and buffers for 
solubilising proteins such as 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS), N-dodecyl-N,N-dimethylammonio)undecanoate (DDMAU), 
N-dodecyl-N,N-dimethylammonio)butyrate (DDMAB), SDS, pentaethyleneglycol 
monodecyl ether (C10E5) and radioimmunoprecipitation assay buffer (RIPA)  (Krishna et 
al., 1989; Landolfi et al., 1993; Damhof et al., 1994; Welling-Wester et al., 1998).  
 
During protein solubilisation several attempts were carried out to optimise solubilisation of 
HSV-1 gD and VZV gE using RIPA buffer and two types of detergents (CHAPS, C10E5). 
However the best result was obtained using a method described previously by Welling-
Wester et al., (1998) using a non ionic detergent (C10E5) with some modification.  Welling-
Wester et al., (1998) studied the viability of using DDMAU, DDMAB, C10E5, 
Octylglucoside, Dodecyl-b-D-maltoside, and Hecameg detergents for extraction and 
purification of HSV-1 gD recombinant protein expressed in insect cells. In their study, gD 
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recombinant protein was solubilised with 1% to 2% final concentration of each detergent, 
and the recombinant protein was purified using High-Performance Liquid Chromatography 
(HPLC). Protein purification results showed that the optimum protein yields were obtained 
using 1% DDMAU, DDMAB and C10E5 (24.3-37.8 mg/L). Although the DDMAU and 
DDMAB gave similar and slightly higher protein yields (37.8 mg/l) than C10E5 (24.3 mg/l), 
these detergents could not be obtained commercially. Therefore C10E5 was used in this 
study. Recombinant protein solubilisation was carried out as described in the previous 
study but extending the incubation step from 1 h to 2 h on ice.  Solubilisation was assessed 
by SDS and immunoblot assay. Results showed that recombinant proteins could be 
solubilised from the insect cell membrane.     
 
The supernatant of the solubilising mixture after ultracentrifugation was used for protein 
purification. The first attempts to purify gD and gE were unsuccessful. Based on the 
purification kit instructions a 1x dilution of the 4x elution buffer (4 M imidazole, 2 M 
NaCl, 80 mM Tris-HCl, pH 7.9) provided within the kit can be used for eluting most of the 
his-tag proteins. However SDS and dot blot results showed that after elution the protein 
was observed in the solubilised sample, but not in other samples taken from the 
purification process (column flow, 1st wash, 2nd wash and eluted sample). These results 
suggests that the recombinant protein was bound to the resin, and was not eluted using 1x 
elution buffer (1M imidazole, 0.5 mM NaCl, 20mM Tris-HCl, pH 7.9). Therefore, in an 
attempt to optimise the elution step a serial concentration of the elution buffer was used. 
The best result was obtained by increasing the concentration of the elution buffer to 3x 
(3M imidazole, 0.70 mM NaCl, 26.7mM Tris-HCl, pH 7.9). The need for this high 
concentration of imidazole suggests that the recombinant proteins were bound strongly to 
the Ni2+ resin. This strong binding of the recombinant protein with the resin may be related 
to the length of the histidine tag. Indeed such results were reported previously by Mohanty 
et al., (2004). In their study the effect of the polyhistidine tag length (6 his or 10 his) and 
position (N or C terminal) during expression of membrane proteins in E.Coli was 
investigated. The study concluded that both the length and position significantly affected 
protein yield, purification, and solution properties. Expression of proteins with a 10 
histidine tag increases the binding affinity of the protein to the resin, but neither affect 
detergent extraction nor change the secondary structure of the protein (Mohanty et al., 
2004). The protein concentration obtained by InsectDirect and BacMagic expression 
systems as determined by BCA protein assay was higher than previously reported for the 
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full-length of HSV-1 gD (6 mg/L using InsectDirect and 15mg/L using BacMagic) (Sisk et 
al., 1994). As for HSV-1 gD, similar VZV gE protein yields were obtained using both 
systems.  
 
In general, HSV-1 gD and VZV gE glycoproteins were expressed in both expression 
system as early as 2 days p.i, and yielded the same proteins with no differences in size or 
immunoreactivity. The only differences found between the two systems were the protein 
yields. Such results were expected because each system was originally designed for 
different purposes. Although the InsectDirect system protein yield can be scaled up by 
using several culture bottles, it is not cost effective for production of recombinant protein 
in large quantities, since reagents such as plasmid purification kits and insect GeneJuice 
are required constantly for protein expression. However the system is ideal for small-scale 
screening and production of recombinant protein. In contrast the BacMagic system is a 
virus based system, therefore it is suitable for large production of recombinant protein. 
Virus titre can be scaled up and stored at +4 ºC with 5% foetal calf serum for as long as 6 
months or can be stored at -70 0C for longer periods.  
 
At this stage the immunoreactivity of the expressed type common antigen HSV (gD) and 
VZV gE proteins were tested by Western blot and dot blot methods using the appropriate 
monoclonal antibody. However in order to differentiate between HSV-1 and HSV-2 
antibody in the proposed assay, a novel immunodominant epitope of glycoprotein G2 
presented in a branched chain format (peptide 55) was utilised. HSV-1 and HSV-2 have 
approximately 83% nucleotide sequence similarity, and for some proteins they share more 
than 85% identity (Dolan et al., 1998). Both serotypes therefore show extensive serological 
cross-reactivity. However, a variety of studies have concluded that only glycoprotein G 
(gG2) expresses epitopes specific for HSV-2 (Marsden et al., 1984; Roizman et al., 1984). 
Consequently, this glycoprotein has been used as the basis of type-specific serological 
assays for the diagnosis of HSV-2 infection (Ashley et al., 1988; Ashley et al., 1998; 
Hashido et al., 1997; Parkes et al., 1991; Ribes et al., 2002). Epitope mapping of gG2 by 
Levi et al., (1996), suggested that some epitopes may cross-react with HSV-1-specific 
antibody. Therefore in an effort to develop even greater selectivity for HSV-2, several 
research groups have studied HSV-2 type-specific epitopes within gG2. Regions 
comprising amino acids 350 to 427 and 525 to 587 and also regions comprising amino 
acids 625 to 641 and 676 to 699 were identified by two independent groups (Grabowska et 
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al., 1999; Levi et al., 1996), and a secreted protein of gG2 comprising amino acids 23 to 
340 was described by Liljeqvist et al., (2002) and Gorander et al. (2003). Marsden et al. 
(1998) also developed multiple antigenic peptides corresponding to residues 561 to 578 of 
gG2, designated peptide 55. This peptide comprises four peptide copies attached to a 
branched lysine core and separated from the lysine core by four glycine residues. The 
sensitivity of the peptide for the detection of HSV-2 antibody was evaluated by screening a 
panel of HSV-2-positive human serum samples previously characterised by virus isolation 
and typed by indirect immunofluorescence with a type-specific monoclonal antibody. 
Peptide 55 was found to be sensitive and specific and no false-positive results were 
detected with HSV-1 antibody positive or HSV-1 or HSV-2 antibody-negative samples. In 
addition Oladepo et al., (2000) compared the performance of an assay based on peptide 55 
with that of a commercially available HSV-2 specific IgG ELISA assay kit based on 
affinity-purified gG2 (Gull Laboratories) and found that peptide 55 had the same 
sensitivity. However, the assay using peptide 55 was found to have higher specificity than 
that using the complete protein. Nilsen et al., (2003) tested the performance of an ELISA 
based on peptide 55 and compared it with the performance of two different assays; an 
ELISA developed by Ho et al., (1992) based upon native gG2 selected by affinity to Helix 
pomatia lectin, and an ELISA based on affinity-purified gG2 (Gull Laboratories), and 
found that the performance of the assay with peptide 55 was better than that of the other 
ELISA methods.  
 
Based on the results of these previous studies, peptide 55 seemed to be a good candidate 
for the proposed assay. However, in order to confirm previous reports, and to test the 
sensitivity and specifity of this peptide, a comparative study between an ELISA assay 
based on peptide 55 (Omega) with another type specific HSV-2 ELISA assay (Bioelisa and 
HerpeSelect) was carried out. In the study the sensitivity and specificity for detection of 
HSV-1 IgG antibody with each assay was tested by screening a well characterised serum 
panel (panel 1). This panel consisted of 254 samples which had been previously tested for 
the presence of HSV-1 and HSV-2 antibody using type common and type specific assays. 
Based on these earlier assay results the panel was subdivided into 4 different groups 
(section 3.10).  In order to evaluate the performance of peptide 55 and the other ELISA kits 
for detecting HSV-1 IgG antibody in this panel, all samples were tested with all three 
assays. Comparative results showed that the overall agreement between the three kits was 
90.94% (231/254), and no false-positive test results were detected by any of the three 
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assays. The 23remaining discordant samples (9.06%) were further tested using the Western 
blot assay.  Results showed that 21 samples were positive for HSV-2 and 1 was negative. 
The remaining sample was counted as Western blot equivocal since no gG1 or gG2 band 
could be detected. Using the HerpeSelect assay as a reference test, the sensitivity and 
specifity of the Omega and Bioelisa assays were calculated. The Omega assay showed 
higher sensitivity in detecting HSV-2 antibody (93.6%) when compared to the Bioelisa 
(71.6%). This may indicate that the antigen used by the Omega assay (peptide 55) is more 
sensitive than the one used by the Bioelisa. On the other hand, the specificity of the 
Bioelisa assay was slightly higher (98.3%) when compared with the Omega assay (96.6%). 
Furthermore, comparison of the results obtained from the Omega assay for the 4 
designated groups, showed that the total number of samples correctly identified by the 
Omega assay was 249 (98.0%) out of 254 samples tested. Such results reinforce the view 
that the region comprising peptide 55 is clearly an immunodominant epitope and that the 
design of anchoring multiple copies of peptide 55 within a branched lysine core allows 
contact with both arms of an antibody having the cognate paratope and permits the highly 
sensitive detection of antibodies of even low affinities. In addition, although the 
concordance between the individual assays for HSV-2 was relatively poor and was poor in 
comparison to the “gold standard,” the Western blot immunoassay, of the three assays 
evaluated, the results of the Omega assay showed the greatest concordance with those of 
Western blotting. Such results were not unexpected. Western blotting identifies antibody 
reactivity with separated bands of protein. It is therefore of inherently greater specificity 
than an assay reliant upon the detection of antibody to a single protein antigen or peptide.  
 
The comparative study results showed the superior performance of the Omega assay in 
comparison to the performance of the Bioelisa and the HerpeSelect assays, in accordance 
with data provided previously (Oladepo et al., 2000; Nilsen et al., 2003). On the basis of 
these results peptide 55 was found to be suitable to be used in the proposed assay for 
differentiation between HSV-1 and HSV-2 antibody. In order to evaluate the sensitivity 
and specificity of the baculovirus expressed proteins of HSV gD and VZV gE for the 
detection of human antibody, in-house ELISAs for each protein were developed.  
 
Initially an in-house ELISA assay for each antigen was developed and optimised by 
checkerboard titration using the recombinant HSV-1 gD and VZV gE proteins. During this 
stage a number of factors were investigated including antigen concentration, ELISA plate 
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type, antigen diluent buffers, number of washing steps required, conjugate concentration 
and the incubation time required between each step. A constant amount of each antigen 
(50µg/well) diluted in 1 X PBS (pH 7.3), incubated overnight at 4 ºC was found to be the 
optimum protein concentration for coating each of the Costar ELISA plates (medium 
binding). In addition, ELISA results showed that the maximum OD reading was obtained 
using this antigen concentration in combination with 1/100 dilution of the standard positive 
human serum, detected with 1/2000 of anti-human IgG conjugate. ELISA assay 
reproducibility was tested by measuring intra and inter assay variation using 10 human 
samples. Results showed that the reproducibility of the developed ELISA assays using 
these conditions was less than 10%. Therefore these conditions were selected for the 
standard ELISA procedure, in which all serum panels were tested.  
 
The performance of the developed in-house ELISA assays in the present study were 
evaluated by screening 6 well characterised serum panels using the ELISA standard 
method. For evaluating HSV-1 gD ELISA, 5 serum panels were used. Using panel 1 sera 
(previously used to evaluate peptide 55), gD ELISA assay showed that 86.2% (219/254) of 
the samples were positive and 13.8 % (35/254) were negative for HSV. Of these 254 
samples 150/254 were previously tested with a type common HSV assay (DiaMedix 
Herpes 1+2 ELISA). In the DiaMedix assay, a mixture of purified and inactivated herpes 
simplex virus 1 and 2 were used to coat the polystyrene microwells. Comparison of gD 
ELISA assay results with the DiaMedix results showed that both assays agreed in 90% 
(135/150) of the samples (Table 3.18). The remaining 15 samples were found to be 
positive by the gD ELISA and negative by the DiaMedix assay. Interestingly, 12 of these 
samples were positive by the Virotech HSV-1 IgG assay and 2 were positive by the 
Bioelisa HSV-2 IgG assay. Thus, it appears that the gD ELISA detected HSV positive 
samples that the DiaMedix assay missed, suggesting a higher sensitivity. The higher level 
of detection may be due to the type of antigen used in the assay. In addition, of the false 
negative results obtained by the DiaMedix assay 10% (15/150) may be due to the fact the 
antibody level in these samples was below the detection level of the assay.  Comparison of 
the gD ELISA results with the remaining assays used for characterising the panel or used 
to test the performance of peptide 55 showed 100% agreement with gD ELISA (Table 
3.20). Such results indicate the sensitivity of the developed assay for detecting HSV type 
common antibody.   
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Using the serum samples from panel 2, the HSV-1 gD ELISA showed 94.3% (66/70) 
agreement with the gold standard assay (Chiron assay). The remaining 4 samples were 
identified as negative by the Chiron assay but found to be positive by the gD ELISA. 
Originally, panel 2 sera were characterised using a number of commercially available 
assays, each assay used a different format of gG2 antigen (section 3.12.1.2). However, 
analysis of the results for these 4 samples obtained from the previous assays together with 
their clinical data showed that 3 samples were found to be positive by the CFT and IF 
assays and the remaining sample was positive by CFT assay. In addition the clinical data 
for all these samples indicate an HSV-1 or HSV-2 infection (Table 3.21). The most likely 
explanation for these results is that the type common antigen utilised in the Chiron 
immunoassay lacks specificity. The Chiron RIBA HSV-1 and HSV-2 Strip Immunoblot 
Assay utilised recombinant HSV-1 gG1, gG2 together with gD2 equivalents and a 
synthetic peptide for HSV-1 gB-1 immobilised on nitrocellulose strips. Therefore, it may 
be that the gD2 used in the assay lacks some of the epitopes needed for the recognition by 
the antibody. On the other hand, using the full-length gD in the in-house ELISA assay 
increases the possibility of recognition by the different types of antibody produced in the 
human sera against the several epitopes found within the gD antigen. An alternative 
explanation may be that the gD antibody titre found in this sample was not sufficient to 
allow binding to the gD2 found in the Chiron assay.      
 
In order to evaluate the performance of the gD ELISA in a high HSV-2 prevalence 
population, serum panel 3 was used. Serum panel 3 consisted of 90 samples obtained from 
a population with a very high level of sexually transmitted disease (including large 
numbers with genital herpes). Originally samples had been tested to determine the HSV 
serostatus and HSV subtype using a number of ELISA assays including; HSV-1 and HSV-
2 Bioelisa, Gull, CAPTIA Select HSV-2-G, Biotest, Clark assays and the Chiron RIBA 
HSV Type 1 and 2 Strip Immunoblot Assay (the gold standard assay). In this panel, the gD 
ELISA assay showed 100% agreement with the Chiron assay. Such agreement in this panel 
was not unexpected, because in such a group the production of antibody against type 
specific antigens (gG) usually occurs later after the appearance of the type common 
antigen (gD) antibody.  
 
In order to further evaluate the performance of the gD assay in a different population 200 
samples selected from among 8000 pregnant women of different age groups attending an 
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antenatal clinic was tested (panel 4). These samples were previously tested for HSV IgG 
antibody using the Bioelisa HSV-1 IgG and HSV-2 type specific assay (Appendix B Table 
3). The gD assay results showed a 73.5% (147/200) agreement with the previous results. 
The remaining 53 samples were positive by the gD ELISA and negative by both of the 
Bioelisa assays. In this panel no type common assay had been used to determine the 
serostatus of these samples, however, looking to the age of these patients reveals they were 
all over 20 years of age. Based on seroprevalence studies in developed countries, 85% of 
the population become seropositive by early adolescence (Whitley et al., 2001; Pebody et 
al., 2004). Therefore, in this case it is likely that all these patients have been exposed to 
HSV-1 infection. Such results indicate that in a clinical setting screening samples for HSV 
serostatus should be performed using a type common assay rather than type specific 
assays.  
 
Similar findings were obtained following screening of serum panel 5. This panel consisted 
of 60 samples obtained from 75 patients attending a GUM clinic. The samples had been 
previously tested for HSV IgG antibody using Bioelisa HSV-1 and HSV-2 IgG assay. The 
patient ages ranged from 13 to 67 years and virus isolation results for 45 out of 60 samples 
were available. The gD ELISA assay showed 66.67% (40/60) agreement with the Bioelisa 
HSV-1 and HSV-2 IgG assy. The remaining 20 samples were positive by the gD ELISA 
and negative by both Bioelisa assays. Analysis of the virus isolation results of theses 
samples showed that in 13 samples, the virus was isolated, whereas it was not in the other 
7 samples. In addition patient age ranged from 15 to 53 years. It is know that the antibody 
response could be detected in the absence of the virus. Indeed, in 7 samples from this 
panel, although no virus was isolated, IgG antibody for HSV was detected. In addition, the 
age of the patients suggests that they would be likely to have had HSV-1 infection. 
 
For evaluation of the VZV gE ELISA assay two serum panels were used; panel 1 and panel 
6.  As stated earlier, panel 1 serum consisted of 254 samples, 150 of these samples were 
tested previously for VZV IgG antibody by Human VZV IgG assay, whereas the remaining 
samples were not tested. Therefore in order to provide a baseline test for comparison all 
sera were retested for VZV IgG using the Liaison VZV IgG assay. The Liaison VZV IgG 
assay is an automated quantitative assay that uses magnetic particles coated with VZV 
antigens (partially purified extract of infected cell cultures, ROD strain). Using this panel, 
gE ELISA assay showed 98.8 % (251/254) agreement with the Liaison VZV IgG assay. 
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The remaining 3 samples were positive by gE ELISA and equivocal by the Liaison assay 
even after retesting. Interestingly these 3 samples were positive by the Humana assay. In 
addition, comparing the 150 sample results obtained from the Humana assay with the gE 
ELISA results showed 100% agreement. The other panel used for evaluating VZV gE 
ELISA was panel 6. Panel 6 consisted of 100 samples previously tested by the Liaison 
VZV IgG assay. Furthermore of these 100 samples 37/100 had also been tested by the new 
AtheNA Multi-Lyte® MMRV IgG Plus assay. This new assay was developed by Zeus 
Scientific and is based on Luminex technology for detecting and determining IgG antibody 
response to Measles, Mumps, Rubella and Varicella Zoster virus in the same sample. The 
assay uses a mixture of beads conjugated with VZV antigen (the manufacturer’s leaflets 
does not define which type of antigen was used) or other virus antigens. Using this panel, 
the VZV gE ELISA showed 99% (99/100) agreement with the Liaison and 100% (37/37) 
with the AtheNA Multi-Lyte® MMRV IgG Plus assays (Table 3.23). The equivocal sample 
in the Liaison assay was positive by the AtheNA Multi-Lyte® MMRV IgG Plus assay. 
When the Liaison assay is considered as the reference assay, the sensitivity,  specificity, 
positive and negative predictive value for the in-house ELISA were 98.75%, 100%, 100%, 
100% in  panel 1 and 98.93 %, 100%, 100%, 100% in panel 6 respectively. The high 
correlation between the two assays and the gE ELISA indicates that the developed ELISA 
assay is suitable for detection of VZV IgG antibody in human serum.  
 
In general the results obtained from all serum panels showed good correlation between the 
developed ELISAs and the commercial ELISA assays. Such high correlation indicates that 
the expressed proteins used in this assays are highly purified and sensitive. In addition the 
epitopes found in these proteins were correctly displayed. Therefore, based on all the 
above results it was concluded that both proteins and peptide 55 were suitable to be used in 
the triplex assay.  
 
For the purpose of developing the triplex assay peptide 55 was kindly provided by Dr 
Howard Marsden, Institute of Virology, Glasgow. Initially an assay for each analyte was 
developed individually as a monoplex assay by direct conjugation of each antigen (gD, gE, 
peptide 55) to the carboxylated microsphere. Previous studies have reported the instability 
of some monoclonal antibodies during the conjugation procedure, because some antibodies 
cannot tolerate adherence to a solid support (Hermanson 1996; Peppard 2000; Al-Jindan 
2009). In addition, other studies have reported that in some cases exposure of the protein 
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(monoclonal antibody) to the chemical conjugation procedure may lead to changes in the 
protein structure which leads to the instability of the proteins and denaturation (Hermanson 
1996; Peppard 2000). The conjugation procedure was carried out using a two step 
carbodiimide chemical reaction (Staros et al., 1986). The principle of this reaction is based 
on a reaction between the carboxyl group on the surface of each microsphere with a water 
soluble EDC, resulting in production of an unstable amine reacting intermediate.  This 
unstable molecule was stabilised by the addition of Sulpho-NHS, allowing cross-linking 
from substitution of succinimide moieties for lysine E-amino groups of the protein 
(Grabarek and Gergely 1990). The mechanism of the two step reaction is summarised in 
Figure 4.1.     
 
The most important step in assay development was found to be optimisation of the 
conjugation procedure. During experimental work this step was found to be difficult, due 
to the fact that any small changes in the optimum conditions are likely to affect the 
conjugation of the microspheres to the antigens. A number of factors were investigated 
including activation buffer preparation; washing buffer content; number of washing steps; 
beads concentration; nonspecific binding; peptide or baculovirus expressed protein 
concentration; incubation time required between each step; and finally the buffer used for 
storage of the activated beads.  
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Figure 4.1 Two step carbodiimide reaction in which antigens are cross linked with the 
carboxyl group at the surface of the microsphere.  Taken from 
www.piercenet.com/.../browse.cfm?fldID=02030312 (accessed on 10/8/2010).  
 
 
During this stage of assay development a number of factors were found to have a major 
impact on the conjugation reaction. For example, reagent stability was found to be an 
important factor in the conjugation reaction especially EDC and sulpho-NHS. Both 
reagents are very sensitive to light and humidity and they need to be stored properly. It was 
noted during different optimisation experiments that using these reagents straight from the 
freezer had an effect on the conjugation process. This can be explained by the increasing 
humidity of reagents which occurred when the reagent bottle is opened and exposed to a 
warmer atmosphere within the laboratory. In such a case reagent performance will be 
affected and this will become apparent with time. To ensure reproducibility of experiments 
a number of standard procedures were always followed, these included: 
 
1- All reagents needed were labelled with the day and time on which they were first 
used and they were not used beyond the expiry date.  
2- Reagent bottles were stored in accordance with manufacturer’s instructions in a 
sealed container to ensure a humidity free atmosphere.  
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3- Before opening any containers all reagents were placed at room temperature for 1 h 
before use. 
4- PBS required for conjugation and washing buffers was always freshly prepared as a 
500 ml volume, stored at 4ºC and used for only 5 days.  
5- Microsphere bead sets were always stored in the fridge (4ºC), removed only when 
needed and placed on an orbital shaker in the dark at room temperature for 1 h 
before use.  
6- Conjugation buffers were always freshly prepared in 10 ml volumes and used on 
the same day. 
 
Following standardised procedures for conjugation and handling of reagents during the 
process of assay optimisation and development improved the performance, stability and 
reproducibility of each assay. The Phycoerthyrin Streptavidin R-Phycoerythrin purchased 
from Europa was used in the assay based on the recommendation of Luminex Ltd and was 
found out to give good results. Antigen concentration required for the assay was optimised 
by coupling each bead set with different concentration of each antigen (25 µg/ml, 50 
µg/ml, 100 µg/ml). However the best results were obtained with 50µg/ml and 25 µg/ml for 
gD/gE and peptide 55 respectively.  
 
Another factor that needed to be taken into account to produce the Luminex assay was 
reducing the non-specific binding. One of the major problems with Luminex assays is that 
human sera may contain antibody (heterophile antibodies) that can bind directly to the 
beads (Martins et al., 2004; Martins et al., 2006).  Several studies have reported the 
presence of these antibodies in different serum panels and their frequency was found to 
vary between 59 to 80% (Kricka 1999; Waterbore et al., 2005). Such binding may result in 
strong background reactivity independent of the antigen coupled to the beads. High 
backgrounds can also result from interaction between different reagents. This may be 
through the adherence of reagents to microsphere beads. In the present study the choice of 
microsphere bead type in combination with adequate blocking buffer was found to be 
important. Although several microsphere bead types are available commercially the 
SeroMap microsphere beads were selected. These microspheres were developed by 
Luminex to reduce the non-specific binding found within human serum samples. 
Waterbore et al., (2006) studied the suppression of non-specific binding in serological 
Luminex assays using two types of Luminex beads (MultiAnalyte, SeroMap). In the study, 
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human sera was first pre-incubated with 0.5% polyvinylacohol (PVA), 0.8% 
polyvinylpyrrolidone (PVP) or 0.5% Super ChemiBlock (CBS-K) and then added to each 
of the bead types coupled with E6 protein of the human papillomavirus (HPV) type 16. 
Results showed that when the MultiAnalyte beads (not derivatised with glutathione) were 
used, the MFI value exceeded 5000 in some sera. In contrast using the MultiAnalyte beads 
together with a PVP, PVA, CBS-K or with a combination of PVP and PVA (PVX) the 
non-specific binding was slightly reduced (MFI 250-700). However, optimum results were 
obtained when using the beads with a mixture of PVX and CBS-K (MFI 70). When 
SeroMap beads were used in the absence of additives to the pre-incubation buffer the non-
specific binding was reduced by 69%. The study concluded that non-specific binding can 
be eliminated by SeroMap beads and/or pre-incubated human sera in PVX and CBS-K 
buffer. Similar results were also reported by Martin et al., (2006) who compared the MFI 
generated from three types of Luminex beads (Lot A, Lot B (Multi-Analyte), SeroMap) 
after diluting the human sera in diluent buffer containing 10% fetal bovine serum (FBS). 
Background binding was reduced by up to 83%, 47.6% and 90.2% in Lot A, Lot B and in 
SeroMap beads respectively.  
 
In the present study the effect of using the SeroMap beads together with 0.05 -0.1% of 
Tween and 1-2% of NBBS for preventing the non-specific binding was investigated. 
Compared to all of the blocking reagents used, a sample diluent buffer containing 1% 
NBBS, PBS pH 7.3, and 0.05% Tween 20 was found to be the best choice due to its high 
blocking of the non-specific background. In addition, use of such buffer resulted in a high 
signal to noise ratio (a measure of signal strength relatively to the background). The MFI 
value obtained from all monoplex assays was generally less than 25. Such results indicate 
that a combination of highly purified antigen together with an efficient diluent buffer and 2 
washing steps between each assay step limited the background in each monoplex assy. 
Similar results was obtained from each bead set in the triplex assay. The MFI value 
obtained for each antigen in the triplex assay was less than 18.    
 
Bead interference is important to consider during development of multiplex assays. In the 
triplex assay this was evaluated by comparing the MFIs obtained from each monoplex 
assay with its corresponding assay in the triplex assay format. Results showed a lower 
background MFI obtained in the triplex compared to the monoplex assay (MFI 13.5-18). 
This indicates that the recovery rate and the stability of the assay was not affected by 
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mixing three beads sets together. The optimised triplex assay reproducibility and 
sensitivity was calculated. The reproducibility of the triplex assay was tested by calculating 
the percentage coefficient of variation (%CV) of 10 samples tested in duplicate within the 
same day and on different days. In general, the mean of the CVs of all tested samples was 
less than 10%. Similar CV value results in newly developed assays were reported in 
previous studies (Martins et al., 2009a; Xia et al., 2010). The sensitivity of the assay was 
also determined by testing 10 samples and the limit of detection of each was determined. 
Due to the difficulty of obtaining a standard serum sample with known antibody 
concentration for each antigen, a clinical reference serum sample known to have high 
levels of antibodies to each of the antibodies to be detected was used to generate a standard 
curve in which the concentration of antibody found within the sample could be calculated. 
The concentration of antibody for each analyte within unknown samples was reported as 
arbitrary units (ABU/ml). Based on the triplex assay results the limit of detection (LOD) 
for the assay was found to be 1.2 ABU/ml and 1.5 ABU/ml for VZV and HSV 
respectively. In addition there were no significant differences between the LOD of the 
monoplex and the triplex assays for each viral antibody.   
 
The performance of the triplex assay in detection and quantitation of antibody response to 
HSV-1, HSV-2 and VZV viruses was evaluated by screening panel 1 serum. As stated 
above, the panel was tested for these viruses using a number of assays including the 
developed in–house ELISA for HSV gD and VZV gE. Results showed a 100% agreement 
with the in-house ELISA for both HSV-1 gD and VZV gE. For peptide 55 the two assays 
(Omega, peptide 55 microbeads) agreed in 99.2 % (252/254) of the samples. The 
remaining two samples were determined negative by the Omega assay and positive by 
peptide 55 microbead assay. Reanalysis of the results of these two samples from the 
Omega assay revealed that these two samples gave OD values (0.451 and 0.462) near the 
cut-off point (0.470). In addition they were determined as HSV-2 positive by the Western 
blot assay. Such results indicate that the peptide 55 microbead assay has a higher 
sensitivity than the Omega ELISA assay.  Furthermore a linear regression analysis between 
the triplex assay results and results obtained from each relevant antigen ELISA assay 
showed a correlation of 0.988, 0.956 and 0.968 for peptide 55, HSV-1 gD and VZV gE 
respectively. Similar correlation has been reported in some studies (Van Gageldonk et al., 
2008; Al-Jindan 2009) and a poorer correlation found in others (Pickering et al., 2002; De 
Voer et al., 2008).  
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At the start of this study a Luminex assay for the detection of HSV-1, HSV-2 and VZV in 
the same sample was not available and the initial aim was to develop such an assay. In the 
last 3 years,  3 multiplex flow immunoassays for identifying HSV-1 and HSV-2 type 
specific IgG (AtheNA Multi-Lyte HSV type specific test system, BioPlex 2200 and Plexus 
HerpesSelect) were approved by the American Food and Drug Administration (FDA) 
(Martins et al., 2009a; Binnicker et al., 2010). The AtheNA Multi-Lyte HSV type specific 
assay (Zeus Scientific) employs recombinant gG1 and gG2 antigen coupled microspheres. 
The assay was evaluated by screening 2 well characterised serum panels (317 and 150 
samples obtained from sexually active adults and expectant mothers). Assay sensitivity and 
specificity for HSV-1 was 98.4%, and 92.5% respectively in sexually active adults and 
100.0% and 96.2% expectant mothers respectively. In the case of HSV-2 sensitivity and 
specificity was 97.6% and 96.2% in sexually active adults and 100% and 97.8% in 
expectant mothers, respectively. The BioPlex 2200 HSV-1 and HSV-2 assay (Bio-Rad 
Laboratories) employs an HSV-1 gG1 specific recombinant antigen and HSV-2 gG2 
specific synthetic peptide. This assay was evaluated by screening 289 and 286 samples 
from sexually active individuals for HSV-1 and HSV-2 respectively. In addition, 399 
samples from expectant mothers were tested. Assay sensitivity and specificity for HSV-1 
was 97.6% and 90.1% in sexually active individuals and 96.3% and 99.0% in expectant 
mothers. In the case of the HSV-2 assay sensitivity and specificity were 90.6% and 98.2 in 
sexually active adults and 96.9% and 100% in expectant mothers. The Plexus HerpesSelect 
HSV-1 and HSV-2 (Focus Diagnostic) assay utilises a recombinant HSV-1 gG1 and HSV-
2 gG2. Samples obtained from sexually active adults (300) and expectant mothers (300) 
were used to evaluate this assay and showed respective sensitivities and specificities of; 
96.5%, 92.2% for HSV-1; 94.3%, 95.5% for HSV-2 in expectant mothers; and 91.0%; 
96.5% for HSV-1; 96.3%, 97.4% for HSV-2 in sexually active adults. 
 
The performance of the AtheNA assay was also evaluated in comparison with immunoblot 
(HerpeSelect 1 and 2 immunoblot), Western blot and ELISA (HerpeSelect HSV-1 and 
HSV-2 IgG) assays by Martins et al., (2009a). In their study 332 well characterised serum 
samples categorised into 5 groups were tested by the multiplex and the HerpeSelect HSV 1 
and 2 ELISA assays. In the case of HSV-1 results showed an agreement of 94.8% and the 
sensitivity and specifity of the assay was 95.8% and 93.4% respectively. For HSV-2 the 
two assays agreed on 96.9% of samples and the sensitivity and specifity of the multiplex 
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assay was 92.6% and 98.7% respectively. In comparison for the immunoblot assay (the 
assay was composed of 4 bands; recombinant gG1and gG2, antihuman serum control band 
and a HSV-1 and 2 whole-virus lysate band) results of the two assays agreed in 95.8% of 
samples and showed a higher sensitivity (97.9%) but lower specificity (92.9%) for HSV-1. 
In the case of HSV-2 the assay agreed in 97.9% and the sensitivity and specificity was 
better than previously reported by the ELISA assay; 96.7% and 98.3% respectively. The 
remaining discrepant samples (n=50) were further tested by Western blot and the results 
were compared to those obtained with the multiplex assay. Analysis of the results showed 
that the overall agreement between the two assays were 95.8% and 98.8% for HSV-1 and 
HSV-2 respectively, and  the sensitivity and specificity of the multiplex assay was 94.9% 
and 97.0% for HSV-1 and 98.9% and 98.7% for HSV-2. Of the 50 discrepant samples 11 
were found to be positive by the immunoblot assay (using the type common band), 
however they were not typed. Three out of these 11 samples reacted in the multiplex assay, 
2 were gG1 positive and the remaining sample was gG2 positive. In addition, 3 samples of 
the 50 discrepant samples showed positive results by the immunoblot assay for gG1 or gG2 
but were negative for the type common band, therefore they were classified as atypical 
samples. Three samples were reported positive for either HSV-1 or HSV-2 by the 
multiplex, ELISA and Western blot assays. The study reported that these samples should 
be reported as negative. However, based on the results of other assays they are most likely 
to be false negative results.  The study concluded that all of the three assays preformed 
equally well, however, it was noted that although both the ELISA and the immunoblot 
employed the same recombinant antigen (gG1 and gG2); there were no great concordances 
between the two assays. For example in the group of samples that contained either HSV-1 
or HSV-2 antibodies the immunoblot assay gave a better performance compared to 
Western blot assay. In contrast the ELISA assay performs well in dual infected and 
seronegative samples compared to the western blot assay and the immunoblot assay. In 
addition the study reported that including a type common antigen band in the immunoblot 
assay was an advantage over the ELISA and the multiplex assays.  
 
Binnicker et al., (2010) evaluated the performance of the three multiplex flow 
immunoassays for the simultaneous detection of HSV-1 and HSV-2 type specific antibody 
by screening 505 serum samples. In the study, all samples (505) were tested for the 
presence of HSV-1 and HSV-2 type specific antibody using HerpeSelect 1 and 2 ELISA 
and then tested by the three assays. Discordant samples between all the assays were further 
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tested by HSV type specific Western blot assay. After resolving all discordant samples (16 
samples) the total agreement of the three assays with the HerpeSelect ELISA assay for 
HSV-1 was 96.8%, 98.8% and 97.6% for the AtheNA, Bio-Plex and Plexus respectively. 
In the case of HSV-2 the total agreement was 88.5%, 97.8% and 97.2 for each assay 
respectively. In addition, qualitative intra and inter assays reproducibility when testing 20 
samples (positive and negative result) was 100%. Furthermore the timing required for full 
analysis of 90 samples by the AtheNA, Bio-Plex and Plexus assays were 6.1, 2.6 and 4.7 
hours  respectively, versus 5.2 h for the HerpeSelect ELISA assay. The study concluded 
that the three assays performed well in detecting HSV-1 and HSV-2. However, the clinical 
data and previous laboratory results for the tested samples used in the study were not 
available, so the results could not be correlated with the clinical picture. Therefore the 
performance of the tested assays was only based on its correlation with the HerpeSelect 
ELISA assay.  
 
Taking into account the findings of the present study comparing the individual developed 
ELISA assays and the triplex assay with the commercially available assays, clearly shows 
that the developed triplex assay performed well in comparison to the relevant ELISAs and 
Western blots. In addition the developed assay has the advantage of using an HSV type 
common antigen that showed 100% agreement with all ELISA assays used and with 
Western blot. The employment of peptide 55 for detecting HSV-2 type specific antibody 
gave results that showed better agreement with Western blot than the other evaluated HSV-
2 type specific ELISA assays. The ability of the assay to detect antibody responses to 
HSV-1, HSV-2 and VZV viruses in 90 samples within approximately 2.5 h using only 2µl 
of sample volume in comparison to 5-10 µl by the previous multiplex and 10-50 µl by the 
other ELISA assays is a distinctive advantage .  
 
As stated earlier detection of viral specific antibody within the CNS compartment 
(intrathecal antibody) is known to be a reliable method for diagnosis of viral encephalitis. 
However, as a consequence of such infection the permeability of the BBB may be affected. 
Therefore in order to confirm the production of intrathecal antibody an antibody index has 
to be calculated. Traditional methods used nowadays for calculating antibody index are 
time, labour and sample consuming. In the present study a biplex assay based on Luminex 
technology developed in this department by Al-Jindan (2009) was utilised. The assay is 
based on 2 microsphere beads sets each coupled with either anti-human IgG or anti-human 
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albumin. Because phycoerythrin conjugated anti-human albumin antibody was not 
available commercially, an anti-human albumin monoclonal antibody labelled with biotin 
was used with streptavidin-coupled phycoerythrin. The assay was previously optimised, 
validated and evaluated by testing CSF quality control samples obtained from the United 
Kingdom National External Quality Assessment Service (NEQAS). The Biplex assay 
results were found to be highly correlated with the NEQAS samples results and the 
correlation coefficient of albumin and IgG was 0.9629 and 0.9921 respectively.  The assay 
was also used to test 63 paired samples (CSF and serum) obtained from Malawian children 
with pneumococcal meningitis in order to assess the relationship between infection and 
hearing loss (Al-Jindan 2009).  
 
The biplex assay protocol was adapted with some modifications (the microsphere beads 
types, sample diluent buffer, washing buffer and incubation times used were different). 
Although the original biplex assay showed a good correlation with the NEQAS sample 
results, it also showed a high MFI background. In the previous study several attempts were 
made to reduce the background to an acceptable reading these measures included pre-
incubating the plates with blocking agent (Tween-20, 0.02%) and increasing the washing 
steps and the washing intervals. However even after introducing these modifications the 
MFI was only reduced to 452 and 820 for IgG and albumin respectively. These MFIs are 
higher than that obtained for the triplex assay (13.5-18). Therefore, a new attempt was to 
reduce the background levels in this assay before including it with the triplex assay. The 
assay was repeated using the same conditions determined as optimal for the triplex assay. 
Interestingly using these conditions reduced the MFI of the assay to 280 and 350 for IgG 
and albumin respectively. Such results confirm the previous findings that using the 
SeroMAP and the diluent buffer has a positive effect on blocking of the nonspecific 
binding to the beads. Other attempts to reduce the background even further by increasing 
numbers of washing steps or altering NBBS and Tween-20 concentration in sample diluent 
buffer were not successful. Therefore, the obtained background was considered as an 
optimal background results for the albumin/IgG biplex assay.  
 
After obtaining an acceptable background for the biplex assay, the main challenge in 
developing the multiplex was to obtain a standard serum sample capable of generating a 
good standard curve for all 5 analytes in order to determine their concentration in the same 
sample. Since such a standard was not available commercially, the previous clinical 
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standard serum used in the ELISA and the triplex assay was used. To determine the IgG 
and albumin concentration in the standard sample, a serial dilution of the clinical standard 
serum was tested 3 times in duplicate using the biplex assay and then the mean value for 
each dilution was calculated. Using the biplex results, different concentrations of the 
clinical standard sample were used to generate a suitable standard curve for the 5 analytes. 
However during this step it was not possible to generate a good standard curve for all 5 
analytes together using any of the two assays conditions (serum dilution). In the triplex 
assay, the best standard curve was generated by making two-fold dilutions of the standard 
serum starting from 1/10 to 1/10240. In contrast the best standard curve for the biplex 
assay was generated by making two-fold dilutions of the standard sample starting from 
1/10000 to 1/5120000. When the triplex assay starting dilution was used for the multiplex 
assay the MFI reading obtained for the IgG and albumin was higher than the capacity of 
the machine to read (>24000 MFI). In contrast when the starting dilution of the biplex was 
used it was not possible to obtain good MIF reading (< 400). Therefore, In order to 
generate a standard curve for HSV-1 gD, VZV gE and peptide 55 4-fold dilutions of the 
standard serum starting from 1/10 to 1/2621440 at an IgG and albumin concentration of 
0.3g/l and 0.05g/l respectively were made. At this starting point the standard sample 
contained 4800 and 3200 ABU of HSV-1, HSV-2 and VZV respectively. The standard 
thus consisted of 12 points. The first 6 points (1/10 to 1/10240) were used to generate a 
standard curve for HSV-1, HSV-2 and VZV, whereas the remaining 6 points (1/40960 to 
1/2621440) were used for IgG and albumin. In order to obtain a good standard curve for 
HSV-1, HSV-2 and VZV the results of the last 6 points in the standard curve (S7 to S12) 
had to be masked. The reading obtained from S7 point in the standard curve for HSV-1, 
HSV-2 and VZV is equal to the blank well. In contrast the first 6 points in the standard 
curve (S1 to S6) had to be masked in order to generate a good standard curve for IgG and 
albumin. The reading obtained for IgG and albumin in these points was over 24000 MFI. 
Such standard dilution factor used in the multiplex assay (4 fold) is widely used in similar 
multiplex assays (van Gageldonk et al., 2008; Martins et al., 2009b).  
 
Once a good standard curve had been obtained for each analyte the dilution factor for 
serum and CSF samples was investigated. In the triplex assay a dilution factor of 1/100 
was found to be an optimal dilution for serum samples. In contrast the optimal dilution 
factor used previously in the biplex was 1/10000 and 1/1000000 for IgG and albumin 
respectively. Therefore in order to determine the best dilution factor for each sample (CSF 
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and serum) for the multiplex assay, a series of dilution factors were tested (1/100, 1/500, 
1/1000, 1/5000, 1/10000). Based on the results 1/5000 and 1/500 was used as the optimal 
dilution factors for serum and CSF respectively. These dilutions were selected in order to 
allow the normal antibodies for HSV-1, HSV-2 and VZV to fall in the median range of the 
first 6 points (S3-S4) and in the median of the last 6 points for the IgG and albumin (S9-
S10). After determining the sample dilution factor, the sensitivity and reproducibility of the 
multiplex assay was then evaluated by calculating the intra and inter assay variation, the 
percentage CV was found to be less than 10%. In addition combination of the two assays 
in a multiplex assay did not affect the sensitivity or limit of detection of the two assays. 
The multiplex assay results showed good correlation with previous results obtained from 
each individual assay. However it was noted that the background MFIs obtained from the 
triplex analytes (gD, gE, peptide 55) were increased to approximately 220 MFI. This 
increase in the MFI was due to the combination of the 5 analytes in a single assay. Since 
using the same reagents and experiment conditions in the triplex assay alone did not affect 
the assay background levels (13.5-18). Generally the background of the 5 analytes in the 
multiplex assay ranged from 250 to 350 MFI. Such background levels are better than 
reported in the biplex assay and is still within the acceptable ranges in comparison to 
similar assays. For example, based on the Plexus HerpeSelect HSV-1 and HSV-2 assay, a 
test run is acceptable with a blank well background reading of ≤ 800 MFI. The obtained 
background reading from the multiplex was well below this value and was therefore 
determined to be the optimal background reading for the multiplex assay. Following 
optimisation of the multiplex assay the next step was assay validation. However in the 
present study it was not possible to validate the assay due to the difficulty of obtaining 
paired samples from cases with and without neurological symptoms.  
 
 
In summary, although the alphaherpesviruses are known to cause local cutaneous 
infections, however each virus is associated with a number of neurological complications 
including encephalitis. The CNS is well protected against such infections being protected 
in the bony compartment and surrounded by the CSF. Therefore in normal conditions the 
entry of peripheral immune cells to the CNS is limited. However when the infection occurs 
the CNS is capable of initiating an immune response. In clinical practice diagnosis requires 
the use of different immuno assays in order to detect each virus specific antibodies in 
human sera and CSF samples. Different assays settings may increase the possibility of 
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aliquot errors, testing time as will as sample volume required for each assay. Therefore in 
the present study the visibility of using Luminex technology to improve the diagnosis of 
these viruses and their complications were investigated.  
 
In the present study two immuno dominant proteins of HSV-1, HSV-2 (gD) and VZV (gE) 
were expressed in insect cells using baculovirus expression systems. Expressed proteins 
were purified, characterised and used to develop two in-house ELISAs. The performances 
of the developed in-house ELISAs were tested by screening with characterise serum 
panels. Results have showed the superior performance of each in-house ELISAs in 
detecting HSV and VZV antibody in comparison to the commercially available ELISA 
assays. These results indicate that each expressed protein displays conformation-dependent 
epitopes capable of detecting antibodies for each virus. Therefore the developed ELISAs 
which are proven to be sensitive and specific can be utilised in central or local laboratories 
for detecting HSV and VZV antibodies in human sera. In addition, in order to differentiate 
between HSV-1 and HSV-2 antibody and due to the high risk of neonatal herpes infection 
when primary maternal genital HSV infection occurs, a comparative study was carried out 
to evaluate a newly developed ELISA assay based on peptide 55 for the detection of HSV-
2 type specific antibody. Assay performance was compared with two other HSV-2 type 
specific assays by screening a will characterised serum panel. Comparative results have 
showed that the new assay had better performance than other evaluated assay with high 
level of agreement with Western blot assay results. Therefore the new assay can be a 
sensitive serological test for diagnosis of HSV-2 genital infection, especially during 
pregnancy. Moreover with the increasing test volumes required every year for diagnosis of 
these viruses and there complications the two expressed proteins together with peptide 55 
were used to develop a triplex fluorescent microbead immunoassay for the simultaneous 
detection and quantitation of anti-viral antibody in the same human sera (Binnicker 2010). 
Assay sensitivity was tested by screening a well characterised serum panel and the assay 
was found to be sensitive, specific, reducible and showed high level of agreement with 
other commercially approved immuno assays used to evaluate the serum panel. The 
advantage of the developed triplex assay is its ability to measure antibody to the three 
viruses. The developed Luminex assay by contrast, is sensitive, rapid and requires very low 
test sample volumes; as little as 2µl can be used to detect antibody to the three viruses in 
comparison to other immuno assays which requires 5-30µl (5-10µl for each virus). The 
latter finding is particularly important when attempting to detect antibody in a sample such 
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as CSF where only low test volumes are commonly available. Therefore the triplex assay 
can be a valuable serological method for diagnosis of alphaherpesviruses infections in 
laboratories in where it can save labour, reagent cost, and time required for diagnosis of 
infection with these viruses. In order to improve the diagnosis of alphaherpesviruses CNS 
infection, a multiplex fluorescent microbead immunoassay was developed by combining 
the triplex assay with a biplex assay designed to detect and quantitate both human IgG and 
albumin in serum and CSF samples. The multiplex assay developed in this study was 
optimised, tested using standard samples and has proved its reproducibility and ability to 
detect and quantitate each virus antibody as well as human IgG and albumin in the same 
sample.  
 
In order to validate the multiplex assay a series of paired samples from proven cases of 
HSE and ADEM should be tested as well as paired samples from normal patients (control 
groups). The latter samples will be required to determine the normal ranges of values of 
IgG index and albumin ratios Serum:CSF using this novel assay. Previous reported values 
for these parameters may or may not be valid for this new assay due to its higher 
sensitivity and lower detection limits. It is of course difficult to obtain samples of CSF 
from normal i.e. non-diseased individuals due to the invasiveness of the lumbar puncture 
procedure. However it may be possible to obtain CSF samples either from patients without 
neurological disease who are undergoing procedures leading to the removal of CSF such as 
pregnant women undergoing any epidural injections or patients undergoing spinal 
anastasia. A series of paired serum and CSF pairs are available to validate the novel assay 
through the UK National encephalitis study. Unfortunately these were not available at the 
time of this project. In order to properly calculate the antibody index to confirm the 
production of intrathecal antibody paired samples (i.e. serum and CSF taken at the same 
time) from each patient are necessary. There are many factors can contribute the variation 
in antibody index level including the timing in which the two samples were taken. The 
immune response of each patient may influence the degree of BBB damage and intrathecal 
IgG production. Selection of the timing in which the paired samples were taken is also 
important. As stated before although the production of intrathecal antibody may be 
detected in the early stage of CNS infection (Klapper et al., 1981).  Reliable detection of 
intrathecal antibody synthesis is not achieved until 14 or more days after the onset of the 
neurological infection. Therefore sample from the convalescent stage are required. This 
does not affect the important value of detecting of intrathecal antibody as a diagnostic 
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method. Once the multiplex assay has been validated it can be utilised for the diagnosis of 
alphaherpesviruses CNS infections. In addition it can be also used for diagnosing other 
encephalitis cases with unknown aetiology. It is reported that 85% of encephalitis cases 
reported world wide are of unknown aetiology (Davison et al., 2003; Granerod and 
Crowcroft 2007). In a recent multi-centre study in the UK by Granerod et al,.(2010) the 
infectious cause in 203 cases of encephalitis was found only in 63% of cases, in which the 
specific aetiologies included HSV (19%), ADEM (11%), autoantibody-associated (8%), 
VZV (5%) and Mycobacterium tuberculosis (5%). However in 37% of these cases no 
aetiology was reported. The developed multiplex assay can be combined with baculovirus 
based expression system developed in this study to allow the immune response to a much 
wider rang of pathogens to be identified. The application of this technique, particularly in 
the study of most forms of encephalitis not associated with active CNS infection (e.g. 
ADEM) promises to dramatically improve the diagnostic yield in encephalitis.       
 
The advantage of the Luminex technology is apparent, particularly in its ability of 
expansion to include 100 targets of interest in a single assay which can be individually 
discriminated. The simultaneous detection and quantitation of specific antibody response 
to individual targets in a small volume of a single sample can be achieved. In addition 
savings of reagent cost and assay time can be acquired from using such an assay. In 
comparison to conventional methods these advantages are clearly a strong impetus for the 
routine use of this assay in the clinical laboratory and for research purposes.  
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Table 1 Summary of the Results Obtained from the Different ELISA Assays for Panel 1 Sera. 
 
Sample 
NO Age
DIAMEDIX HSV 
1+2 T/C 
Assay
Results
Bioelisa HSV 1 
IgG T/C 
Assay 
Results 
Bioelisa HSV 2 
IgG T/C 
Assay 
Results 
Virotech 
HSV-1 
Assay 
Result 
Human VZ 
IgG T/C 
Assay 
Results 
1 52 1.01 POS - - - - 0.532 POS - - 
2 56 4.97 POS - - - - 1.691 POS 11.8 POS 
3 48 5 POS - - - - 1.414 POS 5.3 POS 
4 34 4.51 POS - - - - 1.311 POS - - 
5 58 3.66 POS - - -  1.498 POS 5.4 POS 
6 38 - - 3.41 POS 7.94 POS 0.921 POS 9.6 POS 
7 95 30 POS 7.5 POS 13.7 POS 1.982 POS - - 
8 34 4.15 POS - - - - 1.516 POS 7.2 POS 
9 36 1.69 POS - - - - 0.64 POS 8.4 POS 
10 69 4.06 POS - - - - 1.492 POS 9 POS 
11 51 4.53 POS - - - - 1.732 POS 6.3 POS 
12 46 1.23 POS - - - - 0.693 POS - - 
13 25 4.61 POS - - - - 1.55 POS - - 
14 31 - - 2.87 POS 0.16 NEG 0.893 POS - - 
15 54 2.56 POS - - - - 0.937 POS 8.2 POS 
16 50 - - 5.55 POS 3.07 POS 1.01 POS - - 
17 23 - - 0.27 NEG 0.17 NEG 0.915 POS - - 
18 28 3.77 POS - - - - 1.343 POS 5.2 POS 
19 88 4.71 POS - - -  1.514 POS - - 
20 47 4.57 POS - - - - 1.443 POS - - 
21 42 - - 3.59 POS 0.32 NEG 0.941 POS 6.2 POS 
22 64 4.53 POS - - - - 1.352 POS 3.9 POS 
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Sample 
NO Age
DIAMEDIX HSV 
1+2 T/C 
Assay
Results
Bioelisa HSV 1 
IgG T/C 
Assay 
Results 
Bioelisa HSV 2 
IgG T/C 
Assay 
Results 
Virotech 
HSV-1 
Assay 
Result 
Human VZ 
IgG T/C 
Assay 
Results 
23 50 5.34 POS - - - - 1.615 POS 1.5 POS 
24 28 4.8 POS - - - - 1.671 POS - - 
25 37 5.03 POS - - - - 1.484 POS 6.6 POS 
26 75 4.78 POS - - - - 1.533 POS - - 
27 63 5.48 POS - - - - 2.175 POS 9.7 POS 
28 26 5.38 POS - - - - 1.69 POS 3.6 POS 
29 42 4.93 POS - - - - 1.553 POS - - 
30 47 4.31 POS - - - - 1.387 POS 6.5 POS 
31 42 4.16 POS - - - - 1.374 POS 11.2 POS 
32 84 5.11 POS - - - - 1.799 POS 11.4 POS 
33 35 1.2 POS - - - - 0.489 POS 5.2 POS 
34 35 3.37 POS - - - - 0.56 POS 3.4 POS 
35 61 5.43 POS - - - - 0.56 POS 4.1 POS 
36 74 2.48 POS - - - - 1.151 POS - - 
37 7 4.62 POS - - - - 1.74 POS 2.5 POS 
38 52 4.62 POS - - - - 1.764 POS 4.6 POS 
39 5 2.61 POS - - - - 1.228 POS 3 POS 
40 29 - - 2.01 POS 0.59 NEG 0.761 POS - - 
41 72 5.1 POS - - - - 1.754 POS 0.8 NEG 
42 62 4.94 POS - - - - 1.835 POS 5.1 POS 
43 62 4.58 POS - - - - 1.526 POS 3.8 POS 
44 72 4.67 POS - - - - 1.644 POS 0.4 NEG 
45 53 4.46 POS - - - - 1.747 POS 3.2 POS 
46 11 3.59 POS - - - - 1.525 POS 1.9 POS 
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Sample 
NO Age
DIAMEDIX HSV 
1+2 T/C 
Assay
Results
Bioelisa HSV 1 
IgG T/C 
Assay 
Results 
Bioelisa HSV 2 
IgG T/C 
Assay 
Results 
Virotech 
HSV-1 
Assay 
Result 
Human VZ 
IgG T/C 
Assay 
Results 
47 55 1.03 POS - - - - 0.636 POS 7.8 POS 
48 67 4.5 POS - - - - 1.567 POS - - 
49 52 3.66 POS - - - - 1.387 POS 7.6 POS 
50 36 4.41 POS - - - - 1.642 POS 6.5 POS 
51 56 2.98 POS - - - - 1.255 POS 4.6 POS 
52 45 - - 3.99 POS 0.14 NEG 1.20 POS - - 
53 37 - - 4.35 POS 2.97 POS 1.765 POS 7.5 POS 
54 58 4.45 POS - - - - 1.653 POS - - 
55 28 - - 2.56 POS 0.13 NEG 1.32 POS - - 
56 42 - - 4.4 POS 0.17 NEG 0.982 POS - - 
57 58 2.51 POS - - - - 0.749 POS 6.2 POS 
58 21 - - 1.21 POS 0.22 NEG 0.992 POS - - 
59 4 3.92 POS - - - - 1.273 POS 5.8 POS 
60 29 - - 1.27 POS 0.1 NEG 1.230 POS - - 
61 32 - - 3.64 POS 0.43 NEG 1.341 POS - - 
62 47 1.94 POS - - - - 0.652 POS 0.4 NEG 
63 37 2.11 POS - - - - 0.789 POS - - 
64 67 3.97 POS - - - - 1.384 POS 0.3 NEG 
65 52 4.69 POS - - - - 1.812 POS - - 
66 62 3.9 POS - - - - 1.441 POS 3.5 POS 
67 24 -  1.35 POS 0.49 NEG 1.563 POS - - 
68 48 4.08 POS - - - - 1.491 POS - - 
69 30 4.99 POS - - - - 1.678 POS - - 
70 74 4.56 POS - - - - 1.503 POS 6.7 POS 
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Sample 
NO Age
DIAMEDIX HSV 
1+2 T/C 
Assay
Results
Bioelisa HSV 1 
IgG T/C 
Assay 
Results 
Bioelisa HSV 2 
IgG T/C 
Assay 
Results 
Virotech 
HSV-1 
Assay 
Result 
Human VZ 
IgG T/C 
Assay 
Results 
71 49 4.11 POS - - - - 1.291 POS 6.1 POS 
72 58 5.38 POS - - - - 1.548 POS - - 
73 37 - - 5.75 POS 0.11 NEG 1.342 POS - - 
74 57 - - 6.02 POS 0.55 NEG 0.875 POS - - 
75 50 - - 5.68 POS 4.56 POS 0.991 POS - - 
76 38 - - 3.7 POS 4.45 POS 1.231 POS - - 
77 47 - - 3.82 POS 0.2 NEG 0.897 POS - - 
78 38 - - 6.6 POS 0.09 NEG 1.021 POS 6.3 POS 
79 21 - - 4.81 POS 0.18 NEG 1.231 POS - - 
80 20 - - 0.3 NEG 6.57 POS 0.761 POS - - 
81 48 - - 1.47 POS 0.16 NEG 0.879 POS - - 
82 32 - - 0.07 NEG 1.7 POS 0.997 POS - - 
83 49 - - 5.51 POS 0.5 NEG 1.230 POS - - 
84 60 4.83 POS - - - - 1.862 POS - - 
85 55 4.79 POS - - - - 1.825 POS - - 
86 25 4.88 POS - - - - 1.63 POS 8.1 POS 
87 66 3.47 POS - - - - 1.324 POS 2.1 POS 
88 100 20.3 POS - - - - 1.964 POS 2187 POS 
89 26 4.26 POS - - - - 1.618 POS - - 
90 48 4.7 POS - - - - 1.514 POS 5.4 POS 
91 38 23 POS - - - - 1.934 POS - - 
92 37 12.4 POS - - - - 1.444 POS 1934 POS 
93 51 - - 0.09 NEG 2.73 POS 1.320 POS - - 
94 44 - - 3.57 POS 3.82 POS 0.998 POS 4.7 POS 
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Sample 
NO Age
DIAMEDIX HSV 
1+2 T/C 
Assay
Results
Bioelisa HSV 1 
IgG T/C 
Assay 
Results 
Bioelisa HSV 2 
IgG T/C 
Assay 
Results 
Virotech 
HSV-1 
Assay 
Result 
Human VZ 
IgG T/C 
Assay 
Results 
95 46 - - 0.18 NEG 0.77 NEG 0.124 NEG - - 
96 68 - - -0.01 NEG 0.09 NEG 1.937 POS - - 
97 45 - - -0.01 NEG 0.21 NEG 1.695 POS 7 POS 
98 20 - - 0.87 NEG 1.04 E 1.317 POS - - 
99 16 - - 2.18 POS 0.1 NEG 1.202 POS - - 
100 30 - - -0.01 NEG 3.33 POS 1.346 POS - - 
101 32 - - 4.54 POS 1.54 POS 0.981 POS - - 
102 62 - - 5.85 POS 0.08 NEG 1.431 POS 8.7 POS 
103 53 - - 5.71 POS 0.12 NEG 0.963 POS - - 
104 31 - - 0.46 NEG 5.73 POS 0.875 POS - - 
105 49 - - 7.07 POS 3.19 POS 1.475 POS - - 
106 24 - - 11.35 POS 0.33 NEG 1.561 POS - - 
107 41 - - 5.71 POS 0.3 NEG 0.921 POS - - 
108 47 - - 8.85 POS 0.5 NEG 1.321 POS - - 
109 49 - - 6.98 POS 5.94 POS 0.992 POS - - 
110 25 - - 7.35 POS - - 0.998 POS 2.4 POS 
111 35 - - 3.78 POS 0.05 NEG 0.768 POS - - 
112 40 - - 0.05 NEG 2.18 POS 0.643 POS - - 
113 42 - - 3.56 POS 0.49 NEG 0.797 POS - - 
114 23 - - 3.64 POS 0.23 NEG 0.832 POS - - 
115 28 - - 2.83 POS 0.57 NEG 0.786 POS - - 
116 63 4.55 POS - - - - 1.626 POS 4.6 POS 
117 68 4.21 POS - - - - 1.675 POS 4.3 POS 
118 86 4.45 POS - - - - 1.634 POS - - 
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Sample 
NO Age
DIAMEDIX HSV 
1+2 T/C 
Assay
Results
Bioelisa HSV 1 
IgG T/C 
Assay 
Results 
Bioelisa HSV 2 
IgG T/C 
Assay 
Results 
Virotech 
HSV-1 
Assay 
Result 
Human VZ 
IgG T/C 
Assay 
Results 
119 67 4.32 POS - - - - 1.635 POS 5.1 POS 
120 47 1.96 POS - - - - 0.867 POS 6.4 POS 
121 13 - - 0.31 NEG 0.2 NEG 0.076 NEG - - 
122 34 - - 0.41 NEG 0.18 NEG 0.109 NEG - - 
123 41 - - 0.25 NEG 4.27 POS 1.512 POS - - 
124 21 - - 0.35 NEG 0.23 NEG 0.137 NEG - - 
125 23 - - 0.37 NEG 0.27 NEG 0.111 NEG - - 
126 29 - - 0.45 NEG 0.36 NEG 1.201 POS - - 
127 37 - - 0.74 NEG 0.64 NEG 0.088 NEG - - 
128 26 - - - - - - 0.128 NEG - - 
129 49 - - 0.1 NEG 2.2 POS 1.148 POS - - 
130 29   2.01 POS 0.13 NEG 0.856 POS - - 
131 50 4.3 POS - - - - 1.845 POS - - 
132 45 - - 0.13 NEG 0.15 NEG 0.171 NEG - - 
133 35 29.8 POS - - - - 1.688 POS 960.6 POS 
134 31 0.57 NEG - - - - 0.255 NEG - - 
135 9 - - 0.2 NEG 0.5 NEG 0.094 NEG 4000 POS 
136 20 0.5 NEG - - - - 1.134 POS 477 POS 
137 40 - - 3.7 POS 0.5 NEG 0.764 POS - - 
138 50 - - 1.5 POS 0.5 NEG 0.683 POS - - 
139 45 - - 3.3 POS 14.8 POS 0.675 POS - - 
140 47 - - 2.7 POS 4.8 POS 0.821 POS - - 
141 33 - - 3.5 POS 0.5 NEG 0.634 POS - - 
142 51 30 POS - - - - 1.665 POS 2672 POS 
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Sample 
NO Age
DIAMEDIX HSV 
1+2 T/C 
Assay
Results
Bioelisa HSV 1 
IgG T/C 
Assay 
Results 
Bioelisa HSV 2 
IgG T/C 
Assay 
Results 
Virotech 
HSV-1 
Assay 
Result 
Human VZ 
IgG T/C 
Assay 
Results 
143 34 - - 3.8 POS 3.4 POS 0.677 POS - - 
144 45 - - 3.1 POS 7.8 POS 0.853 POS - - 
145 45 - - 3.7 POS 0.5 NEG 0.712 POS - - 
146 44 - - 4.4 POS 0.5 NEG 0.873 POS - - 
147 33 30 POS - - - - 1.575 POS - - 
148 105 - - 4.3 POS 8.8 POS 0.990 POS - - 
149 67 - - 4.2 POS 0.8 NEG 0.985 POS - - 
150 105 22.7 POS - - - - 1.639 POS 1503 POS 
151 38 9.1 POS - - - - 0.838 POS 1715 POS 
152 105 24.2 POS - - - - 1.527 POS 1395 POS 
153 54 30 POS - - - - 1.497 POS - - 
154 64 21.2 POS - - - - 1.477 POS 3276 POS 
155 59 30 POS - - - - 1.713 POS 1130 POS 
156 68 30 POS - - - - 1.52 POS 1470 POS 
157 47 30 POS - - - - 1.729 POS - - 
158 24 1.13 POS - - - - 0.852 POS - - 
159 39 25.1 POS - - - - 1.374 POS 723.4 POS 
160 69 26.5 POS - - - - 1.639 POS - - 
161 27 20.5 POS - - - - 1.602 POS 1490 POS 
162 89 17.7 POS - - - - 1.695 POS 468.2 POS 
163 47 21.8 POS - - - - 1.746 POS 2766 POS 
164 22 15.3 POS - - - - 1.032 POS - - 
165 30 - - 3.9 POS 0.8 NEG 0.932 POS - - 
166 21 - - 4.6 POS 0.5 NEG 1.201 POS - - 
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Sample 
NO Age
DIAMEDIX HSV 
1+2 T/C 
Assay
Results
Bioelisa HSV 1 
IgG T/C 
Assay 
Results 
Bioelisa HSV 2 
IgG T/C 
Assay 
Results 
Virotech 
HSV-1 
Assay 
Result 
Human VZ 
IgG T/C 
Assay 
Results 
167 52 - - 4.2 POS 0.5 NEG 1.101 POS - - 
168 44 - - 3.2 POS 0.5 NEG 0.987 POS - - 
169 81 - - 4.9 POS 0.5 NEG 0.991 POS - - 
170 19 0.5 NEG - - - - 0.078 NEG 1158 POS 
171 37 30 POS - - - - 0.882 POS - - 
172 49 - - 7.4 POS 0.5 NEG 0.765 POS - - 
173 47 2.3 POS - - - - 1.505 POS - - 
174 46 23.5 POS - - - - 1.543 POS 797.5 POS 
175 71 24.1 POS - - - - 1.766 POS 4000 POS 
176 53 28.6 POS - - - - 1.751 POS 441.7 POS 
177 24 18.9 POS - - - - 1.846 POS 2759 POS 
178 36 30 POS - - - - 1.668 POS 530.5 POS 
179 62 20.6 POS - - - - 1.644 POS - - 
180 48 0.5 NEG - - - - 0.091 NEG 10.59 NEG 
181 25 0.5 NEG - - - - 0.057 NEG - - 
182 46 20.1 POS - - - - 1.878 POS 471.4 POS 
183 5 0.5 NEG - - - - 0.077 NEG 1120 POS 
184 21 - - 0.1 NEG 0.5 NEG 0.064 NEG - - 
185 27 - - 0.2 NEG 0.5 NEG 0.048 NEG - - 
186 38 0.5 NEG - - - - 0.082 NEG 2271 POS 
187 39 0.5 NEG - - - - 0.072 NEG - - 
188 6 0.5 NEG - - - - 0.083 NEG - - 
189 27 0.5 NEG - - - - 1.986 POS - - 
190 53 0.5 NEG 0.5 NEG 0.5 NEG 0.095 NEG - - 
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Sample 
NO Age
DIAMEDIX HSV 
1+2 T/C 
Assay
Results
Bioelisa HSV 1 
IgG T/C 
Assay 
Results 
Bioelisa HSV 2 
IgG T/C 
Assay 
Results 
Virotech 
HSV-1 
Assay 
Result 
Human VZ 
IgG T/C 
Assay 
Results 
191 4 -  0.1 NEG 0.5 NEG 0.076 NEG - - 
192 7 0.5 NEG - - - - 0.114 NEG 23.84 NEG 
193 64 0.5 NEG - - - - 0.705 POS - - 
194 38 0.5 NEG - - - - 0.33 NEG - - 
195 28 0.64 NEG - - - - 0.085 NEG - - 
196 15 0.5 NEG - - - - 0.036 NEG 273.3 POS 
197 42 - - 5 POS 0.5 NEG 1.153 POS - - 
198 84 - - 4.7 POS 0.5 NEG 1.342 POS - - 
199 32 - - 4.3 POS 1.3 POS 0.998 POS - - 
200 14 0.69 NEG - - - - 0.048 NEG - - 
201 27 - - 2.9 POS 0.5 NEG 0.886 POS - - 
202 42 0.5 NEG - - - - 0.077 NEG - - 
203 38 - - 4.4 POS 0.5 NEG 0.994 POS 28.65 POS 
204 3 0.5 NEG - - - - 1.43 POS 11.44 NEG 
205 27 0.5 NEG - - - - 0.074 NEG - - 
206 37 - - 4.5 POS 0.5 NEG 1.211 POS - - 
207 66 - - 4.2 POS 6.7 POS 0.931 POS - - 
208 4 0.5 NEG - - - - 0.089 NEG 14.86 NEG 
209 5 0.5 NEG - - - - 0.098 NEG 12.68 NEG 
210 21 0.5 NEG - - - - 0.116 NEG - - 
211 51 - - 4.4 POS 0.5 NEG 1.531 POS 1266 POS 
212 26 - - 4.9 POS 0.5 NEG 1.223 POS - - 
213 60 0.5 NEG - - - - 0.064 NEG - - 
214 25 0.5 NEG - - - - 0.05 NEG 185.7 POS 
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Sample 
NO Age
DIAMEDIX HSV 
1+2 T/C 
Assay
Results
Bioelisa HSV 1 
IgG T/C 
Assay 
Results 
Bioelisa HSV 2 
IgG T/C 
Assay 
Results 
Virotech 
HSV-1 
Assay 
Result 
Human VZ 
IgG T/C 
Assay 
Results 
215 60 - - 5.2 POS 0.5 NEG 0.994 POS - - 
216 3 0.5 NEG - - - - 1.82 POS - - 
217 52 - - 2.9 POS 1 E 0.763 POS 1837 POS 
218 53 - - 4 POS 5.7 POS 1.210 POS - - 
219 34 - - 1.2 POS 3.3 POS 0.651 POS - - 
220 28 - - 1.1 POS 11.6 POS 0.723 POS - - 
221 26 29.9 POS 1.1 POS 4.5 POS 0.665 POS - - 
222 32 - NT 0.8 NEG 4.6 POS 0.531 POS - - 
223 30 - NT 0.8 NEG 1.3 POS 0.123 NEG - - 
224 31 - NT 1.3 POS 6.1 POS 0.735 POS - - 
225 28 - NT 4.6 POS 2.6 POS 1.320 POS - - 
226 35 - POS 2.4 POS 5.5 POS 1.21 POS - - 
227 35 - NT 3.8 POS 1.9 POS 0.892 POS - - 
228 57 - NT 4.3 POS 1.9 POS 1.112 POS - - 
229 37 - NT 4.4 POS 8.3 POS 1.221 POS - - 
230 39 - NT 3.1 POS 1.1 POS 0.988 POS - - 
231 45 - NT 5.8 POS 3.5 POS 1.341 POS - - 
232 49 - NT 8.1 POS 2.2 POS 1.632 POS - - 
233 35 - NT 4.0 POS 9.0 POS 1.221 POS - - 
234 12 - NT 3.2 POS 6.0 POS 1.132 POS - - 
235 30 - NT 4 POS 4.2 POS 1.213 POS - - 
236 34 - NT 5.1 POS 5.2 POS 1.231 POS - - 
237 46 - NT 5.1 POS 2.0 POS 1.301 POS - - 
238 29 - - 4.4 POS 2.9 POS 1.251 POS - - 
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Sample 
NO Age
DIAMEDIX HSV 
1+2 T/C 
Assay
Results
Bioelisa HSV 1 
IgG T/C 
Assay 
Results 
Bioelisa HSV 2 
IgG T/C 
Assay 
Results 
Virotech 
HSV-1 
Assay 
Result 
Human VZ 
IgG T/C 
Assay 
Results 
239 60 - - 3.2 POS 7.3 POS 1.021 POS - - 
240 43 - - 4.6 POS 2.4 POS 1.321 POS - - 
241 42 - - 4.3 POS 2.2 POS 1.215 POS - - 
242 38 - - 4.3 POS 1.2 POS 1.431 POS - - 
243 23 - - 3.7 POS 1.4 POS 1.324 POS - - 
244 36 - - 0.69 NEG 4.25 POS 0.210 NEG - - 
245 22 - - 0.78 NEG 1.98 POS 0.130 NEG 9.9 POS 
246 55 - - 0.19 NEG 1.52 POS 0.218 NEG - - 
247 47 - - 0.09 NEG 7.54 POS 0.232 NEG - - 
248 43 - - 0.1 NEG 1.7 POS 0.112 NEG - - 
249 46 - - 0.19 NEG 4.11 POS 0.242 NEG - - 
250 39 - - 0.04 NEG 5.43 POS 0.045 NEG - - 
251 4 - - 0.05 NEG 2.02 POS 0.032 NEG - - 
252 44 - - 0.08 NEG 1.55 POS 0.045 NEG - - 
253 54 - - 0.14 NEG 5.87 POS 0.012 NEG - - 
254 24 - - 0.29 NEG 5.09 POS 0.120 NEG - - 
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Table 2 Summary of the Results Obtained from Omega, Focus, Biokit and Western blot Assays for Panel 1 Sera.  
 
Sample 
No 
Omega OD 
Reading 
Omega 
Result 
BioKit OD 
Reading 
BioKit  
Result 
Focus OD 
Reading  Focus  Result
Virotech  
OD  
Reading 
Virotech  
Result 
Western 
blot  result 
1 0.899 POS 0.074 NEG 0.728 POS 0.532 POS POS 
2 0.059 NEG 0.022 NEG 0.018 NEG 1.691 POS - 
3 0.067 NEG 0.017 NEG 0.02 NEG 1.414 POS - 
4 0.163 NEG 0.033 NEG 0.054 NEG 1.311 POS - 
5 0.692 POS 0.535 POS 0.025 NEG 1.498 POS POS 
6 1.2 POS 1.094 POS 2.345 POS - - - 
7 2.745 POS 1.236 POS 3.615 POS 1.982 POS - 
8 0.057 NEG 0.032 NEG 0.063 NEG 1.516 POS - 
9 0.097 NEG 0.075 NEG 0.386 POS 0.64 POS - 
10 0.109 NEG 0.04 NEG 0.036 NEG 1.492 POS - 
11 0.094 NEG 0.033 NEG 0.033 NEG 1.732 POS POS 
12 0.132 NEG 0.006 NEG 0.011 NEG 0.693 POS - 
13 0.069 NEG 0.021 NEG 0.073 NEG 1.55 POS - 
14 0.301 NEG 0.02 NEG 0.195 NEG - - - 
15 1.56 POS 0.841 POS 2.065 POS 0.937 POS - 
16 1.72 POS 0.739 POS 2.262 POS 0 NT - 
17 0.067 NEG 0.016 NEG 0.039 NEG 0.915 POS - 
18 0.2 NEG 0.025 NEG 0.046 NEG 1.343 POS - 
19 0.097 NEG 0.028 NEG 0.044 NEG 1.514 POS - 
20 0.0278 NEG 0.083 NEG 0.134 NEG 1.443 POS - 
21 0.068 NEG 0.017 NEG 0.03 NEG - - - 
  
 276 
Sample 
No 
Omega OD 
Reading 
Omega 
Result 
BioKit OD 
Reading 
BioKit  
Result 
Focus OD 
Reading  Focus  Result
Virotech  
OD  
Reading 
Virotech  
Result 
Western 
blot  result 
22 0.061 NEG 0.013 NEG 0.013 NEG 1.352 POS - 
23 0.103 NEG 0.023 NEG 0.019 NEG 1.615 POS - 
24 0.048 NEG 0.015 NEG 0.031 NEG 1.671 POS - 
25 0.085 NEG 0.37 NEG 0.177 NEG 1.484 POS - 
26 0.073 NEG 0.061 NEG 0.022 NEG 1.533 POS - 
27 0.104 NEG 0.065 NEG 0.029 NEG 2.175 POS - 
28 0.048 NEG 0.03 NEG 0.063 NEG 1.69 POS - 
29 0.064 NEG 0.015 NEG 0.016 NEG 1.553 POS - 
30 0.046 NEG 0.011 NEG 0.009 NEG 1.387 POS - 
31 0.057 NEG 0.13 NEG 0.066 NEG 1.374 POS - 
32 0.249 NEG 0.14 NEG 0.07 NEG 1.799 POS - 
33 0.157 NEG 0.101 NEG 0.035 NEG 0.489 POS - 
34 0.108 NEG 0.032 NEG 0.02 NEG 0.56 POS - 
35 0.147 NEG 0.153 NEG 0.022 NEG 0.56 POS - 
36 0.156 NEG 0.025 NEG 0.022 NEG 1.151 POS - 
37 0.14 NEG 0.078 NEG 0.138 NEG 1.74 POS - 
38 0.069 NEG 0.041 NEG 0.033 NEG 1.764 POS - 
39 0.067 NEG 0.017 NEG 0.012 NEG 1.228 POS - 
40 0.399 NEG 0.057 NEG 0.024 NEG - - NEG 
41 2.3 POS 1.123 POS 2.516 POS 1.754 POS - 
42 1.98 POS 0.273 NEG 0.683 POS 1.835 POS POS 
43 0.104 NEG 0.022 NEG 0.047 NEG 1.526 POS - 
44 2.921 POS 0.89 POS 2.614 POS 1.644 POS - 
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Sample 
No 
Omega OD 
Reading 
Omega 
Result 
BioKit OD 
Reading 
BioKit  
Result 
Focus OD 
Reading  Focus  Result
Virotech  
OD  
Reading 
Virotech  
Result 
Western 
blot  result 
45 0.074 NEG 0.019 NEG 0.049 NEG 1.747 POS - 
46 0.05 NEG 0.011 NEG 0.013 NEG 1.525 POS - 
47 0.076 NEG 0.022 NEG 0.056 NEG 0.636 POS - 
48 0.087 NEG 0.023 NEG 0.035 NEG 1.567 POS - 
49 0.985 POS 0.393 NEG 1.913 POS 1.387 POS POS 
50 2.101 POS 1.183 NEG 0.621 POS 1.642 POS POS 
51 0.07 NEG 0.008 NEG 0.015 NEG 1.255 POS  
52 0.074 NEG 0.018 NEG 0.087 NEG - - - 
53 0.052 NEG 0.012 NEG 0.018 NEG 1.765 POS - 
54 0.082 NEG 0.029 NEG 0.066 NEG 1.653 POS - 
55 0.067 NEG 0.02 NEG 0.04 NEG - - - 
56 0.137 NEG 0.031 NEG 0.032 NEG - - - 
57 0.078 NEG 0.007 NEG 0.042 NEG 0.749 POS - 
58 0.167 NEG 0.017 NEG 0.021 NEG - - - 
59 0.21 NEG 0.018 NEG 0.066 NEG 1.273 POS - 
60 0.169 NEG 0.009 NEG 0.026 NEG - - - 
61 0.293 NEG 0.062 NEG 0.123 NEG - - - 
62 0.099 NEG 0.062 NEG 0.019 NEG 0.652 POS - 
63 0.114 NEG 0.007 NEG 0.028 NEG 0.789 POS - 
64 0.045 NEG 0.017 NEG 0.014 NEG 1.384 POS - 
65 0.057 NEG 0.038 NEG 0.046 NEG 1.812 POS - 
66 0.157 NEG 0.064 NEG 0.031 NEG 1.441 POS - 
67 0.526 POS 0.105 NEG 0.065 NEG - - E 
68 0.121 NEG 0.014 NEG 0.065 NEG 1.491 POS - 
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Sample 
No 
Omega OD 
Reading 
Omega 
Result 
BioKit OD 
Reading 
BioKit  
Result 
Focus OD 
Reading  Focus  Result
Virotech  
OD  
Reading 
Virotech  
Result 
Western 
blot  result 
69 3.2 POS 1.066 POS 2.266 POS 1.678 POS - 
70 0.077 NEG 0.021 NEG 0.04 NEG 1.503 POS - 
71 0.067 NEG 0.013 NEG 0.022 NEG 1.291 POS - 
72 0.17 NEG 0.046 NEG 0.133 NEG 1.548 POS - 
73 0.088 NEG 0.024 NEG 0.023 NEG - - - 
74 0.125 NEG 0.021 NEG 0.019 NEG - - - 
75 1.561 POS 1.442 POS 3.625 POS - - - 
76 2.5 POS 1.002 POS 2.348 POS - - - 
77 0.11 NEG 0.021 NEG 0.022 NEG - - - 
78 0.434 NEG 0.02 NEG 0.04 NEG - - - 
79 0.086 NEG 0.019 NEG 0.018 NEG - - - 
80 3.955 POS 1.452 POS 3.764 POS - - - 
81 0.12 NEG 0.02 NEG 0.026 NEG - - - 
82 2.102 POS 0.406 NEG 1.471 POS - - POS 
83 0.055 NEG 0.022 NEG 0.046 NEG - -  
84 0.549 POS 0.045 NEG 0.374 POS 1.862 POS POS 
85 0.082 NEG 0.028 NEG 0.076 NEG 1.825 POS - 
86 0.095 NEG 0.027 NEG 0.022 NEG 1.63 POS - 
87 0.24 NEG 0.07 NEG 0.116 NEG 1.324 POS - 
88 1.8 NEG 0.675 POS 2.414 POS 1.964 POS POS 
89 0.123 NEG 0.038 NEG 0.044 NEG 1.618 POS - 
90 0.207 NEG 0.028 NEG 0.058 NEG 1.514 POS - 
91 0.062 NEG 0.83 NEG 0.018 NEG 1.934 POS - 
92 0.139 NEG 0.024 NEG 0.035 NEG 1.444 POS - 
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Sample 
No 
Omega OD 
Reading 
Omega 
Result 
BioKit OD 
Reading 
BioKit  
Result 
Focus OD 
Reading  Focus  Result
Virotech  
OD  
Reading 
Virotech  
Result 
Western 
blot  result 
93 1.7 POS 0.863 POS 2.22 POS - - - 
94 1.792 POS 0.467 POS 1.519 POS - - - 
95 0.176 NEG 0.015 NEG 0.042 NEG 0.124 NEG - 
96 0.065 NEG 0.013 NEG 0.028 NEG 1.937 POS - 
97 0.152 NEG 0.012 NEG 0.036 NEG 1.695 POS - 
98 0.107 NEG 0.055 NEG 0.027 NEG 1.317 POS - 
99 0.079 NEG 0.026 NEG 0.045 NEG - - - 
100 3.1 POS 0.887 POS 2.395 POS - -  
101 1.062 POS 0.401 NEG 1.223 POS - - POS 
102 0.058 NEG 0.015 NEG 0.007 NEG - - - 
103 0.107 NEG 0.022 NEG 0.013 NEG - - - 
104 2.294 POS 1.469 POS 3.497 POS - - - 
105 1.612 POS 0.829 POS 2.481 POS - - - 
106 0.05 NEG 0.029 NEG 0.028 NEG - - - 
107 0.127 NEG 0.03 NEG 0.024 NEG - - - 
108 0.068 NEG 0.026 NEG 0.045 NEG - - - 
109 1.656 POS 0.787 POS 2.297 POS - - - 
110 0.182 NEG 0.051 NEG 0.02 NEG - - - 
111 0.123 NEG 0.03 NEG 0.032 NEG - - - 
112 1.601 POS 0.0433 NEG 2.662 POS - - POS 
113 0.107 NEG 0.053 NEG 0.01 NEG - - - 
114 0.167 NEG 0.016 NEG 0.034 NEG - - - 
115 0.234 NEG 0.174 NEG 0.088 NEG - - - 
  
 280 
Sample 
No 
Omega OD 
Reading 
Omega 
Result 
BioKit OD 
Reading 
BioKit  
Result 
Focus OD 
Reading  Focus  Result
Virotech  
OD  
Reading 
Virotech  
Result 
Western 
blot  result 
116 0.084 NEG 0.02 NEG 0.003 NEG 1.626 POS - 
117 0.089 NEG 0.017 NEG 0.028 NEG 1.675 POS - 
118 0.451 NEG 0.119 NEG 0.054 NEG 1.634 POS POS 
119 0.089 NEG 0.029 NEG 0.176 NEG 1.635 POS - 
120 0.103 NEG 0.009 NEG 0.021 NEG 0.867 POS - 
121 0.122 NEG 0.017 NEG 0.029 NEG 0.076 NEG - 
122 0.121 NEG 0.022 NEG 0.022 NEG 0.109 NEG - 
123 2.554 POS 0.91 POS 2.215 POS 1.512 POS - 
124 0.111 NEG 0.018 NEG 0.031 NEG 0.137 NEG - 
125 0.249 NEG 0.018 NEG 0.072 NEG 0.111 NEG - 
126 1.074 POS 0.165 NEG 1.056 POS 1.201 POS POS 
127 0.247 NEG 0.011 NEG 0.033 NEG 0.088 NEG - 
128 0.236 NEG 0.013 NEG 0.056 NEG 0.128 NEG - 
129 2.165 POS 1.038 POS 2.732 POS 1.148 POS - 
130 0.064 NEG 0.017 NEG 0.022 NEG - - - 
131 0.066 NEG 0.02 NEG 0.043 NEG 1.845 POS - 
132 0.113 NEG 0.011 NEG 0.009 NEG 0.171 NEG - 
133 1.735 POS 1.041 POS 3.748 POS 1.688 POS - 
134 0.1 NEG 0.023 NEG 0.049 NEG 0.255 NEG - 
135 0.169 NEG 0.034 NEG 0.036 NEG 0.094 NEG - 
136 0.198 NEG 0.21 NEG 0.06 NEG 1.134 NEG - 
137 0.104 NEG 0.029 NEG 0.034 NEG - - - 
138 0.092 NEG 0.29 NEG 0.11 NEG 0.683 POS - 
139 2.34 POS 1.528 POS 3.671 POS - - - 
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Sample 
No 
Omega OD 
Reading 
Omega 
Result 
BioKit OD 
Reading 
BioKit  
Result 
Focus OD 
Reading  Focus  Result
Virotech  
OD  
Reading 
Virotech  
Result 
Western 
blot  result 
140 1.562 POS 0.623 POS 1.747 POS - - - 
141 0.146 NEG 0.054 NEG 0.064 NEG - - - 
142 1.365 POS 0.43 NEG 1.237 POS 1.665 POS POS 
143 1.2 POS 0.703 POS 1.821 POS - - - 
144 3.1 POS 1.303 POS 2.921 POS - - - 
145 0.187 NEG 0.042 NEG 0.022 NEG - - - 
146 0.054 NEG 0.034 NEG 0.013 NEG - - - 
147 0.167 NEG 0.03 NEG 0.035 NEG 1.575 POS - 
148 1.523 POS 1.283 POS 2.612 POS - - - 
149 0.094 NEG 0.021 NEG 0.034 NEG - - - 
150 0.126 NEG 0.035 NEG 0.025 NEG 1.639 POS - 
151 0.152 NEG 0.039 NEG 0.104 NEG 0.838 POS - 
152 0.063 NEG 0.036 NEG 0.011 NEG 1.527 POS - 
153 0.112 NEG 0.017 NEG 0.022 NEG 1.497 POS - 
154 0.614 POS 0.057 NEG 0.14 NEG 1.477 POS POS 
155 2.658 POS 0.511 POS 0.971 POS 1.713 POS - 
156 0.073 NEG 0.019 NEG 0.011 NEG 1.52 POS - 
157 0.063 NEG 0.043 NEG 0.35 NEG 1.729 POS - 
158 1.25 POS 0.148 NEG 1.784 POS 0.852 POS  
159 0.077 NEG 0.021 NEG 0.014 NEG 1.374 POS - 
160 0.06 NEG 0.028 NEG 0.01 NEG 1.639 POS - 
161 1.987 POS 1.246 POS 2.236 POS 1.602 POS - 
162 0.082 NEG 0.033 NEG 0.024 NEG 1.695 POS - 
163 0.119 NEG 0.828 POS 1.341 POS 1.746 POS POS 
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Sample 
No 
Omega OD 
Reading 
Omega 
Result 
BioKit OD 
Reading 
BioKit  
Result 
Focus OD 
Reading  Focus  Result
Virotech  
OD  
Reading 
Virotech  
Result 
Western 
blot  result 
164 0.083 NEG 0.019 NEG 0.025 NEG 1.45 POS - 
165 0.165 NEG 0.024 NEG 0.053 NEG - - - 
166 0.144 NEG 0.016 NEG 0.085 NEG - - - 
167 0.086 NEG 0.021 NEG 0.026 NEG - - - 
168 0.111 NEG 0.027 NEG 0.037 NEG - - - 
169 0.076 NEG 0.02 NEG 0.032 NEG - - - 
170 0.13 NEG 0.021 NEG 0.007 NEG 0.078 NEG - 
171 1.07 POS 0.032 NEG 0.243 NEG - - POS 
172 0.28 NEG 0.022 NEG 0.016 NEG - - - 
173 0.098 NEG 0.014 NEG 0.008 NEG 1.505 POS - 
174 0.061 NEG 0.027 NEG 0.002 NEG 1.543 POS - 
175 0.072 NEG 0.055 NEG 0.02 NEG 1.766 POS - 
176 0.23 NEG 0.019 NEG 0.048 NEG 1.751 POS - 
177 0.06 NEG 0.018 NEG 0.007 NEG 1.846 POS - 
178 0.127 NEG 1.539 POS 0.036 NEG 1.668 POS  
179 3.1 POS 0.016 NEG 3.111 POS 1.644 POS - 
180 0.146 NEG 0.017 NEG 0.074 NEG 0.091 NEG - 
181 0.183 NEG 0.05 NEG 0.048 NEG 0.057 NEG - 
182 1.128 POS 0.203 NEG 0.465 POS 1.878 POS POS 
183 0.284 NEG 0.119 NEG 0.019 NEG 0.077 NEG - 
184 0.314 NEG 0.064 NEG 0.022 NEG 0.064 NEG - 
185 0.083 NEG 0.051 NEG 0.029 NEG 0.048 NEG - 
186 0.196 NEG 0.056 NEG 0.028 NEG 0.082 NEG - 
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Sample 
No 
Omega OD 
Reading 
Omega 
Result 
BioKit OD 
Reading 
BioKit  
Result 
Focus OD 
Reading  Focus  Result
Virotech  
OD  
Reading 
Virotech  
Result 
Western 
blot  result 
187 0.064 NEG 0.046 NEG 0.016 NEG 0.072 NEG - 
188 0.258 NEG 0.039 NEG 0.028 NEG 0.083 NEG - 
189 0.145 NEG 0.102 NEG 0.028 NEG 1.986 POS - 
190 0.277 NEG 0.083 NEG 0.037 NEG 0.095 NEG - 
191 0.158 NEG 0.106 NEG 0.032 NEG 0.076 NEG - 
192 0.145 NEG 0.108 NEG 0.057 NEG 0.114 NEG - 
193 0.079 NEG 0.044 NEG 0.016 NEG 0.705 POS - 
194 0.089 NEG 0.71 NEG 0.012 NEG 0.33 NEG - 
195 0.09 NEG 0.027 NEG 0.049 NEG 0.085 NEG - 
196 0.086 NEG 0.03 NEG 0.015 NEG 0.036 NEG - 
197 0.222 NEG 0.111 NEG 0.019 NEG - - - 
198 0.13 NEG 0.032 NEG 0.018 NEG - - - 
199 2.312 POS 0.38 POS 1.074 POS - - - 
200 0.083 NEG 0.044 NEG 0.024 NEG 0.048 NEG - 
201 0.097 NEG 0.08 NEG 0.025 NEG - - - 
202 0.097 NEG 0.034 NEG 0.016 NEG 0.077 NEG - 
203 0.085 NEG 0.047 NEG 0.015 NEG - - - 
204 0.055 NEG 0.021 NEG 0.004 NEG 1.43 POS - 
205 0.234 NEG 0.039 NEG 0.018 NEG 0.074 NEG - 
206 3.2 POS 1.236 POS 3.275 POS - - - 
207 2.281 POS 1.067 POS 2.527 POS - - - 
208 0.194 NEG 0.102 NEG 0.002 NEG 0.089 NEG - 
209 0.112 NEG 0.066 NEG 0.017 NEG 0.098 NEG - 
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Sample 
No 
Omega OD 
Reading 
Omega 
Result 
BioKit OD 
Reading 
BioKit  
Result 
Focus OD 
Reading  Focus  Result
Virotech  
OD  
Reading 
Virotech  
Result 
Western 
blot  result 
210 0.116 NEG 0.044 NEG 0.073 NEG 0.116 NEG - 
211 0.063 NEG 0.054 NEG 0.016 NEG - - - 
212 0.292 NEG 0.127 NEG 0.283 POS - - - 
213 0.067 NEG 0.038 NEG 0.018 NEG 0.064 NEG - 
214 0.228 NEG 0.076 NEG 0.028 NEG 0.05 NEG - 
215 0.194 NEG 0.08 NEG 0.35 NEG - - - 
216 0.078 NEG 0.062 NEG 0.054 NEG 1.82 POS - 
217 2.321 POS 0.257 NEG 0.78 POS - - POS 
218 3.08 POS 0.862 POS 1.893 POS - - - 
219 0.122 NEG 1.047 POS 0.793 POS - - - 
220 1.865 POS 1.493 POS 2.681 POS - - - 
221 1.99 POS 0.684 POS 1.342 POS - - - 
222 2.912 POS 0.731 POS 0.944 POS - - - 
223 1.35 POS 0.32 NEG 0.582 POS - - - 
224 1.146 POS 0.698 POS 1.645 POS - - - 
225 1.482 POS 0.493 NEG 1.024 POS - - - 
226 3.22 POS 1.121 POS 1.389 POS - - - 
227 1.274 POS 0.517 NEG 0.744 POS - - - 
228 3.12 POS 0.453 NEG 1.079 POS - - - 
229 2.998 POS 1.215 POS 1.665 POS - - - 
230 0.462 NEG 0.335 NEG 0.314 POS - - - 
231 3.1 POS 0.511 NEG 1.205 POS - - - 
232 2.218 POS 1.06 POS 1.703 POS - - - 
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Sample 
No 
Omega OD 
Reading 
Omega 
Result 
BioKit OD 
Reading 
BioKit  
Result 
Focus OD 
Reading  Focus  Result
Virotech  
OD  
Reading 
Virotech  
Result 
Western 
blot  result 
233 2.125 POS 0.934 POS 1.904 POS - - - 
234 2.952 POS 1.456 POS 2.27 POS - - - 
235 2.75 POS 0.832 POS 1.634 POS - - - 
236 2.552 POS 1.354 POS 2.045 POS - - - 
237 2.854 POS 0.746 POS 1.756 POS - - - 
238 2.213 POS 0.696 POS 2.389 POS - - - 
239 2.654 POS 1.592 POS 1.421 POS - - - 
240 1.404 POS 0.987 POS 0.71 POS - - - 
241 3.1 POS 0.59 POS 0.053 NEG - - - 
242 0.081 NEG 0.046 NEG 2.49 POS - - - 
243 3.1 POS 1.662 POS 2.382 POS - - - 
244 2.954 POS 1.839 POS 2.735 POS - - - 
245 0.103 NEG 0.067 NEG 0.037 NEG - - - 
246 0.253 NEG 0.044 NEG 0.054 NEG - - - 
247 1.98 POS 1.472 POS 2.136 POS - - - 
248 2.101 POS 0.875 POS 1.28 POS - - - 
249 2.654 POS 1.46 POS 1.189 POS - - - 
250 2.765 POS 1.59 POS 2.3 POS - - - 
251 2.34 POS 0.726 POS 1.225 POS - - - 
252 1.454 POS 0.558 POS 0.942 POS - - - 
253 3.2 POS 1.438 POS 2.171 POS - - - 
254 2.102 POS 1.066 POS 1.725 POS ? POS - 
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Table 3 Summaries of the Results Obtained from HSV-1 gD, Peptide 55, VZV gE, VZV LIAISON ELISAs and HSV-1 gD, Peptide 55 and 
VZV gE Triplex Immunoassay.   
 
Sample 
No 
HSV-1 
gD ELISA
OD 
Reading 
Result 
HSV-1 gD
Luminex 
MFI 
Reading 
Result
Peptide 55 
ELISA 
OD Reading
Result
Peptide 55
Luminex 
MFI 
Reading 
Result 
VZV gE 
ELISA 
OD Reading
Results
VZV gE 
Luminex
MFI 
Reading 
Results 
 
VZV 
LIAISON 
Assay 
Results 
1 0.51 POS 2200 POS 0.899 POS 2164 POS 2.46 POS 5760 POS 3258 POS 
2 0.673 POS 3650 POS 0.059 NEG 220 NEG 0.75 POS 1568 POS 1342 POS 
3 0.808 POS 4589 POS 0.067 NEG 230 NEG 0.531 POS 1236 POS 696 POS 
4 0.786 POS 3350 POS 0.163 NEG 231 NEG 0.786 POS 1810 POS 987 POS 
5 1.003 POS 5430 POS 0.692 POS 2230 POS 0.618 POS 1750 POS 865 POS 
6 1.01 POS 5429.5 POS 1.2 POS 3500 POS 1.012 POS 2560 POS 1569 POS 
7 0.414 POS 1989 POS 2.745 POS 6200 POS 0.861 POS 2112 POS 1360 POS 
8 0.834 POS 3887 POS 0.057 NEG 199 NEG 0.712 POS 1680 POS 1120 POS 
9 0.319 POS 1800 POS 0.097 NEG 210 NEG 1.236 POS 3210 POS 1650 POS 
10 1.561 POS 7510 POS 0.109 NEG 234 NEG 1.3 POS 3399 POS 1625 POS 
11 0.863 POS 4859.8 POS 0.094 NEG 250 NEG 0.863 POS 1998 POS 1210 POS 
12 0.319 POS 1450 POS 0.132 NEG 265 NEG 0.319 POS 983 POS 640 POS 
13 0.739 POS 3158 POS 0.069 NEG 256 NEG 0.521 POS 1561 POS 527 POS 
14 0.877 POS 4596 POS 0.301 NEG 354 NEG 0.701 POS 1967 POS 1133 POS 
15 0.486 POS 2351 POS 1.56 POS 3980 POS 0.98 POS 2987 POS 1892 POS 
16 1.32 POS 6883 POS 1.72 POS 3500 POS 0.368 POS 1003 POS 486 POS 
17 0.091 NEG 279.3 NEG 0.067 NEG 264 NEG 0.982 POS 2697 POS 1610 POS 
18 0.652 POS 2980 POS 0.2 NEG 238 NEG 0.554 POS 1987 POS 762 POS 
19 0.865 POS 4120 POS 0.097 NEG 197 NEG 1.81 POS 5120 POS 2654 POS 
20 0.517 POS 2310 POS 0.0278 NEG 125 NEG 0.521 POS 1456 POS 676 POS 
21 0.66 POS 3450 POS 0.068 NEG 129 NEG 0.432 POS 980 POS 161 EQV 
22 0.882 POS 4190 POS 0.061 NEG 189 NEG 0.425 POS 1098 POS 391 POS 
  
 287 
Sample 
No 
HSV-1 
gD ELISA
OD 
Reading 
Result 
HSV-1 gD
Luminex 
MFI 
Reading 
Result
Peptide 55 
ELISA 
OD Reading
Result
Peptide 55
Luminex 
MFI 
Reading 
Result 
VZV gE 
ELISA 
OD Reading
Results
VZV gE 
Luminex
MFI 
Reading 
Results 
 
VZV 
LIAISON 
Assay 
Results 
23 1.025 POS 5610 POS 0.103 NEG 164 NEG 0.391 POS 867 POS 563 POS 
24 0.809 POS 3665 POS 0.048 NEG 189 NEG 1.75 POS 4675 POS 2098 POS 
25 0.86 POS 4535.5 POS 0.085 NEG 285 NEG 0.86 POS 2269 POS 1260 POS 
26 0.56 POS 2350 POS 0.073 NEG 168 NEG 0.42 POS 1165 POS 825 POS 
27 1.081 POS 5150 POS 0.104 NEG 365 NEG 1.081 POS 2680 POS 1983 POS 
28 0.94 POS 4890 POS 0.048 NEG 156 NEG 0.425 POS 1350 POS 426 POS 
29 0.851 POS 3576.5 POS 0.064 NEG 186 NEG 0.761 POS 2001 POS 1210 POS 
30 0.461 POS 1850 POS 0.046 NEG 146 NEG 0.628 POS 1490 POS 1120 POS 
31 0.714 POS 3450 POS 0.057 NEG 167 NEG 1.029 POS 2643 POS 1654 POS 
32 0.984 POS 4766.8 POS 0.249 NEG 354 NEG 1.608 POS 4562 POS 2261 POS 
33 0.325 POS 1268 POS 0.157 NEG 129 NEG 0.515 POS 1235 POS 663 POS 
34 0.565 POS 2260 POS 0.108 NEG 123 NEG 0.462 POS 850 POS 249 POS 
35 0.95 POS 4370.8 POS 0.147 NEG 146 NEG 0.673 POS 1456 POS 711 POS 
36 0.454 POS 2200 POS 0.156 NEG 185 NEG 0.421 POS 1203 POS 570 POS 
37 0.74 POS 4210 POS 0.14 NEG 136 NEG 0.398 POS 780 POS 246 POS 
38 0.941 POS 5010 POS 0.069 NEG 133 NEG 1.31 POS 3651 POS 1867 POS 
39 0.286 POS 1230 POS 0.067 NEG 136 NEG 0.286 POS 995 POS 526 POS 
40 0.757 POS 3800 POS 0.399 NEG 520 NEG 0.757 POS 2361 POS 1101 POS 
41 0.988 POS 4761 POS 2.3 POS 5400 POS 0.213 NEG 210 NEG 15 NEG 
42 0.972 POS 4980 POS 1.98 POS 3980 POS 0.972 POS 2645 POS 828 POS 
43 1.12 POS 5304 POS 0.104 NEG 165 NEG 1.12 POS 3125 POS 1410 POS 
44 0.959 POS 5120 POS 2.921 POS 7560 POS 0.215 NEG 254 NEG 158 NEG 
45 0.946 POS 4943.3 POS 0.074 NEG 129 NEG 0.561 POS 1986 POS 593 POS 
46 0.394 POS 1955.5 POS 0.05 NEG 128 NEG 0.394 POS 1563 POS 502 POS 
47 1.104 POS 5520 POS 0.076 NEG 210 NEG 2.011 POS 4982 POS 2486 POS 
48 0.831 POS 4300 POS 0.087 NEG 205 NEG 0.986 POS 2563 POS 1189 POS 
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49 0.588 POS 3480 POS 0.985 POS 2900 POS 0.785 POS 2310 POS 1765 POS 
50 0.59 POS 3290 POS 2.101 POS 4800 POS 0.705 POS 2596 POS 1741 POS 
51 0.482 POS 2190 POS 0.07 NEG 198 NEG 0.482 POS 1236 POS 411 POS 
52 0.876 POS 3860 POS 0.074 NEG 198 NEG 0.851 POS 2456 POS 1564 POS 
53 0.546 POS 2614 POS 0.052 NEG 179 NEG 1.32 POS 3654 POS 1456 POS 
54 0.814 POS 4050 POS 0.082 NEG 209 NEG 0.697 POS 2289 POS 661 POS 
55 0.448 POS 2600 POS 0.067 NEG 201 NEG 1.689 POS 4789 POS 2364 POS 
56 0.642 POS 2756 POS 0.137 NEG 297 NEG 0.642 POS 1569 POS 938 POS 
57 0.247 POS 1090 POS 0.078 NEG 198 NEG 0.468 POS 1256 POS 592 POS 
58 0.284 POS 1210.9 POS 0.167 NEG 256 NEG 0.59 POS 1299 POS 544 POS 
59 0.56 POS 2925.5 POS 0.21 NEG 325 NEG 0.895 POS 2216 POS 1669 POS 
60 0.476 POS 1950 POS 0.169 NEG 260 NEG 0.957 POS 1987 POS 1314 POS 
61 0.851 POS 4024 POS 0.293 NEG 380 NEG 0.439 POS 1654 POS 568 POS 
62 0.111 NEG 187.8 NEG 0.099 NEG 168 NEG 0.111 NEG 125 NEG 23 NEG 
63 0.519 POS 2350 POS 0.114 NEG 245 NEG 0.616 POS 958 POS 734 POS 
64 0.707 POS 3735.3 POS 0.045 NEG 135 NEG 0.098 NEG 325 NEG 30 NEG 
65 1.18 POS 6120 POS 0.057 NEG 156 NEG 1.95 POS 5361 POS 2265 POS 
66 0.603 POS 3329 POS 0.157 NEG 314 NEG 0.603 POS 1896 POS 722 POS 
67 0.397 POS 1750 POS 0.526 POS 1650 POS 1.32 POS 3589 POS 1569 POS 
68 0.846 POS 4281 POS 0.121 NEG 246 NEG 0.75 POS 2563 POS 1653 POS 
69 0.978 POS 4500 POS 3.2 POS 7214 POS 0.523 POS 1254 POS 614 POS 
70 0.985 POS 4422.3 POS 0.077 NEG 168 NEG 1.52 POS 4258 POS 1498 POS 
71 0.625 POS 2498 POS 0.067 NEG 186 NEG 0.753 POS 1711 POS 698 POS 
72 0.881 POS 4620 POS 0.17 NEG 224 NEG 0.881 POS 2890 POS 871 POS 
73 0.686 POS 3250 POS 0.088 NEG 198 NEG 2.009 POS 5780 POS 2753 POS 
74 0.852 POS 3990 POS 0.125 NEG 213 NEG 0.431 POS 780 POS 282 POS 
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75 1.212 POS 6150 POS 1.561 POS 3459 POS 1.369 POS 3256 POS 1953 POS 
76 1.043 POS 5480 POS 2.5 POS 5800 POS 0.638 POS 1982 POS 897 POS 
77 0.839 POS 4590 POS 0.11 NEG 199 NEG 0.618 POS 1792 POS 536 POS 
78 1.015 POS 5210 POS 0.434 NEG 985 NEG 2.514 POS 6125 POS 3139 POS 
79 0.678 POS 2987 POS 0.086 NEG 189 NEG 1.64 POS 4899 POS 2610 POS 
80 0.624 POS 2469 POS 3.955 POS 7800 POS 0.981 POS 2598 POS 860 POS 
81 0.53 POS 2896 POS 0.12 NEG 192 NEG 1.963 POS 5698 POS 3012 POS 
82 0.526 POS 2399 POS 2.102 POS 5600 POS 1.39 POS 3990 POS 1420 POS 
83 0.612 POS 2730 POS 0.055 NEG 178 NEG 2.315 POS 6752 POS 3129 POS 
84 1.074 POS 5190 POS 0.549 POS 1590 POS 0.129 NEG 213 NEG 15 NEG 
85 0.933 POS 5230 POS 0.082 NEG 188 NEG 0.933 POS 3259 POS 1560 POS 
86 0.999 POS 4990 POS 0.095 NEG 196 NEG 2.31 POS 6213 POS 3102 POS 
87 0.376 POS 1541 POS 0.24 NEG 267 NEG 0.311 NEG 398 NEG 69 NEG 
88 0.511 POS 2343 POS 1.8 NEG 3900 NEG 1.461 POS 4259 POS 1770 POS 
89 0.62 POS 2680 POS 0.123 NEG 211 NEG 0.531 POS 1459 POS 390 POS 
90 0.912 POS 5090 POS 0.207 NEG 243 NEG 0.912 POS 2350 POS 890 POS 
91 0.686 POS 2850 POS 0.062 NEG 139 NEG 0.789 POS 1986 POS 748 POS 
92 0.776 POS 3820 POS 0.139 NEG 229 NEG 1.231 POS 3012 POS 1542 POS 
93 0.516 POS 2597.9 POS 1.7 POS 3789 POS 0.516 POS 1280 POS 526 POS 
94 0.725 POS 2988 POS 1.792 POS 3860 POS 0.985 POS 2367 POS 817 POS 
95 0.103 NEG 260 NEG 0.176 NEG 298 NEG 1.125 POS 3450 POS 1659 POS 
96 0.878 POS 3960 POS 0.065 NEG 198 NEG 1.023 POS 3159 POS 1275 POS 
97 0.77 POS 3598 POS 0.152 NEG 201 NEG 1.21 POS 3569 POS 1236 POS 
98 0.284 POS 1130 POS 0.107 NEG 189 NEG 1.254 POS 3856 POS 1568 POS 
99 0.681 POS 2865 POS 0.079 NEG 188 NEG 0.998 POS 2310 POS 940 POS 
100 0.986 POS 5160 POS 3.1 POS 6200 POS 0.986 POS 2459 POS 666 POS 
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101 0.761 POS 3250 POS 1.062 POS 2640 POS 0.957 POS 2685 POS 963 POS 
102 0.823 POS 4650 POS 0.058 NEG 167 NEG 2.541 POS 6541 POS 2559 POS 
103 0.726 POS 3123 POS 0.107 NEG 270 NEG 1.953 POS 4685 POS 2198 POS 
104 0.743 POS 3254 POS 2.294 POS 4860 POS 1.854 POS 4390 POS 1985 POS 
105 0.938 POS 5110 POS 1.612 POS 4209 POS 0.621 POS 980 POS 607 POS 
106 0.786 POS 3984 POS 0.05 NEG 199 NEG 0.621 POS 1120 POS 894 POS 
107 0.586 POS 2689 POS 0.127 NEG 290 NEG 0.498 POS 789 POS 610 POS 
108 1.112 POS 5980 POS 0.068 NEG 165 NEG 0.874 POS 2689 POS 1269 POS 
109 0.874 POS 4461 POS 1.656 POS 3756 POS 0.897 POS 2597 POS 1563 POS 
110 0.594 POS 3265 POS 0.182 NEG 266 NEG 0.594 POS 1128 POS 154 EQV 
111 0.915 POS 4250 POS 0.123 NEG 237 NEG 0.915 POS 2687 POS 1221 POS 
112 0.943 POS 4985 POS 1.601 POS 4340 POS 1.402 POS 3490 POS 1466 POS 
113 0.826 POS 4710 POS 0.107 NEG 310 NEG 1.23 POS 2690 POS 1485 POS 
114 0.479 POS 2380 POS 0.167 NEG 259 NEG 1.115 POS 3210 POS 1821 POS 
115 0.907 POS 5012 POS 0.234 NEG 340 NEG 1.019 POS 2389 POS 1226 POS 
116 1.187 POS 6120 POS 0.084 NEG 157 NEG 1.112 POS 2260 POS 870 POS 
117 0.62 POS 3125 POS 0.089 NEG 169 NEG 0.691 POS 1456 POS 680 POS 
118 0.562 POS 2350 POS 0.451 NEG 1390 POS 0.562 POS 1256 POS 662 POS 
119 0.735 POS 3490 POS 0.089 NEG 193 NEG 0.735 POS 1689 POS 1120 POS 
120 0.285 POS 1219 POS 0.103 NEG 223 NEG 1.712 POS 4126 POS 2015 POS 
121 0.092 NEG 271.9 NEG 0.122 NEG 235 NEG 0.092 NEG 169 NEG 16 NEG 
122 0.231 POS 1012 POS 0.121 NEG 229 NEG 1.428 POS 2987 POS 1438 POS 
123 0.26 POS 1050 POS 2.554 POS 5789 POS 1.567 POS 3658 POS 1600 POS 
124 0.109 NEG 190 NEG 0.111 NEG 216 NEG 2.601 POS 6650 POS 2706 POS 
125 0.097 NEG 290 NEG 0.249 NEG 311 NEG 0.989 POS 1987 POS 1227 POS 
126 0.24 POS 1125 POS 1.074 POS 3120 POS 2.256 POS 5421 POS 2994 POS 
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127 0.126 NEG 216 NEG 0.247 NEG 325 NEG 2.1 POS 5998 POS 2504 POS 
128 0.108 NEG 199 NEG 0.236 NEG 328 NEG 1.023 POS 2108 POS 950 POS 
129 0.505 POS 2310 POS 2.165 POS 4798 POS 2.641 POS 6423 POS 3365 POS 
130 0.87 POS 4790 POS 0.064 NEG 196 NEG 1.26 POS 2965 POS 1393 POS 
131 0.657 POS 2943 POS 0.066 NEG 240 NEG 0.858 POS 1568 POS 610 POS 
132 0.096 NEG 210 NEG 0.113 NEG 206 NEG 1.365 POS 4000 POS 1760 POS 
133 0.595 POS 2456 POS 1.735 POS 3960 POS 0.987 POS 2219 POS 981 POS 
134 0.124 NEG 168 NEG 0.1 NEG 225 NEG 0.854 POS 1983 POS 1048 POS 
135 0.103 NEG 209 NEG 0.169 NEG 268 NEG 2.315 POS 6315 POS 3159 POS 
136 0.118 NEG 275 NEG 0.198 NEG 310 NEG 0.489 POS 1456 POS 470 POS 
137 0.592 POS 3200 POS 0.104 NEG 199 NEG 1.491 POS 3259 POS 1600 POS 
138 0.11 POS 198 NEG 0.092 NEG 160 NEG 1.198 POS 2458 POS 1315 POS 
139 0.624 POS 3125 POS 2.34 POS 5210 POS 1.198 POS 2459 POS 1213 POS 
140 0.526 POS 2202 POS 1.562 POS 4380 POS 1.301 POS 2999 POS 1259 POS 
141 0.681 POS 2816 POS 0.146 NEG 240 NEG 1.109 POS 2789 POS 1475 POS 
142 0.707 POS 3210 POS 1.365 POS 3950 POS 2.159 POS 5462 POS 2986 POS 
143 0.63 POS 2465 POS 1.2 POS 3150 POS 0.864 POS 1921 POS 1172 POS 
144 0.629 POS 3402 POS 3.1 POS 7210 POS 2.31 POS 5987 POS 3269 POS 
145 0.597 POS 2950 POS 0.187 NEG 290 NEG 2.917 POS 7460 POS 3782 POS 
146 1.008 POS 5210 POS 0.054 NEG 169 NEG 0.621 POS 1730 POS 496 POS 
147 0.864 POS 4680 POS 0.167 NEG 29 NEG 0.891 POS 1890 POS 964 POS 
148 0.948 POS 5213 POS 1.523 POS 3250 POS 0.912 POS 2010 POS 735 POS 
149 0.689 POS 2856 POS 0.094 NEG 164 NEG 1.128 POS 2589 POS 1330 POS 
150 0.584 POS 2578 POS 0.126 NEG 219 NEG 0.835 POS 1838 POS 1314 POS 
151 0.243 POS 1120 POS 0.152 NEG 248 NEG 1.312 POS 2921 POS 1736 POS 
152 0.572 POS 2420 POS 0.063 NEG 149 NEG 0.989 POS 1987 POS 901 POS 
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153 0.644 POS 2856 POS 0.112 NEG 227 NEG 0.589 POS 1789 POS 615 POS 
154 0.569 POS 2498 POS 0.614 POS 1650 POS 2.758 POS 6415 POS 2987 POS 
155 0.745 POS 3589 POS 2.658 POS 5741 POS 0.581 POS 1598 POS 794 POS 
156 0.807 POS 4500 POS 0.073 NEG 146 NEG 0.459 POS 1601 POS 1342 POS 
157 0.554 POS 2689 POS 0.063 NEG 260 NEG 2.159 POS 5862 POS 3129 POS 
158 0.325 POS 1489 POS 1.25 POS 2982 POS 2.321 POS 5983 POS 3561 POS 
159 0.436 POS 1691 POS 0.077 NEG 136 NEG 0.432 POS 1328 POS 751 POS 
160 0.795 POS 4150 POS 0.06 NEG 166 NEG 2.328 POS 5561 POS 2998 POS 
161 0.668 POS 2987 POS 1.987 POS 4150 POS 1.236 POS 2896 POS 1278 POS 
162 0.634 POS 2589 POS 0.082 NEG 197 NEG 0.261 NEG 321 NEG 169 NEG 
163 0.737 POS 3350 POS 0.119 NEG 250 NEG 3.102 POS 7391 POS 3841 POS 
164 0.907 POS 4980 POS 0.083 NEG 210 NEG 1.128 POS 2987 POS 1311 POS 
165 0.41 POS 1653 POS 0.165 NEG 209 NEG 1.39 POS 3251 POS 1125 POS 
166 0.864 POS 4760 POS 0.144 NEG 211 NEG 0.569 POS 1852 POS 656 POS 
167 0.797 POS 3350 POS 0.086 NEG 195 NEG 1.025 POS 2890 POS 1148 POS 
168 0.353 POS 1987 POS 0.111 NEG 180 NEG 2.314 POS 6103 POS 2987 POS 
169 0.965 POS 5220 POS 0.076 NEG 173 NEG 0.51 POS 1102 POS 648 POS 
170 0.076 NEG 250 NEG 0.13 NEG 167 NEG 1.065 POS 2351 POS 1309 POS 
171 0.488 POS 1989 POS 1.07 POS 2685 POS 0.524 POS 1985 POS 522 POS 
172 0.95 POS 4590 POS 0.28 NEG 260 NEG 0.861 POS 2361 POS 712 POS 
173 0.714 POS 3125 POS 0.098 NEG 187 NEG 1.19 POS 3150 POS 1052 POS 
174 0.647 POS 2975 POS 0.061 NEG 129 NEG 0.897 POS 2982 POS 897 POS 
175 0.831 POS 4520 POS 0.072 NEG 161 NEG 2.961 POS 7640 POS 3785 POS 
176 0.918 POS 4910 POS 0.23 NEG 295 NEG 0.983 POS 2321 POS 942 POS 
177 0.742 POS 2968 POS 0.06 NEG 186 NEG 2.678 POS 7356 POS 2987 POS 
178 0.44 POS 2560 POS 0.127 NEG 235 NEG 1.651 POS 3724 POS 1620 POS 
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179 0.695 POS 3210 POS 3.1 POS 6987 POS 2.674 POS 7025 POS 3681 POS 
180 0.153 NEG 189 NEG 0.146 NEG 297 NEG 0.126 NEG 215 NEG 165 NEG 
181 0.093 NEG 280 NEG 0.183 NEG 230 NEG 0.921 POS 2150 POS 1624 POS 
182 0.915 POS 5010 POS 1.128 POS 2753 POS 0.652 POS 1985 POS 552 POS 
183 0.177 NEG 198 NEG 0.284 NEG 365 NEG 1.159 POS 2931 POS 835 POS 
184 0.126 NEG 125 NEG 0.314 NEG 420 NEG 2.402 POS 6710 POS 2658 POS 
185 0.083 NEG 278 NEG 0.083 NEG 195 NEG 1.865 POS 4653 POS 1855 POS 
186 0.092 NEG 289 NEG 0.196 NEG 228 NEG 1.987 POS 4569 POS 2337 POS 
187 0.123 NEG 167 NEG 0.064 NEG 146 NEG 1.116 POS 2986 POS 1183 POS 
188 0.063 NEG 260 NEG 0.258 NEG 359 NEG 0.128 NEG 215 NEG 164 NEG 
189 1.003 POS 5210 POS 0.145 NEG 167 NEG 2.782 POS 7715 POS 3780 POS 
190 0.118 NEG 191 NEG 0.277 NEG 294 NEG 1.231 POS 2980 POS 989 POS 
191 0.058 NEG 210 NEG 0.158 NEG 193 NEG 0.318 NEG 280 NEG 165 NEG 
192 0.116 NEG 167 NEG 0.145 NEG 236 NEG 0.115 NEG 325 NEG 120 NEG 
193 0.298 POS 1395 POS 0.079 NEG 188 NEG 0.892 POS 2210 POS 768 POS 
194 0.085 NEG 266 NEG 0.089 NEG 123 NEG 1.925 POS 4982 POS 2269 POS 
195 0.149 NEG 199 NEG 0.09 NEG 199 NEG 3.1 POS 7853 POS 3864 POS 
196 0.067 NEG 254 NEG 0.086 NEG 180 NEG 0.459 POS 1201 POS 615 POS 
197 0.677 POS 3150 POS 0.222 NEG 311 NEG 1.026 POS 2651 POS 1745 POS 
198 0.668 POS 3128 POS 0.13 NEG 195 NEG 0.561 POS 1250 POS 854 POS 
199 0.612 POS 3298 POS 2.312 POS 5190 POS 0.876 POS 2130 POS 1068 POS 
200 0.108 NEG 185 NEG 0.083 NEG 203 NEG 1.506 POS 3989 POS 1796 POS 
201 0.456 POS 2651 POS 0.097 NEG 210 NEG 0.684 POS 1689 POS 668 POS 
202 0.111 NEG 196 NEG 0.097 NEG 199 NEG 1.865 POS 4563 POS 1917 POS 
203 0.795 POS 4380 POS 0.085 NEG 187 NEG 1.598 POS 3912 POS 1941 POS 
204 0.321 POS 1280 POS 0.055 NEG 169 NEG 0.098 NEG 316 NEG 159 NEG 
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205 0.11 NEG 195 NEG 0.234 NEG 365 NEG 0.982 POS 2310 POS 829 POS 
206 0.407 POS 2130 POS 3.2 POS 7190 POS 1.011 POS 2410 POS 1109 POS 
207 0.694 POS 3125 POS 2.281 POS 4990 POS 0.695 POS 1850 POS 749 POS 
208 0.038 NEG 210 NEG 0.194 NEG 198 NEG 0.086 NEG 192 NEG 164 NEG 
209 0.04 NEG 297.6 NEG 0.112 NEG 225 NEG 0.057 NEG 184 NEG 142 NEG 
210 0.218 POS 1012 POS 0.116 NEG 231 NEG 1.19 POS 3201 POS 1138 POS 
211 0.753 POS 3456 POS 0.063 NEG 169 NEG 1.021 POS 2231 POS 1678 POS 
212 0.836 POS 4390 POS 0.292 NEG 345 NEG 0.069 NEG 159 NEG 161 NEG 
213 0.045 NEG 198 NEG 0.067 NEG 182 NEG 0.452 POS 1150 POS 653 POS 
214 0.344 POS 1650 POS 0.228 NEG 312 NEG 0.652 POS 1967 POS 162 EQV 
215 0.703 POS 3560 POS 0.194 NEG 259 NEG 0.788 POS 1980 POS 913 POS 
216 0.499 POS 1897 POS 0.078 NEG 195 NEG 1.192 POS 2789 POS 1547 POS 
217 0.398 POS 1611 POS 2.321 POS 5160 POS 1.458 POS 3215 POS 1585 POS 
218 0.611 POS 2986 POS 3.08 POS 6841 POS 1.325 POS 3250 POS 1396 POS 
219 0.947 POS 5140 POS 0.122 NEG 260 NEG 2.568 POS 6983 POS 2827 POS 
220 0.734 POS 3310 POS 1.865 POS 3960 POS 1.36 POS 4120 POS 2105 POS 
221 0.748 POS 3179 POS 1.99 POS 4489 POS 0.756 POS 1986 POS 661 POS 
222 0.413 POS 2259 POS 2.912 POS 6290 POS 0.897 POS 1985 POS 863 POS 
223 0.453 POS 1987 POS 1.35 POS 3260 POS 1.269 POS 3216 POS 1742 POS 
224 0.791 POS 3643 POS 1.146 POS 2786 POS 0.459 POS 1120 POS 569 POS 
225 0.666 POS 2981 POS 1.482 POS 2864 POS 0.563 POS 1269 POS 664 POS 
226 0.387 POS 1598 POS 3.22 POS 7150 POS 1.098 POS 2715 POS 1128 POS 
227 0.776 POS 3750 POS 1.274 POS 2987 POS 2.861 POS 6980 POS 3785 POS 
228 0.623 POS 3210 POS 3.12 POS 7190 POS 1.25 POS 3120 POS 955 POS 
229 0.723 POS 3158 POS 2.998 POS 6487 POS 0.217 POS 253 POS 150 POS 
230 0.325 POS 1298 POS 0.462 NEG 1453 POS 1.321 POS 3145 POS 1747 POS 
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231 0.772 POS 3854 POS 3.1 POS 7150 POS 1.357 POS 2897 POS 898 POS 
232 0.595 POS 3125 POS 2.218 POS 4280 POS 2.645 POS 7160 POS 2816 POS 
233 0.499 POS 2219 POS 2.125 POS 4590 POS 1.3 POS 3210 POS 950 POS 
234 0.443 POS 1820 POS 2.952 POS 6380 POS 2.956 POS 7230 POS 3569 POS 
235 0.599 POS 2546 POS 2.75 POS 5780 POS 0.549 POS 1120 POS 887 POS 
236 0.788 POS 3978 POS 2.552 POS 5940 POS 0.036 NEG 328 NEG 165 NEG 
237 0.773 POS 3468 POS 2.854 POS 6125 POS 2.876 POS 7761 POS 3852 POS 
238 0.693 POS 3210 POS 2.213 POS 5210 POS 0.996 POS 2315 POS 960 POS 
239 0.471 POS 1856 POS 2.654 POS 5689 POS 1.106 POS 3210 POS 985 POS 
240 0.711 POS 3190 POS 1.404 POS 3290 POS 0.698 POS 1894 POS 662 POS 
241 0.733 POS 3800 POS 3.1 POS 6420 POS 2.657 POS 7469 POS 3241 POS 
242 0.706 POS 3165 POS 0.081 NEG 179 NEG 1.524 POS 3510 POS 1569 POS 
243 0.522 POS 2156 POS 3.1 POS 6811 POS 3.15 POS 8001 POS 3785 POS 
244 0.635 POS 2874 POS 2.954 POS 6998 POS 0.658 POS 1359 POS 693 POS 
245 0.31 POS 1349 POS 0.103 NEG 2.9 NEG 2.86 POS 7645 POS 3258 POS 
246 0.108 NEG 222 NEG 0.253 NEG 324 NEG 1.265 POS 2897 POS 1116 POS 
247 0.479 POS 2290 POS 1.98 POS 4397 POS 0.904 POS 1987 POS 808 POS 
248 0.488 POS 1987 POS 2.101 POS 4130 POS 2.75 POS 7750 POS 3681 POS 
249 0.632 POS 2678 POS 2.654 POS 5711 POS 0.699 POS 2158 POS 576 POS 
250 0.507 POS 2341 POS 2.765 POS 5860 POS 2.759 POS 6980 POS 2856 POS 
251 0.588 POS 2680 POS 2.34 POS 4620 POS 0.61 POS 1860 POS 750 POS 
252 0.388 POS 1965 POS 1.454 POS 3145 POS 0.096 NEG 167 NEG 163 NEG 
253 0.797 POS 4123 POS 3.2 POS 7612 POS 1.687 POS 5120 POS 2180 POS 
254 0.776 POS 4210 POS 2.102 POS 4710 POS 1.56 POS 4325 POS 2567 POS 
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Table 1 Summary of the Results Obtained from the Different Assays for Panel 2 Sera. 
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Table 2 Summaries of the Results Obtained from the Different Assays for Panel 3 Sera. 
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Table 3 Summaries of the Results Obtained from the Different Assays for Panel 4 Sera. 
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       Table 4 Results Bioelisa HSV-1 and HSV-2 IgG assays in Patients Attending the Genito-Urinary Medicine Clinic (Panel 5). 
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